

**AlixPartners, LLP**

**Exhibit A**

**Detailed Description of AlixPartners' Fees and Hours  
by Matter Category During the Sixth Interim Period**



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/01/2021	GJK	Call with S Lemack (AlixPartners) re: next steps for IT work plan.	0.4
06/01/2021	SKL	Call with G. Koch (AlixPartners) re: next steps for IT work plan.	0.4
06/01/2021	SKL	Meeting with H. Ghnaimeh (Purdue) re: open items re: IT transfer work plan.	0.2
06/01/2021	SKL	Review latest notes and feedback provided on the change of control process and update the IT transfer work plan accordingly.	2.1
06/01/2021	SKL	Continue to prepare updates to the IT transfer work plan to review and discuss with H. Ghnaimeh (Purdue).	1.5
06/02/2021	SKL	Meeting with H. Ghnaimeh (Purdue) to review the latest IT work plan updates.	0.4
06/02/2021	SKL	Review latest work plan updated provided by H. Ghnaimeh (Purdue) and update to master work plan accordingly.	2.2
06/02/2021	SKL	Update the change of control high-level outline and timeline to be distributed to the change of control working group for additional sign-off.	1.7
06/02/2021	SKL	Continue to review latest notes and feedback re: change of control/transfer work plan process and finalize latest overview deck.	2.1
06/03/2021	LJD	Call with J. O'Connell, J. Turner, R. Schnitzler, T. Melvin (all PJT), M. Huebner, E. Vonnegut, C. Robertson, J. Lowne, M. Kesselman, B. Kaminetzky, R. Aleali (all Davis Polk), L. Donahue, J. DelConte (all AlixPartners) re: weekly catch up and planning meeting.	0.6
06/03/2021	SKL	Finalize updates to the change of control overview deck and circulate update accordingly.	1.6
06/03/2021	SKL	Review latest IT asset breakdown provided by H. Ghnaimeh (Purdue) and begin updated the IT work plan accordingly.	2.4
06/03/2021	JD	Call with J. O'Connell, J. Turner, R. Schnitzler, T. Melvin (all PJT), M. Huebner, E. Vonnegut, C. Robertson, J. Lowne, M. Kesselman, B. Kaminetzky, R. Aleali (all Davis Polk), L. Donahue, J. DelConte (all AlixPartners) re: weekly catch up and planning meeting.	0.6
06/04/2021	GJK	Call with L. Donahue, J. DelConte, G. Koch, A. DePalma, H. Bhattal, S. Lemack, L. Nguyen (all AlixPartners) re: weekly update	0.5
06/04/2021	LJD	Call with L. Donahue, J. DelConte, G. Koch, A. DePalma, H. Bhattal, S. Lemack, L. Nguyen (all AlixPartners) re: weekly update	0.5
06/04/2021	HSB	Call with L. Donahue, J. DelConte, G. Koch, A. DePalma, H. Bhattal, S. Lemack, L. Nguyen (all AlixPartners) re: weekly update	0.5
06/04/2021	HSB	Prepare notes and agenda for Purdue team meeting and discussion of next steps on open items	0.4
06/04/2021	LTN	Call with L. Donahue, J. DelConte, G. Koch, A. DePalma, H. Bhattal, S. Lemack, L. Nguyen (all AlixPartners) re: weekly update	0.5
06/04/2021	SKL	Meeting with H. Ghnaimeh and Z. Hasseb (both Purdue) re: the latest re: IT transfer work plan and next steps.	0.5
06/04/2021	SKL	Call with L. Donahue, J. DelConte, G. Koch, A. DePalma, H. Bhattal, S. Lemack, L. Nguyen (all AlixPartners) re: weekly update	0.5
06/04/2021	SKL	Create updated high-level overview deck of the change of control process and circulate internally for sign-off.	2.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/04/2021	SKL	Continue to review latest updates provided H. Ghnaimeh (Purdue) during this mornings' IT update call and prepare updates to the transfer work plan accordingly.	2.0
06/04/2021	ADD	Call with L. Donahue, J. DelConte, G. Koch, A. DePalma, H. Bhattal, S. Lemack, L. Nguyen (all AlixPartners) re: weekly update	0.5
06/04/2021	JD	Call with L. Donahue, J. DelConte, G. Koch, A. DePalma, H. Bhattal, S. Lemack, L. Nguyen (all AlixPartners) re: weekly update	0.5
06/06/2021	SKL	Meeting with E. Turray (Davis Polk) re: updated change of control overview deck.	0.2
06/06/2021	GJK	Make edits and comments on Emergence Transfer Process Overview deck from S Lemack (AlixPartners).	0.8
06/07/2021	GJK	Multiple calls with S. Lemack (AlixPartners) to debrief following IT working session and discuss other open items related to the change of control process	0.6
06/07/2021	GJK	Call with Purdue Legal and IT and S Lemack (AlixPartners) re: IT work plan updates for change of control.	0.6
06/07/2021	GJK	Review edits to Change of Control deck for sharing with Purdue and Davis Polk for feedback.	0.4
06/07/2021	SKL	Meeting with H. Ghnaimeh, Z. Hasseb, K. McCarthy, S. Hoffman (all Purdue) and G. Koch (AlixPartners) to review latest updates re: IT transfer work plan.	0.6
06/07/2021	SKL	Review latest notes and feedback on the change of control overview deck and circulate updated deck to the change of control working group accordingly.	1.3
06/07/2021	SKL	Call with E. Turray (Davis Polk) re: latest updates re: change of control overview deck and open items for the Davis Polk team.	0.1
06/07/2021	SKL	Continue to prepare updated IT work plan for this afternoon's working session with the IT subgroup.	2.2
06/07/2021	SKL	Finalize remaining updates to the latest IT work plan and circulate for further review with the IT subgroup.	1.9
06/07/2021	SKL	Multiple calls with G. Koch (AlixPartners) to debrief following IT working session and discuss other open items related to the change of control process	0.6
06/08/2021	GJK	Update and coordinate on weekly Change of Control working group call.	0.9
06/08/2021	GJK	Call with S Lemack (AlixPartners) re: latest updates and open items re: change of control process.	0.5
06/08/2021	GJK	Review proposed agenda and tracker for change of control working group call and provide feedback; prep for call.	0.6
06/08/2021	SKL	Call with K. McCarthy (Purdue) re: latest updates and open items re: change of control process and to debrief following call with IT.	0.3
06/08/2021	SKL	Call with J. Narlis and K. McCarthy (Purdue) re: sharepoint setup.	0.3
06/08/2021	SKL	Call with G. Koch (AlixPartners) re: latest updates and open items re: change of control process.	0.5
06/08/2021	SKL	Meeting with K. McCarthy, Z. Haseeb (both Purdue), C. Robertson, E. Turay, and A. Lele (all Davis Polk) re: weekly change of control/transfer work plan	1.0
06/08/2021	SKL	Calls with A. DePalma (AlixPartners) re: status of various case related matters.	0.6
06/08/2021	ADD	Calls with S. Lemack (AlixPartners) re: status of various case related matters.	0.6
06/09/2021	GJK	Review latest IP change of control work plan.	0.8



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/09/2021	SKL	Call with A. DePalma (AlixPartners) re: various case related matters.	0.1
06/09/2021	ADD	Call with S. Lemack (AlixPartners) re: various case related matters.	0.1
06/10/2021	LJD	Call with C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin, J. Arsic (all PJT), M. Huebner, E. Vonnegut (both Davis Polk), L. Donahue, J. DelConte, H. Bhattal, G. Koch (all AlixPartners) re: case update and planning call.	0.6
06/10/2021	GJK	Call with C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin, J. Arsic (all PJT), M. Huebner, E. Vonnegut (both Davis Polk), L. Donahue, J. DelConte, H. Bhattal, G. Koch (all AlixPartners) re: case update and planning call.	0.6
06/10/2021	SKL	Update the latest change of control overview deck and circulate for additional sign-off.	0.4
06/10/2021	SKL	Continue to review the latest notes and feedback provided by the IT transfer work plan group and update the activity breakdown for a touchbase call with the IT team.	2.6
06/10/2021	HSB	Call with C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin, J. Arsic (all PJT), M. Huebner, E. Vonnegut (both Davis Polk), L. Donahue, J. DelConte, H. Bhattal, G. Koch (all AlixPartners) re: case update and planning call.	0.6
06/10/2021	JD	Call with C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin, J. Arsic (all PJT), M. Huebner, E. Vonnegut (both Davis Polk), L. Donahue, J. DelConte, H. Bhattal, G. Koch (all AlixPartners) re: case update and planning call.	0.6
06/10/2021	JD	Prepare agenda for weekly call with management and advisors.	0.3
06/11/2021	GJK	Call with H. Bhattal, G. Koch, A. DePalma, L. Nguyen (all AlixPartners) re: weekly update	0.4
06/11/2021	GJK	Call with R. Aleali (Purdue), D. Consla, T. Matlock, C. Robertson, E. Diggs (all Davis Polk), J. DelConte, H. Bhattal, G. Koch (all AlixPartners), P. Flink, S. Pohl, B. Kelly, K. Davis (all Brown Rudnick), J. Bessonette, H. Stoopack, J. Taub, J. Rosenbaum, D. Lyons (all Kramer Levin), B. Bromberg (FTI) re: Purdue work transfer diligence and related matters	1.0
06/11/2021	LTN	Call with H. Bhattal, G. Koch, A. DePalma, L. Nguyen (all AlixPartners) re: weekly update	0.4
06/11/2021	HSB	Call with H. Bhattal, G. Koch, A. DePalma, L. Nguyen (all AlixPartners) re: weekly update	0.4
06/11/2021	HSB	Prepare notes and agenda for Purdue team meeting and discussion of next steps on open items	0.3
06/11/2021	ADD	Call with H. Bhattal, G. Koch, A. DePalma, L. Nguyen (all AlixPartners) re: weekly update	0.4
06/14/2021	GJK	Call with S. Lemack (AlixPartners) re: latest updates re: change of control process.	0.4
06/14/2021	GJK	Review updated IT work plan from S. Lemack.	0.8
06/14/2021	SKL	Finalize updates to the IT transfer work plan and circulate for today's meeting with the IT team.	2.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/14/2021	SKL	Call with G. Koch (AlixPartners) re: latest updates re: change of control process.	0.4
06/15/2021	LJD	Meeting with J. O'Connell, J. Turner, R. Schnitzler, T. Melvin (all PJT), L. Donahue, G. Koch, J. DelConte, H. Bhattal (all AlixPartners), E. Vonnegut, M. Huebner, C. Robertson (all Davis Polk) re: update and planning call.	0.5
06/15/2021	GJK	Meeting with J. O'Connell, J. Turner, R. Schnitzler, T. Melvin (all PJT), L. Donahue, G. Koch, J. DelConte, H. Bhattal (all AlixPartners), E. Vonnegut, M. Huebner, C. Robertson (all Davis Polk) re: update and planning call.	0.5
06/15/2021	HSB	Meeting with J. O'Connell, J. Turner, R. Schnitzler, T. Melvin (all PJT), L. Donahue, G. Koch, J. DelConte, H. Bhattal (all AlixPartners), E. Vonnegut, M. Huebner, C. Robertson (all Davis Polk) re: update and planning call.	0.5
06/15/2021	JD	Meeting with J. O'Connell, J. Turner, R. Schnitzler, T. Melvin (all PJT), L. Donahue, G. Koch, J. DelConte, H. Bhattal (all AlixPartners), E. Vonnegut, M. Huebner, C. Robertson (all Davis Polk) re: update and planning call.	0.5
06/16/2021	GJK	Weekly change of control/transfer work plan update meeting with K. McCarthy (Purdue), Z. Haseeb (Purdue), C. Robertson, E. Turay, A. Lele (all Davis Polk) and S. Lemack (AlixPartners).	0.5
06/16/2021	GJK	Call with Purdue Legal and IT, Davis Polk and S Lemack (AlixPartners) to update on IT work plan for change of control process.	1.1
06/16/2021	GJK	Update and coordinate on weekly change of control working group call with Purdue Legal, Davis Polk and S Lemack (AlixPartners).	0.8
06/16/2021	LTN	Call with H. Bhattal (AlixPartners) re: various case related matters	0.2
06/16/2021	HSB	Call with L. Nguyen (AlixPartners) re: various Purdue related matters	0.2
06/16/2021	SKL	Meeting with H. Ghnaimh, K. McCarthy, S. Hoffman (all Purdue) and G. Koch (AlixPartners) re: the IT transfer work plan.	1.1
06/16/2021	SKL	Continue to review latest notes and feedback re: change of control process and prepare updated PMO tracker and agenda for today's weekly update call.	2.7
06/16/2021	SKL	Review latest IP contract reconciliation and circulate updated meeting invite re: further with the Davis Polk team.	0.8
06/16/2021	SKL	Weekly change of control/transfer work plan update meeting with K. McCarthy (Purdue), Z. Haseeb (Purdue), C. Robertson, E. Turay, A. Lele (all Davis Polk) and G. Koch (AlixPartners).	0.5
06/17/2021	GJK	Call with S Lemack (AlixPartners) re: change of control process next steps.	0.3
06/17/2021	GJK	Meeting with R. Aleali (Purdue), K. McCarthy (Purdue), L. Diggs, S. Massman, A. Lele, W. Taylor, T. Matlock (Davis Polk), E. Turay (all Davis Polk), B. Angstadt, T. Coyne, R. Werth R. Daniel, J. Neely (all GT) and S. Lemack (AlixPartners) re: transfer of PPLP subsidiaries	0.6
06/17/2021	GJK	Follow-up on open change of control items including IT work plan and agreement and overall contracts.	0.9
06/17/2021	SKL	Meeting with R. Aleali (Purdue), K. McCarthy (Purdue), L. Diggs, S. Massman, A. Lele, W. Taylor, T. Matlock (Davis Polk), E. Turay (all Davis Polk), B. Angstadt, T. Coyne, R. Werth R. Daniel, J. Neely (all GT) and G. Koch (AlixPartners) re: transfer of PPLP subsidiaries	0.6



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/17/2021	SKL	Call with G. Koch (AlixPartners) re: next steps re: IP change of control process.	0.3
06/18/2021	LTN	Call with J. DelConte, H. Bhattal, A. DePalma, G. Koch, S. Lemack, L. Nguyen, (all AlixPartners) re: weekly team update call.	1.0
06/18/2021	HSB	Call with J. DelConte, H. Bhattal, A. DePalma, G. Koch, S. Lemack, L. Nguyen, (all AlixPartners) re: weekly team update call.	1.0
06/18/2021	HSB	Prepare agenda and list of open items for Purdue team meeting and discussion of next steps on open items	0.5
06/18/2021	ADD	Call with J. DelConte, H. Bhattal, A. DePalma, G. Koch, S. Lemack, L. Nguyen, (all AlixPartners) re: weekly team update call.	1.0
06/18/2021	SKL	Meeting with R. Aleali, K. McCarthy (both Purdue), L. Diggs, S. Massman, D. Consla, L. Altus, T. Matlock, E. Turay (all Davis Polk), N. Bouchard, P. Flink, S. Pohl, B. Kelly, K. Davis (all Brown Rudnick), J. Bessonette (Kramer Levin), H. Stoopack, J. Taub, J. Rosenbaum, D. Lyons (all Kramer Levin), and G. Koch (AlixPartners) re: the regulatory matters process.	0.8
06/18/2021	SKL	Call with J. DelConte, H. Bhattal, A. DePalma, G. Koch, S. Lemack, L. Nguyen, (all AlixPartners) re: weekly team update call.	1.0
06/18/2021	JD	Call with J. DelConte, H. Bhattal, A. DePalma, G. Koch, S. Lemack, L. Nguyen, (all AlixPartners) re: weekly team update call (partial attendance)	0.6
06/21/2021	SKL	Call with L. Diggs (Davis Polk) re: IP transfer work plan process.	0.1
06/22/2021	LJD	Call with J. O'Connell, J. Turner, T. Melvin, R. Schnitzler (all PJT), J. DelConte, G. Koch, L. Donahue, H. Bhattal (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk) re: weekly update and planning call.	0.5
06/22/2021	GJK	Call with S Lemack (AlixPartners) to prep for Change of Control Working Group call.	0.2
06/22/2021	GJK	Update and coordinate on weekly change of control process call with Purdue Legal, Davis Polk and S Lemack (AlixPartners).	1.0
06/22/2021	GJK	Weekly change of control/transfer work plan update meeting with R. Aleali (Purdue), K. McCarthy (Purdue), Z. Haseeb (Purdue), C. Robertson (Davis Polk), E. Turay (Davis Polk), A. Lele (Davis Polk) and S. Lemack, H. Bhattal (AlixPartners).	0.7
06/22/2021	JD	Call with J. O'Connell, J. Turner, T. Melvin, R. Schnitzler (all PJT), J. DelConte, G. Koch, L. Donahue, H. Bhattal (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk) re: weekly update and planning call.	0.5
06/22/2021	SKL	Review IP notes and feedback provided by S. Hoffman (Purdue) and prepare for afternoon IP transfer work plan meeting.	0.9
06/22/2021	SKL	Review latest notes and feedback provided by the change of control subgroups and update the PMO tracker.	2.7
06/22/2021	SKL	Finalize updates to the change of control tracker and prepare agenda for weekly change of control update call.	2.1
06/22/2021	SKL	Meeting with K. McCarthy, S. Hoffman, B. Koch, R. Inz, J. Doyle and R. Kreppel (all Purdue) re: the IP contract reconciliation process.	1.6
06/22/2021	SKL	Call with G. Koch (AlixPartners) re: upcoming change of control meeting.	0.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/22/2021	HSB	Call with J. O'Connell, J. Turner, T. Melvin, R. Schnitzler (all PJT), J. DelConte, G. Koch, L. Donahue, H. Bhattal (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk) re: weekly update and planning call.	0.5
06/23/2021	GJK	Call with S Lemack (AlixPartners) to provide updates on each change of control workstream and discuss upcoming inventory sell-through meeting.	0.5
06/23/2021	GJK	Follow-up on open items and emails re: Change of Control process.	0.3
06/23/2021	SKL	Call with G. Koch (AlixPartners) to provide updates on each change of control workstream and discuss upcoming inventory sell-through meeting.	0.5
06/23/2021	SKL	Meeting with D. McGuire, D. Fogel, R. Aleali, K. McCarthy, S. Hoffman, Z. Haseeb, J. Doyle, M. Kroese, J. Northington, B. Evans, V. Manicinielli (all Purdue), W. McConagha, M. Florence, J. Bragg (all Skadden) re: FDA talking points re: inventory sell-through process.	1.2
06/23/2021	SKL	Review latest notes and feedback and prepare for upcoming inventory sell-through meeting.	1.1
06/23/2021	JD	Prepare agenda for weekly call with management and advisors.	0.3
06/23/2021	JD	Review independent analysis of independent director effects on plan of reorganization as it pertains to Purdue.	0.4
06/24/2021	LJD	Weekly catch up and planning call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. DelConte, L. Donahue, H. Bhattal, G. Koch (all AlixPartners), J. O'Connell, J. Turner, T. Melvin (all PJT), M. Kesselman, J. Lowne, R. Aleali (all Purdue) re: update and planning	0.6
06/24/2021	GJK	Meeting with R. Aleali, K. McCarthy, S. Hoffman, H. Smith (all Purdue), B. Chen, S. Brecher, C. Robertson (all Davis Polk) and S. Lemack (AlixPartners) re: next steps re: employee invention agreements.	0.4
06/24/2021	GJK	Weekly catch up and planning call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. DelConte, L. Donahue, H. Bhattal, G. Koch (all AlixPartners), J. O'Connell, J. Turner, T. Melvin (all PJT), M. Kesselman, J. Lowne, R. Aleali (all Purdue) re: update and planning	0.6
06/24/2021	GJK	Review existing HR forms.	0.4
06/24/2021	SKL	Call with Z. Levine (Davis Polk) re: indemnification agreements.	0.2
06/24/2021	SKL	Meeting with R. Aleali, K. McCarthy, S. Hoffman, H. Smith (all Purdue), B. Chen, S. Brecher, C. Robertson (all Davis Polk) and G. Koch (AlixPartners) re: next steps re: employee invention agreements.	0.4
06/24/2021	SKL	Call with S. Hoffman (Purdue) re: latest IP inquiry.	0.1
06/24/2021	HSB	Weekly catch up and planning call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. DelConte, L. Donahue, H. Bhattal, G. Koch (all AlixPartners), J. O'Connell, J. Turner, T. Melvin (all PJT), M. Kesselman, J. Lowne, R. Aleali (all Purdue) re: update and planning	0.6
06/24/2021	JD	Weekly catch up and planning call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. DelConte, L. Donahue, H. Bhattal, G. Koch (all AlixPartners), J. O'Connell, J. Turner, T. Melvin (all PJT), M. Kesselman, J. Lowne, R. Aleali (all Purdue) re: update and planning	0.6
06/25/2021	GJK	Call with H. Bhattal, G. Koch, S. Lemack, A. DePalma, L. Nguyen (all AlixPartners) re: weekly update	0.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/25/2021	SKL	Call with H. Bhattal, G. Koch, S.Lemack, A. DePalma, L. Nguyen (all AlixPartners) re: weekly update	0.7
06/25/2021	HSB	Call with H. Bhattal, G. Koch, S.Lemack, A. DePalma, L. Nguyen (all AlixPartners) re: weekly update	0.7
06/25/2021	HSB	Prepare agenda and list of open items for Purdue team meeting and discussion of next steps on open items	0.4
06/25/2021	LTN	Call with H. Bhattal, G. Koch, S.Lemack, A. DePalma, L. Nguyen (all AlixPartners) re: weekly update	0.7
06/25/2021	ADD	Call with H. Bhattal, G. Koch, S.Lemack, A. DePalma, L. Nguyen (all AlixPartners) re: weekly update	0.7
06/28/2021	SKL	Review the latest notes and feedback provided on the change of control workstream and prepare updates to the PMO tracker accordingly.	2.1
06/28/2021	GJK	Review updated PMO tracker for Change of Control process from S Lemack (AlixPartners).	0.4
06/28/2021	GJK	Review emails and documents from Purdue IP and Legal related to change of control process and open economic items.	0.8
06/28/2021	GJK	Review IT contract priority breakdown.	0.8
06/29/2021	SKL	Finalize updated layout for the change of control high-level outline and circulate internally for additional notes and feedback.	2.1
06/29/2021	SKL	Review latest notes and feedback provided by H. Ghnaimh (Purdue) and provide update to the change of control group accordingly.	0.6
06/29/2021	HSB	Call with M.Huebner, C. Robertson (Davis Polk), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT) re: update and planning.	0.3
07/01/2021	SKL	Participate in meeting with D. McGuire, D. Fogel, R. Aleali, K. McCarthy, S. Hoffman, Z. Haseeb, J. Doyle, M. Kroese, J. Northington, B. Evans, V. Manicinielli (all Purdue), W. McConagha, M. Florence, J. Bragg (all Skadden) and G. Koch (AlixPartners) to discuss FDA talking points re: inventory sell-through process.	1.2
07/01/2021	SKL	Meeting with R. Aleali, K. McCarthy, Z. Haseeb (all Purdue), C. Robertson, E. Turay, A. Lele (all Davis Polk) and G. Koch (AlixPartners) re: change of control/transfer work plan update.	0.5
07/01/2021	SKL	Finalize updates to the weekly change of control PMO tracker and prepare updated agenda for today's weekly update meeting.	2.2
07/01/2021	SKL	Continue to review latest feedback provided re: change of control process, and update transfer work plans and PMO tracker accordingly.	1.2
07/01/2021	GJK	Update and coordinate on weekly change of control working group call.	0.5
07/01/2021	GJK	Participate in meeting with D. McGuire, D. Fogel, R. Aleali, K. McCarthy, S. Hoffman, Z. Haseeb, J. Doyle, M. Kroese, J. Northington, B. Evans, V. Manicinielli (all Purdue), W. McConagha, M. Florence, J. Bragg (all Skadden) and S. Lemack (AlixPartners) to discuss FDA talking points re: inventory sell-through process.	1.2
07/01/2021	GJK	Review ongoing change of control workstream priorities.	0.7





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/01/2021	GJK	Meeting with R. Aleali, K. McCarthy, Z. Haseeb (all Purdue), C. Robertson, E. Turay, A. Lele (all Davis Polk) and S. Lemack (AlixPartners) re: change of control/transfer work plan update.	0.5
07/06/2021	LJD	Call with C. Robertson (Davis Polk), J. Turner, J. Arsic, R. Schnitzler, T. Melvin (all PJT), L. Donahue, H. Bhattal, J. DelConte (both AlixPartners) re: update and planning.	0.5
07/06/2021	SKL	Finalize updates to the weekly change of control PMO tracker and prepare updated agenda for tomorrow's weekly update meeting.	2.2
07/06/2021	HSB	Call with C. Robertson (Davis Polk), J. Turner, J. Arsic, R. Schnitzler, T. Melvin (all PJT), L. Donahue, H. Bhattal, J. DelConte (both AlixPartners) re: update and planning.	0.5
07/06/2021	JD	Call with C. Robertson (Davis Polk), J. Turner, J. Arsic, R. Schnitzler, T. Melvin (all PJT), L. Donahue, H. Bhattal, J. DelConte (both AlixPartners) re: update and planning.	0.5
07/07/2021	GJK	Update and coordinate on weekly Change of Control call.	0.4
07/07/2021	GJK	Review change of control updates for IP, FDA, IT.	1.7
07/07/2021	SKL	Meeting with J. Doyle, B. Koch, R. Krappel, R. Inz, K. McCarthy, Z. Haseeb and S. Hoffman (all Purdue) to discuss the IP transfer work plan	1.0
07/07/2021	SKL	Call with G. Koch (AlixPartners) to discuss updated PMO tracker and change of control process.	0.1
07/07/2021	SKL	Call with C. Robertson (Davis Polk), J. DelConte, S. Lemack, H. Bhattal (all AlixPartners), J. Lowne, S. Daniel, J. Lauriat, C. Russo (all Purdue) re: contract rejection and assumption.	0.8
07/07/2021	SKL	Weekly change of control/transfer work plan update meeting with R. Aleali (Purdue), K. McCarthy (Purdue), Z. Haseeb (Purdue), C. Robertson (Davis Polk), E. Turay (Davis Polk) and A. Lele (Davis Polk).	0.7
07/07/2021	SKL	Prepare additional updates to the PMO tracker based on the latest feedback received and circulate accordingly for today's change of control update call.	1.4
07/07/2021	SKL	Finalize updates to the latest consolidated contract listing and circulate to the IP working group following our weekly update call.	0.5
07/07/2021	JD	Create agenda for weekly call with advisors and management tomorrow.	0.3
07/07/2021	GJK	Call with S. Lemack (AlixPartners) to discuss updated PMO tracker and change of control process.	0.1
07/08/2021	GJK	Call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), C. Robertson, A. Libby (Davis Polk), J. Turner, J. Arsic, R. Schnitzler, T. Melvin (all PJT), J. DelConte, G. Koch (both AlixPartners) re: update and planning.	0.8
07/08/2021	SKL	Call with G. Koch (AlixPartners) to touch base on the latest updates re: change of control process.	0.3
07/08/2021	HSB	Call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), C. Robertson, A. Libby (Davis Polk), J. Turner, J. Arsic, R. Schnitzler, T. Melvin (all PJT), J. DelConte, G. Koch (both AlixPartners) re: update and planning.	0.8



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/08/2021	JD	Participate in weekly update call with C. Landau, M. Kesselman, R. Aleali, J. Lowne (all Purdue), C. Robertson, E. Vonnegut, W. Taylor (all Davis Polk), J. O'Connell, J. Turner, T. Melvin, J. Arsic (all PJT), J. DelConte, H. Bhattal G. Koch (all AlixPartners) re: weekly update and planning call.	0.8
07/08/2021	GJK	Call with S. Lemack(AlixPartners) to touch base on the latest updates re: change of control process.	0.3
07/09/2021	LTN	Weekly team update call with J. DelConte, K. McCafferty, H. Bhattal, G. Koch, A. DePalma, S. Lemack, L. Nguyen (all AlixPartners)	0.6
07/09/2021	SKL	Call with G. Koch (AlixPartners) to discuss latest updates re: change of control process.	0.1
07/09/2021	SKL	Call with J. DelConte, K. McCafferty, H. Bhattal, A. DePalma, G. Koch, S. Lemack, L. Nguyen, (all AlixPartners) re: weekly team update call.	0.6
07/09/2021	HSB	Call with J.DelConte, K.McCafferty G.Koch, S.Lemack, A.DePalma, L.Nguyen (all AlixPartners) re: weekly update	0.6
07/09/2021	HSB	Prepare agenda and list of open items for discussion prior to meeting with Purdue advisory team	0.5
07/09/2021	JD	Call with J.DelConte, K.McCafferty G.Koch, S.Lemack, A.DePalma, L.Nguyen (all AlixPartners) re: weekly update	0.6
07/09/2021	ADD	Weekly team update call with J. DelConte, K. McCafferty, H. Bhattal, G. Koch, A. DePalma, S. Lemack, L. Nguyen (all AlixPartners)	0.6
07/09/2021	GJK	Call with S. Lemack (AlixPartners) to discuss latest updates re: change of control process.	0.1
07/09/2021	GJK	Weekly team update call with J. DelConte, K. McCafferty, H. Bhattal, G. Koch, A. DePalma, S. Lemack, L. Nguyen (all AlixPartners)	0.6
07/09/2021	KM	Weekly team update call with J. DelConte, K. McCafferty, H. Bhattal, G. Koch, A. DePalma, S. Lemack, L. Nguyen (all AlixPartners)	0.6
07/12/2021	GJK	Call with S Lemack (AlixPartners) to discuss change of control process workstream.	0.4
07/12/2021	SKL	Meeting with H. Ghnaimh, K. McCarthy, S. Hoffman and Z. Haseeb (all Purdue) to discuss latest IT transfer work plan and provide/receive update accordingly.	0.7
07/12/2021	SKL	Meeting with J. Doyle, D. Fogel, K. McCarthy, R. Aleali, S. Hoffman, Z. Haseeb, B. Evans, J. Northington, M. Krosse (all Purdue), J. Bragg (Skadden), B. McConagha (Skadden), M. Florence (Skadden) to discuss latest inventory sell-through talking points and FDA process.	1.0
07/12/2021	SKL	Call with G. Koch (AlixPartners) to touch base on the latest updates re: change of control process.	0.4
07/12/2021	SKL	Review latest notes and feedback provided on the IT transfer work plan and began making updates to the upcoming IT meeting accordingly.	1.3
07/13/2021	JD	Participate in weekly professionals catch up meeting with J. O'Connell, J. Turner, T. Melvin (all PJT), E. Vonnegut, C. Robertson, W. Taylor (all Davis Polk), J. DelConte, H. Bhattal (both AlixPartners).	0.4
07/13/2021	SKL	Weekly IP change of control update meeting with K. McCarthy, Z. Haseeb, S. Hoffman, R. Inz, B. Koch, J. Doyle, R. Kreppel (all Purdue).	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/13/2021	SKL	Weekly change of control/transfer work plan update meeting with R. Aleali (Purdue), K. McCarthy (Purdue), Z. Haseeb (Purdue), C. Robertson (Davis Polk), E. Turay (Davis Polk), and A. Lele (Davis Polk).	0.5
07/13/2021	SKL	Multiple calls with H. Bhattal (AlixPartners) to discuss plan matters.	0.4
07/13/2021	SKL	Review latest notes and feedback provided on the change of control workstream and prepare updated PMO tracker and weekly agenda accordingly.	2.5
07/13/2021	SKL	Review latest notes and feedback from today's weekly update call and circulate updates notes and action items accordingly for this week.	0.8
07/13/2021	HSB	Call with E.Vonnegut, C. Robertson, W.Taylor (all Davis Polk), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), J.DelConte (AlixPartners) re: update and planning.	0.4
07/16/2021	GJK	Call with L.Donahue, G.Koch, H. Bhattal, S.Lemack, A.DePalma, L.Nguyen (all AlixPartners) re: weekly update	0.5
07/16/2021	GJK	Call with Z. Haseeb (Purdue) and S. Lemack (AlixPartners) to discuss latest employee change of control questions.	0.5
07/16/2021	GJK	Call with Z Haseeb (Purdue) and S Lemack (AlixPartners) to walk through employee resources questions.	0.5
07/16/2021	GJK	Review change of control planning and open items following discussion with S Lemack (AlixPartners).	1.3
07/16/2021	LJD	Call with L.Donahue, G.Koch, H. Bhattal, S.Lemack, A.DePalma, L.Nguyen (all AlixPartners) re: weekly update	0.5
07/16/2021	SKL	Call with Z. Haseeb (Purdue) and G. Koch (AlixPartners) to discuss latest employee change of control questions.	0.5
07/16/2021	SKL	Call with L.Donahue, G.Koch, H. Bhattal, S.Lemack, A.DePalma, L.Nguyen (all AlixPartners) re: weekly update	0.5
07/16/2021	SKL	Meeting with Z. Haseeb (Purdue) and G. Koch (AlixPartners) to discuss employee matters open items.	0.5
07/16/2021	HSB	Call with L.Donahue, G.Koch, H. Bhattal, S.Lemack, A.DePalma, L.Nguyen (all AlixPartners) re: weekly update	0.5
07/16/2021	HSB	Prepare agenda and list of open items for discussion prior to meeting with Purdue advisory team	0.6
07/16/2021	LTN	Call with L.Donahue, G.Koch, H. Bhattal, S.Lemack, A.DePalma, L.Nguyen (all AlixPartners) re: weekly update	0.5
07/16/2021	ADD	Call with L.Donahue, G.Koch, H. Bhattal, S.Lemack, A.DePalma, L.Nguyen (all AlixPartners) re: weekly update	0.5
07/18/2021	GJK	Review IT Agreement Chart from B Trost (Davis Polk).	0.2
07/19/2021	SKL	Weekly IT catch-up meeting with H. Ghnaimh, K. McCarthy, Z. Haseeb and S. Hoffman (all Purdue).	0.4
07/20/2021	LJD	Prepare for weekly meeting with advisors, PJT and Davis Polk	0.3
07/20/2021	GJK	Call with Purdue Legal, Davis Polk and S. Lemack (AlixPartners) to update and coordinate on weekly change of control call.	0.5
07/20/2021	GJK	Prepare for contract and change of control discussions.	0.8
07/20/2021	GJK	Follow-up on open change of control issues from working team call.	0.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/20/2021	SKL	Weekly change of control/transfer work plan update meeting with R. Aleali (Purdue), K. McCarthy (Purdue), Z. Haseeb (Purdue), C. Robertson (Davis Polk), E. Turay (Davis Polk), and A. Lele (Davis Polk).	0.6
07/20/2021	SKL	Call with A. DePalma (AlixPartners) to discuss latest diligence request and next steps.	0.2
07/20/2021	SKL	Meeting with H. Bhattal (AlixPartners) to discuss plan related matters.	0.1
07/20/2021	SKL	Review latest notes and feedback provided by the change of control subgroups and prepare updated PMO tracker accordingly.	2.3
07/20/2021	HSB	Call with M.Huebner, E.Vonnegut, C. Robertson, W.Taylor (all Davis Polk), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), J.DelConte (AlixPartners) re: update and planning.	0.4
07/20/2021	JD	Call with M. Huebner, C. Robertson, E. Vonnegut, A. Libby (all Davis Polk), J. DelConte, H. Bhattal (all AlixPartners), J. O'Connell, T. Melvin, J. Turner, R. Schnitzler (all PJT) re: weekly professionals catch up and planning call.	0.4
07/20/2021	SKL	Call with Purdue Legal, Davis Polk and G. Koch (AlixPartners) to update and coordinate on weekly change of control call.	0.5
07/21/2021	GJK	Calls with S Lemack (AlixPartners) to coordinate on change of control process.	0.4
07/21/2021	GJK	Weekly IP change of control update meeting with S. Lemack (AlixPartners) K. McCarthy, Z. Haseeb, S. Hoffman, R. Inz, B. Koch, J. Doyle, (all Purdue).	0.5
07/21/2021	GJK	Review current status of change of control work streams.	1.3
07/21/2021	SKL	Meeting with C. Robertson and S. Brecher (both Davis Polk) to discuss latest Ceridian questionnaire.	0.3
07/21/2021	SKL	Weekly IP change of control update meeting with G. Koch (AlixPartners) K. McCarthy, Z. Haseeb, S. Hoffman, R. Inz, B. Koch, J. Doyle, (all Purdue).	0.5
07/21/2021	SKL	Call with A. DePalma (AlixPartners) to discuss latest diligence request and next steps.	0.2
07/21/2021	SKL	Call with H. Bhattal (AlixPartners) to discuss plan related matters.	0.4
07/21/2021	SKL	Calls with G. Koch (AlixPartners) to provide update on the change of control process and discuss open items.	0.4
07/21/2021	SKL	Review latest feedback and notes provided by Purdue IP and prepare updated agenda and talking points accordingly.	0.6
07/21/2021	JD	Prepare agenda for biweekly call with management and advisors tomorrow.	0.3
07/22/2021	LJD	Participate in weekly call with J. Lowne, M. Kesselman, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, H. Bhattal, L. Donahue (all AlixPartners), M. Huebner, C. Robertson, E. Vonnegut, A. Libby (all Davis Polk) re: catch up and go forward planning.	1.1
07/22/2021	GJK	Call with S Lemack to discuss change of control process.	0.1
07/22/2021	GJK	Review change of control deck and potential updates for AHC advisors.	0.6
07/22/2021	SKL	Meeting with Z. Haseeb (Purdue), C. Robertson (Davis Polk), S. Brecher (Davis Polk) and G. Koch (AlixPartners) to discuss latest Ceridian questionnaire.	0.3
07/22/2021	SKL	Meeting with G. Koch (AlixPartners) to debrief following employee change of control call.	0.1



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/22/2021	HSB	Call with M.Kesselman, J.Lowne, R.Aleali (all Purdue), M.Huebner, C. Robertson, A.Libby (Davis Polk), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), L.Donahue, J.DelConte (AlixPartners) re: update and planning.	1.1
07/22/2021	JD	Participate in weekly call with J. Lowne, M. Kesselman, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, H. Bhattal, L. Donahue (all AlixPartners), M. Huebner, C. Robertson, E. Vonnegut, A. Libby (all Davis Polk) re: catch up and go forward planning.	1.1
07/22/2021	GJK	Meeting with Z. Haseeb (Purdue), C. Robertson (Davis Polk), S. Brecher (Davis Polk) and S. Lemack (AlixPartners) to discuss latest Ceridian questionnaire.	0.3
07/23/2021	GJK	Call with S Lemack (AlixPartners) to discuss change of control planning.	0.1
07/23/2021	GJK	Review potential transition issues in emergence.	1.4
07/23/2021	SKL	Meeting with R. Aleali, L. Kusinski, K. Laurel, C. DeStefano, D. Cabral, Z. Haseeb (all Purdue), C. Robertson (Davis Polk) and S. Brecher (Davis Polk) to discuss open questions from Ceridian.	1.0
07/23/2021	SKL	Calls with G. Koch (AlixPartners) to provide update on the change of control process and discuss open items.	0.1
07/27/2021	GJK	Call with S Lemack (AlixPartners) re: change of control employee matters and working group call.	0.1
07/27/2021	GJK	Review change of control working group PMO tracker.	0.2
07/27/2021	SKL	Update Project Change Intralinks exchange with new Davis Polk users and update access.	0.3
07/27/2021	SKL	Weekly change of control/transfer work plan update meeting with R. Aleali (Purdue), K. McCarthy (Purdue), Z. Haseeb (Purdue), C. Robertson (Davis Polk), E. Turay (Davis Polk), and A. Lele (Davis Polk).	0.8
07/27/2021	SKL	Meeting with K. McCarthy, J. Doyle, R. Kreppel, B. Koch, R. Inz, S. Hoffman and Z. Hasseb (all Purdue) to discuss latest updates re: the IP change of control process.	0.8
07/27/2021	SKL	Review latest notes and feedback provided by the change of control subgroups and prepare updated PMO tracker accordingly.	2.4
07/27/2021	SKL	Call with C. Robertson (Davis Polk) to discuss latest change of control IP items and questions related to contract assumptions.	0.2
07/27/2021	SKL	Multiple calls with A. DePalma (AlixPartners) to discuss various case related matters.	0.2
07/27/2021	SKL	Call with G. Koch (AlixPartners) to discuss the change of control process.	0.1
07/27/2021	SKL	Review latest Project Change inquiry provided by Davis Polk and update Intralinks site accordingly.	0.4
07/27/2021	SKL	Review latest updates to the IP transfer workplan and prepare updates accordingly prior to IP change of control call.	0.9
07/27/2021	ADD	Multiple calls with S. Lemack (AlixPartners) to discuss various case related matters.	0.2
07/28/2021	SKL	Multiple calls & working session to discuss Purdue due diligence related analysis with H. Bhattal (AlixPartners).	2.0
07/29/2021	HSB	Call with H. Bhattal, L. Nguyen (AlixPartners) re: new MOR format update	0.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/29/2021	JD	Call with M. Kesselman, C. Landau, J. Lowne, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: weekly catch up and planning call.	0.6
07/30/2021	GJK	Call with L. Donahue, J. DelConte, H. Bhattal, A. DePalma, G. Koch, S. Lemack, L. Nguyen, (all AlixPartners) re: weekly team update call.	0.8
07/30/2021	LJD	Weekly team update call with J. DelConte, H. Bhattal, G. Koch, L. Donahue, K. McCafferty, S. Lemack, L. Nguyen (all AlixPartners)	0.8
07/30/2021	HSB	Call with L. Donahue, J. DelConte, H. Bhattal, A. DePalma, G. Koch, S. Lemack, L. Nguyen, (all AlixPartners) re: weekly team update call.	0.8
07/30/2021	HSB	Prepared agenda and list of open items for team meeting in connection with various Purdue plan related items	0.4
07/30/2021	HSB	Call with H. Bhattal, L. Nguyen (AlixPartners) re: new MOR format update	0.1
07/30/2021	SKL	Call with L. Donahue, J. DelConte, H. Bhattal, A. DePalma, G. Koch, S. Lemack, L. Nguyen, (all AlixPartners) re: weekly team update call.	0.8
07/30/2021	JD	Call with L. Donahue, J. DelConte, H. Bhattal, A. DePalma, G. Koch, S. Lemack, L. Nguyen, (all AlixPartners) re: weekly team update call.	0.8
07/30/2021	KM	Call with H. Bhattal, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, L. Nguyen (all AlixPartners) re: weekly team update call.	0.8
07/30/2021	LTN	Weekly team update call with J. DelConte, H. Bhattal, G. Koch, L. Donahue, K. McCafferty, S. Lemack, L. Nguyen (all AlixPartners)	0.8
08/02/2021	GJK	Call with S. Lemack (AlixPartners) re: change of control process.	0.5
08/02/2021	SKL	Call with G. Hoch (AlixPartners) re: change of control process.	0.5
08/02/2021	SKL	Meeting with S. Breacher (Davis Polk), R. Aleali, C. DeStefano, K. Laurel, L. Kusinski, D. Cabral (Davis Polk), Z. Haseeb (all Purdue) and the Grant Thornton team to discuss payroll and tax related matters.	0.9
08/02/2021	SKL	Continue to finalize updates to the latest contract breakdown and prepare for discussion with S. Daniel (Purdue) to discuss open items.	1.9
08/02/2021	SKL	Review latest IP and IT feedback provided on the change of control process and prepare for latest workplan updates accordingly.	1.4
08/03/2021	SKL	Meeting with H. Ghnaimh and S. Hoffman (both Purdue) to review latest IT workplan and discuss open items and next steps.	0.4
08/03/2021	SKL	Call with K. McCarthy (Purdue) to discuss latest updates to the change of control workstream.	0.2
08/03/2021	SKL	Meeting with K. McCarthy, J. Doyle, Z. Haseeb, S. Hoffman, B. Koch, R. Kreppel and R. Inz (all Purdue) to discuss the latest on the IP transfer workplan process.	1.0
08/03/2021	SKL	Review latest notes and feedback provided by the change of control subgroups and prepare updated PMO tracker accordingly.	2.4
08/03/2021	SKL	Weekly change of control/transfer work plan update meeting with K. McCarthy, Z. Haseeb (both Purdue), C. Robertson, E. Turay, and A. Lele (all Davis Polk).	0.6
08/03/2021	SKL	Meeting with K. McCarthy, S. Hoffman, Z. Haseeb, J. Nelson, T. Delehant, H. Ramsey (all Purdue) to discuss product labeling process.	0.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/04/2021	SKL	Meeting with R. Kreppel, R. Inz, B. Koch, J. Doyle and S. Hoffman (all Purdue) to discuss latest Purdue IP change of control items.	0.6
08/04/2021	JD	Prepare agenda for weekly call with professionals and management tomorrow.	0.3
08/05/2021	LJD	Call with C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin, R. Schnitzler (all PJT), M. Huebner, E. Vonnegut, C. Robertson, A. Libby (all Davis Polk), L. Donahue, J. DelConte, H. Bhattal, G. Koch (all AlixPartners) re: weekly professionals and management update and planning call.	0.6
08/05/2021	HSB	Call with C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin, R. Schnitzler (all PJT), M. Huebner, E. Vonnegut, C. Robertson, A. Libby (all Davis Polk), L. Donahue, J. DelConte, H. Bhattal, G. Koch (all AlixPartners) re: weekly professionals and management update and planning call.	0.6
08/05/2021	JD	Call with C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin, R. Schnitzler (all PJT), M. Huebner, E. Vonnegut, C. Robertson, A. Libby (all Davis Polk), L. Donahue, J. DelConte, H. Bhattal, G. Koch (all AlixPartners) re: weekly professionals and management update and planning call.	0.6
08/06/2021	GJK	Call with L. Donahue, H. Bhattal, A. DePalma, G. Koch, S. Lemack (all AlixPartners) re: weekly team update call.	0.4
08/06/2021	ADD	Call with L. Donahue, H. Bhattal, A. DePalma, G. Koch, S. Lemack (all AlixPartners) re: weekly team update call.	0.4
08/06/2021	HSB	Call with L. Donahue, H. Bhattal, A. DePalma, G. Koch, S. Lemack (all AlixPartners) re: weekly team update call.	0.4
08/06/2021	HSB	Prepare agenda and list of open items for team meeting in connection with various Purdue plan related items	0.3
08/06/2021	SKL	Call with L. Donahue, H. Bhattal, A. DePalma, G. Koch, S. Lemack (all AlixPartners) re: weekly team update call.	0.4
08/10/2021	GJK	Call with C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin, R. Schnitzler (all PJT), M. Huebner, E. Vonnegut, C. Robertson, A. Libby (all Davis Polk), J. DelConte, H. Bhattal, G. Koch (all AlixPartners) re: weekly professionals and management update and planning call.	0.5
08/10/2021	HSB	Call with C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin, R. Schnitzler (all PJT), M. Huebner, E. Vonnegut, C. Robertson, A. Libby (all Davis Polk), J. DelConte, H. Bhattal, G. Koch (all AlixPartners) re: weekly professionals and management update and planning call.	0.5
08/10/2021	SKL	Weekly IP change of control meeting with K. McCarthy, J. Doyle, R. Kreppel, B. Koch, R. Inz and S. Hoffman (all Purdue) to discuss latest updates to the IP workstream.	0.4
08/10/2021	SKL	Review latest IP master tracker including latest notes/feedback provided by the IP team and prepare updated agenda and action items for this afternoon's meeting with IP team.	0.8



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/10/2021	SKL	Review latest notes and subgroup feedback re: change of control workstreams, and update the PMO tracker and weekly action item/agenda accordingly.	2.4
08/10/2021	SKL	Call with S. Hoffman (Purdue) to discuss latest updates on the IP change of control process.	0.2
08/10/2021	JD	Call with C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin, R. Schnitzler (all PJT), M. Huebner, E. Vonnegut, C. Robertson, A. Libby (all Davis Polk), J. DelConte, H. Bhattal, G. Koch (all AlixPartners) re: weekly professionals and management update and planning call.	0.5
08/11/2021	SKL	Weekly change of control update meeting with R. Aleali, K. McCarthy, Z. Haseeb, J. Doyle, S. Hoffman (all Purdue), C. Robertson (Davis Polk) to discuss latest updates to the change of control workstream.	0.7
08/11/2021	SKL	Weekly change of control labeling update meeting with K. McCarthy, Z. Haseeb, J. Doyle, S. Hoffman, B. Evans, J. Nelson, T. Delehant (all Purdue) to discuss latest updates re: labeling/inventory sell-through.	0.7
08/13/2021	SKL	Consolidate subgroup feedback re: counterparty info and prepared and circulated updated breakdown for Purdue sign-off.	1.9
08/16/2021	SKL	Continue to develop updated change of control workplan for the payroll transfer process.	2.2
08/16/2021	SKL	Review notes and open items from latest discussions with the Change of Control Labeling team and continue to prepare updated workplan accordingly.	1.6
08/17/2021	SKL	Weekly IP change of control meeting with K. McCarthy, J. Doyle, R. Kreppel, B. Koch, R. Inz and S. Hoffman (all Purdue) to discuss latest updates to the IP workstream.	0.5
08/17/2021	SKL	Weekly change of control update meeting with R. Aleali, K. McCarthy, Z. Haseeb, J. Doyle, S. Hoffman (all Purdue), C. Robertson (Davis Polk) to discuss latest updates to the change of control workstream.	0.7
08/17/2021	SKL	Review latest notes and subgroup feedback re: change of control workstreams, and update the PMO tracker and weekly action item/agenda accordingly.	2.3
08/17/2021	SKL	Review latest notes and feedback provided on the IP weekly change of control call and begin preparing updates to the IP by entity breakout accordingly.	1.3
08/17/2021	SKL	Finalize updates to the IP by legal entity listing and circulate to the IP team for notes/feedback.	1.4
08/17/2021	SKL	Review latest information provided by the Grant Thornton and HR teams and prepare updated notes and talking points for tomorrow's call with Ceridian.	1.3
08/17/2021	HSB	Multiple calls with L.Nguyen (AlixPartners) to discuss various Purdue bankruptcy related matters	0.2
08/17/2021	LTN	Multiple calls with H. Bhattal (AlixPartners) to discuss Purdue Plan related diligence requests.	0.2
08/18/2021	SKL	Weekly change of control payroll transfer process meeting with D. Cabral, L. Kusinski (both Purdue), A. Duymun (Ceridian) and H. Bellovin (Grant Thornton) to discuss payroll transfer process updates.	0.6





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/18/2021	SKL	Weekly IT change of control update meeting with H. Ghnaimeh, J. Narlis, K. McCarthy, S. Hoffman, and K. Haase (all Purdue) to discuss latest updates on the IT workplan.	1.0
08/18/2021	SKL	Weekly change of control labeling update meeting with K. McCarthy, R. Kreppel, Z. Haseeb, J. Doyle, S. Hoffman, B. Evans, J. Nelson, T. Delehant (all Purdue) to discuss latest updates re: labeling/inventory sell-through.	0.9
08/18/2021	SKL	Review latest meeting notes and feedback from subgroups and prepare updated agenda and open items list re: weekly change of control labeling.	1.1
08/18/2021	SKL	Review latest notes and updates on the IT transfer workplan and prepare updated talking points and open items re: weekly IT change of control.	1.0
08/19/2021	SKL	Review latest Ceridian payroll transfer process outline provided by D. Cabral (Purdue) and continue to prepare updates to the change of control workplan accordingly.	2.4
08/20/2021	GJK	Call with S Lemack (AlixPartners) to update on change of control process.	0.3
08/20/2021	GJK	Call with J.DelConte, G.Koch, S.Lemack, L.Nguyen, K.McCafferty, H. Bhattal (all AlixPartners) re: weekly update	0.6
08/20/2021	SKL	Call with J.DelConte, G.Koch, S.Lemack, L.Nguyen, K.McCafferty, H. Bhattal (all AlixPartners) re: weekly update	0.6
08/20/2021	SKL	Review update list of dependencies for each of the IT transfer workplan items and begin preparing updated transfer workplan for the team accordingly.	2.3
08/20/2021	SKL	Continue to review latest notes and feedback provided by the IT change of control team and finalize updated transfer workplan and begin scheduling workshops with additional subgroups.	2.3
08/20/2021	KM	Call with J.DelConte, G.Koch, S.Lemack, L.Nguyen, K.McCafferty, H. Bhattal (all AlixPartners) re: weekly update	0.6
08/20/2021	HSB	Call with J.DelConte, G.Koch, S.Lemack, L.Nguyen, K.McCafferty, H. Bhattal (all AlixPartners) re: weekly update	0.6
08/20/2021	HSB	Prepare agenda and list of open items for team meeting in connection with various Purdue plan related items	0.3
08/20/2021	LTN	Call with J. DelConte (AlixPartners) to discuss various case matters	0.3
08/20/2021	LTN	Call with J.DelConte, G.Koch, S.Lemack, L.Nguyen, K.McCafferty, H. Bhattal (all AlixPartners) re: weekly update	0.6
08/20/2021	JD	Call with J. DelConte and L. Nguyen (both AlixPartners) re: ongoing workstreams.	0.3
08/20/2021	JD	Call with J.DelConte, G.Koch, S.Lemack, L.Nguyen, K.McCafferty, H. Bhattal (all AlixPartners) re: weekly update	0.6
08/20/2021	SKL	Call with G. Koch (AlixPartners) to update on change of control process.	0.3
08/21/2021	SKL	Finalize updates to the IT change of control transfer workplan and circulate to the team accordingly.	1.9
08/22/2021	SKL	Review latest notes provided by J. Lowne (Purdue) and K. McCarthy (Purdue) re: IT subgroup meetings, and prepare updated feedback accordingly.	0.3
08/23/2021	SKL	Meeting with D. Cabral (Purdue), L. Kusinski (Purdue) and H. Bellovin (Grant Thornton) to discuss latest open items and next steps re: payroll transfer process.	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/23/2021	SKL	Weekly HR change of control catch-up call with D. Cabral, L. Kusinski, J. Beck-Sechow, S. Darvesh, J. Narlis, and J. Bachman (all Purdue).	0.5
08/24/2021	SKL	Meeting with J. Lowne, J. Narlis, H. Ghnaimeh, B. Sielert, K. McCarthy, S. Cho, J. Knight, H. Benson, J. Carlisle, E. Ruiz (all Purdue) to discuss the Finance and IT related items for the change of control process.	1.1
08/24/2021	SKL	Weekly change of control update meeting with R. Aleali, K. McCarthy, Z. Haseeb, J. Doyle, S. Hoffman (all Purdue), C. Robertson (Davis Polk) to discuss latest updates to the change of control workstream.	0.6
08/24/2021	SKL	Weekly IP change of control meeting with K. McCarthy, J. Doyle, R. Kreppel, B. Koch, R. Inz and S. Hoffman (all Purdue) to discuss latest updates to the IP workstream.	1.0
08/24/2021	SKL	Review latest notes and subgroup feedback re: change of control workstreams, and update the PMO tracker and weekly action item/agenda accordingly.	1.7
08/24/2021	SKL	Review latest notes and feedback provided by the IP group and prepare updated agenda and tracker accordingly.	0.6
08/24/2021	SKL	Finalize updates to the IP by entity breakdown based on the latest feedback from this afternoon's meeting with IP and circulate to IP/Legal for final sign-off.	1.4
08/24/2021	JM	Prepare for work planning and status discussions	0.5
08/24/2021	JM	Meeting with S. Lamack (AlixPartners) to discuss claim analysis and next steps.	0.7
08/25/2021	SKL	Weekly change of control payroll transfer process meeting with D. Cabral, L. Kusinski (both Purdue), A. Duymun (Ceridian) and H. Bellovin (Grant Thornton) to discuss payroll transfer process updates.	0.4
08/25/2021	SKL	Weekly change of control labeling update meeting with K. McCarthy, R. Kreppel, Z. Haseeb, J. Doyle, S. Hoffman, B. Evans, J. Nelson, T. Delehant (all Purdue) to discuss latest updates re: labeling/inventory sell-through.	0.3
08/25/2021	SKL	Weekly IT change of control update meeting with H. Ghnaimeh, J. Narlis, K. McCarthy, S. Hoffman, and K. Haase (all Purdue) to discuss latest updates on the IT workplan.	0.4
08/25/2021	SKL	Review latest updates to the IT transfer workplan and circulate list of times to J. Northington (Purdue) to discuss the quality related systems.	0.5
08/25/2021	SKL	Review latest notes and feedback from the IT change of control team and prepare for upcoming meeting.	0.4
08/25/2021	SKL	Review latest notes and feedback from the regulatory and supply chain teams and circulate updated agenda and talking points for weekly labeling meeting.	0.3
08/25/2021	SKL	Review latest notes provided by the IP team related to the latest counterparty contract inquiry and circulate update to C. Robertson (Davis Polk) accordingly.	1.7
08/26/2021	JD	Participate in weekly Purdue update call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. DelConte, H. Bhattal, G. Koch (all AlixPartners), J. O'Connell, J. Turner, T. Melvin, R. Schnitzler (all PJT), M. Kesselman, J. Lowne, R. Aleali (all Purdue).	0.8
08/26/2021	HSB	Call with M.Kesselman, J.Lowne, R.Aleali (all Purdue), M.Huebner, C. Robertson, E.Vonnegut (Davis Polk), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), G. Koch, J.DelConte (AlixPartners) re: update and planning.	0.8



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/26/2021	SKL	Meeting with H. Ghnaimeh, J. Narlis, K. McCarthy and J. Northington (all Purdue) to discuss IT requirements related to the quality systems.	0.5
08/26/2021	SKL	Continue to work through the latest counterparty contract inquiry and prepare updated notes and feedback for the IP team to review.	1.2
08/27/2021	GJK	Weekly team update call with J. DelConte, H. Bhattal, G. Koch, L. Nguyen (all AlixPartners)	0.5
08/27/2021	GJK	Review open documents for transfer of change of control (including labeling and IP).	1.5
08/27/2021	HSB	Weekly team update call with J. DelConte, H. Bhattal, G. Koch, L. Nguyen (all AlixPartners) (left meeting early)	0.4
08/27/2021	SKL	Continue to review latest feedback provided on the latest contract inquiry and prepare updated breakdown for the IP team accordingly.	1.4
08/27/2021	JD	Weekly team update call with J. DelConte, H. Bhattal, G. Koch, L. Nguyen (all AlixPartners)	0.5
08/27/2021	LTN	Weekly team update call with J. DelConte, H. Bhattal, G. Koch, L. Nguyen (all AlixPartners)	0.5
08/30/2021	GJK	Call with S. Lemack (AlixPartners) to discuss change of control progress.	0.3
08/30/2021	HSB	Review list of Purdue open items for discussion with team	0.3
08/30/2021	SKL	Call with D. McGuire, K. McCarthy, J. Narlis, A. Raina, and H. Ghnaimeh (all Purdue) to discuss technical operation requirements from the IT group.	0.5
08/30/2021	SKL	Meeting with D. Cabral (Purdue), L. Kusinski (Purdue) and H. Bellovin (Grant Thornton) to discuss latest open items and next steps re: payroll transfer process.	0.5
08/30/2021	SKL	Weekly HR change of control catch-up call with D. Cabral, L. Kusinski, J. Beck-Sechow, S. Darvesh, J. Narlis, and J. Bachman (all Purdue).	0.5
08/30/2021	SKL	Prepare meeting invites and next steps for with Tech. Ops and Corp. Communications to discuss the latest IT transfer workplan activities and requirements.	0.5
08/31/2021	HSB	Call with J.O'Connell, J.Turner, T. Melvin (PJT), M.Huebner, E.Vonnegut, C.Robertson (Davis Polk), J.DelConte (AlixPartners) re: update and planning.	0.5
08/31/2021	JD	Call with M. Huebner, E. Vonnegut (both Davis Polk), J. O'Connell, T. Melvin, J. Turner (PJT), J. DelConte, H. Bhattal (both AlixPartners) re: weekly planning and update call.	0.5
08/31/2021	SKL	Meeting with L. Eklund, A. Raina, B. Purdon, J. Northington, H. Ghnaimeh, K. McCarthy (all Purdue) to discuss quality specific requirements for the IT change of control process.	0.5
08/31/2021	SKL	Call with J. Doyle (Purdue) to discuss updates to the IP by entity listing.	0.3
08/31/2021	SKL	Prepare additional updates to the IP by entity listing following discussion with J. Doyle (Purdue) and circulate to B. Koch (Purdue) accordingly.	1.1
08/31/2021	SKL	Weekly change of control update meeting with R. Aleali, K. McCarthy, Z. Haseeb, J. Doyle, S. Hoffman (all Purdue), E. Turay(Davis Polk) to discuss latest updates to the change of control workstream.	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/31/2021	SKL	Weekly IP change of control meeting with K. McCarthy, J. Doyle, R. Kreppel, B. Koch, R. Inz and S. Hoffman (all Purdue) to discuss latest updates to the IP workstream.	1.1
08/31/2021	SKL	Finalize updates to the latest contract cure inquiry and circulate updated breakdown to the Purdue IP team and Davis Polk for feedback.	1.4
08/31/2021	SKL	Review latest notes and subgroup feedback re: change of control workstreams, and update the PMO tracker and weekly action item/agenda accordingly.	2.3
08/31/2021	SKL	Review latest notes and feedback from today's IP workshop and circulate list of action items accordingly.	0.5
09/01/2021	JM	Call with S. Lemack (AlixPartners) to discuss matters related to the KEIP/KERP process.	0.2
09/01/2021	SKL	Call with J. Muskovich (AlixPartners) to discuss matters related to the KEIP/KERP process.	0.2
09/01/2021	JD	Prepare agenda for weekly call with professionals and management tomorrow.	0.3
09/01/2021	SKL	Continue to buildout the latest IT transfer workplan and update based on the latest discussions with Tech Ops and Finance.	1.6
09/01/2021	SKL	Meeting with Purdue management to discuss Tech Ops requirements for the IT transfer workplan.	0.6
09/01/2021	SKL	Meeting with Purdue management to discuss requirements from IT re: change of control process.	0.4
09/01/2021	SKL	Meeting with Purdue management to discuss additional IT requirements to incorporate into the IT transfer workplan.	0.5
09/01/2021	SKL	Review latest notes and feedback provided by the IT team and prepare updated talking points and refreshed workplan for today's call.	1.3
09/01/2021	SKL	Review latest notes and feedback related to the labeling/inventory sell-through process and prepare updated notes and talking points for today's call.	0.8
09/01/2021	SKL	Weekly change of control labeling update meeting with Purdue management to discuss latest updates re: labeling/inventory sell-through.	0.3
09/01/2021	SKL	Weekly change of control payroll transfer process meeting with Purdue management, A. Duymun (Ceridian) and H. Bellovin (Grant Thornton) to discuss payroll transfer process updates.	0.5
09/01/2021	SKL	Weekly IT change of control update meeting with Purdue management to discuss latest updates on the IT workplan.	0.5
09/02/2021	GJK	Participate in weekly call with M. Kesselman, C. Landau, J. Lowne, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, W. Taylor (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: weekly catch up and planning call.	1.1
09/02/2021	HSB	Participate in weekly call with M. Kesselman, C. Landau, J. Lowne, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, W. Taylor (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: weekly catch up and planning call.	1.1



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/02/2021	JD	Participate in weekly call with M. Kesselman, C. Landau, J. Lowne, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, W. Taylor (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: weekly catch up and planning call.	1.1
09/02/2021	SKL	Finalize updates to the IP workplan based on the latest discussions and feedback for Friday's review.	1.1
09/02/2021	SKL	Finalize updates to the labeling/inventory sell-through transfer workplan for discussion with the full change of control group tomorrow.	1.6
09/02/2021	SKL	Meeting with Purdue management to discuss IT applications and updates required related to the change of control process.	0.5
09/02/2021	SKL	Meeting with Purdue management and L. Ehrgott (Ceridian) to discuss Dayforce/onboarding processes.	1.0
09/02/2021	SKL	Meeting with Purdue management to discuss upcoming transfer workplan review and other open items.	0.6
09/02/2021	SKL	Prepare updates to the IP workplan based on the latest discussions and feedback for Friday's review.	2.5
09/02/2021	SKL	Prepare updates to the labeling/inventory sell-through transfer workplan for discussion with the full change of control group tomorrow.	2.0
09/03/2021	SKL	Bi-weekly change of control update meeting with Purdue management, E. Turay (Davis Polk) to discuss latest updates to the change of control workstream.	0.9
09/03/2021	SKL	Finalize additional meeting notes and feedback into the PMO tracker and circulate prior to this afternoon's meeting with the change of control team.	1.5
09/03/2021	SKL	Finalize updates to the clinical trials transfer workplan to discuss during this afternoon's meeting with the change of control team.	1.1
09/03/2021	SKL	Prepare and finalize updates to the PMO tracker and agenda for today's change of control call.	2.6
09/03/2021	SKL	Prepare updates to the clinical trials transfer workplan to discuss during this afternoon's meeting with the change of control team.	2.3
09/03/2021	SKL	Review latest feedback provided by the Ceridian team re: onboarding/Dayforce.	0.5
09/07/2021	GJK	Call with T.Melvin, R.Schnitzler (PJT), J.DelConte, G.Koch and H. Bhattal (all AlixPartners), A.Lele (Davis Polk) re: Purdue chapter 11 planning.	0.2
09/07/2021	HSB	Call with T.Melvin, R.Schnitzler (PJT), J.DelConte, G.Koch and H. Bhattal (all AlixPartners), A.Lele (Davis Polk) re: Purdue chapter 11 planning.	0.2
09/07/2021	JD	Call with T.Melvin, R.Schnitzler (PJT), J.DelConte, G.Koch and H. Bhattal (all AlixPartners), A.Lele (Davis Polk) re: Purdue chapter 11 planning.	0.3
09/07/2021	HSB	Meeting with H. Bhattal and S. Lemack (both AlixPartners) re: the latest updates re: NAPCS/NAICS revenue by code breakdown.	0.3
09/07/2021	HSB	Review Purdue work transfer related info prepared by S.Lemack (AlixPartners)	0.8
09/07/2021	SKL	Call with Purdue management to discuss various IT updates required to the quality systems and batch-reports.	0.5
09/07/2021	SKL	Call with Purdue management to discuss IT and Corporate Communication updates re: change of control process.	0.8



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/07/2021	SKL	Review latest feedback from the IT/Quality meeting and schedule follow-up call with Purdue management for tomorrow.	0.5
09/07/2021	SKL	Review latest Finance change of control tracker and circulate updated meeting request for next week.	1.0
09/07/2021	SKL	Review latest notes and feedback provided and prepare updates to the PMO tracker for today's change of control discussion.	2.1
09/07/2021	SKL	Review latest notes from today's change of control bi-weekly call and schedule follow-up call for later this week.	0.6
09/07/2021	SKL	Review latest updates to the IP change of control workplan and prepare for afternoon meeting with the IP team.	1.2
09/07/2021	SKL	Weekly change of control update meeting with Purdue management and E. Turay (Davis Polk) to discuss latest updates to the change of control workstream.	0.5
09/07/2021	SKL	Weekly HR change of control catch-up call with Purdue management.	0.8
09/07/2021	SKL	Weekly IP change of control meeting with Purdue management to discuss latest updates to the IP workstream.	1.1
09/08/2021	JM	Review files provided by client and coordinate transfer of information to Davis Polk team	1.3
09/08/2021	JD	Correspondence with PJT and management re: call agenda.	0.2
09/08/2021	SKL	Meeting with Purdue management to discuss updates to the IT transfer workplan.	0.3
09/08/2021	SKL	Meeting with Purdue management to discuss IT updates required to various quality systems and batch-reports.	0.3
09/08/2021	SKL	Multiple calls with Purdue management related to the change of control process and DUNS application process.	0.3
09/08/2021	SKL	Multiple calls with the D&B team to discuss latest updates to the DUNS application and follow-up re: est. timing.	2.4
09/08/2021	SKL	Review latest feedback provided by the Purdue IP team, update the latest contract cure tracker accordingly and provided update to C. Robertson and D. Consla (both Davis Polk) accordingly.	2.3
09/08/2021	SKL	Weekly change of control labeling update meeting with Purdue management to discuss latest updates re: labeling/inventory sell-through.	0.4
09/09/2021	HSB	Meeting with S. Lemack (AlixPartners) to discuss the latest updates re: HSR filing.	0.2
09/09/2021	HSB	Call with M.Kesselman, J.Lowne, R.Aleali (all Purdue), M.Huebner, E.Vonnegut (Davis Polk), J.Turner, J.O'Connell, R.Schnitzler, T. Melvin (all PJT), L. Donahue, J.DelConte, G.Koch (AlixPartners) re: update and planning.	0.7
09/09/2021	JD	Call with M.Kesselman, J.Lowne, R.Aleali (all Purdue), M.Huebner, E.Vonnegut (Davis Polk), J.Turner, J.O'Connell, R.Schnitzler, T. Melvin (all PJT), L. Donahue, J.DelConte, G.Koch (AlixPartners) re: update and planning.	0.7
09/09/2021	LJD	Partial participation in call with M.Kesselman, J.Lowne, R.Aleali (all Purdue), M.Huebner, E.Vonnegut (Davis Polk), J.Turner, J.O'Connell, R.Schnitzler, T. Melvin (all PJT), L. Donahue, J.DelConte, G.Koch (AlixPartners) re: update and planning.	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/09/2021	SKL	Call with Purdue management to discuss the latest contract cure dispute and provide update to the Davis Polk team accordingly.	0.2
09/09/2021	SKL	Finalize additional updates to the HR change of control workplan based on the latest Dayforce/onboarding checklist.	1.3
09/09/2021	SKL	Multiple calls with the D&B team to discuss the latest status and open items re: DUNS application and provided updated confirmation to R. Aleali (Purdue) accordingly.	2.1
09/09/2021	SKL	Review latest notes and feedback provided by the HR team and circulate EIN and LLC paperwork accordingly.	0.4
09/09/2021	SKL	Weekly change of control payroll transfer process meeting with Purdue management, A. Duymun (Ceridian) and H. Bellovin (Grant Thornton) to discuss payroll transfer process updates.	0.5
09/09/2021	SKL	Weekly change of control payroll transfer process meeting with Purdue management and A. Duymun (Ceridian) to discuss payroll transfer process updates.	0.5
09/09/2021	SKL	Weekly IT change of control update meeting with Purdue management to discuss latest updates on the IT workplan.	0.6
09/10/2021	ADD	Call with L. Donahue, H. Bhattal, J. DelConte, J. Muskovich, A. DePalma, K. McCafferty, L. Nguyen (all AlixPartners) re: weekly team update call.	0.5
09/10/2021	HSB	Call with L. Donahue, H. Bhattal, J. DelConte, J. Muskovich, A. DePalma, K. McCafferty, L. Nguyen (all AlixPartners) re: weekly team update call.	0.5
09/10/2021	JM	Call with L. Donahue, H. Bhattal, J. DelConte, J. Muskovich, A. DePalma, K. McCafferty, L. Nguyen (all AlixPartners) re: weekly team update call.	0.5
09/10/2021	JD	Call with L. Donahue, H. Bhattal, J. DelConte, J. Muskovich, A. DePalma, K. McCafferty, L. Nguyen (all AlixPartners) re: weekly team update call.	0.5
09/10/2021	KM	Call with L. Donahue, H. Bhattal, J. DelConte, J. Muskovich, A. DePalma, K. McCafferty, L. Nguyen (all AlixPartners) re: weekly team update call.	0.5
09/10/2021	LTN	Call with L. Donahue, H. Bhattal, J. DelConte, J. Muskovich, A. DePalma, K. McCafferty, L. Nguyen (all AlixPartners) re: weekly team update call.	0.5
09/10/2021	LJD	Call with L. Donahue, H. Bhattal, J. DelConte, J. Muskovich, A. DePalma, K. McCafferty, L. Nguyen (all AlixPartners) re: weekly team update call.	0.5
09/10/2021	HSB	Prepare agenda and list of open items for team meeting to discuss Purdue Chapter 11 case and related planning	0.4
09/10/2021	HSB	Review Purdue documents in connection with work transfer and post emergence planning	0.9
09/13/2021	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue bankruptcy related matters	0.4
09/13/2021	SKL	Call with H. Bhattal (AlixPartners) to discuss various case related matters.	0.4
09/13/2021	SKL	Meeting with Purdue management to discuss latest open items and next steps re: payroll transfer process.	0.6
09/13/2021	SKL	Review latest feedback provided by Purdue management and circulate follow-up inquiry re: NAPCS codes.	1.0
09/13/2021	SKL	Review latest feedback provided by the Grant Thornton team and schedule follow-up meeting accordingly.	1.0



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/13/2021	SKL	Review latest notes and feedback provided by Purdue HR and the Ceridian teams and refresh the latest workplan accordingly.	2.7
09/13/2021	SKL	Weekly HR change of control catch-up call with Purdue management.	0.4
09/14/2021	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue bankruptcy related matters	0.2
09/14/2021	SKL	Calls with H. Bhattal (AlixPartners) to discuss various case related matters.	0.2
09/14/2021	HSB	Review draft of Purdue deck prepared by Davis Polk	0.3
09/14/2021	SKL	Meeting with Purdue management and H. Bellovin (Grant Thornton) to discuss the payroll transfer process.	0.6
09/14/2021	SKL	Meeting with Purdue management to discuss the finance/treasury change of control process.	0.5
09/14/2021	SKL	Review latest feedback provided on the IP workplan and prepare for upcoming meeting accordingly.	0.6
09/14/2021	SKL	Review latest notes and feedback provided and prepare updates to the PMO tracker for today's change of control discussion.	2.2
09/14/2021	SKL	Review latest SAP transition planning document provided by J. Lowne (Purdue) and prepare for upcoming meeting accordingly.	0.9
09/14/2021	SKL	Review latest SKU detailed tracker provided by Purdue management and prepare for upcoming labeling meeting accordingly.	0.8
09/14/2021	SKL	Weekly change of control update meeting with Purdue management, C. Robertson, A. Lele and E. Turay (all Davis Polk) to discuss latest updates to the change of control workstream.	0.7
09/14/2021	SKL	Weekly IP change of control meeting with Purdue management to discuss latest updates to the IP workstream.	0.3
09/15/2021	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue bankruptcy related matters	0.2
09/15/2021	SKL	Meeting with H. Bhattal (AlixPartners) to discuss various case related matters.	0.2
09/15/2021	SKL	Finalize review of latest feedback provided by Purdue management re: the labeling process and prepare updated notes/talking points for this afternoon's discussion.	0.8
09/15/2021	SKL	Meeting with Purdue management to discuss website changes related to the change of control process.	0.6
09/15/2021	SKL	Multiple calls with Purdue management to discuss latest updates related to the change of control process.	0.6
09/15/2021	SKL	Review latest discussion points from this morning's website/IT meeting and circulate updated tracker and meeting invite for next week to discuss website related changes and requirements.	0.9
09/15/2021	SKL	Review latest feedback provided by Purdue management and prepare for the weekly IT meeting accordingly.	0.9
09/15/2021	SKL	Review latest list of regulatory comments/questions and circulate updated meeting invite to Purdue management accordingly to discuss.	0.9
09/15/2021	SKL	Review latest notes and feedback provided by the Employee Matters team and prepare updated high-level outline slides for review with Purdue management.	2.7
09/15/2021	SKL	Weekly change of control labeling update meeting with Purdue management to discuss latest updates re: labeling/inventory sell-through.	0.5





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/15/2021	SKL	Weekly change of control payroll transfer process meeting with Purdue management and A. Duymun (Ceridian) to discuss payroll transfer process updates.	0.4
09/16/2021	HSB	Call with S. Lemack (AlixPartners) to discuss Purdue bankruptcy related matters	0.4
09/16/2021	SKL	Call with H. Bhattal (AlixPartners) to discuss various case related matters.	0.4
09/16/2021	HSB	Call with J. Lowne, C. Landau, R. Aleali (all Purdue), E. Vonnegut, C. Robertson (both Davis Polk), J. Turner, T. Melvin, R. Schnitzler (all PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners) re: weekly catch up and planning call.	0.6
09/16/2021	JD	Call with J. Lowne, C. Landau, R. Aleali (all Purdue), E. Vonnegut, C. Robertson (both Davis Polk), J. Turner, T. Melvin, R. Schnitzler (all PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners) re: weekly catch up and planning call.	0.6
09/16/2021	LJD	Call with J. Lowne, C. Landau, R. Aleali (all Purdue), E. Vonnegut, C. Robertson (both Davis Polk), J. Turner, T. Melvin, R. Schnitzler (all PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners) re: weekly catch up and planning call.	0.6
09/16/2021	JD	Prepare agenda for call with management tomorrow.	0.3
09/16/2021	SKL	Continue review of the latest SAP transition plan and begin preparing high-level outline slides for the Finance workstream of the change of control process accordingly.	2.6
09/16/2021	SKL	Meeting with Purdue management to discuss high-level employee matters outline.	0.8
09/16/2021	SKL	Meeting with Purdue management to discuss open regulatory questions.	0.6
09/16/2021	SKL	Review latest feedback provided by Purdue management and finalize updates to the Employee Matters high-level outline deck.	1.9
09/16/2021	SKL	Weekly change of control update meeting with Purdue management, A. Lele and C. Robertson (both Davis Polk) to discuss latest updates to the change of control workstream.	0.5
09/17/2021	ADD	Weekly team update call with J. DelConte, H. Bhattal, L. Donahue, J. Muskovich, A. DePalma, L. Nguyen (all AlixPartners) re: status updates	0.6
09/17/2021	JM	Weekly team update call with J. DelConte, H. Bhattal, L. Donahue, J. Muskovich, A. DePalma, L. Nguyen (all AlixPartners) re: status updates	0.6
09/17/2021	JD	Weekly team update call with J. DelConte, H. Bhattal, L. Donahue, J. Muskovich, A. DePalma, L. Nguyen (all AlixPartners) re: status updates	0.6
09/17/2021	LTN	Weekly team update call with J. DelConte, H. Bhattal, L. Donahue, J. Muskovich, A. DePalma, L. Nguyen (all AlixPartners) re: status updates	0.6
09/17/2021	LJD	Weekly team update call with J. DelConte, H. Bhattal, L. Donahue, J. Muskovich, A. DePalma, L. Nguyen (all AlixPartners) re: status updates	0.6
09/17/2021	HSB	Multiple calls with S.Lemack (AlixPartners) to discuss Purdue bankruptcy related matters	0.3
09/17/2021	SKL	Multiple calls with H. Bhattal (AlixPartners) to discuss various case related matters.	0.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/17/2021	HSB	Prepare agenda and list of open items for Purdue planning call	0.4
09/17/2021	SKL	Call with Purdue management, H. Bellovin, M. Caiazzo, and J. Cianciotta (all Grant Thornton) to discuss Purdue registration documents.	0.9
09/17/2021	SKL	Call with Purdue management to discuss the IT slides related to the change of control process.	0.2
09/17/2021	SKL	Call with Purdue management to discuss the latest matters related to the change of control process.	0.1
09/17/2021	SKL	Call with R. Aleali (Purdue) and S. Brecher (Davis Polk) to discuss employee benefit plans.	0.6
09/17/2021	SKL	Call with R. Aleali (Purdue) to discuss the employee matters slides re: change of control process.	0.3
09/17/2021	SKL	Finalize updates to the Finance change of control high-level outline slides and circulate internally for final feedback.	1.4
09/17/2021	SKL	Follow-up meeting with Purdue management to discuss the employee matters overview slides.	0.3
09/17/2021	SKL	Meeting with Purdue management, S. Brecher (Davis Polk), P. Tivolacci, P. Farrell, S. Forrester, J. Pina and B. Mukama (all Mercer) to discuss the change of control process.	0.4
09/17/2021	SKL	Prepare final updates to the various change of control high-level outline slides following discussion with J. DelConte (AlixPartners) and circulate for inclusion in the broader deck.	2.3
09/17/2021	SKL	Review latest talking points from discussion with Purdue management and finalize updates to the IT high-level outline slides accordingly.	2.3
09/20/2021	GJK	Telephone call with S Lemack (AlixPartners) to discuss change of control process.	0.4
09/20/2021	SKL	Telephone call with G. Koch (AlixPartners) to discuss the change of control process and related updates.	0.4
09/20/2021	HSB	Telephone call with S.Lemack (AlixPartners) to discuss Purdue bankruptcy related matters	0.1
09/20/2021	SKL	Telephone call with H. Bhattal (AlixPartners) to discuss various case related matters.	0.1
09/20/2021	JD	Call with J. DelConte and S. Lemack (both AlixPartners) re: NewCo finance transition.	0.3
09/20/2021	SKL	Call with J. DelConte (AlixPartners) to discuss various updates related to the change of control process.	0.3
09/20/2021	HSB	Update excel summary with Purdue info and emailed to Davis Polk	0.8
09/20/2021	JD	Review and provide comments on finance transition to NewCo slides for meeting with the AHC.	0.6
09/20/2021	SKL	Finalize remaining updates to the Finance change of control overview and circulate to J. Lowne (Purdue) for feedback.	2.2
09/20/2021	SKL	Meeting with Purdue management and H. Bellovin (Grant Thornton) to discuss latest open items and next steps re: payroll transfer process.	0.5
09/20/2021	SKL	Meeting with Purdue management to discuss tomorrow morning's call re: website changes.	0.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/20/2021	SKL	Meeting with Purdue management to discuss the latest Grant Thornton change of control questionnaire.	0.8
09/20/2021	SKL	Meeting with Purdue management to discuss Corporate Communications updates relates to the change of control process.	0.3
09/20/2021	SKL	Review latest notes and feedback provided re: website updates, and prepare for tomorrow's meeting with the subgroups accordingly.	1.9
09/20/2021	SKL	Review latest feedback provided by J. Lowne (Purdue) re: change of control overview and prepare updates accordingly.	0.9
09/20/2021	SKL	Weekly HR change of control catch-up call with Purdue management.	0.5
09/21/2021	JD	Participate in weekly professionals update and planning meeting with J. Turner, T. Melvin, R. Schnitzler, J. Arsic (all PJT), E. Vonnegut, C. Robertson, D. Klein (all Davis Polk), J. DelConte, H. Bhattal (all AlixPartners).	0.5
09/21/2021	HSB	Call with S. Lemack (AlixPartners) to discuss Purdue bankruptcy related matters	0.6
09/21/2021	SKL	Meeting with H. Bhattal (AlixPartners) to discuss various case related matters.	0.6
09/21/2021	SKL	Call with Purdue management to discuss website changes related to the change of control process.	1.0
09/21/2021	SKL	Continue to review latest feedback provided by Purdue IP re: contract cure inquiry, and circulate update to the Davis Polk team accordingly.	0.8
09/21/2021	SKL	Finalize review of latest change of control overview slides and prepare for afternoon meeting with change of control team accordingly.	1.2
09/21/2021	SKL	Review latest feedback provided by Purdue management re: employee cost center report and prepare update accordingly.	1.4
09/21/2021	SKL	Review latest notes and feedback provided and prepare updates to the PMO tracker for today's change of control discussion.	1.8
09/21/2021	SKL	Review latest notes and feedback provided by Purdue IP re: trademarks and employee invention agreements and follow-up with Purdue IP accordingly.	0.5
09/21/2021	SKL	Weekly change of control update meeting with Purdue management, C. Robertson (Davis Polk), A. Lele (Davis Polk) and E. Turay (Davis Polk) to discuss latest updates to the change of control workstream.	1.0
09/21/2021	SKL	Weekly IP change of control meeting with Purdue management to discuss latest updates to the IP workstream.	0.6
09/22/2021	SKL	Review latest commercial contract request and prepare updated summary chart accordingly.	0.7
09/22/2021	SKL	Review latest feedback provided by the Corporate Communications team re: website required updates, and prepare for upcoming weekly IT update meeting accordingly.	1.8
09/22/2021	SKL	Review latest information provided by Purdue IP re: disclaimer language on the Avrio/OTC site and circulate to the IT team for further discussions.	0.6
09/22/2021	SKL	Review latest SKU prioritization tracker and prepare updated SharePoint folder accordingly.	1.2
09/22/2021	SKL	Weekly change of control labeling update meeting with Purdue management to discuss latest updates re: labeling/inventory sell-through.	0.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/22/2021	SKL	Weekly change of control payroll transfer process meeting with Purdue management, H. Bellovin (Grant Thornton), and A. Duymun (Ceridian) to discuss payroll transfer process updates.	0.5
09/22/2021	SKL	Weekly IT change of control update meeting with Purdue management to discuss latest updates on the IT workplan.	0.8
09/23/2021	HSB	Meeting with J. Lowne, M. Kesselman, R. Aleali (all Purdue), J. O'Connell, J. Turner, J. Arsic, R. Schnitzler (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), H. Bhattal, J. DelConte (all AlixPartners) re: update and planning	0.5
09/23/2021	JD	Meeting with J. Lowne, M. Kesselman, R. Aleali (all Purdue), J. O'Connell, J. Turner, J. Arsic, R. Schnitzler (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), H. Bhattal, J. DelConte (all AlixPartners) re: update and planning	0.5
09/23/2021	SKL	Meeting with Purdue management and H. Bellovin (Grant Thornton) to discuss state registration process.	0.6
09/23/2021	SKL	Prepare additional updates to the weekly change of control PMO tracker and prepare for upcoming change of control call accordingly.	2.3
09/23/2021	SKL	Review latest accounts payable/counterparty inquiry provided by Purdue management and update the approved vendor report and prepare updated invoice release list accordingly.	1.4
09/23/2021	SKL	Review latest commercial contracts provided by the Davis Polk team and prepare updated commercial contract breakdown accordingly.	2.4
09/23/2021	SKL	Weekly change of control update meeting with Purdue management, A. Lele (Davis Polk) and C. Robertson (both Davis Polk) to discuss latest updates to the change of control workstream.	0.6
09/24/2021	ADD	Telephone call with H. Bhattal, A. DePalma, L. Nguyen (all AlixPartners) re: update and planning	0.3
09/24/2021	HSB	Telephone call with H. Bhattal, A. DePalma, L. Nguyen (all AlixPartners) re: update and planning	0.3
09/24/2021	LTN	Telephone call with H. Bhattal, A. DePalma, L. Nguyen (all AlixPartners) re: update and planning	0.3
09/24/2021	HSB	Prepare agenda and list of open items for Purdue update call	0.3
09/24/2021	JD	Review draft emergence transfer workstream checklist.	0.4
09/27/2021	SKL	Finalize reconciliation and breakdown of latest commercial contracts provided by the Davis Polk team and circulate update accordingly.	2.3
09/27/2021	SKL	Review latest updates to the SKU prioritization tracker and update the Purdue SharePoint site accordingly.	1.4
09/28/2021	HSB	Call with L.Nguyen and H. Bhattal (AlixPartners) to discuss Purdue chapter 11 related matters	0.2
09/28/2021	LTN	Call with L.Nguyen and H. Bhattal (AlixPartners) to discuss Purdue chapter 11 related matters	0.2
09/28/2021	HSB	Multiple calls with S. Lemack and H. Bhattal (both AlixPartners) to discuss updates related to the change of control process and other case updates.	0.9



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/28/2021	SKL	Multiple calls with S. Lemack and H. Bhattal (both AlixPartners) to discuss updates related to the change of control process and other case updates.	0.9
09/28/2021	GJK	Calls with S Lemack (AlixPartners) re: change of control process.	0.3
09/28/2021	SKL	Call with G. Koch (AlixPartners) to discuss the change of control process.	0.3
09/28/2021	GJK	Weekly professionals meeting with J. Turner, T. Melvin, R. Schnitzler, J. Arsic (all PJT), E. Vonnegut, A. Libby, C. Robertson (all Davis Polk), J. DelConte, L. Donahue, G. Koch, H. Bhattal (all AlixPartners) re: catch up and planning call.	0.4
09/28/2021	HSB	Weekly professionals meeting with J. Turner, T. Melvin, R. Schnitzler, J. Arsic (all PJT), E. Vonnegut, A. Libby, C. Robertson (all Davis Polk), J. DelConte, L. Donahue, G. Koch, H. Bhattal (all AlixPartners) re: catch up and planning call.	0.4
09/28/2021	JD	Weekly professionals meeting with J. Turner, T. Melvin, R. Schnitzler, J. Arsic (all PJT), E. Vonnegut, A. Libby, C. Robertson (all Davis Polk), J. DelConte, L. Donahue, G. Koch, H. Bhattal (all AlixPartners) re: catch up and planning call.	0.4
09/28/2021	LJD	Weekly professionals meeting with J. Turner, T. Melvin, R. Schnitzler, J. Arsic (all PJT), E. Vonnegut, A. Libby, C. Robertson (all Davis Polk), J. DelConte, L. Donahue, G. Koch, H. Bhattal (all AlixPartners) re: catch up and planning call.	0.4
09/28/2021	GJK	Review latest NewCo transfer workplan tracker.	0.3
09/28/2021	SKL	Call with Purdue management to provide update on the payroll tax open items and questions.	0.4
09/28/2021	SKL	Call with E. Turay (Davis Polk) to discuss open inquiry following our weekly change of control update call.	0.1
09/28/2021	SKL	Call with Purdue management to discuss latest open items and updates related to the website/IT workplan.	0.4
09/28/2021	SKL	Finalize updates to the latest IP transfer workplan and circulate updated contract breakdown and agenda to the IP team accordingly.	1.4
09/28/2021	SKL	Meeting with Purdue management and H. Bellovin (Grant Thornton) to catch-up on the payroll transfer process.	0.5
09/28/2021	SKL	Meeting with Purdue management, S. Tabrizi, R. Lievanos (both Ceridian) and H. Bellovin (Grant Thornton) to discuss Schedule D preparations and filing.	0.9
09/28/2021	SKL	Review latest TopCo entity documentation provided by R. Aleali (Purdue) and submit D&B application accordingly.	0.7
09/28/2021	SKL	Review latest updates to the change of control workstream provided throughout the last week and update the upcoming agenda and PMO tracker accordingly.	2.3
09/28/2021	SKL	Weekly change of control update meeting with R. Aleali and others from Purdue, C. Robertson, A. Lele and E. Turay (all Davis Polk) to discuss latest updates to the change of control workstream.	0.6
09/28/2021	SKL	Weekly IP change of control meeting with Purdue management to discuss latest updates to the IP workstream.	0.4
09/29/2021	JD	Prepare agenda for weekly call with management and professionals tomorrow morning.	0.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/29/2021	SKL	Final call with D&B team to discuss the D&B application and confirm nothing else required re: DUNS number.	1.1
09/29/2021	SKL	Multiple calls with the D&B team to discuss the latest NOAT Holdings LLC application and follow-up for additional updates.	2.4
09/29/2021	SKL	Review DUNS confirmation to ensure everything is captured correctly and circulate update to R. Aleali (Purdue) accordingly.	0.7
09/29/2021	SKL	Review latest feedback and inquiries provided re: regulatory and labeling process, and circulate updated talking points and agenda for labeling meeting accordingly.	0.9
09/29/2021	SKL	Review latest feedback provided by Purdue IP re: Avrio/OTC websites and circulate follow-up email to the rest of the website team accordingly.	1.6
09/29/2021	SKL	Weekly change of control labeling update meeting with R. Aleali and others from Purdue to discuss latest updates re: labeling/inventory sell-through.	0.9
09/29/2021	SKL	Weekly IT change of control update meeting with Purdue management to discuss latest updates on the IT workplan.	0.7
09/30/2021	HSB	Call with S. Lemack (AlixPartners) to discuss updates related to the change of control process and other case updates.	0.3
09/30/2021	SKL	Call with H. Bhattal (AlixPartners) to discuss updates related to the change of control process and other case updates.	0.3
09/30/2021	GJK	Call with E. Vonnegut, A. Libby, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin, J. Arsic (all PJT), C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), J. DelConte, H. Bhattal, G. Koch (all AlixPartners) re: weekly catch-up and planning meeting.	0.6
09/30/2021	HSB	Call with E. Vonnegut, A. Libby, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin, J. Arsic (all PJT), C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), J. DelConte, H. Bhattal, G. Koch (all AlixPartners) re: weekly catch-up and planning meeting.	0.6
09/30/2021	JD	Call with E. Vonnegut, A. Libby, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin, J. Arsic (all PJT), C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), J. DelConte, H. Bhattal, G. Koch (all AlixPartners) re: weekly catch-up and planning meeting.	0.6
09/30/2021	JD	Call with R. Aleali (Purdue) re: various open workstreams.	0.6
09/30/2021	SKL	Follow-up with Purdue management re: inventory/labeling sharepoint site, and circulate update accordingly to the Purdue labeling team.	0.8
09/30/2021	SKL	Meeting with Purdue management, H. Monaco, A. Hayes (both Fidelity), J. Wooters (Fidelity) and S. Brecher (Davis Polk) to discuss the pension plan.	0.7
09/30/2021	SKL	Review latest inquiry provided by E. Turay (Davis Polk) and circulate update accordingly.	0.5
09/30/2021	SKL	Review latest invoice approval request from Purdue management and approve/circulate latest approved invoice release lists.	1.3
09/30/2021	SKL	Review latest NOAT Holdings LLC entity information and provided to Purdue management accordingly along with additional follow-up responses re: state registrations.	0.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

<u>DATE</u>	<u>CONSULTANT</u>	<u>DESCRIPTION OF SERVICES</u>	<u>HOURS</u>
09/30/2021	SKL	Update weekly PMO tracker based on the latest information received throughout the week and prepare agenda and talking points for the weekly update call accordingly.	2.1
09/30/2021	SKL	Weekly change of control payroll transfer process meeting with Purdue management, H. Bellovin (Grant Thornton) and A. Duymun (Ceridian) to discuss payroll transfer process updates and schedule D preparation.	0.6
09/30/2021	SKL	Weekly change of control update meeting with R. Aleali and others from Purdue, C. Robertson, A. Lele and E. Turay (all Davis Polk) to discuss latest updates to the change of control workstream.	0.6
09/30/2021	SKL	Weekly meeting with Purdue management, H. Bellovin, J. Cianciotta and M. Caiazzo (all Grant Thornton) to discuss Knoa registration forms.	0.5
<b>Total Professional Hours</b>			<b><u>441.0</u></b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Chapter 11 Process/Case Management  
Code: 1.1 / 101

<b>PROFESSIONAL</b>	<b>TITLE</b>	<b>RATE</b>	<b>HOURS</b>	<b>FEES</b>
Lisa Donahue	Managing Director	\$1,295	9.7	\$ 12,561.50
Jesse DelConte	Managing Director	\$1,055	23.6	24,898.00
Kevin M McCafferty	Director	\$980	2.5	2,450.00
Jason Muskovich	Director	\$980	3.8	3,724.00
Gabe J Koch	Director	\$865	46.5	40,222.50
HS Bhattal	Director	\$865	31.6	27,334.00
Sam K Lemack	Senior Vice President	\$665	309.0	205,485.00
Andrew D DePalma	Vice President	\$625	6.4	4,000.00
Lan T Nguyen	Vice President	\$530	7.9	4,187.00
<b>Total Professional Hours and Fees</b>			<b>441.0</b>	<b>\$ 324,862.00</b>





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Cash Management  
Code: 1.3 / 103

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/01/2021	HSB	Review Purdue weekly cash reports prepared by L. Nguyen (AlixPartners) for weeks ending 5/14 and 5/21	0.6
06/01/2021	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 05.21.2021 and updated the weekly cash report deck	1.1
06/01/2021	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 05.21.2021 and updated the weekly cash report deck	0.9
06/01/2021	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 05.28 cash report	1.8
06/01/2021	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 05.28 cash report	1.6
06/01/2021	LTN	Prepare a list of open items to R. Brown, T. Gabriele, C. Hobbick, M. Santonastaso (Purdue) and updated week ended 05.28.2021 cash actuals report based on their feedback	0.8
06/01/2021	LTN	Revised the April PEO monthly flash report based on J. Lowne (Purdue) feedback and circulate to DWP	0.4
06/01/2021	JD	Provide comments on the latest 2 weekly cash flow forecast to actual reports.	0.6
06/04/2021	LTN	Reconcile the latest IAC transactions and prepared the updated IAC summary section for week ended 05.28 cash actuals report	0.5
06/04/2021	LTN	Reconcile the interest receipts, bank charges for May 2021 activities provided by T. Gabriele (Purdue) and revised the weekly cash actual balances	0.7
06/04/2021	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 05.28.2021 and updated the weekly cash report deck	1.4
06/04/2021	LTN	Compiled restructuring fee data since the filing date and circulate to H. Bhattal (AlixPartners)	0.3
06/04/2021	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 05.28.2021 and updated the weekly cash report deck	1.6
06/07/2021	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 06.04 cash report	1.7
06/07/2021	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 06.04 cash report	1.8
06/08/2021	LTN	Reconcile the latest IAC transactions and prepared the updated IAC summary section for week ended 06.04 cash actuals report	0.4
06/08/2021	LTN	Prepare a list of open items to R. Brown, T. Gabriele, C. Hobbick, M. Santonastaso (Purdue) and updated week ending 06.04.2021 cash actuals report based on their feedback	0.7
06/09/2021	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 06.04.2021 and updated the weekly cash report deck	1.5
06/09/2021	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 06.04.2021 and updated the weekly cash report deck	0.9
06/14/2021	LTN	Call with J. Marsha (Purdue) to walk through the 13 week cash flow forecast overview	1.5
06/14/2021	HSB	Review weekly cash report prepared by L. Nguyen (AlixPartners) and provided comments	0.6
06/15/2021	LTN	Correspondence with M. Jack (Purdue) re: 13 cash flow forecast files	0.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Cash Management  
Code: 1.3 / 103

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/15/2021	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 06.11 cash report	2.4
06/15/2021	LTN	Call with J. Marsha (Purdue) re: AR categorization and IAC receipt forecast for 13w cash flows starting 06.18 period	1.5
06/15/2021	HSB	Review Purdue weekly cash report prepared by L. Nguyen (AlixPartners) for week ended 06/04.	0.6
06/16/2021	LTN	Reconcile and categorize the latest Paysource cash transactions and update the week ended 06.11 cash report	1.8
06/16/2021	LTN	Prepare a list of open items to R. Brown, T. Gabriele, C. Hobbick, M. Santonastaso (Purdue) and updated w.e. 06.11.2021 cash actuals report based on their feedback	0.7
06/16/2021	LTN	Reconcile the latest IAC transactions and prepared the updated IAC summary section for week ended 06.11 cash actuals report	0.6
06/16/2021	LTN	Call with J. Marsha (Purdue) re: Accounts Payable categorization and operating expense for 13w cash flows starting 06.18 period	1.9
06/16/2021	LTN	Prepare the updated weekly sales reports as of 06.11 for Rhodes provided by P. Phouthasone (Purdue) and circulated for CFO review	0.3
06/16/2021	LTN	Review the latest fee applications from the docket filed by Retained professionals and update the tracker	1.0
06/16/2021	LTN	Review the latest fee applications from the docket filed by Restructuring professionals and update the tracker	1.9
06/17/2021	LTN	Update the Restructuring and retained professional fee section to the latest 13w cash forecast beginning week 06.18	1.6
06/17/2021	LTN	Review the case professional tracker prepared by J. DelConte (AlixPartners) and update the fee forecast section of the Restructuring/ Retained prof tracker	0.6
06/17/2021	LTN	Call with J. Marsha (Purdue) re: IAC disbursement, legal and restructuring sections for 13w cash flows forecast starting 06.18 period	2.0
06/17/2021	JD	Review and provide comments on the last two weekly cash forecast to actual reports.	0.5
06/17/2021	JD	Correspondence with Davis Polk re: cash flow breakdown analysis.	0.3
06/18/2021	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 06.11.2021 and updated the weekly cash report deck	1.6
06/18/2021	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 06.11.2021 and updated the weekly cash report deck	0.9
06/21/2021	LTN	Prepare the Customer rebates section of Purdue 13-week cash forecast beginning 06.18	2.0
06/21/2021	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 06.18 cash report	1.8
06/21/2021	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 06.18 cash report	1.7
06/21/2021	LTN	Call with J. Marsha (Purdue) to continue working on legal and restructuring sections for 13w cash flows forecast starting 06.18	1.4
06/21/2021	HSB	Review Purdue cash forecast prepared by L. Nguyen (AlixPartners)	0.7
06/22/2021	JD	Review and provide comments on the latest cash forecast to actual report.	0.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Cash Management  
Code: 1.3 / 103

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/22/2021	LTN	Prepare the IAC receipts and IAC disbursements section of Rhodes 13-week cash forecast beginning 06.18	0.7
06/22/2021	LTN	Prepare the customer receipts section of the Rhodes 13 week cash forecast beginning period 06.18	1.5
06/22/2021	LTN	Prepare the operating expense section of Rhodes 13-week cash forecast beginning 06.18	1.7
06/22/2021	LTN	Prepare the legal, and other receipts/ expenses sections of Rhodes 13-week cash forecast beginning 06.18	1.0
06/22/2021	LTN	Review the latest rebates tracker provided by D. Krishnan (Purdue) as of May and updated the 13-week cash forecast	1.5
06/22/2021	LTN	Prepare the updated weekly sales reports as of 06.20 for Rhodes provided by E. Nowakowski (Purdue) and circulated for CFO review	0.6
06/22/2021	LTN	Call with M. Jack (Purdue) re: Rhodes 13w cash forecast starting 06.18 period	1.9
06/23/2021	LTN	Finalize the Purdue 13-w cash forecast beginning week 06.18 and circulate for internal review	2.1
06/23/2021	LTN	Finalize the Rhodes 13-w cash forecast beginning week 06.18 and circulate for internal review	1.7
06/23/2021	LTN	Finalize the 13-w cash forecast deck beginning week 06.18 based on internal feedback and circulated for CFO review	1.7
06/23/2021	LTN	Prepare the latest 13 week forecast to actuals variance summaries report for PPLP and Rhodes beginning 06.18 period	0.8
06/23/2021	LTN	Reconcile the latest IAC transactions and prepared the updated IAC summary section for week ended 06.18 cash actuals report	0.4
06/23/2021	LTN	Prepare a list of open items to R. Brown, T. Gabriele, C. Hobbick, M. Santonastaso (Purdue) and updated w.e. 06.18.2021 cash actuals report based on their feedback	0.5
06/23/2021	LTN	Correspondence with M. Jack (Purdue) re: 13 cash flow forecast	0.2
06/23/2021	LTN	Review the case professional tracker prepared by J. DelConte (AlixPartners) and update the fee forecast section of the Restructuring/ Retained prof tracker	0.6
06/23/2021	LTN	Call with M. Jack (Purdue) to finalize the 13w cash forecast	0.5
06/23/2021	LTN	Call with H. Bhattal (AlixPartners) re: sales proceeds for the 13w cash forecast	0.2
06/23/2021	HSB	Review Purdue cash forecast prepared by L. Nguyen (AlixPartners)	1.1
06/23/2021	HSB	Call with L. Nguyen (AlixPartners) re: sales proceeds for the 13w cash forecast	0.2
06/23/2021	HSB	Review data in connection with Purdue cash forecasts prepared by L. Nguyen (AlixPartners)	0.1
06/23/2021	JD	Review and provide comments on the latest version of the 13 week cash flow forecast from L. Nguyen (AlixPartners).	0.8
06/23/2021	JD	Review and provide comments on an updated draft 13 week cash flow forecast before sending to management.	0.3
06/24/2021	SKL	Finalize review of the latest cash forecast and circulate update internally.	1.8
06/24/2021	HSB	Call with L. Nguyen (AlixPartners) re: updates to the 13 week cash forecast	0.3
06/24/2021	LTN	Revise the latest cash forecast and correspondence with J. Lowne, R. Aleali (Purdue)	1.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Cash Management  
Code: 1.3 / 103

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/24/2021	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 06.18.2021 and updated the weekly cash report deck	2.3
06/24/2021	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 06.18.2021 and updated the weekly cash report deck	0.8
06/24/2021	LTN	Call with H. Bhattal (AlixPartners) re: updates to the 13 week cash forecast	0.3
06/24/2021	JD	Correspondence with management and L. Nguyen (AlixPartners) re: management comments on the latest 13 week cash flow.	0.3
06/28/2021	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 06.25 cash report	1.6
06/28/2021	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 06.25 cash report	1.8
06/29/2021	HSB	Review Purdue weekly cash report prepared by L. Nguyen (AlixPartners)	0.7
06/29/2021	LTN	Finalize the latest 13 week cash forecast based on J. Lowne (Purdue) feedback and circulate to Davis Polk	1.1
06/30/2021	JD	Review latest forecast to actual cash reporting.	0.3
06/30/2021	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 06.25.2021 and update the weekly cash report deck	1.6
06/30/2021	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 06.25.2021 and update the weekly cash report deck	0.9
06/30/2021	LTN	Prepare a list of open items to R. Brown, T. Gabriele, C. Hobbick, M. Santonastaso (Purdue)	0.2
06/30/2021	LTN	Update week ended 06.18 cash report based on their feedback	0.3
07/01/2021	HSB	Review Purdue weekly cash report prepared by L. Nguyen (AlixPartners)	0.8
07/01/2021	JD	Provide comments on last week's forecast to actual cash report.	0.4
07/01/2021	LTN	Reconcile and update Adlon and Avrio Health financials section of the May 2021 PEO monthly flash report	1.4
07/01/2021	LTN	Reconcile and update the Purdue and Rhodes financials section of the May 2021 PEO monthly flash report	1.7
07/01/2021	LTN	Review May 2021 Financial statement deck and update Consolidated financials section for May PEO monthly flash report	2.1
07/07/2021	LTN	Prepare a list of open items to R. Brown, T. Gabriele, C. Hobbick, M. Santonastaso (Purdue) and update week ended 07.02 cash report based on their feedback	0.5
07/07/2021	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 07.02 cash report	1.7
07/07/2021	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 07.02 cash report	2.0
07/08/2021	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 07.02 and update the weekly cash report deck	1.6
07/08/2021	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 07.02 and update the weekly cash report deck	1.1
07/08/2021	HSB	Review Purdue cash forecast prepared by L. Nguyen (AlixPartners)	0.8
07/08/2021	JD	Review and provide comments on the latest forecast to actual cash report.	0.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Cash Management  
Code: 1.3 / 103

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/12/2021	LTN	Prepare a list of open items to R. Brown, T. Gabriele, C. Hobbick, M. Santonastaso (Purdue) and update week ended 07.09 cash report based on their feedback	0.4
07/12/2021	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 07.09 cash report	1.8
07/12/2021	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 07.09 cash report	1.7
07/13/2021	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 07.09 and update the weekly cash report deck	1.2
07/13/2021	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 07.09 and update the weekly cash report deck	0.8
07/14/2021	HSB	Review Purdue financial forecasts prepared by L.Nguyen (AlixPartners)	0.7
07/15/2021	LTN	Finalize the May PEO monthly flash report and circulate for internal review	1.7
07/16/2021	LTN	Review the latest fee applications from the docket filed by Restructuring professionals and update the tracker	2.2
07/16/2021	LTN	Review the latest fee applications from the docket filed by Retained professionals and update the tracker	1.3
07/19/2021	JD	Review and provide comments on latest weekly cash forecast to actual report.	0.4
07/21/2021	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 07.16 cash report	1.8
07/21/2021	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 07.16 cash report	1.6
07/23/2021	SKL	Meeting with J. Lowne (Purdue), E. Ruiz (Purdue), E. Nowakowski (Purdue), L. Scheinbach (Purdue), T. Melvin (PJT), J. DelConte (AlixPartners) and H. Bhattal (AlixPartners) to discuss NewCo CF projections.	0.3
07/23/2021	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 07.16 and update the weekly cash report deck	1.4
07/23/2021	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 07.16 and update the weekly cash report deck	0.9
07/23/2021	LTN	Call among J. DelConte, S. Lemack, H. Bhattal, L. Nguyen (AlixPartners), J. Lowne, L. Scheinbach (Purdue) to discuss Newco Cashflow breakdown.	0.3
07/23/2021	LTN	Prepare a list of open items to R. Brown, T. Gabriele, C. Hobbick, M. Santonastaso (Purdue) and update week ended 07.16 cash report based on their feedback	0.6
07/27/2021	JH	Correspondence with C. Oluwole (Davis Polk) re confidentiality designations.	0.2
07/28/2021	JD	Review and provide comments on latest weekly cash forecast to actual report.	0.5
07/28/2021	JD	Correspondence with J. Tran (Purdue) re: Avrio performance.	0.2
07/28/2021	HSB	Review Purdue weekly cash forecast prepared by L.Nguyen (AlixPartners)	0.7
07/28/2021	HSB	Review Purdue MOR draft prepared by L.Nguyen (AlixPartners)	0.4
07/28/2021	LTN	Prepare the Customer rebates section of Purdue 13-week cash forecast beginning 07.23	1.5
07/28/2021	LTN	Download AP data from SAP, categorize the operating expense section of Purdue & Rhodes 13-week cash forecast beginning 07.23	2.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Cash Management  
Code: 1.3 / 103

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/28/2021	LTN	Download AR data from SAP, categorize Account Receivables section of Purdue & Rhodes 13w cash forecast beginning 07.23	2.0
07/29/2021	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 07.23 cash report	2.0
07/29/2021	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 07.23 cash report	1.8
07/29/2021	LTN	Review the latest rebates tracker provided by D. Krishnan (Purdue) as of Jul 2021 and updated the 13-week cash forecast	1.0
07/29/2021	LTN	Prepare the customer receipts section of Purdue 13 week cash forecast beginning 07.23 based on the latest sales forecast provided by J. Knight (Purdue)	1.0
07/29/2021	LTN	Prepare the updated weekly sales reports as of 07.23 for Rhodes provided by P. Phouthasone (Purdue) and circulated for CFO review	0.8
07/29/2021	LTN	Prepare the updated weekly sales reports as of 07.23 for Purdue provided by E. Nowakowski (Purdue) and circulated for CFO review	0.5
07/29/2021	LTN	Revise OCP report for June 2021 invoices based on updated data from C. MacDonald (Purdue) and circulate to DavisPolk	1.5
07/29/2021	LTN	Prepare the IAC receipts and IAC disbursements section of Purdue 13-week cash forecast beginning 07.23	0.7
07/30/2021	JD	Review and update the latest case professional fee tracker for the next version of the 13 week cash flow forecast.	0.5
07/30/2021	LTN	Update the Restructuring and retained professional fee section to the latest 13w cash forecast beginning week 07.23	2.0
07/30/2021	LTN	Review Professional fee forecast prepared by J. DelConte (AlixPartners) and update the latest 13 week cash forecast beginning week 07.23	0.8
07/31/2021	LTN	Prepare the customer rebates section of Rhodes 13 week cash forecast beginning period 07.23	1.2
07/31/2021	LTN	Prepare the Professional fees, IACs and the remaining sections of Rhodes 13-week cash forecast beginning 07.23	1.4
07/31/2021	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 07.23 and update the weekly cash report deck	0.8
07/31/2021	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 07.23 and update the weekly cash report deck	1.5
07/31/2021	LTN	Prepare the Customer Receipts and Operating Expenses section of Rhodes 13 week cash forecast beginning period 07.23	2.0
08/02/2021	LTN	Finalize the Purdue 13-w cash forecast beginning week 07.23 and circulate for internal review	2.1
08/02/2021	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 07.30 cash report	1.9
08/02/2021	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 07.30 cash report	1.7
08/02/2021	LTN	Prepare a list of open items to R. Brown, T. Gabriele, C. Hobbick, M. Santonastaso (Purdue) and update week ended 07.30 cash report based on their feedback	0.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Cash Management  
Code: 1.3 / 103

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/03/2021	LTN	Finalize the Rhodes 13-w cash forecast beginning week 07.23 and circulate for internal review	1.8
08/03/2021	LTN	Review June 2021 Financial statement deck and update Consolidated financials section for June PEO monthly flash report	2.0
08/04/2021	LTN	Review big annual fee expenses items in 2020 and incorporate to Purdue/ Rhodes 13-w cash forecast deck beginning week 07.23	0.6
08/05/2021	HSB	Review Purdue cash forecast prepared by L.Nguyen (AlixPartners) and provided comments	1.8
08/05/2021	HSB	Call with S. Lemack (AlixPartners) re: Purdue cash forecasts	0.3
08/05/2021	SKL	Call with H. Bhattal (AlixPartners) re: Purdue cash forecasts	0.3
08/05/2021	LTN	Calculate 2021 KERP payments provided by HR (Purdue) and incorporate to Purdue / Rhodes 13 week forecast beginning 07.23 period	1.0
08/05/2021	LTN	Bridge the ending cash balance of the 13w cash forecast to the Business plan and correspondence with J. Delconte (AlixPartners)	0.7
08/05/2021	LTN	Review 2021 KEIP/ KERP from the docket to calculate payroll for the next 13 week cash forecast	0.8
08/05/2021	LTN	Finalize the 13-w cash forecast deck beginning week 07.23 based on internal feedback and circulated for CFO review	2.3
08/05/2021	JD	Review and provide comments on the latest 13 week cash flow forecast.	0.7
08/10/2021	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 07.30 and update the weekly cash report deck	1.7
08/10/2021	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 07.30 and update the weekly cash report deck	1.4
08/10/2021	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 08.06 cash report	1.7
08/10/2021	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 08.06 cash report	2.0
08/12/2021	HSB	Review Purdue's weekly cash report prepared by L.Nguyen (AlixPartners)	0.6
08/13/2021	HSB	Review weekly cash report prepared by L.Nguyen (AlixPartners)	0.5
08/13/2021	JD	Review and provide comments on the latest forecast to actual cash reports.	0.4
08/16/2021	LTN	Prepare a list of open items to R. Brown, T. Gabriele, C. Hobbick, M. Santonastaso (Purdue) and update week ended 08.06 cash report based on their feedback	0.5
08/16/2021	LTN	Reconcile the interest receipts, bank charges for July 2021 activities provided by T. Gabriele (Purdue) and revised the weekly cash actual balances	0.6
08/16/2021	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 08.06 and update the weekly cash report deck	0.8
08/16/2021	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 08.06 and update the weekly cash report deck	1.4
08/17/2021	HSB	Review Purdue weekly cash report prepared by L.Nguyen (AlixPartners) and provided comments	0.8
08/17/2021	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 08.13 cash report	2.0



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Cash Management  
Code: 1.3 / 103

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/17/2021	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 08.13 cash report	1.7
08/17/2021	JD	Review and comment on the latest cash forecast to actual report.	0.4
08/18/2021	LTN	Prepare the updated weekly sales reports as of 08.13 for Purdue provided by E. Nowakowski (Purdue) and circulated for CFO review	0.5
08/18/2021	LTN	Prepare the updated weekly sales reports as of 08.13 for Rhodes provided by P. Phouthasone (Purdue) and circulated for CFO review	0.7
08/20/2021	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 08.13 and update the weekly cash report deck	1.4
08/20/2021	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 08.13 and update the weekly cash report deck	1.0
08/20/2021	JD	Review and provide comments on the latest weekly forecast to actual report.	0.5
08/23/2021	HSB	Review Purdue weekly cash report prepared by L.Nguyen (AlixPartners) and provided comments	0.8
08/23/2021	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 08.20 cash report	2.2
08/23/2021	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 08.20 cash report	1.8
08/23/2021	LTN	Revise the weekly cash actuals report for the week ended 08.13 based on the internal feedback and circulate for CFO review	0.2
08/25/2021	LTN	Download AR data from SAP, categorize Account Receivables section of Purdue & Rhodes 13w cash forecast beginning 08.27	1.5
08/25/2021	LTN	Download AP data from SAP, categorize the operating expense section of Purdue & Rhodes 13-week cash forecast beginning 08.27	1.7
08/25/2021	LTN	Review the latest fee applications from the docket filed by Retained professionals and update the tracker	1.3
08/25/2021	LTN	Review the latest fee applications from the docket filed by Restructuring professionals and update the tracker	2.2
08/25/2021	LTN	Prepare 13w cash forecast overview and circulate to J. Marsha (Purdue) ahead of the training	1.4
08/25/2021	LTN	Review restructuring payment file provided by C. MacDonald (Purdue) and reconcile against Paysource	0.5
08/26/2021	LTN	Review the latest rebates tracker provided by D. Krishnan (Purdue) as of August 2021 and updated the 13-week cash forecast	1.6
08/26/2021	LTN	Prepare the Customer rebates section of Purdue 13-week cash forecast beginning 08.27	1.8
08/26/2021	LTN	Call with J. Marsha (Purdue) to walk through the 13 week cash flow forecast, customer receipts and IAC receipts	1.7
08/26/2021	LTN	Prepare a list of open items to R. Brown, T. Gabriele, C. Hobbick, M. Santonastaso (Purdue) and update week ended 08.20 cash report based on their feedback	0.8
08/27/2021	JD	Review and provide comments on the latest 13 week cash flow forecast to actual report.	0.4





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Cash Management  
Code: 1.3 / 103

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/27/2021	JD	Update latest professional fee tracker and forecast for the next version of the cash flow forecast.	0.7
08/27/2021	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 08.20 and update the weekly cash report deck	1.5
08/27/2021	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 08.20 and update the weekly cash report deck	1.0
08/27/2021	LTN	Call with M. Jack (Purdue) re: Accounts Payable categorization and operating expense for 13w cash flows starting 08.27 period	1.5
08/27/2021	LTN	Prepare the customer receipts section of Purdue 13 week cash forecast beginning 08.27 based on the latest sales forecast provided by J. Knight (Purdue)	1.5
08/27/2021	LTN	Prepare the IAC receipts and IAC disbursements section of Purdue 13-week cash forecast beginning 08.27	1.1
08/30/2021	LTN	Update the Restructuring and retained professional fee section to the latest 13w cash forecast beginning week 08.27	2.5
08/30/2021	LTN	Call with M. Jack (Purdue) to work on rebates and IAC disbursement forecast for 13w cash flows starting 08.27 period	1.1
08/30/2021	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 08.27 cash report	1.7
08/30/2021	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 08.27 cash report	2.0
08/30/2021	HSB	Review Purdue weekly cash report prepared by L.Nguyen (AlixPartners)	0.7
08/31/2021	LTN	Call with M. Jack (Purdue) to work on legal and restructuring forecast for 13w cash flows starting 08.27 period	1.1
08/31/2021	LTN	Finalize the 13 week cash forecast summary section of Purdue beginning week 08.27	1.6
08/31/2021	LTN	Prepare the Customer Receipts and Operating Expenses section of Rhodes 13 week cash forecast beginning period 08.27	1.9
09/02/2021	LTN	Call with Purdue management to work on the Rhodes forecast for 13 week cash flows starting 08.27	1.1
09/02/2021	LTN	Finalize the Rhodes cash summary session of 13 week forecast beginning 08.27 period	1.5
09/02/2021	LTN	Prepare the customer rebates section of Rhodes 13 week cash forecast beginning period 08.27	1.1
09/02/2021	LTN	Prepare the deck for the 13 week cash flow forecast beginning 08.27 period	1.3
09/02/2021	LTN	Prepare the Professional fees, IACs and the remaining sections of Rhodes 13-week cash forecast beginning 08.27	0.9
09/03/2021	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 08.27 and update the weekly cash report deck	1.5
09/03/2021	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 08.27 and update the weekly cash report deck	1.3
09/07/2021	HSB	Review Purdue financial projections and forecasted emergence day payments	0.6
09/07/2021	LTN	Finalize the 13 week cash forecast deck beginning week 08.27 based on internal feedback and circulated for CFO review	1.9



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Cash Management  
Code: 1.3 / 103

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/07/2021	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 09.03 cash report	1.6
09/07/2021	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 09.03 cash report	1.8
09/08/2021	JD	Review latest 13 week cash flow forecast update from L. Nguyen and compare against business plan.	0.8
09/10/2021	HSB	Review Purdue weekly cash forecast and related underlying info prepared by L.Nguyen (AlixPartners)	1.3
09/13/2021	JD	Provide comments on the latest 2 forecast to actual cash reports.	0.4
09/13/2021	LTN	Prepare a list of open items for Purdue management and update week ended 09.03 cash report based on their feedback	0.6
09/13/2021	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 09.03 and update the weekly cash report deck	1.3
09/13/2021	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 09.03 and update the weekly cash report deck	0.9
09/13/2021	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 09.10 cash report	1.7
09/13/2021	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 09.10 cash report	2.0
09/14/2021	LTN	Call with S. Lemack, L. Nguyen (both AlixPartners) to discuss an open cash transaction	0.1
09/14/2021	SKL	Call with S. Lemack, L. Nguyen (both AlixPartners) to discuss an open cash transaction	0.1
09/14/2021	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 09.10 and update the weekly cash report deck	1.4
09/14/2021	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 09.10 and update the weekly cash report deck	1.1
09/15/2021	HSB	Review Purdue weekly cash report (8/27 and 9/03) prepared by L.Nguyen (AlixPartners)	1.4
09/15/2021	LTN	Prepare a list of open items Purdue management and update week ended 09.10 cash report based on their feedback	0.8
09/16/2021	LTN	Call with S. Lemack, L. Nguyen (AlixPartners) re: review Account Payable processing in SAP	0.3
09/16/2021	SKL	Call with L. Nguyen (AlixPartners) to discuss the payment/open invoice data pull process.	0.3
09/16/2021	LTN	Run AP Control working file in SAP	0.5
09/16/2021	LTN	Correspondence with J. Delconte (AlixPartners) re: particular payments status in SAP	0.3
09/22/2021	HSB	Review Purdue weekly cash reports prepared by L.Nguyen (AlixPartners)	0.9
09/22/2021	LTN	Prepare a list of open items Purdue management and update week ended 09.17 cash report based on their feedback	0.9
09/22/2021	LTN	Prepare the updated weekly sales reports as of 08.13 for Purdue provided Purdue management and circulated for CFO review	0.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Cash Management  
Code: 1.3 / 103

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/22/2021	LTN	Prepare the updated weekly sales reports as of 08.13 for Rhodes provided by Purdue management and circulated for CFO review	0.6
09/22/2021	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 09.17 cash report	1.7
09/22/2021	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 09.17 cash report	1.8
09/23/2021	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 09.17 and update the weekly cash report deck	1.3
09/23/2021	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 09.17 and update the weekly cash report deck	0.8
09/23/2021	LTN	Review the latest fee applications from the docket filed by Restructuring professionals and update the tracker	2.1
09/23/2021	LTN	Start preparing cash forecast at emergence based on the latest 13 week cash forecast	1.5
09/24/2021	HSB	Review Purdue weekly cash report (9/17) prepared by L.Nguyen (AlixPartners)	0.7
09/24/2021	JD	Review and provide comments on the latest cash forecast to actual.	0.4
09/24/2021	LTN	Reconcile Rebates payments vs latest 13 week cash forecast to prepare cash at emergence	2.0
09/27/2021	LTN	Reconcile Adlon and Avrio Health financials section of the August 2021 PEO monthly flash report	1.4
09/27/2021	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 09.24 cash report	1.6
09/27/2021	LTN	Reconcile and update the Purdue and Rhodes financials section of the August 2021 PEO monthly flash report	1.6
09/27/2021	LTN	Review financial statement deck and update Consolidated financials section for August 2021 PEO monthly flash report	1.8
09/27/2021	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 09.24 cash report	1.9
09/28/2021	LTN	Download AP data from SAP, categorize the operating expense section of Purdue & Rhodes 13-week cash forecast beginning 10.01	1.8
09/28/2021	LTN	Download AR data from SAP, categorize Account Receivables section of Purdue & Rhodes 13w cash forecast beginning 10.01	1.6
09/28/2021	LTN	Finalize the August PEO monthly flash report and circulate for internal review	0.4
09/28/2021	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 09.24 and update the weekly cash report deck	1.5
09/28/2021	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 09.24 and update the weekly cash report deck	0.8
09/28/2021	LTN	Review the latest OCP data provided by Purdue management and prepared OCP report for August 2021 invoices	1.9
09/29/2021	LTN	Prepare the Customer Rebates section of Purdue 13-week cash forecast beginning 10.01	1.5
09/29/2021	LTN	Prepare the Customer Receipts section of Purdue 13 week cash forecast beginning 10.01 based on the latest sales forecast provided by Purdue management.	1.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Cash Management  
Code: 1.3 / 103

<b>DATE</b>	<b>CONSULTANT</b>	<b>DESCRIPTION OF SERVICES</b>	<b>HOURS</b>
09/29/2021	LTN	Prepare the IAC receipts and IAC disbursements section of Purdue 13-week cash forecast beginning 10.01	0.9
09/29/2021	LTN	Prepare the Operating expense section of Purdue 13-week cash forecast beginning week 10.01	1.8
09/29/2021	LTN	Review the latest rebates tracker provided by Purdue management as of October 2021 and updated the 13-week cash forecast	0.9
09/30/2021	LTN	Prepare the Customer Rebates section of Rhodes 13 week cash forecast beginning period 10.01	1.1
09/30/2021	LTN	Prepare the Customer Receipts and Operating Expenses section of Rhodes 13 week cash forecast beginning period 10.01	1.9
09/30/2021	LTN	Prepare the professional fees, IACs and the remaining sections of Rhodes 13-week cash forecast beginning 10.01	0.6
<b>Total Professional Hours</b>			<b>297.0</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Cash Management  
Code: 1.3 / 103

<b>PROFESSIONAL</b>	<b>TITLE</b>	<b>RATE</b>	<b>HOURS</b>	<b>FEES</b>
Jesse DelConte	Managing Director	\$1,055	10.6	11,183.00
HS Bhattal	Director	\$865	18.7	16,175.50
Jamey Hamilton	Director	\$865	0.2	173.00
Sam K Lemack	Senior Vice President	\$665	2.8	1,862.00
Lan T Nguyen	Vice President	\$530	264.7	140,291.00
<b>Total Professional Hours and Fees</b>			<b>297.0</b>	<b>\$ 169,684.50</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/01/2021	ADD	Compile missing information and other open items for Purdue legal team review.	1.8
06/01/2021	ADD	Call with S. Daniel and J. Lauriat (Purdue) re: diligence requests.	0.4
06/02/2021	ADD	Review diligence request and follow up with outstanding items.	1.0
06/03/2021	ADD	Compile responses to diligence request for internal review.	1.5
06/03/2021	JD	Review materials posted per UCC requests.	0.5
06/04/2021	GJK	Meeting with R. Aleali (Purdue), C. Robertson C. Oluwale, E. Turay (all Davis Polk), J. DelConte, S. Lemack, and G. Koch (AlixPartners) re: latest Kramer Levin request re: change of control process.	0.6
06/04/2021	SKL	Meeting with R. Aleali (Purdue), C. Robertson C. Oluwale, E. Turay (all Davis Polk), J. DelConte, S. Lemack, and G. Koch (AlixPartners) re: latest Kramer Levin request re: change of control process.	0.6
06/04/2021	ADD	Compile responses to diligence request for internal review.	1.7
06/04/2021	JD	Meeting with R. Aleali (Purdue), C. Robertson C. Oluwale, E. Turay (all Davis Polk), J. DelConte, S. Lemack, and G. Koch (AlixPartners) re: latest Kramer Levin request re: change of control process.	0.6
06/04/2021	JD	Finalize latest cash flow analysis for the NCSG.	0.8
06/04/2021	JD	Review update on status of latest UCC requests.	0.3
06/04/2021	JD	Review draft flash report for creditor advisors.	0.3
06/07/2021	GJK	Review IAC mapping and commentary from FTI; provide responses.	0.9
06/07/2021	SKL	Prepare updated breakdown of IP assets re: FTI diligence request.	1.2
06/07/2021	SKL	Call with A. DePalma (AlixPartners) re: latest open items re: FTI diligence request.	0.7
06/07/2021	ADD	Compile insurance materials produced during the bankruptcy for Purdue legal team review.	0.8
06/07/2021	ADD	Review previously produced materials and compile available materials responsive to creditor diligence list.	2.8
06/07/2021	ADD	Call with S. Lemack (AlixPartners) re: latest open items re: FTI diligence request.	0.7
06/08/2021	JD	Review potential IP files to be shared with AHC per their open diligence request.	0.3
06/08/2021	GJK	Review IP files with patent information as potential response to AHC diligence request.	0.8
06/09/2021	JD	Meeting with R. Aleali (Purdue), D. Consla (Davis Polk), S. Lemack, J. DelConte and G. Koch (AlixPartners) re: contract analysis and AHC diligence requests.	0.6
06/09/2021	JD	Correspondence with Houlihan Lokey re: open diligence requests.	0.3
06/09/2021	GJK	Meeting with R. Aleali (Purdue), D. Consla (Davis Polk), S. Lemack, J. DelConte and G. Koch (AlixPartners) re: contract analysis and AHC diligence requests.	0.6
06/09/2021	SKL	Meeting with R. Aleali (Purdue), D. Consla (Davis Polk), S. Lemack, J. DelConte and G. Koch (AlixPartners) re: contract analysis and AHC diligence requests.	0.6



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/09/2021	ADD	Prepare materials submitted in response to diligence requests and send to Davis Polk eDiscovery team for upload.	1.4
06/10/2021	JD	Review final change of control timeline and license application to share with creditor advisors.	0.3
06/11/2021	GJK	Review documents and prep for AHC call.	0.4
06/11/2021	LTN	Clean files and circulate to M. Jack (Purdue) re: 13 cash flow forecast process	0.3
06/11/2021	HSB	Call with R.Aleali (Purdue), D.Consla, T.Matlock, C. Robertson, E.Diggs (all Davis Polk), J. DelConte, G. Koch (all AlixPartners), P.Flink, S.Pohl, B.Kelly, K.Davis (all Brown Rudnick), J.Bessonette, H.Stoopack, J.Taub, J.Rosenbaum, D.Lyons (all Kramer Levin), B.Bromberg (FTI) re: Purdue work transfer diligence and related matters	1.0
06/11/2021	JD	Call with E. Turay, W. Taylor, E. Diggs, D. Consla (all Davis Polk), J. DelConte (partial participation), G. Koch, H. Bhattal (all AlixPartners), R. Aleali (Purdue), Kramer Levin and Brown Rudnick re: newco transfer process.	0.7
06/12/2021	GJK	Review debrief notes from R Aleali (Purdue) on AHC call and compare to my notes from call; next steps.	0.3
06/14/2021	GJK	Review status of open transfer workplan items following AHC diligence call.	0.3
06/14/2021	LTN	Call with J.Lowne and L.Scheinbach (both Purdue), T.Melvin (PJT), H. Bhattal, S. Lemack and L. Nguyen (AlixPartners) re: Purdue financial forecasts and related matters	0.3
06/14/2021	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners), L. Scheinbach (Purdue) re: cash flows analysis	0.3
06/14/2021	HSB	Call with L.Scheinbach (Purdue) and L. Nguyen (AlixPartners) re: Purdue financial forecasts and related matters	0.3
06/14/2021	HSB	Call with J.Lowne and L.Scheinbach (both Purdue), T.Melvin (PJT), H. Bhattal, S. Lemack and L. Nguyen (AlixPartners) re: Purdue financial forecasts and related matters	0.3
06/14/2021	ADD	Prepare index of documents for Davis Polk's eDiscovery team to extract.	0.8
06/14/2021	ADD	Prepare materials provided by Davis Polk for upload to the dataroom to creditor committee review.	2.1
06/14/2021	JD	Review long term business plan cost detail files to be uploaded for creditor advisors.	0.8
06/15/2021	GJK	Call with G. Koch, L. Nguyen (AlixPartners), E. Huang, J. Weiner (Davis Polk) and advisors for Sackler Family, Debtors, UCC and AHC to walk through open IAC items.	0.8
06/15/2021	LTN	Attend partial meeting with A. Libby (Davis Polk), J. Ball (Debevoise) and other advisors re: IAC provisions	0.5
06/15/2021	LTN	Call with G. Koch, L. Nguyen (AlixPartners), E. Huang, J. Weiner (Davis Polk) and advisors for Sackler Family, Debtors, UCC and AHC to walk through open IAC items.	0.8
06/17/2021	ADD	Compile diligence materials to share with interested party and draft correspondence outlining response.	0.5
06/17/2021	JD	Correspondence with Davis Polk, Province, FTI and Purdue management re: KEIP/KERP data requests.	0.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/18/2021	GJK	Meeting with R. Aleali, K. McCarthy (both Purdue), L. Diggs, S. Massman, D. Consla, L. Altus, T. Matlock, E. Turay (all Davis Polk), N. Bouchard, P. Flink, S. Pohl, B. Kelly, K. Davis (all Brown Rudnick), J. Bessonette (Kramer Levin), H. Stoopack, J. Taub, J. Rosenbaum, D. Lyons (all Kramer Levin), and S. Lemack (AlixPartners) re: the regulatory matters process.	0.8
06/18/2021	HSB	Review Purdue due diligence related info prepared by A. DePalma (AlixPartners)	0.3
06/18/2021	ADD	Review outstanding diligence requests and draft correspondence to follow up.	0.6
06/18/2021	ADD	Compile materials submitted in response to diligence requests and send documents to Davis Polks eDiscovery team for upload to the data room.	1.4
06/21/2021	ADD	Review outstanding diligence requests and draft correspondence to follow up.	0.9
06/21/2021	ADD	Correspondence re: follow-up to outstanding diligence requests	0.3
06/22/2021	JD	Correspondence with Purdue management re: third party financial projections requests.	0.3
06/22/2021	JD	Draft revised responses to FTI KEIP/KERP diligence request.	0.7
06/22/2021	HSB	Review Purdue financial data in connection with KEIP/KERP diligence request	0.6
06/22/2021	ADD	Compile materials provided in response to diligence requests to provide to Davis Polk for upload.	1.2
06/23/2021	JD	Review and comment on edits to the proposed KEIP/KERP diligence responses.	0.7
06/23/2021	JD	Correspondence with Davis Polk and A. DePalma (AlixPartners) re: creditor business plan diligence request.	0.4
06/23/2021	ADD	Prepare materials provided by Davis Polk's eDiscovery team for upload to the data room.	2.8
06/24/2021	JD	Call with T. Melvin (PJT) re: stakeholder diligence request.	0.2
06/24/2021	JD	Call with J. Lowne (Purdue) and T. Melvin (PJT) re: cash flow analysis.	0.2
06/25/2021	HSB	Review excel files and prepared responses to Purdue due diligence related questions from external parties	1.8
06/25/2021	HSB	Review Purdue due diligence request list and related correspondence from external parties	0.4
06/25/2021	JD	Revise draft responses to follow up diligence questions from the UCC and AHC.	2.2
06/26/2021	JD	Correspondence with Davis Polk re: AHC diligence responses and retention plan.	0.4
06/28/2021	JD	Call with C. Robertson (Davis Polk) re: UCC questions.	0.5
06/28/2021	JD	Call with R. Aleali (Purdue) re: open diligence requests.	0.3
06/28/2021	JD	Review business plan materials to be responsive to discovery request from Goodwin.	0.7
06/28/2021	JD	Review UCC request for indemnification spend details associated with the MOR.	0.4
06/28/2021	JD	Correspondence with Davis Polk re: Goodwin discovery request.	0.2
06/28/2021	JD	Correspondence with Davis Polk and UCC and AHC advisors re: KEIP/KERP diligence questions.	0.7





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/28/2021	GJK	Call with G. Koch, L. Nguyen (both AlixPartners), T. Richards (HCG), C. Klawunder (Province), B. Bromberg (both FTI) re: updates to IAC preferred ownership	0.5
06/28/2021	ADD	Review previously produced materials and consolidate files for interested party review.	1.8
06/28/2021	LTN	Call with G. Koch, L. Nguyen (both AlixPartners), J. Weiner (Davis Polk), B. Kennedy (Milbank), B. Olson (Kokino) and other advisors re: the revised Art 1 and 2 in the Settlement agreement	1.3
06/28/2021	LTN	Call with G. Koch, L. Nguyen (both AlixPartners), T. Richards (HCG), C. Klawunder (Province), B. Bromberg (both FTI) re: updates to IAC preferred ownership	0.5
06/29/2021	GJK	Call with HS. Bhattal, G. Koch, L. Nguyen (both AlixPartners), A. Libby (Davis Polk), J. Ball (Debevoise), G. Coutts, H. Schenk, A. Benjamin (all Houlihan), M. Atkinson (Province), R. Ringer (Kramer Levin), S. Gilbert (Gilbert), M. Diaz (FTI) re: A-side family group credit support proposal	1.6
06/29/2021	JD	Correspondence with AHC advisors re: open diligence questions.	0.3
06/29/2021	HSB	Call with HS. Bhattal, G. Koch, L. Nguyen (both AlixPartners), A. Libby (Davis Polk), J. Ball (Debevoise), G. Coutts, H. Schenk, A. Benjamin (all Houlihan), M. Atkinson (Province), R. Ringer (Kramer Levin), S. Gilbert (Gilbert), M. Diaz (FTI) re: A-side family group credit support proposal	1.6
06/29/2021	ADD	Review previously produced materials and consolidate files for interested party review.	1.8
06/29/2021	ADD	Review documents for third-party confidentiality in preparation for production.	1.4
06/29/2021	LTN	Call with HS. Bhattal, G. Koch, L. Nguyen (both AlixPartners), A. Libby (Davis Polk), J. Ball (Debevoise), G. Coutts, H. Schenk, A. Benjamin (all Houlihan), M. Atkinson (Province), R. Ringer (Kramer Levin), S. Gilbert (Gilbert), M. Diaz (FTI) re: A-side family group credit support proposal	1.6
06/29/2021	LTN	Update intralink access for I. Turner (FTI) and correspondence with FTI	0.2
06/30/2021	HSB	Call with J.Lowne (Purdue), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), J. DelConte, L. Nguyen (all AlixPartners) re: Purdue projections	0.3
06/30/2021	HSB	Call with E.Vonnegut, C.Robertson, S.Massman, Z.Levine, A.Lele, E.Diggs (all Davis Polk), J.Arsic, R.Schnitzler, T. Melvin (all PJT), L. Nguyen (AlixPartners), G. Coutts, A. Benjamin (Houlihan Lokey), B. Bromberg (FTI), M. Atkinson (Province), J.Rosen, J.Bessonette (Kramer Levin) re: Plan Supplement related agreement	0.8
06/30/2021	ADD	Review documents for third-party confidentiality in preparation for production.	2.3
06/30/2021	LTN	Call with E.Vonnegut, C.Robertson, S.Massman, Z.Levine, A.Lele, E.Diggs (all Davis Polk), J.Arsic, R.Schnitzler, T. Melvin (all PJT), H. Bhattal (AlixPartners), G. Coutts, A. Benjamin (Houlihan Lokey), B. Bromberg (FTI), M. Atkinson (Province), J.Rosen, J.Bessonette (Kramer Levin) re: Plan Supplement related agreement	0.8
07/01/2021	JD	Correspondence with Davis Polk and AlixPartners team re: indemnification details request from the UCC.	0.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/01/2021	LTN	Review indemnification data in MOR reports and correspondence with C. MacDonald (Purdue)	0.8
07/01/2021	ADD	Review and compile materials in response to diligence request.	2.3
07/01/2021	ADD	Review documents for third party confidentiality and other sensitivity in preparation for production.	2.4
07/02/2021	LTN	Compile January - May MOR data and provide to R. Aleali (Purdue).	0.3
07/02/2021	ADD	Review list agreements and compile documents in response to diligence requests.	2.9
07/02/2021	ADD	Review materials previously produced in response to diligence request.	1.7
07/02/2021	ADD	Review documents for third party confidentiality and other sensitivity in preparation for production.	0.8
07/03/2021	ADD	Prepare and upload materials provided by Davis Polk's eDiscovery team for upload to the data room.	3.1
07/06/2021	LTN	Call among G. Koch, L. Nguyen (AlixPartners), J. Finelli, A. Libby (Davis Polk) and other advisors to discuss A-Side multipod credit support Annex	2.9
07/06/2021	HSB	Call with R. Aleali, J. Lowne (Purdue), E. Vonnegut, C. Robertson, S. Massman, Z. Levine, W. Taylor (all Davis Polk), J. DelConte, H. Bhattal (both AlixPartners), J. Turner, T. Melvin, J. Arsic (all PJT) re: supplemental plan documents.	0.8
07/06/2021	JD	Call with M. Diaz, B. Bromberg, I. Turner, C. Kim, E. Kurtz (all FTI), G. Coutts, H. Schenk, A. Benjamin, H. Sun (all Houlihan), J. Turner, T. Melvin (both PJT), J. DelConte, H. Bhattal (both AlixPartners) re: plan documents.	0.7
07/06/2021	JD	Review latest long term business plan for underlying long-term compensation assumptions per request from the UCC.	1.2
07/06/2021	JD	Call with B. Bromberg (FTI) re: plan documents.	0.2
07/06/2021	HSB	Call with M. Diaz, B. Bromberg, I. Turner, C. Kim, E. Kurtz (all FTI), G. Coutts, H. Schenk, A. Benjamin, H. Sun (all Houlihan), J. Turner, T. Melvin (both PJT), J. DelConte, H. Bhattal (both AlixPartners) re: plan documents.	0.7
07/07/2021	LTN	Reconcile the cumulative indemnification payments based on data provided by C. MacDonald (Purdue)	0.6
07/07/2021	LTN	Call with C. MacDonald (Purdue) to discuss indemnification fees	0.6
07/07/2021	LTN	Prepare the indemnification payments report by firm based on data provided by C. MacDonald (Purdue)	1.8
07/07/2021	LTN	Continue to prepare the indemnification payments report by Case Type based on data provided by C. MacDonald (Purdue)	1.3
07/07/2021	JD	Call with G. Coutts (Houlihan) re: plan document negotiations.	0.6
07/07/2021	JD	Call with J. Turner (PJT) and G. Coutts (Houlihan) re: plan document negotiations.	0.4
07/07/2021	JD	Create updated analysis of incentive compensation in the long term business plan per UCC diligence request.	0.8
07/07/2021	JD	Correspondence with AHC and UCC advisors re: open diligence questions on the KEIP/KERP.	0.6
07/07/2021	JD	Create summary analysis of breakdown of changes to emergence distributions to share with AHC advisors.	0.8



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/07/2021	JD	Correspondence with FTI and Houlihan re: proposed changes to plan document language.	0.2
07/08/2021	LTN	Correspondence with C. MacDonald (Purdue) re indemnification fees	0.3
07/08/2021	HSB	Review Purdue diligence materials updated by L.Nguyen (AlixPartners) based on info from Purdue	0.3
07/08/2021	ADD	Review outstanding diligence request and compile responsive materials.	1.2
07/09/2021	HSB	Review email with Purdue diligence request received	0.1
07/09/2021	HSB	Review Purdue cash forecasts in connection with diligence request	0.4
07/09/2021	JD	Review and provide comments on the indemnification payment breakdown analysis per UCC diligence request.	0.5
07/10/2021	SKL	Call with H. Bhattal (AlixPartners) to discuss latest KEIP/KERP inquiry provided by the AHC.	0.2
07/10/2021	SKL	Continue to review latest AHC inquiry re: KEIP/KERP, and prepare and circulate update accordingly.	0.6
07/10/2021	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue keip/kerp	0.2
07/12/2021	JD	Call with M. Diaz (FTI) re: KEIP/KERP.	0.1
07/12/2021	JD	Call with S. Burian, G. Coutts, H. Schenk (all Houlihan), M. Kesselman, R. Aleali (both Purdue), J. Turner, T. Melvin (both PJT), M. Diaz, B. Bromberg (both FTI) re: PBM discussions.	1.0
07/12/2021	SKL	Review latest AHC inquiry re: sales to IACs and begin preparing update accordingly.	1.4
07/12/2021	HSB	Call with E.Vonnegut, (Davis Polk), J.Turner, T. Melvin (both PJT), J.DelConte (AlixPartners),G. Coutts, A. Benjamin, H.Sun, A.Benjamin,O.Cohen (all HL), B. Bromberg, M.Diaz (both FTI), M.Kesselman, R.Aleali (both Purdue) re: plan related negotiations	0.7
07/12/2021	LTN	Call with G. Koch, L. Nguyen (both AlixPartners) to discuss model scenarios provided by FTI	0.2
07/12/2021	ADD	Compile files from productions for document reserve.	2.1
07/12/2021	JD	Call with E.Vonnegut, (Davis Polk), J.Turner, T. Melvin (both PJT), H. Bhattal (AlixPartners),G. Coutts, A. Benjamin, H.Sun, A.Benjamin,O.Cohen (all HL), B. Bromberg, M.Diaz (both FTI), M.Kesselman, R.Aleali (both Purdue) re: plan related negotiations	0.7
07/13/2021	JD	Call with G. Coutts (Houlihan) re: PBM discussions.	0.2
07/13/2021	JD	Call with M. Diaz, B. Bromberg (both FTI), J. Turner (PJT) re: open diligence questions.	0.7
07/13/2021	HSB	Call among L. Nguyen (AlixPartners), J.Finelli, A. Libby, J.Weiner (all Davis Polk), J. Ball, C.Rosekrans, J.Rosen (both Debevoise), G. Coutts, H. Schenk, A. Benjamin (all Houlihan), M. Atkinson (Province), J.Rosenbaum, R. Ringer (Kramer Levin), S. Gilbert (Gilbert),E.Miller (Akin Gump), M. Diaz, B.Bromberg (FTI) re: A-side family group credit support proposal	1.7
07/13/2021	LTN	Call among J. Finelli, A. Libby (Davis Polk), J. Ball, C. Rosekans (Debevoise) and other advisors to discuss open items on the multipod credit support Annex	1.7
07/14/2021	SKL	Finalize updated analysis of IAC sales and circulate to FTI accordingly.	0.6



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/14/2021	LTN	Call with G. Koch, L. Nguyen (both AlixPartners) to discuss settlement agreement matters	0.2
07/14/2021	LTN	Call among G. Koch, L. Nguyen (AlixPartners), J. Finelli, A. Libby (Davis Polk), G. Gooding, J. Ball, C. Rosekans (Debevoise) and other advisors to discuss open Settlement Agreement issues, including materiality/breaches and remedies.	1.9
07/14/2021	ADD	Compile vendor data in response to Committee request.	0.5
07/15/2021	LTN	Call with B. Bromberg (FTI) to discuss model examples	0.5
07/16/2021	JD	Call with S. Burian, G. Coutts, H. Shenk (all Houlihan), M. Diaz, B. Bromberg (both FTI), R. Aleali (Purdue), J. Turner, T. Melvin (both PJT), E. Vonnegut, C. Robertson (both Davis Polk), J. DelConte, H. Bhattal (both AlixPartners), M. Florence, J. Bragg (both Skadden) re: PBMs.	0.8
07/16/2021	JD	Review and provide comments on draft responses to UCC cash flow analysis questions.	0.6
07/16/2021	HSB	Call with S. Burian, G. Coutts, H. Shenk (all Houlihan), M. Diaz, B. Bromberg (both FTI), R. Aleali (Purdue), J. Turner, T. Melvin (both PJT), E. Vonnegut, C. Robertson (both Davis Polk), J. DelConte, H. Bhattal (both AlixPartners), M. Florence, J. Bragg (both Skadden) re: PBMs.	0.8
07/16/2021	ADD	Compile agreements in response to monitor request.	0.9
07/17/2021	GJK	Review contract assumption information sent to UCC and AHC advisors from S Lemack (AlixPartners) and comments from C Robertson (Davis Polk) and B Bromberg (FTI).	0.4
07/19/2021	HSB	Call among H. Bhattal, L. Nguyen (AlixPartners), J. Lowne, E. Ruiz (Purdue), T. Melvin (PJT) to discuss Newco Cashflow breakdown	0.2
07/19/2021	JD	Correspondence with FTI, Davis Polk and Purdue management re: KEIP/KERP proposal and counterproposal.	0.8
07/19/2021	JD	Correspondence with Davis Polk and Houlihan re: pharmacy benefit manager analysis.	0.4
07/19/2021	LTN	Call among A. Libby (Davis Polk), E. (Akin) and other advisors re: updates to breach fees	0.7
07/19/2021	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: to review and analyze vendor data.	0.4
07/19/2021	ADD	Review and follow up with outstanding diligence requests.	1.5
07/20/2021	GJK	Call with M. Diaz, B. Bromberg, E. Kurtz, I. Turner (all FTI), M. Atkinson (Province), J. DelConte, G. Koch, H. Bhattal, S. Lemack (all AlixPartners), D. Consla, C. Robertson (both Davis Polk) re: contract assumptions and rejections.	0.7
07/20/2021	SKL	Call with M. Diaz, B. Bromberg, E. Kurtz, I. Turner (all FTI), M. Atkinson (Province), J. DelConte, G. Koch, H. Bhattal, S. Lemack (all AlixPartners), D. Consla, C. Robertson (both Davis Polk) re: contract assumptions and rejections.	0.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/20/2021	HSB	Call with M. Diaz, B. Bromberg, E. Kurtz, I. Turner (all FTI), M. Atkinson (Province), J. DelConte, G. Koch, H. Bhattal, S. Lemack (all AlixPartners), D. Consla, C. Robertson (both Davis Polk) re: contract assumptions and rejections.	0.7
07/20/2021	JD	Call with G. Coutts, H. Schenk, A. Benjamin (all Houlihan), J. Turner (PJT) re: PBM analysis.	0.5
07/20/2021	JD	Call with M. Diaz, B. Bromberg (both FTI) re: KEIP/KERP.	0.5
07/20/2021	JD	Call with M. Diaz, B. Bromberg, E. Kurtz, I. Turner (all FTI), M. Atkinson (Province), J. DelConte, G. Koch, H. Bhattal, S. Lemack (all AlixPartners), D. Consla, C. Robertson (both Davis Polk) re: contract assumptions and rejections.	0.7
07/20/2021	ADD	Call with S. Lemack (AlixPartners) to discuss latest diligence request and next steps.	0.2
07/20/2021	ADD	Upload documents submitted in response to diligence requests to the data room for creditor committee review.	2.3
07/21/2021	JD	Review and provide comments on cash flow by product analysis per UCC diligence request.	0.4
07/21/2021	JD	Call with G. Coutts (Houlihan) re: open diligence requests.	0.2
07/21/2021	ADD	Call with S. Lemack (AlixPartners) to discuss latest diligence request and next steps.	0.2
07/22/2021	SKL	Finalize review of latest info provided by J. Carlisle and E. Nowakowski (both Purdue) and provide update to FTI and Province accordingly.	1.5
07/22/2021	JD	Call with E. Vonnegut (Davis Polk), R. Ringer (Kramer Levin), M. Diaz (FTI) re: KEIP/KERP.	0.3
07/22/2021	JD	Call with C. Robertson, D. Klein, E. Vonnegut (all Davis Polk), M. Florence, J. Bragg (both Skadden), R. Aleali (Purdue) re: PBM analysis.	0.6
07/22/2021	ADD	Review outstanding diligence request.	0.4
07/23/2021	SKL	Call with A. DePalma (AlixPartners) to discuss latest diligence requests.	0.5
07/23/2021	SKL	Continue to review latest notes and feedback re: contract assumptions, and begin preparing updates per FTI/Province request.	2.3
07/23/2021	ADD	Call with S. Lemack (AlixPartners) to discuss latest diligence request and next steps.	0.5
07/24/2021	JD	Call with M. Diaz (FTI) re: KEIP/KERP.	0.2
07/24/2021	JD	Review incoming diligence requests from Houlihan re: operations.	0.2
07/25/2021	JD	Correspondence with Purdue management re: open diligence requests from the government and from the ad hocs.	0.5
07/25/2021	JD	Correspondence with the AHC and UCC advisors re: KEIP/KERP counterproposal.	0.4
07/26/2021	JD	Meeting with J. DelConte, H. Bhattal, S. Lemack, A. DePalma (all AlixPartners) re: status of various inbound diligence requests.	0.7
07/26/2021	JD	Correspondence with FTI, Davis Polk and Purdue management re: KEIP counterproposals.	0.6
07/26/2021	JD	Review operational materials and correspondence with Davis Polk re: AHC operational diligence requests.	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/26/2021	HSB	Meeting with J. DelConte, H. Bhattal, S. Lemack, A. DePalma (all AlixPartners) re: status of various inbound diligence requests.	0.7
07/26/2021	SKL	Meeting with J. DelConte, H. Bhattal, S. Lemack, A. DePalma (all AlixPartners) re: status of various inbound diligence requests.	0.7
07/26/2021	ADD	Compile and format documents provided by the client in response to diligence requests for processing and upload for creditor review.	2.4
07/26/2021	ADD	Review outstanding diligence request and compile responsive materials.	0.9
07/26/2021	ADD	Meeting with J. DelConte, H. Bhattal, S. Lemack, A. DePalma (all AlixPartners) re: status of various inbound diligence requests.	0.7
07/27/2021	JD	Correspondence with management, Davis Polk and FTI re: KEIP/KERP proposals.	0.4
07/27/2021	JD	Correspondence with Davis Polk and Purdue management re: open AHC operating agreement diligence requests.	0.4
07/27/2021	ADD	Compile and format documents provided by the client in response to diligence requests for processing and upload for creditor review.	2.4
07/28/2021	HSB	Call with J.DelConte (AlixPartners), J.O'Connell, J.Turner, T.Melvin (both PJT), K.Benedict, M.Tobak (Davis Polk) re: plan related discussions	0.8
07/28/2021	ADD	Compile list of board materials in response to diligence request.	1.3
07/28/2021	ADD	Review outstanding diligence request and compile responsive materials.	1.2
07/29/2021	HSB	Call with M. Kesselman, C. Landau, J. Lowne, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: weekly catch up and planning call.	0.6
07/29/2021	SKL	Continue to prepare updates to the latest product-by-product RALP sales revenue file and work through the AHC open item list accordingly.	1.8
07/29/2021	SKL	Review latest lease details on the Intralinks site and prepare consolidated breakdown of all leases per AHC request.	1.4
07/29/2021	JD	Correspondence with M. Atkinson (Province) and R. Collura (AlixPartners) re: open UCC tax diligence questions.	0.3
07/29/2021	ADD	Compile list of board materials in response to diligence request.	0.8
07/30/2021	SKL	Consolidate latest AHC diligence materials and prepare for distribution and signoff.	2.2
07/30/2021	ADD	Compile list of board materials in response to diligence request.	1.1
08/02/2021	ADD	Review exhibit list containing contracts and identify the correct files.	2.9
08/02/2021	JD	Review draft materials pulled together in response to AHC request and recommend edits per discussions with management.	0.3
08/02/2021	SKL	Finalize files requested by the AHC and circulate internally for final sign-off.	1.2
08/02/2021	SKL	Finalize updates to the AHC files based on the latest feedback provided and circulate internally for final sign-off.	0.4
08/03/2021	ADD	Compile count of active Intralinks data room users by creditor group per counsel request.	0.8
08/03/2021	JD	Review latest AHC diligence responses and correspondence with Houlihan re: same.	0.5
08/03/2021	JD	Review payroll tax withholding information pulled together per UCC requests.	0.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/04/2021	JD	Review final draft UCC cash flow breakdown response.	0.3
08/05/2021	JD	Correspondence with A. DePalma (AlixPartners) and Davis Polk re: open diligence requests.	0.3
08/05/2021	JD	Review status of open diligence requests from the UCC and AHC.	0.5
08/06/2021	JD	Review latest AHC diligence files and provide comments on draft responses.	0.4
08/06/2021	SKL	Multiple calls with J. Doyle (Purdue) to discuss latest inquiry re: Rhodes leases.	0.5
08/06/2021	SKL	Continue to finalize Purdue lease detail breakdown to provide in regards to the latest AHC inquiry.	1.2
08/06/2021	SKL	Continue to finalize Rhodes lease and sublease detail breakdown to provide in regards to the latest AHC inquiry.	1.8
08/06/2021	SKL	Review latest Rhodes leases provided by J. Doyle (Purdue) and prepare updated lease breakdown in preparation for Monday's discussion with D. Fogel (Purdue).	1.5
08/09/2021	SKL	Meeting with D. Fogel (Purdue) to discuss Rhodes lease inquiry from the AHC.	0.4
08/09/2021	SKL	Meeting with K. McCafferty (AlixPartners) to discuss Rhodes lease inquiry from the AHC.	0.2
08/09/2021	SKL	Meeting with D. Fogel and E. Flath (both Purdue) to discuss Rhodes lease inquiry from the AHC.	0.7
08/09/2021	SKL	Continue to finalize latest Rhodes lease breakdown to provide update to AHC.	1.3
08/09/2021	SKL	Finalize remaining updates to the latest AHC diligence request list and provide latest materials accordingly.	2.3
08/09/2021	SKL	Finalize breakdown of all Purdue/Rhodes lease information and circulate internally.	0.9
08/09/2021	KM	Review expense detailed breakdown for diligence project.	1.9
08/09/2021	ADD	Compile and format materials provided by client in response to diligence requests to provide to creditor committee.	1.7
08/09/2021	JD	Review vendor payment details in response to open creditor diligence request.	0.3
08/09/2021	JD	Review open responses to various AHC operational diligence requests.	0.7
08/10/2021	LTN	Call among A. Libby (Davis Polk), M. Atkinson (Province), B. Bromberg (FTI) to discuss the financial reporting format	0.7
08/10/2021	JD	Call with M. Diaz (FTI) re: insurance questions.	0.5
08/10/2021	JD	Prepare summary insurance correspondence for FTI in response to open AHC insurance diligence requests.	0.7
08/10/2021	JD	Review various diligence project files prior to sharing with the AHC.	0.5
08/10/2021	JD	Correspondence with Purdue team re: follow-up AHC insurance questions.	0.3
08/11/2021	GJK	Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner, E. Hwang (Davis Polk) UCC and AHC to walk through Settlement Agreement open items	1.2
08/11/2021	GJK	Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner, E. Hwang (Davis Polk) Sackler Family, Debtors, UCC and AHC to work through open items in Settlement Agreement before the Confirmation hearing	2.5
08/11/2021	SKL	Review latest contract AHC inquiry and prepare updated notes and feedback accordingly based on the latest materials provided by the company.	0.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/11/2021	LTN	Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner, E. Hwang (Davis Polk) UCC and AHC to walk through Settlement Agreement open items	1.2
08/11/2021	JD	Meeting with C. Ricarte, J. Lowne, M. Kesselman, R. Aleali (all Purdue), K. Eckstein (Kramer Levin), G. Coutts, H. Sun, A. San (all Houlihan), A. Kramer (Reed Smith), M. Diaz, B. Bromberg, A. Whitman (all FTI) re: post-emergence insurance.	1.1
08/11/2021	JD	Correspondence with Purdue management and S. Lemack (AlixPartners) re: contract diligence.	0.4
08/11/2021	JD	Correspondence with Purdue management re: prep for insurance call.	0.3
08/11/2021	LTN	Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner, E. Hwang (Davis Polk) Sackler Family, Debtors, UCC and AHC to work through open items in Settlement Agreement before the Confirmation hearing	2.5
08/11/2021	LTN	Continued call among A. Libby, J. Weiner, E. Hwang (Davis Polk) and other advisors re: open items in the Settlement agreement before the Confirmation hearing	3.0
08/12/2021	JD	Correspondence with Davis Polk re: open contract requests from the AHC.	0.5
08/12/2021	JD	Correspondence with Purdue management and Skadden re: KEIP/KERP diligence.	0.4
08/12/2021	JD	Call with S. Gilbert (Gilbert), K. Eckstein, J. Rosenbaum, T. Lenson (Kramer Levin), M. Kesselman, R. Aleali, M. Jack, C. Ricarte, J. Lowne (all Purdue), M. Diaz, B. Bromberg, A. Whitman (all FTI), P. Figliozzi, B. Oxman (both Marsh), E. Vonnegut, C. Robertson, W. Taylor (all Davis Polk) re: post-emergence insurance.	1.0
08/12/2021	JD	Correspondence with FTI re: open contract diligence questions.	0.3
08/13/2021	SKL	Call with S. Daniel (Purdue) to discuss latest AHC request re: counterparty info.	0.2
08/13/2021	ADD	Call with A. Johnson and G. Baron (FTI) re: Project Omega dataroom walk through.	0.5
08/13/2021	JD	Correspondence with FTI and AlixPartners team re: open contract diligence questions.	0.3
08/13/2021	JD	Begin review of documents received from Purdue management in response to open KEIP/KERP diligence.	0.7
08/17/2021	ADD	Compile materials provided in response to diligence requests for upload to the data room.	3.2
08/17/2021	ADD	Review outstanding diligence requests and follow up with remaining items.	1.0
08/17/2021	JD	Correspondence with FTI re: open insurance diligence questions.	0.4
08/18/2021	ADD	Compile materials provided in response to diligence requests for upload to the data room.	3.2
08/18/2021	ADD	Review previously produced materials in response to diligence question.	1.0
08/19/2021	ADD	Download and compile HR data in response to KERP/KEIP diligence request.	2.9
08/19/2021	ADD	Call with H. Bhattal (AlixPartners) to discuss KERP/KEIP Diligence request.	0.4
08/19/2021	ADD	Create materials responsive to KERP/KEIP diligence request.	3.0
08/19/2021	SKL	Review latest KEIP/KERP AHC inquiry and prepare updated participant breakdown accordingly.	2.1





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/19/2021	HSB	Review Purdue files in connection with diligence request from external parties	1.0
08/19/2021	HSB	Call with A.DePalma (AlixPartners) to discuss Purdue diligence request	0.4
08/19/2021	HSB	Call with L. Nguyen (AlixPartners) re: the July MOR	0.1
08/19/2021	JD	Review and provide comments on insurance overview presentation and email correspondence to send to the AHC.	0.8
08/20/2021	GJK	Call with counsel and financial advisors for Sackler Family Debtor, UCC and AHC and L. Nguyen, G. Koch (both AlixPartners) to discuss Net Proceeds report.	0.6
08/20/2021	ADD	Download and compile HR data in response to KERP/KEIP diligence request.	2.6
08/20/2021	ADD	Call with L. Nguyen (AlixPartners) to discuss KERP/KEIP Diligence request.	0.4
08/20/2021	ADD	Create materials responsive to KERP/KEIP diligence request.	2.8
08/20/2021	SKL	Review the latest RALP product sales info provided by E. Ruiz (Purdue) and begin preparing updated analysis in regards to the recent AHC diligence request.	1.7
08/20/2021	LTN	Call with A. DePalma (AlixPartners) to discuss KEIP/KERP request	0.4
08/20/2021	LTN	Call with counsel and financial advisors for Sackler Family Debtor, UCC and AHC and L. Nguyen, G. Koch (both AlixPartners) to discuss Net Proceeds report.	0.6
08/22/2021	LTN	Review indemnification payments for KEIP participants and correspondence with D. Consla (Davis Polk)	0.7
08/23/2021	SKL	Follow-up call with L. Kusinski (Purdue) to discuss latest AHC request.	0.2
08/23/2021	SKL	Meeting with T. Melvin (PJT) to discuss the latest AHC request.	0.3
08/24/2021	JD	Correspondence with FTI and Purdue management re: insurance update.	0.3
08/24/2021	JD	Correspondence with Province and Alix team re: UCC diligence requests.	0.3
08/24/2021	JD	Review update on UCC diligence requests.	0.3
08/24/2021	ADD	Prepare and upload diligence materials to the data room for creditor committee review.	2.4
08/24/2021	HSB	Multiple calls with S.Lemack (AlixPartners) to discuss various Purdue plan related diligence requests	0.9
08/24/2021	HSB	Call with H. Bhattal, S. Lemack, L. Nguyen (AlixPartners) to discuss data reporting and various Purdue plan related diligence requests	0.4
08/24/2021	HSB	Review Purdue diligence materials prepared in response to requests from external parties	1.5
08/24/2021	SKL	Multiple calls with H. Bhattal (AlixPartners) to discuss Purdue Plan related diligence requests.	0.9
08/24/2021	LTN	Review documents status and correspondence with J. Delconte (AlixPartners) related to a UCC request	0.3
08/24/2021	LTN	Call with H. Bhattal, S. Lemack, L. Nguyen (AlixPartners) to discuss data reporting and various Purdue plan related diligence requests	0.4
08/24/2021	SKL	Call with H. Bhattal, S. Lemack, L. Nguyen (AlixPartners) to discuss data reporting and various Purdue plan related diligence requests.	0.4
08/25/2021	JD	Correspondence with Purdue management and FTI re: AHC insurance follow-ups.	0.4
08/25/2021	ADD	Prepare materials for upload to diligence repository.	1.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/25/2021	HSB	Review Purdue diligence materials prepared in response to requests from external parties	1.4
08/26/2021	JD	Call with B. Bromberg (FTI) re: contract diligence.	0.2
08/26/2021	JD	Correspondence with Purdue management and FTI re: AHC insurance diligence update.	0.4
08/26/2021	JD	Correspondence with Davis Polk and Alix team re: KEIP/KERP diligence.	0.5
08/26/2021	JD	Review materials available in response to open AHC contract diligence questions.	0.5
08/26/2021	HSB	Multiple calls with S.Lemack (AlixPartners) to discuss various Purdue plan related diligence requests	1.4
08/26/2021	SKL	Multiple calls with H. Bhattal (AlixPartners) to discuss Purdue Plan related diligence requests.	1.4
08/27/2021	HSB	Review Purdue diligence materials and emailed files to Davis Polk	1.7
08/27/2021	JD	Correspondence with FTI and Purdue management re: insurance follow up call.	0.4
08/30/2021	JD	Insurance update meeting with M. Kesselman, J. Lowne, R. Aleali, C. Ricarte, M. Jack (all Purdue), S. Birnbaum (Dechert), S. Gilbert (Gilbert), A. Kramer (Reed Smith), B. Bromberg, A. Whitman (FTI), J. Rosenbaum (Kramer).	1.0
08/30/2021	JD	Review latest insurance materials in advance of call with the AHC.	0.3
08/30/2021	JD	Review materials collected re: AHC contract diligence request.	0.3
08/30/2021	HSB	Review Purdue diligence materials in connection with requests	0.7
08/30/2021	HSB	Meeting with S. Lemack (AlixPartners) to discuss open AHC items and various Purdue plan related diligence requests	0.6
08/30/2021	SKL	Meeting with H. Bhattal (AlixPartners) to discuss open AHC items and various Purdue plan related diligence requests	0.6
08/30/2021	SKL	Review latest AHC diligence request and prepare updated contract breakdown for the team to review.	1.3
08/31/2021	ADD	Compile and format materials in response to committee diligence requests.	1.6
09/01/2021	ADD	Compile board materials and other document in response to a request from counsel.	2.3
09/01/2021	ADD	Compile contracts from Purdue's client management system in response to diligence request.	2.6
09/01/2021	ADD	Review contract and other data sources to compile data in response to counterparty relationship information request from creditor committee.	2.9
09/01/2021	ADD	Review outstanding diligence requests from creditor committee and compile necessary materials.	1.2
09/01/2021	HSB	Review Purdue due diligence materials	0.6
09/02/2021	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue diligence requests	0.3
09/02/2021	SKL	Call with H. Bhattal (AlixPartners) to discuss Purdue diligence requests	0.3
09/02/2021	ADD	Compile and format materials in response to creditor committee diligence requests.	1.8
09/02/2021	ADD	Compile data needed for Purdue emergence and request outstanding items from Purdue management.	1.7
09/02/2021	ADD	Review contract and other data sources to compile data in response to counterparty relationship information request from creditor committee.	1.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/02/2021	ADD	Review Purdue contract details in response to diligence request from creditor committees.	2.3
09/03/2021	HSB	Call with L.Nguyen (AlixPartners) to discuss Purdue diligence requests	0.2
09/03/2021	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) to discuss request 1 - vendors description from AHC	0.2
09/03/2021	ADD	Compile data needed for Purdue emergence and request outstanding items from Purdue management.	2.0
09/03/2021	ADD	Review contract and other data sources to compile data in response to counterparty relationship information request from creditor committee.	2.7
09/03/2021	ADD	Review outstanding diligence requests from creditor committee and request outstanding items from Purdue management.	1.0
09/03/2021	ADD	Review Purdue's contract management system to identify documents in response to diligence request.	2.5
09/03/2021	HSB	Prepare excel worksheet in response to Purdue diligence request and emailed to Davis Polk	0.4
09/03/2021	JD	Finalize professional fee detail analysis per UCC diligence request.	0.3
09/07/2021	HSB	Review underlying Purdue contracts in connection with diligence request	1.5
09/07/2021	JD	Review initial diligence items to be provided to the AHC advisors.	0.2
09/08/2021	HSB	Call with L.Nguyen (AlixPartners) to discuss Purdue diligence request	0.3
09/08/2021	LTN	Call with H. Bhattal (AlixPartners) to discuss AHC request for contracts	0.3
09/08/2021	HSB	Two calls with S.Lemack (AlixPartners) to discuss Purdue diligence request	0.3
09/08/2021	SKL	Two calls with H. Bhattal (AlixPartners) to discuss various case related matters.	0.3
09/08/2021	HSB	Prepare summary of Purdue info in connection with diligence request	2.4
09/08/2021	LTN	Finalize the descriptions for vendors in response to AHC request 1 and circulate for internal review	2.0
09/08/2021	LTN	Review contracts and provide descriptions for vendors requested by AHC	2.5
09/09/2021	HSB	Review Purdue diligence documents and sent to Davis Polk	1.1
09/09/2021	HSB	Review summary of Purdue info prepared by L.Nguyen (AlixPartners) in connection with diligence request	0.6
09/09/2021	LTN	Prepare a tracker and update status for all AHC requests	1.3
09/10/2021	ADD	Call with H. Bhattal, A. DePalma, L. Nguyen (AlixPartners) re: AHC contracts updates	0.4
09/10/2021	HSB	Call with H. Bhattal, A. DePalma, L. Nguyen (AlixPartners) re: AHC contracts updates	0.4
09/10/2021	LTN	Call with H. Bhattal, A. DePalma, L. Nguyen (AlixPartners) re: AHC contracts updates	0.4
09/10/2021	ADD	Review Purdue contract details in response to diligence request from creditor committees.	1.8
09/10/2021	ADD	Review outstanding diligence requests and compile necessary information.	1.2
09/10/2021	HSB	Call with T.Melvin (PJT), A.Lele, S.Massman, E.Vonnegut (all Davis Polk) to discuss post emergence related work	0.3
09/10/2021	LTN	Consolidate AHC requests re: contracts and circulate to internal team for review	0.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/13/2021	ADD	Call with H. Bhattal, J. DelConte, S. Lemack, L. Nguyen, A. DePalma (all AlixPartners) re: contract diligence questions from the AHC.	0.5
09/13/2021	HSB	Call with J.DelConte, S.Lemack, A.DePalma and L.Nguyen (all AlixPartners) to discuss Purdue diligence request	0.5
09/13/2021	JD	Call with H. Bhattal, J. DelConte, S. Lemack, L. Nguyen, A. DePalma (all AlixPartners) re: contract diligence questions from the AHC.	0.5
09/13/2021	LTN	Call with J. DelConte, H. Bhattal, L. Nguyen, A. DePalma, S. Lemack (all AlixPartners) to discuss the contracts update and diligence request	0.5
09/13/2021	SKL	Call with H. Bhattal, J. DelConte, S. Lemack, L. Nguyen, A. DePalma (all AlixPartners) re: contract diligence questions from the AHC.	0.5
09/13/2021	ADD	Call with H. Bhattal (AlixPartners) to discuss Purdue bankruptcy related matters	0.2
09/13/2021	HSB	Call with A.DePalma (AlixPartners) to discuss Purdue bankruptcy related matters	0.2
09/13/2021	ADD	Research creditor committee diligence request and compile responsive information.	2.7
09/13/2021	ADD	Review Purdue's contract management system to identify documents in response to diligence request.	2.5
09/13/2021	ADD	Review vendor spend data from Purdue's SAP accounting system to evaluate counterparties in response to creditor diligence request.	2.3
09/13/2021	HSB	Review Purdue contracts in connection with diligence request and prepared summary of info	2.6
09/13/2021	JD	Correspondence with Purdue and Alix team re: vendor payment diligence question from the UCC.	0.3
09/13/2021	LTN	Prepare average compensation data per grade and company requested by J. Lowne (Purdue)	1.6
09/14/2021	ADD	Review and compile data in response to counterparty relationship information request.	2.2
09/14/2021	ADD	Review outstanding diligence requests and compile responsive information.	2.2
09/14/2021	ADD	Review Purdue's contract management system to identify documents in response to diligence request.	3.2
09/14/2021	HSB	Review Purdue financial info in connection with diligence request	0.6
09/14/2021	JD	Call with R. Aleali (Purdue) re: AHC diligence requests.	0.2
09/14/2021	JD	Review and provide comments on initial draft response to UCC vendor question.	0.5
09/14/2021	JD	Review and provide comments on the draft insurance presentation for the AHC update call.	0.7
09/14/2021	JD	Review revised vendor payment materials re: UCC request.	0.4
09/14/2021	LTN	Compile termination provisions of 3rd party vendor contracts for AHC due diligence request	1.9
09/15/2021	HSB	Call with H. Bhattal, L. Nguyen (AlixPartners) to discuss August flash report	0.2
09/15/2021	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) to discuss August flash report	0.2
09/15/2021	ADD	Call with A.DePalma, H. Bhattal and L.Nguyen (AlixPartners) to discuss Purdue diligence request	0.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/15/2021	HSB	Call with A.DePalma, H. Bhattal and L.Nguyen (AlixPartners) to discuss Purdue diligence request	0.4
09/15/2021	LTN	Call with H. Bhattal, L. Nguyen, A. DePalma (AlixPartners) to review requests update	0.4
09/15/2021	ADD	Call with S.Lemack, H. Bhattal, A.DePalma and L.Nguyen (all AlixPartners) to discuss Purdue diligence request and contracts update	0.7
09/15/2021	HSB	Call with S.Lemack, H. Bhattal, A.DePalma and L.Nguyen (all AlixPartners) to discuss Purdue diligence request and contracts update	0.7
09/15/2021	LTN	Call with S.Lemack, H. Bhattal, A.DePalma and L.Nguyen (all AlixPartners) to discuss Purdue diligence request and contracts update	0.7
09/15/2021	SKL	Call with S.Lemack, H. Bhattal, A.DePalma and L.Nguyen (all AlixPartners) to discuss Purdue diligence request and contracts update	0.7
09/15/2021	ADD	Compile contracts in response to creditor committee diligence request.	1.5
09/15/2021	ADD	Review and compile data in response to IAC counterparty relationship.	1.8
09/15/2021	ADD	Review outstanding diligence request and compile responsive documents.	1.8
09/15/2021	ADD	Review vendor spend data from Purdue's SAP accounting system to evaluate counterparties in response to creditor diligence request.	1.9
09/15/2021	HSB	Review Purdue contracts in connection with diligence request and prepared summary of information	1.2
09/15/2021	HSB	Review Purdue diligence materials	0.6
09/15/2021	JD	Call with J. Lowne, M. Kesselman, C. Ricarte, R. Aleali, M. Jack (all Purdue), M. Diaz, B. Bromberg, A. Whitman (all FTI), A. Kramer (Reed Smith), S. Gilbert (Gilbert), J. Taub, T. Lenson (both Kramer Levin), G. Coutts (HL) re: post-emergence insurance.	0.6
09/15/2021	JD	Call with M. Diaz (FTI) re: diligence project.	0.5
09/15/2021	JD	Correspondence with Purdue team re: vendor diligence question from the UCC.	0.4
09/15/2021	JD	Review updated summary data for the vendor diligence request per comments from Purdue management.	0.6
09/15/2021	LTN	Compile Vendor descriptions and termination provisions for IACs in response to AHC due diligence requests	1.4
09/15/2021	LTN	Correspondence with Purdue management re: cash forecast working files	0.3
09/16/2021	ADD	Call with H. Bhattal, A. DePalma, and L. Nguyen (AlixPartners) re: Contract diligence update.	0.6
09/16/2021	HSB	Call with H. Bhattal, A. DePalma, and L. Nguyen (AlixPartners) re: Contract diligence update.	0.6
09/16/2021	LTN	Call with H. Bhattal, A. DePalma, and L. Nguyen (AlixPartners) re: Contract diligence update.	0.6
09/16/2021	ADD	Prepare and upload documents in response to diligence request.	2.2
09/16/2021	ADD	Compile contracts in response to creditor committee diligence request.	1.9
09/16/2021	ADD	Compile data in response to IAC counterparty relationship.	2.8
09/16/2021	ADD	Review payment activity for counter parties as part of creditor committee diligence request.	2.3
09/16/2021	HSB	Review Purdue contracts in connection with diligence request and prepared summary of info	0.8



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/16/2021	JD	Correspondence with A. DePalma (AlixPartners) and M. Atkinson (Province) re: vendor diligence question.	0.5
09/16/2021	JD	Correspondence with Province re: vendor diligence questions.	0.4
09/16/2021	JD	Edit and provide follow-up comments on draft contract analysis in response to AHC contract requests.	1.7
09/16/2021	LTN	Finalize the Vendor contracts related IACs request for AHC due diligence	2.3
09/17/2021	HSB	Weekly team update call with J. DelConte, H. Bhattal, L. Donahue, J. Muskovich, A. DePalma, L. Nguyen (all AlixPartners) re: status updates	0.6
09/17/2021	ADD	Compile contracts in response to creditor committee diligence request.	1.5
09/17/2021	ADD	Organize and compile payment details for counter parties requested by creditor committees.	1.2
09/17/2021	ADD	Review and document third-party counterparty relationships in response to diligence request.	2.6
09/17/2021	ADD	Review relevant contracts in response to creditor committee diligence request.	2.6
09/17/2021	HSB	Review Purdue contracts summary prepared by A.DePalma (AlixPartners)	0.8
09/17/2021	HSB	Review Purdue diligence materials prepared by PJT Partners	1.1
09/17/2021	JD	Correspondence with AlixPartners' team re: AHC contract question responses.	0.3
09/20/2021	ADD	Call with H. Bhattal and A. DePalma (AlixPartners) re: outstanding diligence requests.	0.6
09/20/2021	HSB	Call with A.DePalma (AlixPartners) to discuss Purdue bankruptcy related matters	0.6
09/20/2021	ADD	Review and compile data in response to ongoing counterparty relationships	3.2
09/20/2021	ADD	Review board materials to identify relationships with counterparties requested by the creditors.	2.9
09/20/2021	ADD	Review outstanding diligence requests and follow up with appropriate client contact.	1.4
09/20/2021	HSB	Review Purdue diligence materials and related correspondence	1.1
09/20/2021	JD	Review and provide comments on draft AHC contract diligence request responses.	0.7
09/20/2021	JD	Review and provide comments on draft HSR diligence response data.	0.4
09/21/2021	ADD	Two calls with H. Bhattal and A. DePalma (AlixPartners) re: outstanding diligence requests.	0.4
09/21/2021	HSB	Two calls with A.DePalma (AlixPartners) to discuss Purdue diligence related work	0.4
09/21/2021	ADD	Call with L. Nguyen and A. DePalma (AlixPartners) re: ongoing Purdue diligence overview.	0.7
09/21/2021	LTN	Call with A. DePalma, L. Nguyen (AlixPartners) to work on due diligence and SAP processing	0.7
09/21/2021	HSB	Participate in weekly professionals update and planning meeting with J. Turner, T. Melvin, R. Schnitzler, J. Arsic (all PJT), E. Vonnegut, C. Robertson, D. Klein (all Davis Polk), J. DelConte, H. Bhattal (all AlixPartners).	0.5
09/21/2021	ADD	Compile data in response to ongoing counterparty relationships	2.4
09/21/2021	ADD	Review feedback on contract informations request and incorporate comments.	2.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/21/2021	ADD	Review outstanding diligence requests and follow up with appropriate client contact.	1.5
09/21/2021	HSB	Review Purdue diligence materials and related correspondence	1.2
09/21/2021	JD	Review and provide comments on vendor spend data per UCC request.	0.4
09/21/2021	JD	Review status of latest work on AHC diligence responses.	0.5
09/22/2021	SKL	Calls with A. DePalma (AlixPartners) re: outstanding diligence requests.	0.3
09/22/2021	ADD	Calls with H. Bhattal (AlixPartners) re: outstanding diligence requests.	0.3
09/22/2021	ADD	Call with J.DelConte, A.DePalma, H. Bhattal, L.Nguyen (all AlixPartners) and Purdue management re: Purdue diligence request	0.4
09/22/2021	HSB	Call with J.DelConte, A.DePalma, H. Bhattal, L.Nguyen (all AlixPartners) and Purdue management re: Purdue diligence request (left meeting early).	0.2
09/22/2021	JD	Call with J.DelConte, A.DePalma, H. Bhattal, L.Nguyen (all AlixPartners) and Purdue management re: Purdue diligence request	0.4
09/22/2021	LTN	Call with J.DelConte, A.DePalma, H. Bhattal, L.Nguyen (all AlixPartners) and Purdue management re: Purdue diligence request	0.4
09/22/2021	HSB	Call with L.Nguyen (AlixPartners) to discuss Purdue plan related analysis	0.2
09/22/2021	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) to re: cash forecast at emergence	0.1
09/22/2021	ADD	Compile and analyze data in response to a diligence request from counsel.	1.8
09/22/2021	ADD	Compile diligence productions for processing and inclusion into document repository.	2.1
09/22/2021	ADD	Review and compile responses to contract information submitted in response to creditor diligence request.	1.2
09/22/2021	ADD	Update contract details for counterparties requested by creditor committee.	2.2
09/22/2021	HSB	Review diligence materials in connection with requests from third parties	1.4
09/22/2021	JD	Provide comments to FTI on the status of the outstanding AHC diligence requests.	0.7
09/22/2021	JD	Review final insurance presentation to share with the AHC.	0.3
09/23/2021	ADD	Call with A. DePalma and H. Bhattal (AlixPartners) re: outstanding diligence requests and review of potential responsive materials.	1.5
09/23/2021	HSB	Call with A. DePalma and H. Bhattal (AlixPartners) re: outstanding diligence requests and review of potential responsive materials.	1.5
09/23/2021	ADD	Prepare and compile materials submitted in response to diligence requests in preparation for upload to the data room.	2.6
09/23/2021	ADD	Review and compile responses to contract information submitted in response to creditor diligence request.	1.6
09/23/2021	HSB	Prepare summary of Purdue diligence requests	0.3
09/23/2021	HSB	Review Purdue diligence materials in connection with request from creditors	1.6
09/23/2021	JD	Provide comments on latest AHC diligence request responses.	0.4
09/23/2021	LTN	Clean up product insurance report and circulate to Davis Polk for processing	1.4
09/24/2021	ADD	Call with A. DePalma and H. Bhattal (AlixPartners) re: outstanding diligence requests.	0.2
09/24/2021	HSB	Call with A. DePalma and H. Bhattal (AlixPartners) re: outstanding diligence requests.	0.2
09/24/2021	ADD	Compile and analyze data in response to a diligence request from counsel.	2.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/24/2021	ADD	Prepare materials to assist Purdue legal team with diligence request.	2.8
09/24/2021	ADD	Review and compile responses to contract information submitted in response to creditor diligence request.	0.7
09/24/2021	ADD	Review outstanding diligence request and follow up with relevant parties at Purdue.	1.5
09/24/2021	JD	Correspondence with Davis Polk re: UCC vendor payment requests.	0.2
09/24/2021	LTN	Compile organization charts for each 2018 - 2020 period requested by R. Aleali (Purdue)	1.0
09/27/2021	ADD	Review and follow up with outstanding diligence requests.	2.5
09/27/2021	JD	Review latest responses to open AHC diligence questions.	0.4
09/28/2021	ADD	Compile and format materials submitted in response to diligence request in preparation for provided to creditor committee.	1.6
09/28/2021	ADD	Review diligence requests and compile responsive materials.	2.4
09/28/2021	ADD	Review materials previously submitted in response to diligence request to determine responsiveness to new request.	2.9
09/28/2021	JD	Look into follow-up questions from Province re: vendor payments.	0.5
09/28/2021	JD	Review correspondence between Davis Polk, Purdue management and A. DePalma (AlixPartners) re: DOJ diligence materials.	0.4
09/29/2021	ADD	Compile and provide requested diligence material to counsel.	0.5
09/29/2021	ADD	Download payment data from Purdue's SAP accounting system and compile information in response to UCC diligence request.	1.5
09/29/2021	ADD	Review diligence requests and compile responsive materials.	2.6
09/29/2021	HSB	Prepare Purdue due diligence update for third parties	0.3
09/29/2021	JD	Review update on status of responses to the AHC contract diligence requests.	0.3
09/30/2021	ADD	Review diligence requests and compile responsive materials.	2.4
09/30/2021	JD	Correspondence with Purdue management, Davis Polk and Skadden re: UCC requests.	0.3
<b>Total Professional Hours</b>			<b>445.4</b>





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Communication with Interested Parties  
Code: 1.4 / 104

<b>PROFESSIONAL</b>	<b>TITLE</b>	<b>RATE</b>	<b>HOURS</b>	<b>FEES</b>
Jesse DelConte	Managing Director	\$1,055	64.2	67,731.00
Kevin M McCafferty	Director	\$980	1.9	1,862.00
Gabe J Koch	Director	\$865	13.0	11,245.00
HS Bhattal	Director	\$865	55.0	47,575.00
Sam K Lemack	Senior Vice President	\$665	41.3	27,464.50
Andrew D DePalma	Vice President	\$625	219.2	137,000.00
Lan T Nguyen	Vice President	\$530	50.8	26,924.00
<b>Total Professional Hours and Fees</b>			<b>445.4</b>	<b>\$ 319,801.50</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements  
Code: 1.5 / 105

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/01/2021	LTN	Correspondence with C. Robertson (Davis Polk) re: OCP April report	0.2
06/01/2021	JD	Provide comments on latest monthly OCP report to be filed with the court.	0.3
06/03/2021	JD	Review new MOR requirements.	0.4
06/08/2021	LTN	Submit data requests to various Purdue teams to prepare the May 2021 MOR	0.3
06/09/2021	LTN	Prepare the bank account balances section of the May 2021 monthly operating report	1.7
06/09/2021	LTN	Prepare the cash activity section of the May 2021 monthly operating report	1.9
06/11/2021	JD	Review details from the UST's office on the latest MOR requirements.	0.3
06/17/2021	LTN	Prepare the Insider payments section of May 2021 monthly operating report	1.8
06/17/2021	LTN	Prepare the professional fee payments section of the May 2021 monthly operating report and circulated to C. MacDonald (Purdue) for review	1.7
06/17/2021	LTN	Review MOR new form requirement before the call with DOJ	0.4
06/17/2021	LTN	Call with S. Lemack, L. Nguyen (AlixPartners) and J. Nadkarni (DOJ) re: the new MOR format requirement	0.6
06/17/2021	HSB	Call with S.Lemack (AlixPartners) re: Purdue MOR reporting	0.3
06/17/2021	HSB	Review Purdue due diligence related info prepared by A. DePalma (AlixPartners) in response to request from DOJ	0.4
06/17/2021	SKL	Call with S. Lemack, L. Nguyen (AlixPartners) and J. Nadkarni (DOJ) re: the new MOR format requirement	0.6
06/17/2021	SKL	Call with H. Bhattal (AlixPartners) re: latest MOR updates.	0.3
06/18/2021	LTN	Review financial statements provided by J. Lowne (Purdue) and consolidate May 2021 MOR for the CFO sign-off	2.5
06/18/2021	LTN	Revise professional fee payments section of the May 2021 MOR based on C. MacDonald (Purdue) feedback	1.1
06/18/2021	LTN	Prepare debtor questionnaire section of the May 2021 MOR	0.4
06/18/2021	LTN	Reconcile active/ closed bank accounts based on data provided by J. Marsha (Purdue) and update the bank account balances section of the May 2021 MOR	0.5
06/18/2021	JD	Review and provide comments on draft MOR.	0.3
06/21/2021	JD	Correspondence with Davis Polk, management and H. Bhattal, L. Nguyen (both AlixPartners) re: MOR reporting.	0.4
06/25/2021	LTN	Review the latest OCP data provided by C. MacDonald (Purdue) and prepared OCP report for May 2021 invoices	1.9
06/29/2021	HSB	Review Purdue OCP report prepared by L. Nguyen (AlixPartners) and related documents	0.4
06/29/2021	LTN	Revise the May OCP report based on C. MacDonald (Purdue) feedback and circulate to Davis Polk	1.6
07/01/2021	LTN	Correspondence with R. Robbins (AlixPartners) re: new MOR format	0.3
07/08/2021	LTN	Prepare the bank account balances section of the June 2021 monthly operating report	1.7
07/08/2021	LTN	Prepare the cash activity section of the June 2021 monthly operating report	1.9
07/08/2021	LTN	Finalize the indemnification report based on feedback from C. MacDonald (Purdue) and circulate for internal review	1.1
07/08/2021	LTN	Call with S. Lemack (AlixPartners) to discuss MOR preparation	0.3
07/08/2021	SKL	Call with L. Nguyen (AlixPartners) to discuss MOR preparation.	0.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements  
Code: 1.5 / 105

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/09/2021	SKL	Call with L. Nguyen (AlixPartners) to discuss latest MOR updates.	0.3
07/09/2021	LTN	Call with S. Lemack (AlixPartners) to discuss latest MOR updates	0.3
07/12/2021	LTN	Submit data requests to various Purdue teams to prepare the June 2021 MOR	0.4
07/15/2021	LTN	Prepare a template for cash receipts / disbursements for the new MOR format	1.9
07/15/2021	LTN	Pull SAP data and calculate a Purdue director's total compensation requested by the examiner	1.1
07/16/2021	LTN	Prepare the Insider payments section of June 2021 monthly operating report	2.3
07/16/2021	LTN	Prepare the professional fee payments section of the June 2021 monthly operating report and circulated to C. MacDonald (Purdue) for review	1.2
07/19/2021	JD	Review latest trustee guidance and correspondence with L. Nguyen (AlixPartners) re: MOR reporting requirements.	0.4
07/19/2021	JD	Review draft June financials for the upcoming MOR.	0.2
07/19/2021	LTN	Prepare schedule of cash receipts/ disbursements for June MOR for 24 debtors and upload to the automation toll	2.1
07/19/2021	LTN	Call with A. DePalma, L. Nguyen (AlixPartners) to discuss new MOR form	0.2
07/19/2021	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) to discuss Newco cash flows	0.4
07/19/2021	LTN	Reconcile schedule of cash receipts/ disbursements for June MOR for individual entities vs consolidated cash balances	1.7
07/19/2021	ADD	Call with A. DePalma, L. Nguyen (AlixPartners) re: MOR	0.2
07/22/2021	SKL	Meeting with L. Nguyen (AlixPartners) to discuss MOR format and preparation.	0.5
07/22/2021	SKL	Calls with J. Muskovich (AlixPartners) to discuss latest MOR templates and updating the June MOR accordingly.	1.4
07/22/2021	SKL	Call with J. Clarrey (AlixPartners) to discuss latest MOR templates and updating the June MOR accordingly.	0.3
07/22/2021	SKL	Review latest feedback and prepare updates to MOR format accordingly.	1.9
07/22/2021	HSB	Attend part of call with J.Horgan and L.Nguyen (both AlixPartners) re: MOR	0.3
07/22/2021	JD	Correspondence with Purdue HR re: updated MOR reporting requirements.	0.2
07/22/2021	JD	Correspondence with Davis Polk and Purdue management re: KEIP/KERP negotiations.	0.4
07/22/2021	LTN	Revise the Part 1- cash receipts and disbursement for individual debtors and reconcile against schedule MOR 1a,1b	2.8
07/22/2021	LTN	Call with J. Horgan, H. Bhattal, L. Nguyen (AlixPartners) to discuss part 1 - cash schedule for the new MOR process	0.3
07/22/2021	LTN	Revise the MOR template for individual debtors and upload to the automation form	2.5
07/22/2021	LTN	Correspondence with J. Nadkarni (UST) re new MOR requirement	0.9
07/22/2021	LTN	Prepare employee counts for individual debtors for the new MOR process	1.6
07/23/2021	LTN	Review errors in the MOR template for individual debtors and re-upload to the automation form	1.0
07/26/2021	JD	Review and provide comments on the updated draft MOR form for May.	0.4
07/26/2021	LTN	Prepare debtor questionnaire section of the June 2021 MOR	0.5
07/26/2021	LTN	Review financial statements provided by J. Lowne (Purdue) and consolidate to June 2021 MOR	1.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements  
Code: 1.5 / 105

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/26/2021	LTN	Update Coverage and signature page of the new MOR form for all individual debtors	1.0
07/26/2021	LTN	Call with A. DePalma, L. Nguyen (AlixPartners) to discuss MOR	0.2
07/26/2021	LTN	Call with B. Young (AlixPartners) re: automation tool for the new MOR process	0.2
07/26/2021	LTN	Draft a list of issues re: automation template for uploading MOR to B. Young (AlixPartners)	1.0
07/26/2021	LTN	Prepare a reconciliation between Part 1 - Cash schedule MOR vs intercompany transfers and correspondence with J.DelConte, H. Bhattal (AlixPartners)	2.5
07/26/2021	LTN	Draft a list of new MOR form issues and correspondence with J. Nadkarni (USTP)	1.2
07/26/2021	ADD	Call with A. DePalma, L. Nguyen (AlixPartners) to discuss MOR	0.2
07/27/2021	HSB	Review draft of Purdue MOR prepared by L.Nguyen (AlixPartners) based on new reporting requirements for multiple debtor entities and provided comments	1.8
07/27/2021	LTN	Calculate Q2 2021 US Trustee fee and circulate to H. Benson (Purdue) for processing payment	0.9
07/27/2021	LTN	Finalize reconciliation for calculated cash balances vs actual ending balances for 24 debtors and summarize findings to internal team	1.8
07/27/2021	LTN	Update Part 7- questionnaire of the new MOR form for all individual debtors	1.3
07/27/2021	LTN	Correspondence with J. Nadkarni (USTP) re: open items on the new MOR form	0.8
07/27/2021	LTN	Correspondence with D. Consla, C. Robertson (DavisPolk) re: MOR new requirement	0.5
07/28/2021	JD	Call with J. Lowne, E. Nowakowski (both Purdue), J. DelConte, H. Bhattal, S. Lemack, L. Nguyen (all AlixPartners) re: new MOR form.	0.2
07/28/2021	JD	Correspondence with H. Bhattal and L. Nguyen (both AlixPartners) re: MOR edits.	0.3
07/28/2021	HSB	Call with L.Nguyen (AlixPartners) to discuss Purdue MOR	0.2
07/28/2021	SKL	Meeting with J. Lowne, E. Nowakowski (both Purdue), J. DelConte, H. Bhattal and L. Nguyen (all AlixPartners) to discuss new MOR format.	0.2
07/28/2021	LTN	Consolidate new MOR report for PPLP and individual debtors and circulate for internal review	1.7
07/28/2021	LTN	Review the latest OCP data provided by C. MacDonald (Purdue) and prepared OCP report for June 2021 invoices	1.7
07/28/2021	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) re: new MOR format update	0.2
07/28/2021	LTN	Call among J. DelConte, S. Lemack, H. Bhattal, L. Nguyen (AlixPartners), J. Lowne (Purdue) to discuss new MOR format	0.2
07/28/2021	LTN	Correspondence to J. Lowne (Purdue) re: new MOR format requirement	0.4
07/28/2021	HSB	Call with J. Lowne, E. Nowakowski (both Purdue), J. DelConte, H. Bhattal, S. Lemack, L. Nguyen (all AlixPartners) re: new MOR form.	0.2
07/30/2021	HSB	Call with C. Robertson, D.Consla (both Davis Polk) and L.Nguyen (AlixPartners) re: MOR	0.3
07/30/2021	HSB	Call with J.DelConte and S.Lemack (both AlixPartners) re: diligence materials requested	0.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements  
Code: 1.5 / 105

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/30/2021	HSB	Review MOR prepared by L.Nguyen (AlixPartners) and prepared related writeup	0.5
07/30/2021	SKL	Call with J. DelConte and H. Bhattal (both AlixPartners) to touch base on latest diligence requests.	0.4
07/30/2021	JD	Meeting with J. DelConte, H. Bhattal, S. Lemack (all AlixPartners) re: open diligence requests.	0.4
07/30/2021	LTN	Insert notes and finalize the consolidated June MOR report and circulate to C. Robertson, D. Consla (DavisPolk) for review	2.3
07/30/2021	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners), C. Robertson, D. Consla (both DavisPolk) re: new MOR format update	0.3
07/30/2021	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) re: new MOR format update	0.1
07/30/2021	LTN	Call with A. DePalma, L. Nguyen (both AlixPartners) to update MOR	0.4
07/30/2021	ADD	Call with A. DePalma, L. Nguyen (both AlixPartners) to update MOR	0.4
08/02/2021	HSB	Call with L.Nguyen (AlixPartners) to discuss Purdue MOR	0.1
08/02/2021	LTN	Call with H. Bhattal (AlixPartners) to discuss update on the MOR	0.1
08/03/2021	HSB	Review draft of Purdue MOR prepared by L.Nguyen (AlixPartners)	0.2
08/03/2021	JD	Review updated MOR sent to management for sign-off.	0.2
08/04/2021	LTN	Revise notes to Part 2 -8 MOR form and finalize June MOR report based on D. Consla (DWP) feedback	1.7
08/04/2021	JD	Correspondence with L. Nguyen (AlixPartners) and Davis Polk re: June MOR.	0.2
08/10/2021	LTN	Revise US Trustee fee for Q2 2021 and correspondence with J. Nadkarni (DOJ)	0.7
08/10/2021	LTN	Submit data requests to various Purdue teams to prepare the July 2021 MOR	0.4
08/16/2021	LTN	Prepare the Insider payments section of July 2021 monthly operating report	1.9
08/16/2021	LTN	Prepare the professional fee payments section of the July 2021 monthly operating report and circulated to C. MacDonald (Purdue) for review	1.7
08/16/2021	LTN	Prepare the cash activity section of the July 2021 monthly operating report	2.1
08/18/2021	HSB	Call with L.Nguyen (AlixPartners) to discuss various Purdue bankruptcy related matters	0.2
08/18/2021	LTN	Prepare the bank account balances section of the July 2021 monthly operating report	2.0
08/18/2021	LTN	Prepare Part 1 - Cash receipts and disbursements section of the July 2021 MOR for individual debtors	2.2
08/18/2021	LTN	Call with H. Bhattal (AlixPartners) re: July MOR	0.2
08/19/2021	HSB	Review MOR prepared by L.Nguyen (AlixPartners)	1.1
08/19/2021	LTN	Consolidate the July MOR report and circulate for internal review	2.3
08/19/2021	LTN	Review financial statements provided by J. Lowne (Purdue) and consolidate to July 2021 MOR	0.8
08/19/2021	LTN	Prepare the debtor questionnaire section of the July 2021 MOR	0.6
08/19/2021	LTN	Reconcile Part 1 - Cash schedule vs Intercompany transfers for the July 2021 MOR	2.0
08/19/2021	LTN	Call with H. Bhattal (AlixPartners) re: the July MOR	0.1
08/19/2021	JD	Review and provide comments on the July MOR.	0.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements  
Code: 1.5 / 105

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/20/2021	LTN	Revise the July 2021 MOR report based on the internal feedback and circulate for CFO sign-off	0.6
08/27/2021	HSB	Review Purdue monthly OCP report prepared by L.Nguyen (AlixPartners)	0.4
08/27/2021	LTN	Review the latest OCP data provided by C. MacDonald (Purdue) and prepared OCP report for July 2021 invoices	2.5
08/30/2021	JD	Review and comment on the latest OCP report to be filed with the court.	0.3
09/15/2021	LTN	Prepare the professional fee payments section of the August 2021 monthly operating report and circulate to C. MacDonald (Purdue) for review	1.8
09/15/2021	LTN	Submit data requests to various Purdue teams to prepare the August 2021 MOR	0.5
09/16/2021	LTN	Prepare the Insider payments section of August 2021 monthly operating report	2.0
09/16/2021	LTN	Prepare the bank account balances section of the August 2021 monthly operating report	2.1
09/20/2021	JD	Review and provide comments on draft August MOR.	0.3
09/20/2021	LTN	Consolidate the August MOR report and circulate for internal review	1.9
09/20/2021	LTN	Prepare Part 1 - Cash receipts and disbursements section of the August 2021 MOR for individual debtors	2.2
09/20/2021	LTN	Prepare the cash activity section of the August 2021 monthly operating report	2.1
09/20/2021	LTN	Prepare the debtor questionnaire section of the August 2021 MOR	0.5
09/20/2021	LTN	Review financial statements provided by J. Lowne (Purdue) and consolidate to August 2021 MOR	0.6
09/21/2021	HSB	Review Purdue MOR draft prepared by L.Nguyen (AlixPartners)	0.8
09/21/2021	JD	Review and provide comments on latest business development deal court filing papers.	0.5
09/24/2021	LTN	Reconcile Cash receipts/ disbursement schedule vs cash account balances based on H. Bhattal (AlixPartners) feedback	1.7
09/24/2021	LTN	Reconcile Cash receipts/ disbursement schedule vs Intercompany transfers for individual debtors for the August 2021 MOR	2.0
09/29/2021	HSB	Review monthly OCP report prepared L. Nguyen (AlixPartners)	0.3
09/30/2021	JD	Review and provide comments on monthly OCP report.	0.2
09/30/2021	LTN	Correspondence with Purdue management re: MOR insider expenses	0.1
<b>Total Professional Hours</b>			<b>123.8</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements  
Code: 1.5 / 105

<b>PROFESSIONAL</b>	<b>TITLE</b>	<b>RATE</b>	<b>HOURS</b>	<b>FEES</b>
Jesse DelConte	Managing Director	\$1,055	6.3	6,646.50
HS Bhattal	Director	\$865	7.9	6,833.50
Sam K Lemack	Senior Vice President	\$665	6.2	4,123.00
Andrew D DePalma	Vice President	\$625	0.8	500.00
Lan T Nguyen	Vice President	\$530	102.6	54,378.00
<b>Total Professional Hours and Fees</b>			<b>123.8</b>	<b>\$ 72,481.00</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/01/2021	GJK	Meeting with H Ghnainmeh and Z Haseed (Purdue), S. Lemack (AlixPartners) re: IT work plan transition.	0.5
06/01/2021	GJK	Respond to M Atkinson (Province) and M Diaz (FTI) re: IAC excess cash sweep and Pod 8 backstop.	0.7
06/01/2021	GJK	Call with M Atkinson, C Kaulwalder (Province) and M Diaz (FTI) re: Samantha Sackler and IAC cash sweep.	0.3
06/01/2021	GJK	Review recourse options for default by Samantha Sackler (Pod 8).	0.8
06/01/2021	GJK	Edits to E Hwang (Davis Polk) email re: Sackler Family assets description.	0.7
06/01/2021	GJK	Email to L. Nguyen (AlixPartners) re: detailed follow-up on asset values for Side A and Side B Family	0.8
06/01/2021	GJK	Review Sackler website for any potential challenges to asset information presented in Disclosure Statement supplement.	1.1
06/01/2021	GJK	Calls with E Hwang (Davis Polk) re: additional language for disclosure statement.	0.2
06/01/2021	GJK	Review and edits to blackline versions of language on obligor coverage disclosure.	2.2
06/01/2021	GJK	Review disclosure language and edits for potential issues; loop in J Turner (PJT) and J DelConte (AlixPartners).	1.1
06/01/2021	GJK	Review open Sackler Trust diligence items; email Huron re: updated balance sheets.	0.4
06/01/2021	GJK	Review Side A net asset value breakdown (ongoing).	1.1
06/01/2021	GJK	Assess options for IAC cash sweeps (continued).	0.9
06/01/2021	GJK	Prioritize key items for diligence follow up prior to Disclosure Statement hearing.	0.5
06/01/2021	LTN	Call with A. DePalma, L. Nguyen, S. Lemack (AlixPartners), Z. Haseeb (Purdue) to walk through license application process	0.3
06/01/2021	SKL	Meeting with H. Ghnainmeh, Z. Haseeb (both Purdue) and G. Koch (AlixPartners) to review latest updates re: IT transfer work plan.	0.5
06/01/2021	SKL	Call with A. DePalma (AlixPartners) re: state license application process.	0.2
06/01/2021	SKL	Review latest state license application breakdown and prepare updated notes and feedback accordingly.	1.2
06/01/2021	ADD	Update state (IN) license application and compile open items for Purdue legal team review.	1.8
06/01/2021	ADD	Update state (IA) license application and compile open items for Purdue legal team review.	2.2
06/01/2021	ADD	Review outstanding license applications items and draft correspondence to follow up.	1.5
06/01/2021	JD	Provide comments on latest draft PEO flash report to provide to the creditors.	0.4
06/01/2021	ADD	Call with A. DePalma, L. Nguyen, S. Lemack (AlixPartners), Z. Haseeb (Purdue) to walk through license application process	0.3
06/01/2021	ADD	Call with S. Lemack (AlixPartners) re: state license application process.	0.2
06/01/2021	SKL	Call with A. DePalma, L. Nguyen, S. Lemack (AlixPartners), Z. Haseeb (Purdue) to walk through license application process	0.3
06/02/2021	GJK	Call with L Nguyen (AlixPartners) re: Side A and Side B total assets.	0.5





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/02/2021	GJK	Calls with J Turner (PJT) re: language for Disclosure Statement rider.	0.4
06/02/2021	GJK	Call with M Diaz (FTI) re: Disclosure Statement updated language.	0.1
06/02/2021	GJK	Listen into Disclosure Statement hearing call for updates/guidance required re: language on Settlement Agreement.	1.6
06/02/2021	GJK	Review and comment on disclosure statement addendum comments and edits from Davis Polk.	1.0
06/02/2021	GJK	Ongoing review and comments to Disclosure Statement addendum language from Davis Polk.	1.9
06/02/2021	GJK	Ongoing review and comments on updates to Disclosure Statement rider after sent out for comments to Family counsel, UCC and AHC counsel.	1.7
06/02/2021	GJK	Email exchanges with J Turner (PJT) re: reference to value in the Disclosure Statement addendum.	0.4
06/02/2021	GJK	Compare Congress Hearing disclosures by Sackler to information provided to Financial Advisors per questions during Disclosure Statement hearing.	1.0
06/02/2021	GJK	Review written testimony from Sackler Family members testifying before Congress (along with other documents for House Committee hearing) as follow up to questions on completeness of Sackler Family wealth raised in Disclosure Statement hearing.	0.8
06/02/2021	GJK	Coordinate updates to statement in Disclosure Statement to respond to the Court's questions re: Sackler Family wealth disclosure, including exchanges J Turner (PJT) and A Libby (Davis Polk).	0.8
06/02/2021	GJK	Coordinate updates to statement in Disclosure Statement to respond to the Court's questions re: Sackler Family wealth disclosure, including providing feedback on comments made by A Preis (Akin Gump), and terminology used by Sacklers for IAC number ("Hypothetical IAC Value").	1.6
06/02/2021	GJK	Draft responses to A Preis (Akin Gump) questions re: additional language to Disclosure Statement; review M Atkinson (Province) responses.	0.7
06/02/2021	LJD	Review and comment on correspondence re: expert reports, timing etc for confirmation	0.4
06/02/2021	LTN	Review article 2 section in the latest Settlement agreement	1.6
06/02/2021	LTN	Compare A-side net asset value between the 2019 and 2020 dataset	0.5
06/02/2021	LTN	Call with G. Koch (AlixPartners) re: shareholder value	0.5
06/02/2021	LTN	Revise all A-side asset value report and bridge the 2019 report's variance	2.1
06/02/2021	LTN	Check all A-side groups' asset value data against the proposed groups' data and bridge the variance	1.5
06/02/2021	SKL	Pull latest invoice and payment detail from SAP and review/provide update accordingly.	1.2
06/02/2021	ADD	Review and compile license application open items for Purdue legal team review.	2.3
06/02/2021	ADD	Address Purdue comments in license applications in preparation for application filing.	1.6
06/02/2021	ADD	Update state (HI) license application and compile open items for Purdue legal team review.	0.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/02/2021	ADD	Incorporate Purdue comments in license applications in preparation for application filing.	1.1
06/02/2021	ADD	Compile supplementary materials for MN state license application for final review and filing.	0.9
06/02/2021	ADD	Update state (IL) license application and compile open items for Purdue legal team review.	0.5
06/02/2021	JD	Review 2020 audited financial statements presented to the Audit Committee of the Board.	1.5
06/02/2021	JD	Call with G. Koch (AlixPartners) re: shareholder wealth.	0.2
06/02/2021	GJK	Call with J. DelConte (AlixPartners) re: shareholder wealth.	0.2
06/03/2021	GJK	Update and coordinate on weekly Purdue execs and advisors call.	0.6
06/03/2021	GJK	Call with L. Nguyen (AlixPartners) re: updating Side A and Side B data tables.	0.6
06/03/2021	GJK	Review balance sheet information from Side A informational presentations for timing of updates.	1.4
06/03/2021	GJK	Review balance sheet information from Side B informational presentations for timing of updates.	1.6
06/03/2021	GJK	Compare A Side Collateral values for Individual and Trust Obligor data to Settlement Agreement deck (which reflected earlier values for Pod 2).	0.8
06/03/2021	GJK	Compare Side B paying parties in April Settlement Agreement draft appendix to Side B asset information.	1.1
06/03/2021	GJK	Compare Side B Paying Parties against Raymond Side IAC Structure deck for relationship of trusts.	0.8
06/03/2021	LTN	Finalize the A-side asset value report based on feedback from G. Koch (AlixPartners)	1.8
06/03/2021	LTN	Reconcile B-Side asset value excel report vs the presentation deck and bridge the variance	1.6
06/03/2021	LTN	Call with G. Koch (AlixPartners) re: on shareholder due diligence's next steps	0.6
06/03/2021	LTN	Revise the B-side asset value report based on feedback from G. Koch (AlixPartners)	1.5
06/03/2021	LTN	Categorize A-side parties in the shareholder info deck to pods' Obligors and revise the credit support balances	1.5
06/03/2021	LTN	Call with S. Lemack (AlixPartners) re: various case related matters.	0.5
06/03/2021	SKL	Call with L. Nguyen (AlixPartners) re: various case related matters.	0.5
06/03/2021	ADD	Update state (IL) license application and compile open items for Purdue legal team review.	1.6
06/03/2021	ADD	Update state (HI) license application and compile open items for Purdue legal team review.	0.8
06/03/2021	ADD	Compile license application open items for Purdue legal team review.	1.5
06/03/2021	ADD	Update state (KY) license application and compile open items for Purdue legal team review.	1.7
06/03/2021	ADD	Incorporate Purdue comments in license applications in preparation for application filing.	1.3
06/03/2021	JD	Provide comments on latest change of control timeline.	0.5
06/03/2021	LJD	Review FA expert reports	0.1



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/04/2021	GJK	Call with counsel and advisors from Sackler Family Side A, Debtor, UCC and AHC re: open issues in Side A Term Sheets.	1.5
06/04/2021	GJK	Update and coordinate on AlixPartners team call.	0.4
06/04/2021	GJK	Email exchanges with M Atkinson (Province) re: Side A term sheets.	0.3
06/04/2021	GJK	Read through of Multipod Credit Term Sheet redline.	0.6
06/04/2021	GJK	Read through of Side A Pod 2 Term Sheet red line.	0.7
06/04/2021	GJK	Review Side A Pod 4 Term Sheet redline.	0.8
06/04/2021	GJK	Review updated B-Side Net Asset Report from L Nguyen (AlixPartners).	1.3
06/04/2021	GJK	Review updated change of control schematic from S Lemack (AlixPartners).	0.4
06/04/2021	GJK	Review email from R AleAli re change of control schematic and next steps.	0.3
06/04/2021	GJK	Prepare for call with Debevoise and counsel for Debtor, UCC and AHC re: open items in Side A term sheets.	0.2
06/04/2021	LJD	Review updated timeline	0.4
06/04/2021	HSB	Call with A. DePalma (AlixPartners) re: Purdue bankruptcy related matters and state license application process	0.3
06/04/2021	LTN	Update latest info reg: group 2's obligors to the A-side's total asset value report	1.1
06/04/2021	LTN	Reconcile B-Side payment parties/ trusts in the settlement agreement vs shareholder info deck based on the family charts	2.3
06/04/2021	ADD	Compile liabilities subject to comprise report for May.	2.4
06/04/2021	ADD	Update CA state license application and compile open items for Purdue legal team review.	1.9
06/04/2021	ADD	Upload documents provided by Davis Polk's eDiscovery team for creditor committee review.	2.1
06/04/2021	ADD	Call with H. Bhatta (AlixPartners) re: state license application process and Purdue bankruptcy related matters	0.3
06/04/2021	JD	Correspondence with AlixPartners team re: open requests for assistance from Purdue on new workstreams.	0.4
06/04/2021	JD	Review latest draft responses from Purdue management to open DOJ requests.	0.7
06/06/2021	GJK	Review Annex - Multi-Credit Support rider from Davis Polk.	0.8
06/07/2021	JD	Review and provide comments on draft change of control deck from S. Lemack (AlixPartners).	0.4
06/07/2021	JD	Review compensation analysis from WTW and compare against historical management comp.	0.8
06/07/2021	GJK	Draft open items email to financial advisors for UCC and AHC re: trust balance sheets and IACs.	0.4
06/07/2021	GJK	Call with L Nguyen (AlixPartners) to walk through update Side B Net Assets workbook.	0.7
06/07/2021	GJK	Review Disclosure Statement Collateral B Term Sheet version for language re: how collateral assets value is measured.	0.9
06/07/2021	GJK	Draft response to email from M Atkinson (Province) on open items.	0.3
06/07/2021	GJK	Draft email to Province and FTI re: B-Side payment parties; update B-Side payment parties excel sheet.	0.4
06/07/2021	GJK	Review B Side payment parties information and intermediate entities language in 03.01.21 Raymond Side presentation.	0.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/07/2021	GJK	Prepare for change of control IT work plan discussion with Purdue IT, Legal and S Lemack (AlixPartners).	0.4
06/07/2021	GJK	Review exchanges with Huron for outstanding questions for IAC-impacted diligence.	1.1
06/07/2021	LTN	Finalize B side paying parties reconciliation based on G. Koch (AlixPartners) feedback	1.5
06/07/2021	LTN	Revise B-side paying parties list and correspondence with FTI, Province re the open items	0.6
06/07/2021	LTN	Prepare the incurrence tests analysis for B-side collateral term sheet	2.0
06/07/2021	LTN	Call with G. Koch (AlixPartners) re: on B-side payment parties	0.7
06/07/2021	SKL	Prepare and circulate updated breakdown of restructuring fees accrued and paid to date.	1.0
06/07/2021	HSB	Call with A. DePalma (AlixPartners) re: state license project status.	0.4
06/07/2021	ADD	Call with H. Bhattal (AlixPartners) re: state license project status.	0.4
06/07/2021	ADD	Review in process state license applications and incorporate comments from Purdue legal team.	2.6
06/07/2021	ADD	Prepare state license applications for Purdue Pharmaceuticals.	1.5
06/08/2021	JD	Call with R. Aleali (Purdue) re: change of control process.	0.2
06/08/2021	JD	Call with A. DePalma, J. DelConte, H. Bhattal and L. Nguyen (all AlixPartners) re: licensing workstream and change of control process.	0.4
06/08/2021	JD	Correspondence with Davis Polk and WTW re: compensation analysis.	0.6
06/08/2021	JD	Review revised WTW materials to be shared with advisors.	0.4
06/08/2021	JD	Correspondence with Purdue management re: professional fee payments.	0.3
06/08/2021	JD	Correspondence with H. Bhattal (AlixPartners) and Davis Polk re: Project Plex data room.	0.2
06/08/2021	JD	Create break down of management comp by AIP and LTRP for previous years.	0.5
06/08/2021	GJK	Call with S. Lemack, G. Koch, H. Bhattal, L. Nguyen and A. DePalma (AlixPartners); S. Hoffman and Z. Haseeb (Purdue) re: license application workstream touch base meeting.	0.3
06/08/2021	GJK	Review license tracker from Z Haseeb (Purdue).	0.6
06/08/2021	GJK	Detailed walkthrough of Sackler Family A-Side assets and outstanding diligence requests.	1.4
06/08/2021	GJK	Assess potential future excess cash flows from IACs based on 2021 to 2025 financial projections.	1.4
06/08/2021	LTN	Finalize the incurrence tests analysis draft for B-side's collateral term sheet and circulated to G. Koch (AlixPartners) for review	1.5
06/08/2021	LTN	Call with A. DePalma, J. DelConte, H. Bhattal and L. Nguyen (all AlixPartners) re: licensing workstream and change of control process.	0.4
06/08/2021	LTN	Call with S. Lemack, G. Koch, H. Bhattal, L. Nguyen and A. DePalma (AlixPartners); S. Hoffman and Z. Haseeb (Purdue) re: license application workstream touch base meeting.	0.3
06/08/2021	LTN	Update new scenarios for the incurrence tests analysis draft for B-side's collateral term sheet	2.2
06/08/2021	LTN	Fill state license application for Oklahoma	1.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/08/2021	SKL	Call with S. Lemack, G. Koch, H. Bhattal, L. Nguyen and A. DePalma (AlixPartners); S. Hoffman and Z. Haseeb (Purdue) re: license application workstream touch base meeting.	0.3
06/08/2021	SKL	Finalize review of latest notes and feedback re: change of control process and update the PMO tracker and weekly agenda accordingly.	2.4
06/08/2021	SKL	Finalize updates to the IP transfer work plan and circulate to K. McCarthy (Purdue) accordingly.	0.8
06/08/2021	SKL	Finalize additional updates to the change of control overview deck and circulate accordingly.	0.4
06/08/2021	SKL	Continue to review latest feedback re: IT transfer work plan and update the tracker accordingly.	0.7
06/08/2021	HSB	Call with S. Lemack, G. Koch, H. Bhattal, L. Nguyen and A. DePalma (AlixPartners); S. Hoffman and Z. Haseeb (Purdue) re: license application workstream touch base meeting.	0.3
06/08/2021	HSB	Call with A. DePalma, J. DelConte, H. Bhattal and L. Nguyen (all AlixPartners) re: licensing workstream and change of control process.	0.4
06/08/2021	ADD	Call with S. Lemack, G. Koch, H. Bhattal, L. Nguyen and A. DePalma (AlixPartners); S. Hoffman and Z. Haseeb (Purdue) re: license application workstream touch base meeting.	0.3
06/08/2021	ADD	Call with A. DePalma, J. DelConte, H. Bhattal and L. Nguyen (all AlixPartners) re: licensing workstream and change of control process.	0.4
06/08/2021	ADD	Compile supplementary materials for completed applications for Purdue legal team review.	2.3
06/08/2021	ADD	Prepare state license applications for Purdue Pharmaceuticals.	2.5
06/08/2021	ADD	Review in process state license applications and incorporate comments from Purdue legal team.	1.5
06/08/2021	ADD	Review and provide comments for applications completed by AlixPartners team members.	1.3
06/09/2021	JD	Call with D. Consla (Davis Polk) re: KEIP/KERP analysis.	0.3
06/09/2021	JD	Correspondence with Davis Polk and S. Lemack (AlixPartners) re: payment present value calculations.	0.5
06/09/2021	JD	Correspondence with M. Kesselman (Purdue) re: Monitor assistance.	0.3
06/09/2021	JD	Review and provide comments on draft business development slides for the Board.	0.7
06/09/2021	JD	Correspondence with Davis Polk re: business plan support files.	0.2
06/09/2021	JD	Review and provide comments on various KEIP/KERP materials.	0.6
06/09/2021	LJD	Work on staffing issues	0.3
06/09/2021	GJK	Review updates to Sackler Family Side B Net Asset report by L. Nguyen.	0.9
06/09/2021	GJK	Follow-up on change of control emails re: IP group and contracts.	1.1
06/09/2021	GJK	Walk through creditor comments to Multi-Group Credit Support Annex 2.	1.2
06/09/2021	GJK	Review Collateral B Term Sheet language in Disclosure Statement for updates to incurrence test modeling.	1.3
06/09/2021	GJK	Analyze open IAC entity subsidiary/parent information (ongoing).	1.9



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/09/2021	LTN	Revise the incurrence tests analysis draft for B-side's collateral term sheet based on G. Koch (AlixPartners) feedback	1.6
06/09/2021	LTN	Review the IAC/ Pledged entity ownership file provided by B. Bromberg (FTI)	0.8
06/09/2021	SKL	Review the latest updated notes and timelines from the IT group and prepare updates to the transfer work plan accordingly.	2.3
06/09/2021	SKL	Prepare change of control sharepoint folder breakdown and user access and provide the Purdue IT to update accordingly.	1.5
06/09/2021	SKL	Review latest notes and feedback from the IP change of control call and provide updated feedback accordingly.	0.3
06/09/2021	SKL	Continue review of latest timelines and activity breakdown provided by Purdue IT and update the transfer work plan accordingly.	2.2
06/09/2021	SKL	Review latest non-OCF legal vendor request from C. MacDonald (Purdue) and update the accounts payable database accordingly.	0.5
06/09/2021	ADD	Compile supplementary materials for completed applications for Purdue legal team review.	2.5
06/09/2021	ADD	Prepare state license applications for Purdue Pharmaceuticals.	3.1
06/09/2021	ADD	Draft list of open items for each state application for Purdue legal team..	1.3
06/10/2021	LJD	Review monthly fee statement - April	0.4
06/10/2021	GJK	Call with L Nguyen (AlixPartners) re: Sackler asset analysis.	0.5
06/10/2021	GJK	Update and coordinate on weekly Purdue execs and advisors call.	0.6
06/10/2021	GJK	Call with J Weiner (Davis Polk) to update on Sackler diligence.	0.1
06/10/2021	GJK	Walk through updates to Sackler Family Side B testing.	1.6
06/10/2021	GJK	Bridge Sackler Family assets between balance sheet versions.	0.9
06/10/2021	GJK	Follow-up emails with Davis Polk and Huron on Sackler Family balance sheet updates.	0.3
06/10/2021	GJK	Updates and feedback on Sackler Family Asset high level review based on Hypothetical IAC Values in Congressional filings.	1.1
06/10/2021	GJK	Review open items list for Family diligence and Disclosure Statement addendum support.	0.5
06/10/2021	LTN	Fill state licenses application for North Dakota	0.7
06/10/2021	LTN	Call with A. DePalma (AlixPartners), S. Hoffman (Purdue) re: license application process	0.2
06/10/2021	LTN	Finalize B-side information report based on G. Koch (AlixPartners) feedback	1.3
06/10/2021	LTN	Revise shareholder rate return analysis requested by E. Kim (Davis Polk)	2.4
06/10/2021	LTN	Update new scenarios to the shareholder rate return analysis based on G. Koch (AlixPartners) feedback and circulated for internal review	2.0
06/10/2021	LTN	Review the covenant section in B-side collateral term sheet and update the incurrence test analysis	1.0
06/10/2021	LTN	Call with G. Koch (AlixPartners) re: on shareholder rate return analysis	0.5
06/10/2021	SKL	Meeting with Z. Haseeb, S. Hoffman (both Purdue), and A. DePalma (AlixPartners) re: state license application process.	0.4
06/10/2021	SKL	Review latest notes and patent breakdown provided by B. Koch (Purdue) and circulate weekly update call request.	0.7
06/10/2021	HSB	Call with A. DePalma (AlixPartners) re: Purdue bankruptcy related matters	0.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/10/2021	JD	Call with J. Lowne (Purdue) re: cost analysis.	0.2
06/10/2021	JD	Call with R. Aleali (Purdue) re: case update and cost analysis.	0.3
06/10/2021	JD	Correspondence with Purdue management and Davis Polk re: affiliated party royalty payments.	0.3
06/10/2021	JD	Review various long term cost files received from management for creditor diligence requests.	0.5
06/10/2021	JD	Correspondence with Davis Polk and WTW re: breakdown and analysis of historical compensation packages.	0.7
06/10/2021	ADD	Call with H. Bhattal (AlixPartners) re: state license project resource requirements.	0.3
06/10/2021	ADD	Meeting with Z. Haseeb, S. Hoffman (both Purdue), and A. DePalma (AlixPartners) re: state license application process.	0.4
06/10/2021	ADD	Call with L. Nguyen (AlixPartners); Z. Haseeb (Purdue) re: License Application Status Update	0.2
06/10/2021	ADD	Draft list of open items for each state application for Purdue legal team..	1.7
06/10/2021	ADD	Compile supplementary materials for completed applications for Purdue legal team review.	2.7
06/10/2021	ADD	Prepare state license applications for Purdue Pharmaceuticals.	2.7
06/11/2021	GJK	Call and A Gomez-Wagner (Davis Polk) re: Asset Holdcos.	0.2
06/11/2021	GJK	Review term sheets and settlement agreement for Asset Holdco information.	0.6
06/11/2021	LTN	Format B side info compilation file and circulate to FTI and Province	0.4
06/11/2021	JD	Correspondence with Davis Polk re: insider retention payments.	0.3
06/11/2021	JD	Review and provide comments on mediation analysis from H. Bhattal.	0.8
06/11/2021	ADD	Create tracker and compile open items for in process applications for Purdue legal team.	1.7
06/11/2021	JD	Review the latest WTW compensation analysis.	0.4
06/11/2021	JD	Review discovery responses from L. Nguyen (AlixPartners).	0.2
06/11/2021	ADD	Prepare state license applications for Purdue Pharmaceuticals.	2.5
06/11/2021	ADD	Call with S. Hoffman and Z. Haseeb (Purdue) re: License application status.	0.5
06/11/2021	ADD	Review in process state license applications and incorporate comments from Purdue legal team.	2.0
06/12/2021	JD	Review latest Nalmafene spending to be provided to creditor advisors.	0.2
06/13/2021	JD	Review and sign-off on list of retention participants and final amounts for the second retention payments.	0.5
06/13/2021	JD	Prepare summary fee accruals for May month end accounting for Purdue.	0.3
06/13/2021	GJK	Respond to E Kim (Davis Polk) re: NCSG request, including follow up calls with E Kim and J DelConte (AlixPartners).	0.4
06/14/2021	LJD	Attend Purdue Board Special Committee meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, T.Melvin (PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners), S.Birnbaum (Dechert)	1.0
06/14/2021	LJD	Review and comment on liquidation analysis expert report	1.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/14/2021	GJK	Call with J Weiner (Davis Polk) re: Settlement Agreement payment mechanic language.	0.3
06/14/2021	GJK	Coordinate and follow up on open Sackler Family diligence items including IAC/pledged equity, balance sheets, and excess cash.	1.1
06/14/2021	GJK	Review and tie out L Nguyen (AlixPartners) responses to J Weiner (Davis Polk) Settlement Agreement payment mechanic questions.	0.6
06/14/2021	GJK	Walk through of Annex Credit Support Group 4 draft update from R Dixon (Davis Polk).	1.1
06/14/2021	LTN	Review the latest Article 2 in the settlement agreement and summarized findings to G. Koch (AlixPartners)	2.5
06/14/2021	LTN	Test different payment scenarios in the latest model provided by Millbank to check the language in Article 2 of the settlement agreement	1.3
06/14/2021	HSB	Attend Purdue Board Special Committee meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, T.Melvin (PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners), S.Birnbaum (Dechert)	1.0
06/14/2021	SKL	Update accounts payable files with latest approved vendors provided by C. MacDonald (Purdue).	0.4
06/14/2021	JD	Attend Purdue Board Special Committee meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, T.Melvin (PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners), S.Birnbaum (Dechert)	1.0
06/14/2021	JD	Cost reduction study planning.	0.5
06/14/2021	JD	Correspondence with Davis Polk and Purdue management re: latest version of the cash flow breakdown for the mediator.	0.5
06/14/2021	JD	Prepare analysis of weekly professional fees since filing.	1.0
06/14/2021	JD	Correspondence with Davis Polk and Purdue management re: surety bond assumptions.	0.3
06/15/2021	GJK	Read through of IAC Provisions update from E Hwang (ongoing).	1.8
06/15/2021	GJK	Read through of IAC Provisions redline update for discussion.	2.0
06/15/2021	GJK	Walk through Annex Group 2 Credit Support draft update from R Dixon (Davis Polk).	1.3
06/15/2021	GJK	Walk through Annex for Credit Support Multiparty Draft Update from R Dixon (Davis Polk).	1.6
06/15/2021	LTN	Review IAC provisions in the Settlement agreement provided by E. Huang (Davis Polk) and summarized findings to G. Koch (AlixPartners)	1.6
06/15/2021	LTN	Correspondence with J. Weiner (Davis Polk) re: open items in the latest Article 2 agreement	0.5
06/15/2021	SKL	Update approved vendor list and prepare and circulate updated release list.	1.0
06/15/2021	JD	Provide comments on the latest version of the expert report.	0.7
06/15/2021	JD	Review previous comparable bankruptcy case details.	1.2
06/15/2021	JD	Correspondence with PJT, Purdue management and Houlihan re: board fees.	0.3





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/16/2021	LJD	Review board meeting materials	1.5
06/16/2021	LJD	update call with ken buckfire	0.2
06/16/2021	GJK	Call with G. Koch, S. Lemack, H. Bhattal and A. DePalma (AlixPartners); S. Hoffman and Z. Haseeb (Purdue) re: License application workstream touch base meeting.	0.3
06/16/2021	GJK	Review Net Proceeds calculations as provided by Sackler counsel and compare to previous KPMG calcs.	0.9
06/16/2021	GJK	Review IAC Exhibit E and Exhibit F responses to open questions from T Richards (Huron).	1.9
06/16/2021	GJK	Walk through updated Settlement Agreement mechanics (Articles 1 and 2) provided to creditors and Sackler counsel.	1.7
06/16/2021	HSB	Call with G. Koch, S. Lemack and A. DePalma (all AlixPartners); S. Hoffman and Z. Haseeb (Purdue) re: license application workstream touch base meeting.	0.3
06/16/2021	HSB	Review Purdue finance report prepared by J.Lowne (Purdue)	0.6
06/16/2021	HSB	Review Purdue mid-year board update draft obtained from R.Aleali (Purdue) ahead of board meeting	0.4
06/16/2021	ADD	Call with G. Koch, S. Lemack, H. Bhattal and A. DePalma (AlixPartners); S. Hoffman and Z. Haseeb (Purdue) re: License application workstream touch base meeting.	0.3
06/16/2021	ADD	Review in process state license applications and incorporate comments from Purdue legal team.	2.1
06/16/2021	ADD	Compile supplementary materials for state license applications.	1.8
06/16/2021	ADD	Review state license applications open items and prepare list for Purdue legal team review.	1.3
06/16/2021	SKL	Call with G. Koch, H. Bhattal and A. DePalma (all AlixPartners); S. Hoffman and Z. Haseeb (Purdue) re: license application workstream touch base meeting.	0.3
06/16/2021	JD	Correspondence with Purdue management re: cost detail files for sharing with creditor advisors.	0.4
06/16/2021	JD	Review draft KERP declaration to be filed by Willis Towers.	0.5
06/16/2021	JD	Correspondence with Purdue management and S. Lemack (AlixPartners) re: final contract listing to share with the AHC.	0.3
06/16/2021	JD	Review latest weekly sales by product report for Rhodes.	0.2
06/17/2021	LJD	Attend Purdue Board meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners), S.Birnbaum (Dechert)	4.0
06/17/2021	LJD	Review board composition and new board requirement information	0.6
06/17/2021	GJK	Follow-up on open IAC diligence items including Project Ox status and IAC cash.	1.3
06/17/2021	HSB	Attend Purdue Board meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners), S.Birnbaum (Dechert)	4.0
06/17/2021	HSB	Review Rhodes weekly sales report prepared by L. Nguyen (AlixPartners)	0.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/17/2021	HSB	Review Rhodes mid-year board update draft obtained from R.Aleali (Purdue)	0.5
06/17/2021	ADD	Review in process state license applications and incorporate comments from Purdue legal team.	2.9
06/17/2021	ADD	Prepare state Pharmaceuticals license applications for Purdue Pharmaceuticals.	2.6
06/17/2021	ADD	Compile open items for in process applications for Purdue legal team and update tracker.	1.7
06/17/2021	SKL	Prepare and circulate 12-month fee application breakdown per M. Huebner (Davis Polk) request.	0.6
06/17/2021	JD	Attend Purdue Board meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners), S.Birnbaum (Dechert)	4.0
06/17/2021	JD	Correspondence with Purdue management re: SAP access.	0.2
06/18/2021	GJK	Call with J. DelConte, H. Bhattal, A. DePalma, G. Koch, S. Lemack, L. Nguyen, (all AlixPartners) re: weekly team update call.	1.0
06/18/2021	GJK	Prepare for updates for weekly AlixPartners team call.	0.2
06/18/2021	GJK	Review Annotated Subsidiaries chart for L Diggs (Davis Polk).	0.3
06/18/2021	GJK	Follow-up with advisors from Province and FTI on Huron responses re: IAC excess cash and Project Ox transaction.	1.2
06/18/2021	GJK	Review Settlement Agreement model adjustments by Brian Olson for Sackler Family.	1.6
06/18/2021	GJK	Review Settlement Agreement payment mechanic language and tie out to updated model.	1.3
06/18/2021	ADD	Compile supplementary materials for state license applications.	2.3
06/18/2021	ADD	Review state license applications open items and prepare list for client review.	1.0
06/18/2021	ADD	Address client comments and incorporate information from Purdue legal team.	1.9
06/18/2021	JD	Call with M. Linder, S. Brecher, D. Consola, J. Millerman (all Davis Polk), D. Sims (Willis Towers) re: diligence requests on the KEIP/KERP.	0.5
06/18/2021	JD	Initial review of files received from Purdue HR re: KEIP/KERP requests.	0.5
06/19/2021	GJK	Review Settlement Agreement mechanics language and model from B Olson (ongoing).	1.8
06/19/2021	GJK	Walk through of edits to Settlement Agreement definitions draft.	1.6
06/20/2021	GJK	Review Settlement Agreement A-Side and B-Side payment mechanic language (ongoing).	1.6
06/20/2021	GJK	Review and model Settlement Agreement A-Side payment scenarios related to B-Side adjustments.	1.8
06/20/2021	JD	Prepare summary document outlining all details of Purdue compensation per request from the AHC and UCC.	3.5
06/21/2021	GJK	Review Settlement Agreement sales proceeds deduction language.	0.6
06/21/2021	GJK	Review Settlement Agreement 2.01 (c) language with respect to funding deadlines.	1.2
06/21/2021	GJK	Walk through Settlement Agreement 2.01 (c) , (g) (h) edits related to payment obligations from Side A and Side B depending on prepayments and net proceeds.	2.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/21/2021	GJK	Track updates and revisions to definition of net proceeds in Settlement Agreement.	1.7
06/21/2021	GJK	Walk through of Further Assurances rider from E Hwang (Davis Polk).	1.1
06/21/2021	GJK	Coordinate and follow up on Sackler diligence including email from M Atkinson (Province) re: Deutsche Bank transaction updates.	0.6
06/21/2021	JD	Call with R. Aleali, K. Laurel, C. DeStefano (all Purdue), S. Brecher, M. Linder, D. Consla, J. Millerman (all Davis Polk), J. Gartrell, D. Sims, S. Hinden (all Willis Towers) re: KEIP/KERP.	0.7
06/21/2021	JD	Call with J. Lowne (Purdue) re: KEIP/KERP declaration.	0.3
06/21/2021	JD	Call with E. Vonnegut, M. Linder, S. Brecher, J. Millerman (all Davis Polk), R. Aleali, K. Laurel, C. DeStefano (all Purdue), S. Hinden, D. Sims, J. Gartrell, C. Rogers (all Willis Towers) re: KIEP-KERP.	0.6
06/21/2021	JD	Provide materials to Willis Towers team for KEIP/KERP analysis.	0.5
06/21/2021	JD	Correspondence with Purdue management team re: KEIP/KERP details.	0.7
06/21/2021	JD	Finalize detailed excel compensation file and creditor diligence question responses to share with creditor advisors.	2.7
06/21/2021	JD	Correspondence with J. Lowne, C. DeStefano and D. Warren (all Purdue) re: KEIP/KERP summary file details.	0.5
06/21/2021	SKL	Prepare and provide updated Rhodes Net Sales (actual and forecast) per Davis Polk request.	0.9
06/21/2021	LTN	Review IAC/ Pledged Entity ownership reconciliation for common equity	1.2
06/21/2021	HSB	Review Purdue weekly sales report prepared by L. Nguyen (AlixPartners)	0.1
06/21/2021	HSB	Review Purdue KEIP/KERP related materials and obtained related inputs	0.8
06/21/2021	HSB	Review Purdue forecasts and other supporting files in connection with preparation of KEIP/KERP due diligence materials	1.3
06/21/2021	LTN	Review IAC/ Pledged Entity ownership reconciliation for preferred equity	0.7
06/21/2021	HSB	Review Purdue KEIP/KERP motion and related documents	0.3
06/21/2021	ADD	Address client comments and incorporate information from Purdue legal team to update license applications.	2.5
06/21/2021	ADD	Review state license applications open items and prepare list for client review.	1.8
06/21/2021	ADD	Compile supplementary materials for state license applications.	2.6
06/22/2021	GJK	Call with M Diaz (FTI) re: payment mechanic clauses in draft of Settlement Agreement.	0.7
06/22/2021	GJK	Call with J. O'Connell, J. Turner, T. Melvin, R. Schnitzler (all PJT), J. DelConte, G. Koch, L. Donahue, H. Bhattal (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk) re: weekly update and planning call (left meeting early)	0.5
06/22/2021	GJK	Walk through edits to Credit Support Annex for Side A Multi-Pod.	1.4
06/22/2021	GJK	Walk through B-Side Annex (ongoing).	1.3
06/22/2021	GJK	Walk through of Side B Annex edits (ongoing).	1.6
06/22/2021	GJK	Review FDA talking points for working group discussion from S Lemack (AlixPartners).	0.4
06/22/2021	JD	Respond to questions from management re: SAP NewCo transition.	0.5
06/22/2021	JD	Call with R. Aleali (Purdue) re: KEIP/KERP and NewCo transfer process.	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/22/2021	JD	Call with D. O'Sullivan, M. Linder, E. Vonnegut, S. Brecher, J. Millerman (all Davis Polk), J. DelConte, H. Bhattal (both AlixPartners), S. Hinden, J. Gartrell, D. Sims, C. Rogers (all Willis Towers) re: KEIP/KERP.	0.5
06/22/2021	JD	Call with E. Vonnegut, D. O'Sullivan, M. Linder, S. Brecher, J. Millerman (all Davis Polk), J. DelConte, H. Bhattal (both AlixPartners), R. Aleali, C. DeStefano, K. Laurel (all Purdue), S. Hinden, D. Sims, J. Gartrell, C. Rogers (all Willis Towers) re: KEIP/KERP.	0.5
06/22/2021	JD	Review latest weekly sales report for Purdue to be provided to creditor advisors.	0.3
06/22/2021	JD	Correspondence with Davis Polk team re: KEIP/KERP responses.	0.6
06/22/2021	JD	Review latest version of the KEIP/KERP motion and declarations.	0.8
06/22/2021	JD	Provide comments on updated draft KEIP/KERP responses from Davis Polk.	0.4
06/22/2021	HSB	Call with E. Vonnegut, D. O'Sullivan, M. Linder, S. Brecher, J. Millerman (all Davis Polk), J. DelConte, H. Bhattal (both AlixPartners), R. Aleali, C. DeStefano, K. Laurel (all Purdue), S. Hinden, D. Sims, J. Gartrell, C. Rogers (all Willis Towers) re: KEIP/KERP.	0.5
06/22/2021	ADD	Compile open items for in process applications for Purdue legal team and update tracker.	2.2
06/22/2021	ADD	Prepare state Pharmaceuticals license applications for Adlon Therapeutics L.P..	2.9
06/22/2021	ADD	Compile supplementary materials for state license applications.	2.0
06/23/2021	GJK	Call with J Weiner (Davis Polk) re: confession of judgement for Sackler Family Side A.	0.7
06/23/2021	GJK	Review IAC entity information (ongoing).	1.4
06/23/2021	GJK	Walk through Settlement Agreement updates (ongoing).	1.3
06/23/2021	JD	Review and provide comments on business plan review work plan.	1.0
06/23/2021	JD	Update latest professional fee forecast for recently filed invoices and run rates.	0.6
06/23/2021	JD	Review updated draft KEIP/KERP motion from Davis Polk.	0.7
06/23/2021	ADD	Review and compile materials in preparation for cost assessment project.	2.5
06/23/2021	ADD	Prepare state Pharmaceuticals license applications for Adlon Therapeutics L.P..	2.9
06/24/2021	LJD	Update call with M. Huebner (Davis Polk) re: examiner	0.2
06/24/2021	GJK	Call with L Nguyen (AlixPartners) re: Sackler Family diligence process.	0.4
06/24/2021	GJK	Coordinate and follow up on diligence items including updates to Settlement Agreement model	1.3
06/24/2021	GJK	Review update IAC Rider drafts.	1.8
06/24/2021	GJK	Review IAC entity related questions from Province and FTI.	0.3
06/24/2021	SKL	Meeting with Z. Haseeb, S. Hoffman (both Purdue) re: state license application process.	0.6
06/24/2021	LTN	Review the Settlement agreement and correspondence with G. Koch (AlixPartners) re: open items on the agreement and model	0.6
06/24/2021	LTN	Call with G. Koch (AlixPartners) re: outstanding items on the shareholder due diligence	0.4
06/24/2021	JD	Review draft Lowne KEIP/KERP declaration.	0.5
06/24/2021	JD	Review and comment on attrition analysis.	0.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/24/2021	JD	Review final diligence responses on the KEIP/KERP to send to the UCC and the AHC.	0.6
06/24/2021	JD	Review cash flow analysis from management in conjunction with go-forward PHI costs.	0.4
06/24/2021	JD	Review management comments on the KEIP/KERP motion.	0.3
06/24/2021	JD	Correspondence with Davis Polk and Purdue management re: KEIP/KERP motion and declarations.	0.7
06/24/2021	JD	Review prospective Board materials created by the AHC advisors.	0.8
06/24/2021	JD	Review latest draft Gartrell declaration for the KEIP/KERP.	0.3
06/24/2021	JD	Review draft reliance documents to be shared with Davis Polk.	0.7
06/24/2021	ADD	Address client comments and incorporate information from Purdue legal team to update license applications.	2.1
06/24/2021	ADD	Prepare state Pharmaceuticals license applications for Adlon Therapeutics L.P..	1.5
06/24/2021	ADD	Compile supplementary materials for state license applications.	2.0
06/25/2021	GJK	Call with J Weiner (Davis Polk) re: Sackler diligence.	0.2
06/25/2021	GJK	Follow-up and coordinate with Province and FTI re: open diligence items.	1.1
06/25/2021	GJK	Walk through of AG Nites to Shareholder Agreement.	1.4
06/25/2021	GJK	Follow-up on open question re: Second Tier Obligors from E Hwang, including coordinating outreach to Province and FTI.	0.5
06/25/2021	SKL	Call with J. DelConte and H. Bhattal (AlixPartners) re: latest KEIP/KERP inquiries.	0.1
06/25/2021	SKL	Continue to review latest KEIP/KERP inquiries and prepare updates accordingly.	2.3
06/25/2021	HSB	Review Purdue KEIP/KERP related materials prepared by the debtors	2.2
06/25/2021	HSB	Call with J. DelConte and S.Lemack (both AlixPartners) re: Purdue KEIP/KERP	0.1
06/25/2021	LTN	Review Net Proceeds computation for Asset Sale and Stock Sale report provided by E. Hwang (Davis Polk)	0.6
06/25/2021	LTN	Review Assurances agreement provided by E. Hwang (Davis Polk)	0.4
06/25/2021	LTN	Review the definitions, collateral matters and covenants sections of the B Side credit support annex	1.3
06/25/2021	JD	Call with J. Lowne (Purdue) re: cost assessment work plan.	0.8
06/25/2021	JD	Call with R. Aleali, J. Lowne, C. DeStefano, K. Laurel (all Purdue), E. Vonnegut, S. Brecher, M. Linder (all Davis Polk), J. Gartrell, D. Sims, S. Hinden (all Willis Towers) re: KEIP/KERP.	0.4
06/25/2021	JD	Review follow up diligence questions from the AHC and UCC advisors re: KEIP/KERP.	0.3
06/25/2021	ADD	Address client comments and incorporate information from Purdue legal team to update license applications.	2.6
06/25/2021	ADD	Review state license applications open items and prepare list for client review.	2.3
06/25/2021	JD	Call with H. Bhattal and S.Lemack (both AlixPartners) re: Purdue KEIP/KERP	0.1
06/27/2021	JD	Finalize and send out AHC diligence responses to their follow up KEIP/KERP questions.	0.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/27/2021	JD	Review dataroom files for business plan presentations in response to creditor diligence request.	0.4
06/27/2021	GJK	Walk through Settlement Agreement draft revisions from Milbank (ongoing).	1.7
06/28/2021	JD	Attend Purdue Board Special Committee meeting with board members S.Miller, J.Dubel and M.Cola, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, T.Melvin (PJT), H. Bhattal, J. DelConte (both AlixPartners), S.Birnbaum (Dechert)	0.5
06/28/2021	JD	Call with K. McCafferty (AlixPartners) re: HR programs.	0.3
06/28/2021	JD	Call with S. Brecher, M. Linder, E. Vonnegut, J. Millerman (all Davis Polk), J. Gartrell, S. Hinden, D. Sims, C. Rogers (all Willis Towers) re: KEIP/KERP status.	0.5
06/28/2021	JD	Create an analysis of historical Purdue promotions and compare it with the internal list from Purdue HR.	1.5
06/28/2021	JD	Update detailed KEIP/KERP diligence file to include an additional year of compensation for all individuals per diligence request from the UCC.	2.3
06/28/2021	JD	Analyze the total amount of incentive compensation included in the long term business plan.	1.0
06/28/2021	JD	Review draft analysis of NewCo cash flows through 2029 per request from J. Lowne (Purdue).	0.4
06/28/2021	GJK	Prepare for IAC Entity call.	0.3
06/28/2021	GJK	Call with G. Koch, L. Nguyen (both AlixPartners), J. Weiner (Davis Polk), B. Kennedy (Milbank), B. Olson (Kokino) and other advisors re: the revised Art 1 and 2 in the Settlement agreement	1.3
06/28/2021	GJK	Review unapplied net proceeds language and model example in Settlement Agreement mechanics.	1.2
06/28/2021	GJK	Review revised Settlement Agreement language from Milbank (ongoing) and preparation for call with counsel and advisors for Sackler Family, Debtor, UCC and AHC.	2.2
06/28/2021	GJK	Follow-up on open Sackler Family/IAC diligence issues including cash, entities, modeling.	0.8
06/28/2021	HSB	Attend Purdue Board Special Committee meeting with board members S.Miller, J.Dubel and M.Cola, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, T.Melvin (PJT), H. Bhattal, J. DelConte (both AlixPartners), S.Birnbaum (Dechert)	0.5
06/28/2021	HSB	Review Purdue KEIP/KERP related correspondence from J.Lowne (Purdue) and related supporting files	0.2
06/28/2021	ADD	Compile supplementary materials for state license applications in for client review	1.8
06/28/2021	LTN	Review the latest Article 1 and 2 in the Settlement Agreement	1.5
06/28/2021	LTN	Review the revised section 2.02 (b) in the Settlement Agreement and provided an illustration example	1.0



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/28/2021	LTN	Review section 2.01 (g) in the Settlement Agreement and the model provided by B. Olson (Kokino)	1.1
06/28/2021	LTN	Review the remaining sections of the B Side credit support annex	0.7
06/28/2021	KM	Call with J. DelConte (AlixPartners) re: support and data request for cost assessment.	0.3
06/28/2021	ADD	Call with H. Bhattal (AlixPartners) to discuss application license project status.	0.5
06/29/2021	GJK	Prepare for Multi-pod discussion with counsel and advisors including review of latest multi-pod annex draft.	1.7
06/29/2021	GJK	Coordinate response to B Sherman (Davis Polk) with L Nguyen (AlixPartners) re: Side B Collateral unrealized gains.	0.6
06/29/2021	GJK	Review and respond to B Bromberg (FTI) email re: model illustrative examples.	0.3
06/29/2021	GJK	Assess open economic items for Purdue.	0.8
06/29/2021	GJK	Walk through revisions to IAC Rider (ongoing).	1.9
06/29/2021	GJK	Coordinate with L Nguyen (AlixPartners) re: IAC entity call notes.	0.3
06/29/2021	GJK	Follow-up review of key Multipod issues post call with counsel and financial advisors from Sackler Family, Debtor, UCC And AHC.	1.1
06/29/2021	LTN	Prepare notes from IAC ownership call and circulate to G. Koch (AlixPartners)	0.6
06/29/2021	LTN	Review B-side org chart and correspondence with G. Koch (AlixPartners) re: preferred equity ownership	0.4
06/29/2021	LTN	Correspondence with J. Weiner (Davis Polk) re: section 2.02 b example in the Settlement agreement	0.4
06/29/2021	LTN	Review the definitions, collateral matters and covenants sections of the A Side credit support annex	1.0
06/29/2021	LTN	Review the enforcement, remedies and the remaining sections of the A Side credit support annex	0.5
06/29/2021	ADD	Call with H. Bhattal (AlixPartners) to discuss application license project status.	0.2
06/30/2021	GJK	Call with L Nguyen (AlixPartners) re: Mundipharma executive call.	0.3
06/30/2021	GJK	Call with Mundipharma executives and financial advisors for Sackler Family, Debtor, UCC and AHC re: IAC cash.	0.9
06/30/2021	GJK	Prepare for Mundipharma executive call including review of cash positions and presentation.	1.2
06/30/2021	GJK	Call with Purdue Legal and Finance, Davis Polk and J. DelConte (AlixPartners) re: open economic issues with Mundipharma.	0.5
06/30/2021	GJK	Prepare for Mundipharma open economic issues discussion.	0.6
06/30/2021	GJK	Research on potential leakage of cash from net proceeds due to local regulatory solvency requirements	0.9
06/30/2021	GJK	Walk through of update IAC rider draft (ongoing).	1.9
06/30/2021	GJK	Review open IAC entity information and charts from J Ball (Debevoise).	0.8
06/30/2021	GJK	Review settlement agreement mechanics for potential illustrative model examples to include as Appendix.	1.8
06/30/2021	JD	Call with J. Lowne, M. Kesselman, C. Landau, B. Weingarten (all Purdue), J. DelConte, K. McCafferty (both AlixPartners) re: cost assessment.	0.6



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/30/2021	JD	Call with J. Lowne (Purdue), J. Turner, T. Melvin, J. Arsic (all PJT), J. DelConte, H. Bhattal, L. Nguyen (all AlixPartners) re: 2025-2029 cash flows.	0.3
06/30/2021	JD	Call with J. Lowne, R. Aleali, R. Kreppel, R. Inz, K. McCarthy (all Purdue), A. Libby, E. Vonnegut, C. Robertson, D. Bauer (all Davis Polk) re: IAC agreements.	0.5
06/30/2021	JD	Finalize updated KEIP/KERP detail file.	0.7
06/30/2021	JD	Correspondence with Davis Polk and the creditor advisors re: open KEIP/KERP diligence questions.	0.5
06/30/2021	JD	Provide breakdown of insider compensation over the previous two years to Purdue HR for internal discussions.	0.4
06/30/2021	LTN	Review Mundipharma update deck before the call	0.5
06/30/2021	LTN	Call with G. Koch, L. Nguyen (AlixPartners) and other advisors re: Mundipharma update	1.0
06/30/2021	LTN	Call with G. Koch (AlixPartners) re: Mudipharma executive call	0.3
06/30/2021	LTN	Review clauses on IACs sales proceeds and correspondence to G. Koch (AlixPartners)	1.4
06/30/2021	LTN	Review IAC provisions provided by E. Huang (Davis Polk)	0.8
06/30/2021	LTN	Review NewCo operating agreement before the call	1.2
06/30/2021	ADD	Call with G. Koch, L. Nguyen (AlixPartners) and other advisors re: Mundipharma update	1.0
07/01/2021	LJD	Call with R. Aleali, J. Lowne (both Purdue), C. Robertson, A. Libby (both Davis Polk), J. Turner, T. Melvin, J. Arsic (all PJT), L. Donahue, J. DelConte, G. Koch (all AlixPartners) re: weekly catch up and go forward planning call.	0.6
07/01/2021	JD	Call with R. Aleali, J. Lowne (both Purdue), C. Robertson, A. Libby (both Davis Polk), J. Turner, T. Melvin, J. Arsic (all PJT), L. Donahue, J. DelConte, G. Koch (all AlixPartners) re: weekly catch up and go forward planning call.	0.6
07/01/2021	JD	Call with Z. Haseeb, R. Aleali, J. Lowne, E. Ruiz, K. McCarthy, R. Kreppel, R. Inz (all Purdue), E. Vonnegut, A. Libby, C. Robertson, D. Bauer (all Davis Polk), J. DelConte, G. Koch (both AlixPartners) re: IAC agreements.	0.8
07/01/2021	JD	Correspondence with Davis Polk re: wind down budget estimates.	0.2
07/01/2021	GJK	Call with R. Aleali, J. Lowne (both Purdue), C. Robertson, A. Libby (both Davis Polk), J. Turner, T. Melvin, J. Arsic (all PJT), L. Donahue, J. DelConte, G. Koch (all AlixPartners) re: weekly catch up and go forward planning call.	0.6
07/01/2021	GJK	Call with Z. Haseeb, R. Aleali, J. Lowne, E. Ruiz, K. McCarthy, R. Kreppel, R. Inz (all Purdue), E. Vonnegut, A. Libby, C. Robertson, D. Bauer (all Davis Polk), J. DelConte, G. Koch (both AlixPartners) re: IAC agreements.	0.8
07/01/2021	GJK	Review of updated draft of IAC Rider to Settlement Agreement.	1.5
07/01/2021	GJK	Review of revised draft of Pod 4 Annex to Settlement Agreement.	1.2
07/01/2021	GJK	Scan through proposed revisions to Articles 1 & 2 of the Settlement Agreement as related to prepayments, including email explanation from B Kennedy (Debevoise).	0.7
07/02/2021	JD	Meeting with J. Lowne (Purdue), C. Nweke, A. DePalma, J. DelConte, K. McCafferty (AlixPartners) re: weekly stand-up meeting.	0.5





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/02/2021	JD	Correspondence with Purdue PR team re: insider payments and inbound requests for comment from a reporter.	0.5
07/02/2021	GJK	Review of updated draft and redlines of Articles 1 and 2 of the Settlement Agreement (ongoing).	2.1
07/02/2021	GJK	Review creditor edits and comments to draft of Article 1 and 2 of the Settlement Agreement.	0.9
07/02/2021	GJK	Review model scenario example issue re: prepayment from B Bromberg (FTI) and respond to M. Atkinson (Province) on outreach approach to Sackler advisors.	0.5
07/02/2021	GJK	Review IAC entity information including Germary tax example from Norton Rose.	0.4
07/02/2021	LTN	Review the latest settlement model provided by B. Olson (Kokino), test scenarios and summarize finding for G. Koch (AlixPartners).	2.2
07/02/2021	GJK	Respond to M. Atkinson (Province) on outreach approach to Sackler advisors.	0.2
07/03/2021	GJK	Review prepayment model example email from B. Bromberg (FTI) to B. Olson (Sackler Family Office).	0.3
07/03/2021	GJK	Track document updates from various parties for Settlement Agreement, rider and annexes.	0.6
07/05/2021	JD	Call with T. Melvin (PJT) re: NOAT distribution forecast.	0.4
07/05/2021	JD	Review and provide comments on the updated distribution waterfall analysis from PJT.	0.7
07/05/2021	GJK	Review of updates to IAC Provisions rider of Settlement Agreement (ongoing).	2.2
07/05/2021	GJK	Review of Creditor and Davis Polk updates to IAC Provisions rider of Settlement Agreement (ongoing).	0.9
07/05/2021	GJK	Review redlines of Pod 4 rider to Settlement Agreement from Creditors and Davis Polk.	0.9
07/06/2021	GJK	Call among G. Koch, H. Bhattal, L. Nguyen (AlixPartners), J. Finelli, A. Libby (Davis Polk), J. Ball, C. Rosekans (Debevoise) and other advisors to discuss A-Side multipod credit support Annex	1.4
07/06/2021	GJK	Calls with L Nguyen (AlixPartners) to discuss breach fee model and content for the collar deck	1.1
07/06/2021	GJK	Call among G. Koch, L. Nguyen (AlixPartners), J. Finelli, A. Libby (Davis Polk) and other advisors to discuss A-Side multipod credit support Annex	2.9
07/06/2021	GJK	Review and comment on Financial Statement Template for reporting.	0.9
07/06/2021	GJK	Review Settlement Agreement Material Issues List from E Hwang (Davis Polk)	1.7
07/06/2021	GJK	Review Breach Fee language and analysis by L Nguyen (AlixPartners).	0.9
07/06/2021	LJD	review May fee statement	0.4
07/06/2021	LTN	Prepare breach fee model for B-side family groups	1.5
07/06/2021	LTN	Review the prepayment issue analysis provided by B. Bromberg (FTI) and provide feedback to G. Koch (AlixPartners)	0.6
07/06/2021	LTN	Review outstanding settlement issue list before the call	0.5
07/06/2021	LTN	Review definition and collateral matters section in the A-side multipod credit support annex	1.0
07/06/2021	LTN	Call with G. Koch (AlixPartners) to work on N168	1.1



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/06/2021	LTN	Call among G. Koch, H. Bhattal, L. Nguyen (AlixPartners), J. Finelli, A. Libby (Davis Polk), J. Ball, C. Rosekans (Debevoise) and other advisors to discuss A-Side multipod credit support Annex	1.4
07/06/2021	LTN	Prepare breach fee model for A-side family groups	0.8
07/06/2021	LTN	Finalize breach fee model based on internal feedback and circulate to J. Weiner (DavisPolk)	1.0
07/06/2021	HSB	Call with J.Lowne (Purdue), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), J.DelConte (AlixPartners) re: Purdue projections	0.2
07/06/2021	JD	Call with J. DelConte, H. Bhattal (both AlixPartners), J. Lowne (Purdue), J. Turner, T. Melvin, J. Arsic, L. Schwarzmman (all PJT) re: distribution breakdown.	0.2
07/06/2021	JD	Update analysis of emergence date cash flow payments for the governance term sheet and plan supplements.	1.0
07/06/2021	JD	Review and provide comments on the updated cash flow distribution analysis from PJT.	0.3
07/06/2021	JD	Correspondence with Purdue management, Davis Polk and PJT re: governance and plan document negotiations with the AHC.	0.6
07/07/2021	GJK	Follow-up on Financial Reporting template email from M Atkinson (Province).	0.6
07/07/2021	GJK	Review Milbank revisions to Article 1 and Article 2 rider for Settlement Agreement.	1.3
07/07/2021	GJK	Review of edits to Settlement Agreement (ongoing).	2.2
07/07/2021	GJK	Review of updates and revisions of Settlement Agreement for filing.	2.1
07/07/2021	JD	Review settlement agreement diligence responses to date and correspondence with Davis Polk re: same.	0.5
07/07/2021	ADD	Update liabilities subject to compromise calculation for June month end.	2.3
07/07/2021	ADD	Compile supplementary materials for state license applications.	1.7
07/07/2021	ADD	Update outstanding state license applications and incorporate comments from Purdue legal team.	2.3
07/08/2021	GJK	Review Breach Documents from E Hwang (Davis Polk).	0.8
07/08/2021	GJK	Review Annex B credit support from A Romero-Wagner (Davis Polk).	0.7
07/08/2021	GJK	Review open items list for Settlement Agreement including model outputs for illustrative examples.	1.0
07/08/2021	JD	Call with R. Aleali (Purdue) re: plan documents and emergence planning.	0.4
07/08/2021	JD	Prepare latest month end fee accruals for Purdue accounting.	0.3
07/09/2021	GJK	Call with L Nguyen to coordinate on diligence requests.	0.1
07/09/2021	GJK	Review Group 4 Annex draft revisions from J Finelli (Davis Polk).	0.7
07/09/2021	GJK	Review FTI model and proposed scenarios for Illustrative Examples for Settlement Agreement.	1.3
07/09/2021	GJK	Call with C. Robertson, L. Altus, T. Matlock (all Davis Polk), J. DelConte, G. Koch (both AlixPartners) re: PPI assets.	0.5
07/09/2021	GJK	Review files for information on Purdue Research Associates (PRA) and if information on value.	0.3
07/09/2021	LTN	Review the latest markup in the consolidated Settlement Agreement	1.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/09/2021	LTN	Review the Settlement payment model and test scenarios provided by B. Bromberg (FTI)	1.7
07/09/2021	LTN	Call with G. Koch (AlixPartners) to discuss diligence requests	0.1
07/09/2021	LTN	Call with J. Weiner (DavisPolk) to discuss breach fee model	0.4
07/09/2021	LTN	Revise the breach fee model based on feedback from J. Weiner (DavisPolk) and circulate to DavisPolk	1.2
07/09/2021	LTN	Continue to test scenarios analysis based on examples from B. Bromberg (FTI) and provide comments to G. Koch (AlixPartners)	0.9
07/09/2021	SKL	Review latest approved vendor requests and update/run latest accounts payable release files.	1.0
07/09/2021	HSB	Call with Z.Haseeb (Skadden) and A.DePalma (AlixPartners) re: Purdue state license process update	0.4
07/09/2021	ADD	Update outstanding state license applications and incorporate comments from Purdue legal team.	1.9
07/09/2021	JD	Call with J. Turner (PJT) and J. Lowne (Purdue) re: PHI business plan.	0.3
07/09/2021	JD	Meeting with J. Lowne (Purdue); J.DelConte, K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	0.8
07/09/2021	JD	Call with C. Robertson, L. Altus, T. Matlock (all Davis Polk), J. DelConte, G. Koch (both AlixPartners) re: PPI assets.	0.5
07/09/2021	JD	Correspondence with PJT re: distribution cash flow projections in the operating agreement.	0.3
07/09/2021	JD	Analyze historical sales to Mundipharma and respond to diligence questions from FTI re: same.	0.7
07/09/2021	JD	Review updated interim business plan for PHI.	0.5
07/09/2021	JD	Review updated retention plan payments from Purdue HR.	0.2
07/09/2021	ADD	Call with Z.Haseeb (Skadden) and H. Bhattal (AlixPartners) re: Purdue state license process update	0.4
07/10/2021	HSB	Review Purdue keip/kerp related details and related analysis	0.5
07/10/2021	JD	Correspondence with H. Bhattal, S. Lemack (AlixPartners), Davis Polk and Purdue management re: public insider compensation data in response to a reporter request.	0.4
07/12/2021	JD	Call with E. Vonnegut (Davis Polk) re: KEIP/KERP discussions.	0.2
07/12/2021	JD	Call with M. Kesselman, R. Aleali (both Purdue), E. Vonnegut (Davis Polk), J. Turner (PJT) re: discussion with HL on PBM's.	0.4
07/12/2021	GJK	Call with G. Koch, L. Nguyen (both AlixPartners), M. Atkinson, C. Klawunder (Province), M. Diaz, B. Bromberg (both FTI) re: model scenarios	0.3
07/12/2021	GJK	Call with G. Koch, L. Nguyen (both AlixPartners) to discuss model scenarios provided by FTI	0.2
07/12/2021	GJK	Review revisions to B-Side Family annex to Settlement Agreement from Davis Polk.	1.8
07/12/2021	GJK	Review model updates from Brian Olson.	1.4
07/12/2021	GJK	Update on correspondence and discussions between counsel for Sackler Family, Debtor, UCC and AHC.	0.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/12/2021	GJK	Review of FDA talking points draft from D McGuire (Purdue).	0.6
07/12/2021	GJK	Follow-up on China and Consumer Health Munidpharma businesses.	0.2
07/12/2021	GJK	Follow-up on B-Side asset values with L Nguyen (AlixPartners) for A Romero-Wagner (Davis Polk).	0.1
07/12/2021	GJK	Review and comment on proposed email to B Kennedy (Milbank) and B Olson (Family Office) from B Bromberg (FTI) re: illustrative model examples.	0.7
07/12/2021	GJK	Follow-up planning and coordination for open Settlement Agreement and annex issues for AlixPartners.	0.4
07/12/2021	LTN	Analyze payment examples re provision 2.07 provided by B. Olson (Kokino) and summarize findings to G. Koch (AlixPartners)	0.8
07/12/2021	LTN	Call with G. Koch, L. Nguyen (both AlixPartners), M. Atkinson, C. Klawunder (Province), M. Diaz, B. Bromberg (both FTI) re: model scenarios	0.3
07/12/2021	LTN	Correspondence with A. Romero (DavisPolk) re: B-side asset data	0.2
07/12/2021	LTN	Analyze the latest model v07.10 provided by B. Olson (Kokino) and summarize feedback to G. Koch (AlixPartners)	1.2
07/13/2021	JD	Call with E. Vonnegut (Davis Polk) re: KEIP/KERP.	0.2
07/13/2021	JD	Call with M. Kesselman (Purdue) re: KEIP/KERP.	0.3
07/13/2021	JD	Correspondence with Davis Polk and Purdue management re: KEIP/KERP negotiations.	0.7
07/13/2021	JD	Correspondence with Purdue management re: historic formulary coverage.	0.4
07/13/2021	JD	Review IAC special committee presentation from R. Aleali (Purdue).	0.6
07/13/2021	JD	Review unsecured claims analyses files to be shared through the discovery process.	0.3
07/13/2021	JD	Review projections to be provided for renewal discussions with various insurers.	0.3
07/13/2021	JD	Review attrition analysis prepared by Purdue management for Davis Polk and the KEIP/KERP filings.	0.7
07/13/2021	GJK	Review of Side B Annex proposed final draft from A Romero-Wagner (Davis Polk).	0.7
07/13/2021	GJK	Review Settlement Agreement scenario examples with walkthrough language from B Bromberg (FTI).	0.8
07/13/2021	GJK	Review updates to Breach & Remedies Chart from E Hwang (Davis Polk).	1.4
07/13/2021	SKL	Review latest feedback provided by J. Carlisle (Purdue) re: IAC sales and prepare updated analysis accordingly.	1.0
07/13/2021	HSB	Attended Purdue Board Special Committee meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert)	0.6
07/13/2021	LTN	Prepare meeting notes from the multi-pod credit support Annex call with lawyers / advisors and circulate to G. Koch (AlixPartners)	0.9
07/13/2021	LTN	Review three illustrative examples based on the latest model and payment write-up, provide feedback to FTI	1.1
07/13/2021	LTN	Review markup on the multi-pod credit support Annex before the call	1.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/14/2021	JD	Attended Purdue Board meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. Turner (PJT), H. Bhattal, L. Donahue (both AlixPartners), S.Birnbaum (Dechert)	1.1
07/14/2021	JD	Call with J. DelConte and L. Donahue (both AlixPartners) re: staffing and strategic planning going forward.	0.3
07/14/2021	JD	Meeting with J. Lowne (Purdue); J. DelConte, K. McCafferty and C. Nweke (AlixPartners) re: organization roles and structure scenario evaluation (partial participation).	0.3
07/14/2021	JD	Review report 1B reliance materials prior to providing for confirmation data room.	0.8
07/14/2021	JD	Review analysis of retention payments by EC member.	0.4
07/14/2021	JD	Correspondence with Davis Polk and Purdue management re: L/C's and surety bonds.	0.4
07/14/2021	GJK	Call among G. Koch, L. Nguyen (AlixPartners), J. Finelli, A. Libby (Davis Polk), G. Gooding, J. Ball, C. Rosekans (Debevoise) and other advisors to discuss open Settlement Agreement issues, including materiality/breaches and remedies.	1.9
07/14/2021	GJK	Call with J Weiner (Davis Polk) to discuss Settlement Agreement open issues.	0.2
07/14/2021	GJK	Call with L Nguyen (AlixPartners) to discuss Settlement Agreement model scenarios.	0.2
07/14/2021	GJK	Follow-up on tax question from T Matlock (Davis Polk) re: Huron valuation of assets.	0.4
07/14/2021	GJK	Review updates to Articles 1 & 2 of Settlement Agreement from J Weiner (Davis Polk).	0.4
07/14/2021	GJK	Review settlement agreement model illustrative examples.	0.8
07/14/2021	LJD	Attended Purdue Board meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. Turner (PJT), J. DelConte, H. Bhattal (AlixPartners), S.Birnbaum (Dechert) (partial participation)	0.8
07/14/2021	LJD	Call with J. DelConte and L. Donahue (both AlixPartners) re: staffing and strategic planning going forward.	0.3
07/14/2021	HSB	Attended Purdue Board meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. Turner (PJT), J. DelConte, L. Donahue (both AlixPartners), S.Birnbaum (Dechert)	1.1
07/14/2021	LTN	Review the latest changes of Article 1 & 2 in the Settlement Agreement	1.0
07/14/2021	LTN	Review breach charts for A side and B side credit support annexes	1.6
07/14/2021	LTN	Review breach charts for the Settlement agreement	0.8
07/15/2021	JD	Weekly call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin (all PJT), E. Vonnegut, W. Taylor, C. Robertson (all Davis Polk), J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: catch up and go forward planning call.	0.8



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/15/2021	JD	Call with J. DelConte and G. Koch (both AlixPartners) re: shareholder settlement agreement negotiations.	0.2
07/15/2021	JD	Call with R. Aleali (Purdue) re: ongoing KEIP/KERP negotiations.	0.3
07/15/2021	JD	Call with C. DeStefano (Purdue) re: KEIP/KERP proposal.	0.2
07/15/2021	JD	Call with E. Vonnegut (Davis Polk) re: diligence project.	0.2
07/15/2021	JD	Review updated analysis from Purdue HR re: potential KEIP/KERP counterproposal.	0.4
07/15/2021	JD	Correspondence with Purdue management and K. McCafferty (AlixPartners) re: diligence project.	0.5
07/15/2021	GJK	Partial attendance at call among G. Koch, L. Nguyen (AlixPartners), J. Finelli, A. Libby (Davis Polk) and other advisors to discuss breach fee	1.5
07/15/2021	GJK	Weekly call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin (all PJT), E. Vonnegut, W. Taylor, C. Robertson (all Davis Polk), J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: catch up and go forward planning call.	0.8
07/15/2021	GJK	Call with J DelConte (AlixPartners) to discuss Settlement Agreement progress.	0.2
07/15/2021	GJK	Calls with L Nguyen (AlixPartners) to discuss Settlement Agreement progress.	0.1
07/15/2021	LJD	Weekly call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin (all PJT), E. Vonnegut, W. Taylor, C. Robertson (all Davis Polk), J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: catch up and go forward planning call.	0.8
07/15/2021	LTN	Call among G. Koch, L. Nguyen (AlixPartners), J. Finelli, A. Libby (Davis Polk) and other advisors to discuss breach fee	2.0
07/15/2021	LTN	Review B. Bromberg (FTI) feedback re Article 2 language and provide feedback	1.0
07/15/2021	LTN	Call with G. Koch, L. Nguyen (both AlixPartners) to discuss updates on breach fee	0.1
07/15/2021	ADD	Compile and organize monthly sales data for inventory analysis	2.5
07/16/2021	LJD	review and comment on 5th fee app	0.8
07/16/2021	JD	Call with J. Lowne (Purdue) re: KEIP/KERP.	0.3
07/16/2021	JD	Call with J. Lowne, H. Ghnaimh, J. Carlisle, H. Benson, E. Ruiz, W. Sielert (all Purdue) re: NewCo transition.	0.7
07/16/2021	JD	Call with J. Lowne, M. Kesselman (both Purdue), E. Vonnegut (Davis Polk), J. DelConte, K. McCafferty (both AlixPartners) re: diligence project.	0.8
07/16/2021	JD	Call with J. Turner and R. Schnitzler (both PJT) re: potential BD opportunity.	0.3
07/16/2021	JD	Call with J. Bragg, M. Florence (both Skadden), R. Aleali (Purdue), E. Vonnegut, C. Robertson, Z. Levine (all Davis Polk), J. Turner (PJT) re: PBM discussion follow-up.	0.5
07/16/2021	JD	Review analysis from Purdue management on historic OxyContin formulary coverage.	0.3
07/16/2021	JD	Provide comments on draft KEIP/KERP counterproposal from Purdue management.	0.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/16/2021	JD	Review preliminary diligence project flash report to be shared with management.	0.4
07/16/2021	HSB	Prepare file with Purdue forecast analysis	0.8
07/16/2021	HSB	Review Purdue monthly flash report prepared by L.Nguyen (AlixPartners) and related supporting document	0.9
07/16/2021	ADD	Compile and organize monthly sales data for inventory analysis	2.8
07/16/2021	ADD	Review and address license application comments from Purdue Legal team.	1.9
07/16/2021	KM	Call with J. Lowne, M. Kesselman (both Purdue), E. Vonnegut (Davis Polk), J. DelConte, K. McCafferty (both AlixPartners) re: diligence project.	0.8
07/17/2021	GJK	Review Settlement Agreement rep and covenant draft from E Hwang (Davis Polk).	1.2
07/17/2021	GJK	Review of Settlement Agreement (ongoing).	2.4
07/17/2021	JD	Call with J. Lowne (Purdue) re: proposed KEIP/KERP counterproposal.	0.3
07/17/2021	JD	Correspondence with Davis Polk and Purdue management re: KEIP/KERP response.	0.4
07/18/2021	JD	Review KEIP/KERP counterproposal summary from J. Lowne (Purdue).	0.3
07/18/2021	JD	Call with C. Landau, J. Lowne, K. Laurel (all Purdue), E. Vonnegut (Davis Polk) re: KEIP/KERP counterproposal.	0.5
07/18/2021	GJK	Review revised Side B Annex from J Finelli (Davis Polk).	1.2
07/18/2021	GJK	Review Settlement Agreement scenario walk throughs from B Bromberg (FTI).	0.8
07/18/2021	GJK	Review of blackline of Settlement Agreement from E Hwang (Davis Polk).	1.8
07/18/2021	GJK	Review Sackler redline to Scenario walkthroughs for illustrative examples of Settlement Agreement payment mechanics from B Kennedy (Milbank).	0.8
07/19/2021	GJK	Respond to Davis Polk re: Financial Statement template for Settlement Agreement reporting.	0.6
07/19/2021	GJK	Respond to Atkinson (Province) re: Financial Statement template for Settlement Agreement reporting.	0.3
07/19/2021	GJK	Review Assistance with Litigation related language from Debtor and UCC/AHC counsel.	0.5
07/19/2021	GJK	Review Creditor Comments to B-Side Annex from E Miller (Akin) and A Libby (Davis Polk).	1.3
07/19/2021	GJK	Review edits and comments to Side A Multipod Annex from E Miller (Akin) and A Libby (Davis Polk).	1.1
07/19/2021	GJK	Call when M Atkinson (Province) and B Bromberg (FTI) to discuss financial reporting needs from Sackler parties.	0.3
07/19/2021	GJK	Draft edits to M Atkinson email for FAs to counsel re: Sackler Parties reporting.	0.4
07/19/2021	JD	Review detailed company slides related to a potential Avrio BD opportunity.	0.8
07/19/2021	JD	Call with C. Robertson (Purdue) re: outstanding diligence questions.	0.2
07/19/2021	JD	Call with J. Lowne (Purdue) re: KEIP/KERP discussions and proposals.	0.3
07/19/2021	JD	Call with J. Turner, R. Schnitzler (both PJT), J. Lowne, E. Ruiz, L. Scheinbach (all Purdue) re: Avrio BD opportunity.	0.7
07/19/2021	JD	Review and edit pharmacy benefit manager analysis provided by management.	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/19/2021	JD	Correspondence with Purdue management re: royalty and license fee calculations.	0.3
07/19/2021	JD	Review updated quarterly attrition analysis from Purdue management	0.3
07/19/2021	LTN	Review A side and B side annex markup before the call with DWP and other advisors	1.8
07/19/2021	LTN	Analyze model illustrative examples and write-up provided by B. Kennedy (Milbank)	2.0
07/19/2021	LTN	Prepare notes from the breach fee call and circulate to G. Koch (AlixPartners)	0.8
07/19/2021	LTN	Call with G. Koch, L. Nguyen (AlixPartners) re: updates to reporting for credit support	0.2
07/19/2021	ADD	Address license application open items and incorporate comments from Purdue legal.	2.4
07/19/2021	GJK	Call with G. Koch, L. Nguyen (AlixPartners) re: updates to reporting for credit support	0.2
07/20/2021	GJK	Review call notes re: breaches from L. Nguyen (AlixPartners).	0.3
07/20/2021	SKL	Review latest feedback provided by J. Carlisle (Purdue) and follow-up on open item re: IAC royalties.	1.8
07/20/2021	HSB	Review updated monthly flash report prepared by L. Nguyen (AlixPartners)	0.4
07/20/2021	JD	Call with D. Klein (Davis Polk) re: pharmacy benefit manager analysis.	0.2
07/20/2021	JD	Call with J. Bragg, M. Florence (both Skadden), R. Aleali (Purdue), D. Klein, C. Robertson (both Davis Polk) re: PBM analysis.	0.6
07/20/2021	JD	Correspondence with Purdue management and Davis Polk re: PBM analysis.	0.3
07/20/2021	JD	Review monthly Nalmefene reporting from management prior to providing to creditors.	0.2
07/20/2021	JD	Correspondence with Davis Polk re: PBM contracts.	0.3
07/20/2021	JD	Correspondence with K. McCafferty (AlixPartners) re: diligence project.	0.3
07/20/2021	JD	Review analysis of insurance collateral and potential future requirements.	0.4
07/20/2021	JD	Review PHI settlement overview deck from management.	0.4
07/21/2021	GJK	Review open Sackler Agreement issues.	1.4
07/21/2021	GJK	Review Settlement Agreement payment mechanic scenarios and descriptions of family groups.	1.7
07/21/2021	SKL	Review latest invoice/payment detail and review latest vendor questions re: postpetition payments.	1.0
07/21/2021	KM	Call with J. DelConte and K. McCafferty (both AlixPartners) re: diligence project.	0.4
07/21/2021	KM	Meeting with M. Diaz, P. Shafer, B. Bromberg (FTI Consulting); J. DelConte and K. McCafferty (AlixPartners) re: diligence project.	0.5
07/21/2021	JD	Review and provide comments on draft PJT operating agreement summary document.	0.5
07/21/2021	JD	Call with E. Vonnegut (Davis Polk) re: KEIP/KERP.	0.3
07/21/2021	JD	Call with potential post-emergence trustee.	0.8
07/21/2021	JD	Call with M. Florence, J. Bragg (both Skadden), R. Aleali, M. Ronning, W. Shank, K. Christensen, D. Rosen (all Purdue), D. Klein, C. Robertson (both Davis Polk) re: PBM contracts.	0.9





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/21/2021	JD	Call with J. DelConte and K. McCafferty (both AlixPartners) re: diligence project.	0.4
07/21/2021	JD	Call with J. DelConte, K. McCafferty (both AlixPartners), M. Diaz, B. Bromberg, P. Shafer (all FTI) re: diligence project.	0.5
07/21/2021	JD	Call with J. DelConte, K. McCafferty (both AlixPartners), J. Lowne (Purdue) re: retention observations.	0.5
07/21/2021	JD	Review latest transfer overview presentation provided to HL to see if there's anything that needs to be updated.	0.4
07/21/2021	JD	Prepare professional fee payment summary per Davis Polk request.	0.3
07/21/2021	JD	Review latest PHI overview presentation from Purdue management.	0.4
07/21/2021	JD	Correspondence with Davis Polk re: KEIP/KERP negotiations.	0.5
07/21/2021	JD	Call with J. Turner (PJT) re: PBM analysis and confirmation timing.	0.2
07/22/2021	GJK	Update and coordinate on weekly Purdue exec and advisors call.	1.1
07/22/2021	GJK	Outline potential deck walking through payment mechanics of Settlement Agreement.	0.5
07/22/2021	GJK	Review open items in Settlement Agreement including reporting options.	0.6
07/22/2021	JD	Call with J. DelConte and A. DePalma (both AlixPartners) re: open diligence questions.	0.4
07/22/2021	JD	Review updated PBM analysis from the Purdue commercial team.	0.3
07/22/2021	JD	Review business plan materials to provide to Davis Polk for the confirmation discovery data room.	0.4
07/22/2021	JD	Review Rhodes BD opportunity slides from management.	0.4
07/22/2021	JD	Review latest Mundipharma royalty summary information per AHC diligence request.	0.3
07/22/2021	ADD	Call with J. DelConte and A. DePalma (both AlixPartners) re: open diligence questions.	0.4
07/23/2021	GJK	Provide update on Settlement Agreement and Change of Control work streams to J DelConte and HS Bhattal (AlixPartners).	0.2
07/23/2021	GJK	Review open issues in Settlement Agreement process.	0.9
07/23/2021	SKL	Review latest inquiry provided re: VA/CSP request and begin preparing updates accordingly.	2.3
07/23/2021	JD	Call with J. Lowne, M. Jack, C. Ricarte (all Purdue) re: insurance collateral requirements.	0.6
07/23/2021	JD	Call with J. Lowne (Purdue) re: KEIP/KERP proposal.	0.2
07/23/2021	JD	Correspondence with Purdue management and Davis Polk re: KEIP/KERP counterproposals.	0.5
07/23/2021	JD	Review latest diligence report flash report update.	0.7
07/23/2021	JD	Call among J. DelConte, S. Lemack, H. Bhattal, L. Nguyen (AlixPartners), J. Lowne, L. Scheinbach (Purdue) to discuss Newco Cashflow breakdown.	0.3
07/23/2021	JD	Correspondence with Davis Polk re: employee questions.	0.3
07/23/2021	JD	Correspondence with Davis Polk re: next KEIP/KERP proposal.	0.4
07/23/2021	HSB	Call among J. DelConte, S. Lemack, H. Bhattal, L. Nguyen (AlixPartners), J. Lowne, L. Scheinbach (Purdue) to discuss Newco Cashflow breakdown.	0.3
07/24/2021	JD	Call with E. Vonnegut (Davis Polk) re: KEIP/KERP.	0.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/24/2021	JD	Correspondence with Purdue management and Davis Polk re: KEIP/KERP negotiations.	0.5
07/24/2021	JD	Call with C. Landau (Purdue) re: KEIP/KERP negotiations.	0.2
07/26/2021	GJK	Follow up on Sackler Family balance sheets and reporting requirements with Huron.	0.2
07/26/2021	GJK	Prep for Settlement Agreement issues list call.	1.3
07/26/2021	JD	Call with R. Aleali (Purdue) re: KEIP/KERP.	0.5
07/26/2021	JD	Call with T. Melvin (PJT) re: open diligence questions.	0.2
07/26/2021	JD	Call with C. Landau (Purdue) re: KEIP/KERP.	0.4
07/26/2021	JD	Call with E. Vonnegut (Davis Polk) re: KEIP/KERP.	0.2
07/26/2021	JD	Call with T. Melvin, L. Schwarzmans (both PJT), J. DelConte, H. Bhattal, L. Nguyen and A. DePalma (all AlixPartners) re: cash flow forecast breakdown.	0.3
07/26/2021	JD	Call with E. Nowakowski, A. Graziano, K. McCarthy (all Purdue), J. DelConte, S. Lemack, A. DePalma (all AlixPartners) re: VA GL Reconciliation.	0.6
07/26/2021	JD	Review and provide comments on the May monthly flash report.	0.4
07/26/2021	JD	Review materials pulled together in response to inbound requests from the VA OIG.	0.3
07/26/2021	JD	Review and send the Nalmafene court reporting for June to be posted.	0.2
07/26/2021	JD	Review GL data from Purdue re: open VA OIG diligence requests.	0.3
07/26/2021	JD	Review final draft cash flow forecast analysis from H. Bhattal.	0.3
07/26/2021	SKL	Call with E. Nowakowski, A. Graziano, K. McCarthy (all Purdue), J. DelConte, S. Lemack, A. DePalma (all AlixPartners) re: VA GL Reconciliation.	0.6
07/26/2021	SKL	Review latest info provided re: VA contract process and circulate update accordingly to Purdue team to sign-off.	2.3
07/26/2021	SKL	Review additional organizational info provided by the HR team and update the VA contracting deck accordingly.	1.6
07/26/2021	SKL	Review latest counterparty inquiry provided by C. MacDonald (Purdue) and prepare accounts payable release files.	1.2
07/26/2021	ADD	Call with E. Nowakowski, A. Graziano, K. McCarthy (all Purdue), J. DelConte, S. Lemack, A. DePalma (all AlixPartners) re: VA GL Reconciliation.	0.6
07/26/2021	ADD	Reconcile sales history data with G/L and identify any exceptions and items that do not reconcile.	2.0
07/27/2021	GJK	Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors to discuss Settlement Issues list	3.0
07/27/2021	GJK	Review updated Side B Net Asset report (ongoing).	1.8
07/27/2021	JD	Attended Purdue Board Special Committee meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert), H. Bhattal (both AlixPartners)	0.9
07/27/2021	JD	Call with J. Lowne (Purdue) re: KEIP/KERP.	0.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/27/2021	JD	Meeting with J. O'Connell, J. Turner, T. Melvin, L. Schwarzmann (all PJT), C. Robertson (Davis Polk), J. DelConte, L. Donahue, H. Bhattal (all AlixPartners) re: weekly update and planning meeting.	0.4
07/27/2021	JD	Review draft presentation from management on potential generic business development opportunity.	0.6
07/27/2021	JD	Correspondence with Davis Polk re: open management KEIP/KERP questions.	0.3
07/27/2021	JD	Correspondence with C. MacDonald (Purdue) re: post-petition professional fee payments.	0.3
07/27/2021	LJD	Meeting with J. O'Connell, J. Turner, T. Melvin, L. Schwarzmann (all PJT), C. Robertson (Davis Polk), J. DelConte, L. Donahue, H. Bhattal (all AlixPartners) re: weekly update and planning meeting.	0.4
07/27/2021	HSB	Attended Purdue Board Special Committee meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert), J.DelConte (both AlixPartners)	0.9
07/27/2021	HSB	Call with C. Robertson, W.Taylor (all Davis Polk), J.O'Connell, J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), L.Donahue, J.DelConte (AlixPartners) re: update and planning.	0.4
07/27/2021	HSB	Call with L.Nguyen (AlixPartners) to discuss Purdue MOR	0.2
07/27/2021	SKL	Follow-up meeting with E. Nowakoski, A. Graziano (both Purdue) and A. DePalma (AlixPartners) to discuss GL account reconciliation.	0.6
07/27/2021	LTN	Finalize the B-side asset report and circulate to G. Koch (AlixPartners) for review	1.6
07/27/2021	LTN	Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors to discuss Settlement Issues list	3.0
07/27/2021	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) re: new MOR format update	0.2
07/27/2021	LTN	Review the updated B-side Net Asset Value July 2021 data by Huron and start updating the asset report	2.0
07/27/2021	ADD	Follow-up meeting with E. Nowakoski, A. Graziano (both Purdue) and S. Lemack (AlixPartners) to discuss GL account reconciliation.	0.6
07/27/2021	ADD	Reconcile sales history data with G/L and identify any exceptions and items that do not reconcile.	2.9
07/28/2021	GJK	Review revisions to draft Settlement Agreement illustrative examples from B Bromberg (FTI).	1.3
07/28/2021	JD	Attended Purdue Full Board meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert), H. Bhattal, L.Donahue, J.DelConte (both AlixPartners)	1.4
07/28/2021	JD	Call on confirmation declarations with K. Benedict, E. Kim, M. Tobak (all Davis Polk), J. DelConte, H. Bhattal (both AlixPartners), J. O'Connell, J. Turner, T. Melvin (all PJT).	0.8
07/28/2021	JD	Meeting with J. DelConte and K. McCafferty (both AlixPartners) RE: diligence project.	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/28/2021	JD	Review draft KERP reply from Davis Polk.	0.5
07/28/2021	JD	Review latest attrition calculations for the KEIP/KERP reply.	0.2
07/28/2021	JD	Review J. Lowne KEIP/KERP draft reply declaration.	0.4
07/28/2021	LJD	Attended Purdue Full Board meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert), H. Bhattal, L.Donahue, J.DelConte (both AlixPartners)	1.4
07/28/2021	HSB	Attended Purdue Full Board meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert), L.Donahue, J.DelConte (both AlixPartners)	1.4
07/28/2021	SKL	Review latest vendor inquiry provided by C. MacDonald (Purdue) and prepare updated release lists accordingly.	0.9
07/28/2021	SKL	Finalize updates to latest org. chart inquiry and circulate final update accordingly.	0.7
07/28/2021	SKL	Meeting with E. Nowakoski, A. Graziano (both Purdue) and A. DePalma (AlixPartners) to discuss GL account reconciliation.	1.0
07/28/2021	SKL	Review latest product-by-product sales revenue file provided by E. Ruiz (Purdue) and circulate updated RALP Net Sales file.	2.4
07/28/2021	ADD	Reconcile sales history data with G/L and identify any exceptions and items that do not reconcile.	2.7
07/28/2021	ADD	Meeting with E. Nowakoski, A. Graziano (both Purdue) and S. Lemack (AlixPartners) to discuss GL account reconciliation.	1.0
07/28/2021	ADD	Draft notes and procedures for sales history data and G/L reconciliation.	2.0
07/28/2021	KM	Meeting with J. DelConte and K. McCafferty (both AlixPartners) re: diligence project.	0.5
07/29/2021	GJK	Call with M. Kesselman, C. Landau, J. Lowne, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: weekly catch up and planning call.	0.6
07/29/2021	GJK	Review of updated Settlement Agreement draft from Milbank and Debevoise.	2.2
07/29/2021	HSB	Review Purdue and Rhodes weekly sales reports prepared by L.Nguyen (AlixPartners)	0.2
07/29/2021	SKL	Finalize business model narrative for the latest VA contract material request list and circulate updates accordingly.	2.4
07/29/2021	SKL	Review latest feedback received on the latest VA material request list and prepare updates and update the tracker accordingly.	1.4
07/29/2021	JD	Call with J. DelConte and K. McCafferty (both AlixPartners) re: diligence project.	0.6
07/29/2021	JD	Correspondence with FTI and Davis Polk re: KEIP/KERP proposal.	0.2
07/29/2021	JD	Review details from Purdue management re: Abbot Labs payments.	0.3
07/29/2021	JD	Review latest weekly sales by product details prior to sharing with creditor advisors.	0.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/29/2021	JD	Correspondence with Purdue management and Davis Polk re: KEIP/KERP prep.	0.4
07/29/2021	JD	Review and provide comments on the draft response to open VA OIG diligence request re: business narrative.	0.2
07/29/2021	JD	Review and provide comments on org structure materials from K. McCafferty (AlixPartners) for meeting with management..	0.7
07/29/2021	ADD	Draft notes and procedures for sales history data and G/L reconciliation.	1.8
07/29/2021	ADD	Reconcile sales history data with G/L and identify any exceptions and items that do not reconcile.	3.3
07/29/2021	SKL	Meeting with E. Nowakoski, A. Graziano (both Purdue) and A. DePalma (AlixPartners) to discuss GL account reconciliation.	0.6
07/29/2021	ADD	Meeting with E. Nowakoski, A. Graziano (both Purdue) and S. Lemack (AlixPartners) to discuss GL account reconciliation.	0.6
07/29/2021	KM	Call with J. DelConte and K. McCafferty (both AlixPartners) re: diligence project.	0.6
07/30/2021	GJK	Call with E Hwang and J Weiner (Davis Polk) to discuss net asset definition in Settlement Agreement.	0.1
07/30/2021	GJK	Review of updated Settlement Agreement draft from Milbank and Debevoise (ongoing).	1.5
07/30/2021	HSB	Review OCP report prepared by L.Nguyen (AlixPartners)	0.4
07/30/2021	JD	Meeting with J. Lowne (Purdue); J. DelConte, K. McCafferty and J. Hyun (AlixPartners) re: diligence project weekly stand-up meeting.	0.8
07/30/2021	JD	Meeting with C. Landau, J. Lowne and M. Kesselman (Purdue); J. DelConte, K. McCafferty and J. Hyun (AlixPartners) re: review of G&A and organization recommendations.	0.9
07/30/2021	JD	Call with D. Consola (Davis Polk) re: KEIP/KERP diligence.	0.2
07/30/2021	JD	Call with E. Vonnegut (Davis Polk) RE: diligence project.	0.2
07/30/2021	JD	Meeting with J. DelConte and K. McCafferty (both AlixPartners) RE: diligence project.	0.6
07/30/2021	JD	Review draft June OCP report to be filed with the court.	0.2
07/30/2021	JD	Prepare employee breakdown for Davis Polk and Skadden in response to open KEIP/KERP diligence questions.	2.5
07/30/2021	JD	Correspondence with Purdue management and Davis Polk re: open DOJ questions on the NewCo operating agreement.	0.3
07/30/2021	JD	Email with Purdue management re: KEIP/KERP terms.	0.2
07/30/2021	LTN	Review changes in the latest Settlement agreement ahead of the call	2.0
07/30/2021	ADD	Incorporate license application comments from Purdue legal team.	2.5
07/30/2021	ADD	Update sales history data reconciliation and incorporate client comments.	2.8
07/30/2021	ADD	Review Sales History reconciling items and draft list of open items.	1.2
07/30/2021	KM	Meeting with J. DelConte and K. McCafferty (both AlixPartners) re: diligence project.	0.6
08/01/2021	JD	Call with M. Kesselman, R. Aleali (both Purdue), P. Fitzgerald, M. Florence, J. Bragg (all Skadden), E. Vonnegut, D. Consola (both Davis Polk) re: KEIP/KERP diligence.	0.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/02/2021	GJK	Follow-up on E Hwang email re: minimum thresholds in Settlement Agreement including exchanges with L Nguyen (AlixPartners).	0.8
08/02/2021	ADD	Update sales history to G/L reconciliations to incorporate comments from the Purdue team.	3.0
08/02/2021	ADD	Compile and format data and other materials submitted in response to diligence requests by the client in preparation for processing and upload for creditor committee review.	2.9
08/02/2021	JD	Meeting with C. Landau, M. Kesselman, J. Lowne, M. Ronning, K. Gadski, D. Rosen (all Purdue), R. Schnitzler (PJT), J. DelConte and K. McCafferty (both AlixPartners) re: business updates.	0.8
08/02/2021	JD	Call with J. Lowne (Purdue) re: business updates.	0.2
08/02/2021	JD	Correspondence with Purdue vendor and Purdue management re: past due invoices and payment processing.	0.4
08/02/2021	JD	Correspondence with Purdue management re: KEIP/KERP diligence process.	0.4
08/02/2021	JD	Review the final board search process overview presentation from the AHC.	0.3
08/02/2021	JD	Review analysis from K. McCafferty (AlixPartners).	0.3
08/02/2021	JD	Review comments to the Lowne declaration from other members of Purdue management.	0.4
08/02/2021	KM	Meeting with C. Landau, M. Kesselmann, J. Lowne, M. Ronning (Purdue); and J. DelConte (AlixPartners) re: Adhansia XR forecast and operating plan.	0.8
08/02/2021	LTN	Review related provisions in the latest Settlement agreement to prepare for threshold analysis requested by E. Hwang (DWP)	1.6
08/03/2021	GJK	Follow-up with Province, FTI and Huron on dollar thresholds for Settlement Agreement items.	0.3
08/03/2021	LJD	Review June fee statement and provide comments.	0.3
08/03/2021	ADD	Review and confirm that Intralinks invoice is correct.	0.5
08/03/2021	ADD	Compile and format data and other materials submitted in response to diligence requests by the client in preparation for processing and upload for creditor committee review.	2.9
08/03/2021	ADD	Review outstanding diligence request and follow up with the appropriate client contracts.	1.4
08/03/2021	ADD	Update Sales History to G/L reconciliations to incorporate comments from the Purdue team.	3.0
08/03/2021	JD	Review draft business update presentation.	0.5
08/03/2021	JD	Call with J. Dubel (Purdue board member), M. Kesselman, R. Aleali (both Purdue), E. Vonnegut, D. Consla (both Davis Polk), P. Fitzgerald, M. Florence, J. Bragg (all Skadden) re: KEIP/KERP diligence.	0.4
08/03/2021	JD	Meeting with J. Lowne (Purdue) re: latest business plan update.	0.5
08/03/2021	JD	Correspondence with Purdue management and vendor re: payment status.	0.2
08/03/2021	JD	Correspondence with Purdue management re: ability to share IQVIA data publicly.	0.3
08/03/2021	JD	Create summary KEIP/KERP information for special committee diligence process.	0.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/03/2021	LTN	Prepare threshold analysis for bracketed items in the Settlement Agreement requested by E. Hwang (Davis Polk)	2.2
08/03/2021	LTN	Review the latest A side and B side asset values and payment obligations and incorporate to the threshold analysis	1.0
08/03/2021	ADD	Call with H. Bhattal (AlixPartners) to discuss Purdue due diligence	0.3
08/04/2021	GJK	Revise illustrative examples to Settlement Agreement from Milbank.	0.5
08/04/2021	GJK	Follow-up with A Libby (Davis Polk) on Side A and Side B reporting.	0.8
08/04/2021	ADD	Update Sales History to G/L reconciliations in preparation for final review.	2.1
08/04/2021	ADD	Compile Purdue contracts listed in exhibits for Davis Polk team.	2.8
08/04/2021	ADD	Review exhibit list containing contracts and identify the correct files.	2.6
08/04/2021	SKL	Finalize updates to the NewCo cash sweep detail and circulate for final sign-off.	1.2
08/04/2021	LTN	Review A-side Payment parties deminimis trusts asset report	0.4
08/04/2021	LTN	Review termination even agreement provided by E. Hwang (DWP)	0.5
08/04/2021	LTN	Finalize threshold analysis for the Settlement Agreement and circulate to G. Koch (AlixPartners) for review	2.0
08/04/2021	JD	Call with J. Turner (PJT) re: confirmation prep.	0.7
08/04/2021	JD	Correspondence with Davis Polk re: vendor payment inquiry.	0.3
08/04/2021	JD	Update draft summary for KEIP/KERP diligence per comments from R. Aleali (Purdue).	0.6
08/04/2021	JD	Finalize updated KEIP/KERP diligence file.	0.3
08/04/2021	JD	Correspondence with J. Dubel (board member), management, Skadden and Davis Polk re: KEIP/KERP diligence.	0.3
08/05/2021	GJK	Call with C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin, R. Schnitzler (all PJT), M. Huebner, E. Vonnegut, C. Robertson, A. Libby (all Davis Polk), L. Donahue, J. DelConte, H. Bhattal, G. Koch (all AlixPartners) re: weekly professionals and management update and planning call.	0.6
08/05/2021	ADD	Review produced materials and identify files for Davis Polk eDiscovery team.	1.5
08/05/2021	ADD	Compile Purdue contracts listed in exhibits for Davis Polk team.	2.2
08/05/2021	ADD	Review outstanding diligence request and follow up with the appropriate client contracts.	1.8
08/05/2021	ADD	Update Sales History to G/L reconciliations to incorporate comments from the Purdue team.	2.6
08/05/2021	KM	New	0.5
08/05/2021	JD	Call with J. Lowne (Purdue) re: diligence project.	0.2
08/05/2021	JD	Meeting with K. McCafferty (AlixPartners) re: diligence project.	0.5
08/05/2021	JD	Review updated Purdue retention file from HR.	0.3
08/05/2021	JD	Correspondence with AHC, Purdue management and Davis Polk re: AHC co-defendant diligence requests.	0.5
08/05/2021	JD	Correspondence with Purdue management and Davis Polk re: HSR filings.	0.3
08/05/2021	JD	Review latest professional fees filed and estimates to provide management with estimates for month end accruals.	0.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/05/2021	ADD	Meeting with P. Shafer, G. Baron, A. Johnson (FTI) and K. McCafferty (AlixPartners) re: file sharing.	0.5
08/06/2021	RC	Call with A. DePalma (AlixPartners) to discuss status of response to diligence requests from the UCC.	0.5
08/06/2021	GJK	Follow-up on Group 2 cash and cash equivalents location for Alex Romero-Wagner (Davis Polk).	0.7
08/06/2021	GJK	Review open issues and prep for Settlement Agreement final push.	1.3
08/06/2021	LJD	Call with L. Donahue, H. Bhattal, A. DePalma, G. Koch, S. Lemack (all AlixPartners) re: weekly team update call.	0.4
08/06/2021	ADD	Update liabilities subject to compromise calculating for July month end and prepare updated report.	2.5
08/06/2021	ADD	Call with D. Cabral and J. Beck-Sechow (Purdue) to discuss payroll diligence request.	0.5
08/06/2021	ADD	Call with R. Collura (AlixPartners) to discuss status of response to diligence requests from the UCC.	0.5
08/06/2021	ADD	Compile and format data and other materials submitted in response to diligence requests by the client in preparation for processing and upload for creditor committee review.	2.9
08/06/2021	ADD	Finalize sales history to G/L reconciliations for Purdue finance team review.	2.4
08/06/2021	JD	Call with M. Feltz (Purdue) re: KEIP/KERP diligence.	0.2
08/06/2021	JD	Correspondence with R. Aleali (Purdue) re: KEIP/KERP diligence.	0.3
08/08/2021	GJK	Review Creditor comments to multipod annex of Settlement Agreement.	1.4
08/09/2021	GJK	Call with counsel and advisors for Debtor, UCC and AHC to discuss open A-Side Family issues.	1.3
08/09/2021	LJD	Review response to fee examiner and provide comments.	0.4
08/09/2021	ADD	Update license agreement materials to incorporate comments from Purdue legal team.	2.4
08/09/2021	JD	Call with J. Lowne (Purdue) re: diligence project.	0.1
08/09/2021	JD	Call with M. Diaz and B. Bromberg (both FTI) re: Insurance.	0.6
08/09/2021	JD	Correspondence with Purdue management re: professional fee cash forecast.	0.5
08/09/2021	JD	Correspondence with Purdue HR re: final KEIP/KERP amounts.	0.3
08/09/2021	ADD	Review outstanding diligence request and follow up with the appropriate client contracts.	2.0
08/09/2021	ADD	Review final Sales History to G/L reconciliations.	1.6
08/10/2021	GJK	Review Side B Credit Support Annex.	0.7
08/10/2021	GJK	Review latest updates and open issues to Settlement Agreement annexes.	1.9
08/10/2021	LJD	Attend Special Committee Call	1.5
08/10/2021	LTN	Review the changes in the credit support annexes for A and B sides	0.8
08/10/2021	ADD	Compile and format data and other materials submitted in response to diligence requests by the client in preparation for processing and upload for creditor committee review.	2.6
08/10/2021	JD	Call with J. Lowne, B. Weingarten (both Purdue), K. McCafferty (AlixPartners) re: diligence project.	1.5





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/10/2021	ADD	Review outstanding diligence request and follow up with the appropriate client contracts.	2.2
08/10/2021	JD	Call with J. DelConte, K. McCafferty (both AlixPartners), J. Lowne, M. Kesselman, B. Weingarten (all Purdue) re: diligence project.	0.5
08/10/2021	ADD	Review final Sales History to G/L reconciliations.	1.5
08/11/2021	GJK	Call with L Nguyen (AlixPartners) to debrief on Settlement Agreement discussions.	0.2
08/11/2021	GJK	Review updates to drafts of Settlement Agreement and A Side Pod Credit Support Agreements (ongoing).	1.8
08/11/2021	LJD	Attend Purdue Board Special Committee meeting with Special Committee members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert), L.Donahue, J.DelConte (both AlixPartners)	0.5
08/11/2021	HSB	Attend Purdue Board Special Committee meeting with Special Committee members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert), H. Bhattal, L.Donahue, J.DelConte (all AlixPartners)	0.5
08/11/2021	LTN	Review the latest changes in settlement agreement and credit support annexes ahead of the call	1.2
08/11/2021	LTN	Review Further Assurances Undertaking draft provided by E. Hwang (DavisPolk)	0.5
08/11/2021	ADD	Review outstanding diligence request and follow up with the appropriate client contracts.	0.9
08/11/2021	ADD	Review license project comments from Purdue legal team and open items.	1.2
08/11/2021	JD	Attend Purdue Board Special Committee meeting with Special Committee members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert), L.Donahue, J.DelConte (both AlixPartners)	0.5
08/11/2021	JD	Meeting with J. DelConte and A. DePalma (both AlixPartners) re: update on diligence workstreams.	0.3
08/11/2021	JD	Call with E. Vonnegut (Davis Polk) re: KEIP/KERP.	0.2
08/11/2021	JD	Correspondence with Davis Polk, Kramer Levin and Akin re: settlement discussions.	0.2
08/11/2021	JD	Correspondence with J. Lowne, M. Kesselman and R. Aleali (all Purdue) re: business plan cash flows.	0.3
08/11/2021	JD	Correspondence with Purdue management and Skadden re: KEIP/KERP diligence.	0.4
08/11/2021	JD	Review various presentations and previous analyses in advance of tomorrow's confirmation hearing.	2.2
08/11/2021	LTN	Call with G. Koch (AlixPartners) re: financial reporting format	0.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/11/2021	ADD	Meeting with J. DelConte and A. DePalma (both AlixPartners) re: update on diligence workstreams.	0.3
08/12/2021	GJK	Review updates to drafts of Settlement Agreement drafts and open issues.	1.1
08/12/2021	GJK	Review update drafts and open questions on A-Side Credit Support Annexes	0.8
08/12/2021	GJK	Call with J DelConte (AlixPartners) to discuss Sackler diligence process.	0.4
08/12/2021	GJK	Review A-Side documents and A-Side update balance sheets.	1.8
08/12/2021	LTN	Update Shareholder presentation deck based on the latest changes in the Settlement agreement	2.0
08/12/2021	LTN	Update A-side net asset values based on Jul 2021 data provided by Huron	1.9
08/12/2021	LTN	Update B side asset values section of the Shareholder presentation deck	1.5
08/12/2021	JD	Call with G. Koch (AlixPartners) re: witness prep.	0.4
08/12/2021	JD	Call with J. Lowne (Purdue) re: post-emergence insurance policies.	0.2
08/12/2021	JD	Call with C. Robertson (Davis Polk) re: witness prep.	0.5
08/13/2021	HSB	Review Purdue June monthly flash report prepared by L.Nguyen (AlixPartners)	1.1
08/13/2021	SKL	Review latest approved vendor information provided by C. MacDonald (Purdue) and updated the AP database accordingly.	1.1
08/13/2021	LTN	Finalize the June PEO monthly flash report and circulate for internal review	2.2
08/13/2021	LTN	Reconcile Adlon and Avrio Health financials section of the June 2021 PEO monthly flash report	1.5
08/13/2021	LTN	Reconcile and update the Purdue and Rhodes financials section of the June 2021 PEO monthly flash report	1.8
08/13/2021	JD	Correspondence with Purdue management re: KEIP/KERP diligence.	0.4
08/16/2021	HSB	Review Purdue board presentation prepared by J.Lowne (Purdue)	0.7
08/16/2021	HSB	Attend Purdue Board meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert), J.DelConte (AlixPartners)	0.6
08/16/2021	JD	Catch up with J. Lowne (Purdue) re: 2022 planning.	0.2
08/16/2021	JD	Attend Purdue Board meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert), H. Bhattal (AlixPartners)	0.6
08/16/2021	JD	Review compensation details for 2022 planning.	0.3
08/16/2021	JD	Correspondence with Purdue management, Reed Smith and Dechert re: open AHC insurance questions.	0.4
08/17/2021	LTN	Review the Pledge Agreement for B-side obligors	1.7
08/17/2021	JD	Call with R. Aleali (Purdue) re: confirmation and emergence planning.	0.7
08/17/2021	JD	Call with J. Lowne (Purdue) re: business plan review.	0.2
08/17/2021	JD	Call with K. McCafferty and J. DelConte (AlixPartners) re: business plan review.	0.5
08/17/2021	JD	Review historical summary information for KEIP/KERP diligence.	0.5
08/17/2021	JD	Review distribution detail calculations per open request from Purdue management.	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/17/2021	JD	Review preliminary presentation from management re: 2022 business planning process.	0.7
08/17/2021	JD	Review business plan review presentation from J. Lowne (Purdue).	0.6
08/17/2021	JD	Correspondence with PJT and Purdue management re: distribution details.	0.4
08/18/2021	ADD	Review outstanding diligence request and follow up with the appropriate client contracts.	1.5
08/18/2021	LJD	Review monthly fee application and provide comments.	0.6
08/18/2021	JM	Activities related to the review of internal system search results and file attachments, and coordination of requested search for KEIP/KERP diligence.	0.6
08/18/2021	KM	Meeting with J. Lowne, B. Weingarten (Purdue); and K. McCafferty, J. DelConte (AlixPartners) re: business plan review.	0.9
08/18/2021	HSB	Review Purdue comp related files in connection with request from Davis Polk	1.3
08/18/2021	HSB	Review Purdue financial info in connection with diligence requests	1.1
08/18/2021	HSB	Review Purdue pipeline related files in connection with forecasts	0.8
08/18/2021	HSB	Call with C.Goetz, G.Morrison (both Davis Polk), J.DelConte (AlixPartners) re: NewCo filing with DOJ & FTC	0.4
08/18/2021	HSB	Review Purdue files with financial information required in connection with DOJ filing	1.8
08/18/2021	JD	Call with C. Goetz, G. Morrison, M. Marks (all Davis Polk), J. DelConte and H. Bhattal (both AlixPartners) re: HSR request.	0.4
08/18/2021	JD	Meeting with J. Lowne, B. Weingarten (Purdue); and K. McCafferty, J. DelConte (AlixPartners) re: business plan review.	0.9
08/18/2021	JD	Call with K. McCafferty (both AlixPartners) re: draft business plan review analyses.	0.7
08/18/2021	JD	Review data room for potential HSR materials.	0.4
08/18/2021	JD	Review and provide comments on latest cure amount descriptions.	0.3
08/18/2021	JD	Correspondence with H. Bhattal (AlixPartners) and Purdue management re: open KEIP/KERP diligence.	0.3
08/18/2021	JD	Review and provide comments on weekly sales report details and the June monthly flash report for creditors.	0.8
08/18/2021	JD	Correspondence with Skadden and Wiggins and Dana re: KEIP/KERP diligence.	0.4
08/18/2021	JD	Rereview expert report to determine potential cross examination questions from the DMPs.	2.0
08/18/2021	JD	Review underlying excel analyses surrounding the liquidation analysis in advance of potential testimony tomorrow.	0.7
08/18/2021	KM	Call with J. DelConte (both AlixPartners) re: draft business plan review analyses.	0.5
08/19/2021	ADD	Identify individuals that meet criteria outlined in diligence request.	2.7
08/19/2021	JM	Call with J. Muscovich and J. DelConte (both AlixPartners) re: KEIP/KERP diligence.	0.2
08/19/2021	JM	Call with M. Florence, J. Bragg (both Skadden), R. Hoff (Wiggins and Dana), J. Hamilton, J. DelConte and J. Muscovich (both AlixPartners) re: KEIP/KERP diligence.	0.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/19/2021	JH	Call with J. Muskovich, J. Hamilton and J. DelConte (both AlixPartners) re: searching for reports and KEIP/KERP diligence.	0.4
08/19/2021	JH	Call with M. Florence, J. Bragg (both Skadden), R. Hoff (Wiggins and Dana), J. Hamilton, J. DelConte and J. Muscovich (both AlixPartners) re: KEIP/KERP diligence.	0.4
08/19/2021	HSB	Review Purdue files with financial information required in connection with DOJ filing	1.5
08/19/2021	JD	Call with J. Lowne (Purdue) re: 2022 planning.	0.2
08/19/2021	JD	Call with J. Muscovich and J. DelConte (both AlixPartners) re: KEIP/KERP diligence.	0.2
08/19/2021	JD	Call with J. Muskovich, J. Hamilton and J. DelConte (both AlixPartners) re: searching for reports and KEIP/KERP diligence.	0.4
08/19/2021	JD	Call with M. Florence, J. Bragg (both Skadden), R. Hoff (Wiggins and Dana), J. Hamilton, J. DelConte and J. Muscovich (both AlixPartners) re: KEIP/KERP diligence.	0.4
08/19/2021	JD	Review materials provided by Purdue re: KEIP/KERP diligence.	0.8
08/19/2021	JM	Call with J. Muskovich, J. Hamilton and J. DelConte (both AlixPartners) re: searching for reports and KEIP/KERP diligence.	0.4
08/20/2021	GJK	Review draft Net Proceeds report documentation in preparation for call with counsel and FAs for Sackler Family, Debtor, UCC and AHC.	0.5
08/20/2021	GJK	Walk through of revised draft of IAC Share Pledge Agreement.	0.8
08/20/2021	ADD	Identify individuals that meet criteria outlined in diligence request.	2.5
08/20/2021	JM	Participate in call with Purdue Ethics team to discuss compliance requests and analysis	0.6
08/20/2021	JM	Review of KEIP/KERP diligence search results and file attachments	0.6
08/20/2021	SKL	Multiple calls with H. Bhattal (AlixPartners) to discuss Purdue Plan related diligence requests.	0.2
08/20/2021	HSB	Review Purdue audited financial statements	0.2
08/20/2021	HSB	Multiple calls with S.Lemack (AlixPartners) to discuss various Purdue plan related diligence requests	0.2
08/20/2021	LTN	Review the Net Proceeds Report ahead of the call	0.4
08/20/2021	LTN	Review the IAC share pledge and Security Agreement provided by Davis Polk	1.2
08/20/2021	JD	Call with J. Muscovich and J. DelConte (both AlixPartners) re: KEIP/KERP diligence.	0.2
08/20/2021	JD	Call with M. Kesselman, J. Lowne, R. Aleali, C. Ricarte (all Purdue), A. Kramer (Reed Smith), S. Birnbaum (Dechert) re: Insurance update.	1.1
08/20/2021	JD	Call with J. Lowne, C. DeStefano, D. Warren (all Purdue) re: KEIP/KERP budgeting.	0.2
08/20/2021	JD	Correspondence with Davis Polk and Purdue management re: DMP settlement.	0.3
08/20/2021	JD	Work on initial KEIP/KERP overview analysis to provide to internal HR and finance.	3.2
08/20/2021	JD	Call with J. DelConte, J. Muscovich (all AlixPartners), M. Feltz (Purdue) re: KEIP/KERP diligence.	0.3
08/20/2021	JD	Review updated draft insurance presentation.	0.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/20/2021	JM	Call with J. Muscovich and J. DelConte (both AlixPartners) re: KEIP/KERP diligence.	0.2
08/20/2021	JM	Call with J. DelConte, J. Muscovich (all AlixPartners), M. Feltz (Purdue) re: KEIP/KERP diligence	0.3
08/22/2021	JD	Correspondence with Davis Polk and S. Lemack, L. Nguyen (both AlixPartners) re: KEIP/KERP diligence.	0.3
08/23/2021	JD	Call with T. Melvin (PJT) re: HSR diligence request.	0.2
08/23/2021	JD	Correspondence with Purdue management, Davis Polk and H. Bhattal (AlixPartners) re: post-emergence distribution forecast.	0.4
08/23/2021	HSB	Review Purdue diligence materials prepared by S.Lemack (AlixPartners)	0.7
08/23/2021	SKL	Review HSR requirements and begin preparing updated RALP net sales by product breakout and circulate to D. Fogel (Purdue) for feedback.	2.4
08/23/2021	SKL	Review latest RALP net sales by product information provided by R. Habelin (Purdue) and prepare updates to the HSR revenue breakdown.	2.2
08/23/2021	SKL	Review latest monthly finance deck and being preparing Purdue piece of the HSR requirements.	1.4
08/24/2021	JD	Attend Purdue Board Special Committee meeting with Special Committee members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert), L.Donahue, J.DelConte, H. Bhattal (all AlixPartners)	0.6
08/24/2021	JD	Call with J. DelConte and K. McCafferty (both AlixPartners) re: diligence project.	0.2
08/24/2021	LJD	Attend Purdue Board Special Committee meeting with Special Committee members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert), L.Donahue, J.DelConte, H. Bhattal (all AlixPartners)	0.6
08/24/2021	HSB	Attend Purdue Board Special Committee meeting with Special Committee members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert), L.Donahue, J.DelConte (both AlixPartners)	0.6
08/24/2021	HSB	Review Purdue financial projections	1.6
08/24/2021	LTN	Reconcile Adlon and Avrio Health financials section of the July 2021 PEO monthly flash report	1.3
08/24/2021	LTN	Reconcile and update the Purdue and Rhodes financials section of the July 2021 PEO monthly flash report	2.1
08/24/2021	LTN	Review the Financial statement deck and update Consolidated financials section for July 2021 PEO monthly flash report	1.6
08/24/2021	KM	Call with J. DelConte and K. McCafferty (both AlixPartners) re: diligence project.	0.2
08/25/2021	SKL	Continue to finalize the Purdue revenue by product breakdown for the HSR filing and begin consolidating Purdue and RALP pieces for internal sign-off.	2.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/25/2021	SKL	Finalize remaining updates to the HSR revenue requirements and circulate to J. Lowne (Purdue) for additional review.	1.9
08/25/2021	JM	Review documents and analysis related to ongoing KEIP/KERP diligence.	0.8
08/25/2021	LTN	Format files provided by Davis Polk and upload to Intralink	1.7
08/26/2021	JD	Call with R. Aleali (Purdue) re: ongoing diligence project.	0.7
08/26/2021	JD	Begin preparation of analysis of 2021 incentive compensation expense and accruals given current employee roster.	2.3
08/26/2021	JD	Review and provide comments on latest diligence project slides.	1.0
08/26/2021	GJK	Call with M.Kesselman, J.Lowne, R.Aleali (all Purdue), M.Huebner, C. Robertson, E.Vonnegut (Davis Polk), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), J.DelConte, H. Bhattal (AlixPartners) re: update and planning.	0.8
08/26/2021	HSB	Review Purdue diligence materials prepared by A.DePalma and S.Lemack (AlixPartners)	1.5
08/26/2021	HSB	Call with C.Goetz, G.Morrison (both Davis Polk), S.Lemack (AlixPartners) re: NewCo filing with DOJ & FTC	0.1
08/26/2021	SKL	Meeting with G. Morrison, G. Goetz (both Davis Polk) and H. Bhattal (AlixPartners) to discuss HSR submission requirements.	0.1
08/26/2021	SKL	Review latest updates to the HSR revenue requirements and prepare for upcoming call with the Davis Polk team.	0.4
08/26/2021	SKL	Review latest employee information provided by J. Bachman (Purdue) and prepare updated breakdown for KEIP/KERP analysis accordingly.	2.1
08/26/2021	SKL	Follow-up with J. Bachman (Purdue) to discuss additional questions on the employee information she provided and prepare updates to the KEIP/KERP analysis accordingly.	2.5
08/26/2021	JM	Review analyses and files related to the ongoing KEIP/KERP diligence. Discussion with Purdue HR RE: same.	1.4
08/26/2021	LTN	Correspondence with HS. Bhattal (AlixPartners) re: KEIP/ KERP project	0.2
08/27/2021	JD	Call with J. Lowne, D. Warren, C. DeStefano (all Purdue) re: incentive compensation accounting estimates.	0.3
08/27/2021	JD	Review initial report prepared for KEIP/KERP diligence and correspondence with Purdue management re: same.	0.4
08/27/2021	JD	Prepare updated fee application per company comments.	1.2
08/27/2021	JD	Finalize initial draft KEIP/KERP accounting estimates in advance of call with management.	1.5
08/30/2021	JD	Call with J. DelConte and S. Lemack (both AlixPartners) re: review of ongoing AHC diligence workstreams and HSR requests.	0.5
08/30/2021	JD	Correspondence with Alix team and Purdue management re: recent professional fee payments.	0.3
08/30/2021	JD	Review materials received related to KEIP/KERP diligence and correspondence with Purdue management re: same.	0.5
08/30/2021	JD	Begin preparing incentive compensation rollforward forecast for 2021 estimates and 2022 budgeting.	2.7
08/30/2021	HSB	Review Purdue financial projections in connection with ongoing analysis	0.6
08/30/2021	HSB	Review Purdue emergence date cash forecasts	0.8



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/30/2021	SKL	Call with J. DelConte and S. Lemack (both AlixPartners) re: review of ongoing AHC diligence workstreams and HSR requests.	0.5
08/30/2021	SKL	Review latest feedback on the net sales by NACPS/NAICS code breakdown and circulate updated list of open items to the medical team accordingly.	1.3
08/30/2021	SKL	Finalize KEIP/KERP analyses based on the latest information provided by HR and circulate updated file internally for additional review and sign-off.	2.2
08/31/2021	JM	Activities related to compliance investigation support, document review and preparing master control.	1.4
08/31/2021	GJK	Follow up on excess cash question for A Libby (Davis Polk), including outreach to M Diaz (FTI).	0.9
08/31/2021	HSB	Review Purdue monthly Flash report (July 2021) prepared by L.Nguyen (AlixPartners)	1.2
08/31/2021	HSB	Review Purdue board deck (July 2021) prepared by J.Lowne (Purdue)	0.9
08/31/2021	HSB	Review relevant sections of Purdue audited financial statements for 2020	0.8
08/31/2021	HSB	Review relevant sections of Purdue plan documents in connection with ongoing analysis	1.3
08/31/2021	JD	Call with J. Lowne, B. Weingarten, R. Aleali, D. Saussy (all Purdue), C. Robertson (Davis Polk), R. Schnitzler (PJT) re: potential JV opportunity.	0.5
08/31/2021	JD	Review July flash report	0.3
08/31/2021	JD	Provide comments on July flash report and version to be shared with creditors.	0.9
08/31/2021	JD	Update Prime Clerk payment schedule to be shared with creditors.	0.7
08/31/2021	JD	Create KEIP/KERP payment file for HR given updated roster and latest compensation data.	2.0
08/31/2021	JD	Revise Prime Clerk payment schedule per comments from Prime Clerk.	0.4
08/31/2021	JD	Continue working on incentive compensation accrual and expense roll forward.	0.8
08/31/2021	LTN	Finalize the July PEO monthly flash report and circulate for internal review	0.7
09/01/2021	GJK	Discussion with G. Koch, J. DelConte and L. Nguyen (all AlixPartners) re: potential settlement refinements and shareholder asset value.	0.3
09/01/2021	JD	Discussion with G. Koch, J. DelConte and L. Nguyen (all AlixPartners) re: potential settlement refinements and shareholder asset value.	0.3
09/01/2021	LTN	Discussion with G. Koch, J. DelConte and L. Nguyen (all AlixPartners) re: potential settlement refinements and shareholder asset value.	0.3
09/01/2021	HSB	Call with Purdue management, S.Lemack and H. Bhattal (both AlixPartners) to discuss Purdue diligence request and NAPCS/NAICS codes	0.3
09/01/2021	SKL	Call with Purdue management, S.Lemack and H. Bhattal (both AlixPartners) to discuss Purdue diligence request and NAPCS/NAICS codes	0.3
09/01/2021	GJK	Call with N. Nguyen (AlixPartners) to discuss shareholder asset value	0.4
09/01/2021	LTN	Call with G. Koch (AlixPartners) to discuss shareholder asset value	0.4
09/01/2021	GJK	Call with B. Bromberg and M Diaz (FTI) to discuss excess cash language.	0.2
09/01/2021	HSB	Review Purdue financial projections	0.7
09/01/2021	JM	Compile and standardize master data set from internal system	3.1
09/01/2021	JM	Create listing of current employees for review from TrackWise dataset	0.7
09/01/2021	JD	Review and provide comments on the latest version of the diligence project slides.	0.9



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/01/2021	JD	Review initial details from diligence review.	0.3
09/01/2021	LTN	Analyze the shareholder asset values during 10 year settlement period	2.5
09/01/2021	LTN	Finalize the shareholder asset value based on J. Delconte (AlixPartners) feedback	2.0
09/01/2021	LTN	Reconcile the shareholder asset data for A & B families provided by Huron vs the expert report	2.2
09/01/2021	LTN	Review the expert report by W. Hrycay (Nera), clean data and start analyzing shareholder asset values	2.1
09/01/2021	SKL	Review latest feedback provided re: NAPCS/NAICS codes and update the revenue by code breakout accordingly.	1.4
09/02/2021	HSB	Attend Purdue Board meeting with J.DelConte, H. Bhattal (AlixPartners).	1.2
09/02/2021	JD	Attend Purdue Board meeting with J.DelConte, H. Bhattal (AlixPartners).	1.2
09/02/2021	HSB	Meeting with J. DelConte, S. Lemack, J. Muskovich and H. Bhattal (all AlixPartners) to discuss matters related to ongoing diligence requests.	0.4
09/02/2021	JM	Meeting with J. DelConte, S. Lemack, J. Muskovich and H. Bhattal (all AlixPartners) to discuss matters related to ongoing diligence requests.	0.4
09/02/2021	JD	Meeting with J. DelConte, S. Lemack, J. Muskovich and H. Bhattal (all AlixPartners) to discuss matters related to ongoing diligence requests.	0.4
09/02/2021	SKL	Meeting with J. DelConte, S. Lemack, J. Muskovich and H. Bhattal (all AlixPartners) to discuss matters related to ongoing diligence requests.	0.4
09/02/2021	ADD	Multiple calls with H. Bhattal (AlixPartners) to discuss Purdue diligence requests	0.7
09/02/2021	HSB	Multiple calls with A.DePalma (AlixPartners) to discuss Purdue diligence requests	0.7
09/02/2021	GJK	Review settlement modeling updates by L Nguenyn (AlixPartners).	0.3
09/02/2021	GJK	Partial participation in weekly call with M. Kesselman, C. Landau, J. Lowne, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, W. Taylor (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: weekly catch up and planning call.	0.5
09/02/2021	JM	Participate in status update call with M. Clarens, A. Mendelson (both Davis Polk) to discuss initial findings in data review and discuss additional research requirements.	0.7
09/02/2021	JM	Prepare master analyses for Davis Polk team to summarize initial findings in data review	0.6
09/02/2021	JD	Correspondence with management re: vendor payment processing.	0.3
09/02/2021	JD	Preparation of initial 2021 incentive comp expense and accrual numbers for latest 2021 estimate.	0.9
09/02/2021	JD	Prepare preliminary KERP detailed payment schedule for HR processing.	1.5
09/02/2021	LTN	Format files provided by Davis Polk and upload to Intralink	0.5
09/02/2021	LTN	Review comments by J. DelConte (AlixPartners) and update the shareholder analysis	1.0
09/02/2021	LTN	Review the shareholder return analysis revised by J. Delconte (AlixPartners)	0.7
09/02/2021	SKL	Continue to review latest updates provided re: NAPCS/NAICS codes and circulate updated analysis internally for additional review.	1.3





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/03/2021	JM	Analysis related to the data review initiative.	0.4
09/03/2021	JD	Edit incentive comp analysis to update for change in paygrade for certain employees.	0.4
09/03/2021	JD	Finalize and send around latest view of 2021 incentive comp expense and accruals.	1.0
09/03/2021	JD	Update detailed breakdown of KERP payments for HR.	0.5
09/03/2021	SKL	Meetings with D&B team to discuss the DUNS application process and fill-out the application.	2.1
09/07/2021	SKL	Meeting with H. Bhattal and S. Lemack (both AlixPartners) re: the latest updates re: NAPCS/NAICS revenue by code breakdown.	0.3
09/07/2021	JD	Meeting with J. Lowne (Purdue); K. McCafferty and J. DelConte (AlixPartners) re: diligence project.	1.0
09/07/2021	KM	Meeting with J. Lowne (Purdue); K. McCafferty and J. DelConte (AlixPartners) re: diligence project.	1.0
09/07/2021	ADD	Call with A. DePalma and H. Bhattal (AlixPartners) re: outstanding diligence requests.	0.3
09/07/2021	HSB	Call with A. DePalma and H. Bhattal (AlixPartners) re: outstanding diligence requests.	0.3
09/07/2021	ADD	Update liabilities subject to compromise report for August month end.	2.6
09/07/2021	JM	Analyses related to the ongoing diligence initiative.	0.8
09/07/2021	JD	Review and update latest professional fee forecast for month end accruals.	0.7
09/07/2021	JD	Review initial analysis from Purdue management on incentive compensation budget to actuals.	0.4
09/07/2021	JD	Review initial comments on diligence project from Purdue management.	0.8
09/07/2021	JD	Review initial draft retention recommendations for 2022 KERP.	0.5
09/07/2021	SKL	Review latest feedback provided by Purdue management re: NAPCS/NAICS codes and prepare follow-up request for additional info.	0.6
09/08/2021	JD	Call with K. McCafferty and J. DelConte (both AlixPartners) re: prep for Friday meeting with management.	0.2
09/08/2021	KM	Call with K. McCafferty and J. DelConte (both AlixPartners) re: prep for Friday meeting with management.	0.2
09/08/2021	HSB	Review Purdue financial projections	0.4
09/08/2021	JM	Miscellaneous document review related to diligence research	0.4
09/08/2021	JD	Correspondence with Purdue management and J. Muscovich (AlixPartners) re: diligence.	0.4
09/08/2021	JD	Provide comments on the July monthly flash report prior to posting for creditors.	0.7
09/08/2021	JD	Review and provide comments on the draft diligence project slides.	1.1
09/09/2021	SKL	Meeting with H. Bhattal (AlixPartners) to discuss the latest updates re: HSR filing.	0.2
09/09/2021	HSB	Review draft of Purdue onboarding materials and related documents	0.8
09/09/2021	JM	Miscellaneous document review and correspondence related to ongoing diligence.	0.6
09/09/2021	JD	Correspondence with Purdue management re: 2022 professional fee forecasting.	0.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/09/2021	JD	Review comments from management on the initial KEIP/KERP detail file and make corresponding changes.	3.2
09/10/2021	JD	Meeting with C. Landau, M. Kesselman, J. Lowne, B. Weingarten (Purdue), and K. McCafferty (AlixPartners) re: project Omega diligence review.	2.0
09/10/2021	KM	Meeting with C. Landau, M. Kesselman, J. Lowne, B. Weingarten (Purdue); J. DelConte (AlixPartners) re: project Omega diligence review.	2.0
09/10/2021	JD	Meeting with K. McCafferty (AlixPartners) re: project Omega executive presentation.	1.1
09/10/2021	KM	Meeting with J. DelConte (AlixPartners) re: project Omega executive presentation.	1.1
09/10/2021	JM	Participate in call with HR team to discuss review methodology and availability of pre-2014 material	0.4
09/10/2021	JM	Prepare requested data files for client review.	0.6
09/10/2021	JD	Call with R. Aleali (Purdue) re: diligence project.	0.9
09/10/2021	JD	Review draft diligence materials.	0.3
09/10/2021	JD	Review initial draft slides for potential Board onboarding presentation.	0.6
09/13/2021	HSB	Attend Purdue Board Special Committee meeting with L. Donahue, J. DelConte, H. Bhattal (AlixPartners)	1.2
09/13/2021	JD	Attend Purdue Board Special Committee meeting with L. Donahue, J. DelConte, H. Bhattal (AlixPartners)	1.2
09/13/2021	JM	Participate in update call with M. Clarens, A. Mendolsohn (both Davis Polk) and J. Muskovich, J. DelConte (both AlixPartners) re: research activities status and additional analysis requests	0.6
09/13/2021	JD	Participate in update call with M. Clarens, A. Mendolsohn (both Davis Polk) and J. Muskovich, J. DelConte (both AlixPartners) re: research activities status and additional analysis requests	0.6
09/13/2021	JM	Review and analysis of materials in connection with diligence review.	1.3
09/13/2021	JD	Call with Purdue management re: insurance.	0.7
09/13/2021	JD	Call with R. Aleali (Purdue) re: Newco transfer process.	0.3
09/13/2021	JD	Review employee data in response to Grant Thornton questions for fresh start accounting.	0.3
09/13/2021	LJD	Partial participation in Purdue Board Special Committee meeting with L. Donahue, J. DelConte, H. Bhattal (AlixPartners)	0.8
09/14/2021	JD	Call with J. DelConte, K. McCafferty (both AlixPartners) and Purdue management re: diligence project.	0.4
09/14/2021	KM	Call with J. DelConte, K. McCafferty (both AlixPartners) and Purdue management re: diligence project.	0.4
09/14/2021	HSB	Call with H. Bhattal, L. Nguyen (AlixPartners) to discuss weekly cash reports	0.2
09/14/2021	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) to discuss weekly cash reports	0.2
09/14/2021	GJK	Participate in weekly professional update call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. Turner, T. Melvin, J. O'Connell, R. Schnitzler (all PJT), J. DelConte, G. Koch, H. Bhattal (all AlixPartners).	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/14/2021	HSB	Participate in weekly professional update call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. Turner, T. Melvin, J. O'Connell, R. Schnitzler (all PJT), J. DelConte, G. Koch, H. Bhattal (all AlixPartners).	0.5
09/14/2021	JD	Participate in weekly professional update call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. Turner, T. Melvin, J. O'Connell, R. Schnitzler (all PJT), J. DelConte, G. Koch, H. Bhattal (all AlixPartners).	0.5
09/14/2021	JM	Review and analysis of compliance materials in connection with diligence review.	0.8
09/14/2021	JD	Call with C. Robertson, E. Vonnegut (both Davis Polk), R. Aleali (Purdue), A. Kramer (Reed Smith) re: insurance.	0.8
09/14/2021	JD	Call with Purdue management, A. Kramer (Reed Smith) re: post-emergence insurance.	0.5
09/14/2021	JD	Review and provide comments draft finance transition workplan from Purdue management.	0.6
09/14/2021	JD	Review and provide comments on the materials responsive to Grant Thornton's fresh start accounting requests.	0.5
09/14/2021	JD	Review materials re: potential business development agreement.	0.4
09/14/2021	JD	Review request from management re: updated long term business plan.	0.6
09/15/2021	HSB	Review Purdue onboarding deck draft prepared by PJT Partners	1.5
09/15/2021	JM	Review and analysis of materials in connection with diligence review.	1.6
09/15/2021	JD	Call with Purdue management re: incentive compensation for the long term business plan.	0.5
09/15/2021	SKL	Continue to finalize latest HSR filing request information and circulate follow-up items to J. Carlisle (Purdue) for review.	1.2
09/16/2021	JD	Call with Purdue management, C. Robertson (Davis Polk), J. DelConte, S. Lemack (both AlixPartners) re: finance and accounting transition plan.	0.5
09/16/2021	SKL	Call with Purdue management, C. Robertson (Davis Polk), J. DelConte, S. Lemack (both AlixPartners) re: finance and accounting transition plan.	0.5
09/16/2021	JM	Review and analysis of compliance materials in connection with diligence review.	1.2
09/16/2021	JD	Call with Purdue management re: emergence employee payments.	0.5
09/16/2021	JD	Call with R. Aleali (Purdue) re: diligence project.	0.4
09/16/2021	JD	Review payment details related to a previous BD deal and correspondence with Purdue and Davis Polk re: same.	0.9
09/17/2021	JD	Meeting with J. DelConte and S. Lemack (both AlixPartners) re: finance Newco transfer workplan.	0.4
09/17/2021	SKL	Call with J. DelConte (AlixPartners) to discuss the high-level overview slides related to the change of control process.	0.4
09/17/2021	JM	Review and analysis of compliance materials in connection with diligence review.	1.5
09/17/2021	LTN	Format files provided by Davis Polk and upload to Intralink	1.5
09/17/2021	LTN	Prepare incremental professional fees sensitivity analysis for declaration	2.2
09/17/2021	LTN	Prepare sensitivity analysis on lost present value due to Settlement Payments delay	1.9



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/17/2021	LTN	Revise payment delay analysis based on H. Bhattal (AlixPartners) feedback	1.7
09/20/2021	JD	Meeting with J. Lowne (Purdue), S. Lemack, J. DelConte (both AlixPartners) re: finance transition to NewCo.	0.4
09/20/2021	SKL	Meeting with J. Lowne (Purdue) and J. DelConte (AlixPartners) to discuss open items related to the finance workstream in the change of control process.	0.4
09/20/2021	JD	Call with J. Lowne (both Purdue) re: contract renewals.	0.4
09/20/2021	JD	Review diligence project draft slides to walk through with management.	0.7
09/20/2021	JD	Review updated diligence report from Purdue management.	0.5
09/20/2021	JD	Review updated roster impacts on total KEIP/KERP payments.	0.5
09/20/2021	LTN	Revise payment delay sensitivity analysis and circulate to H. Bhattal (AlixPartners) for review	2.0
09/21/2021	JD	Meeting with K. McCafferty and J. DelConte (both AlixPartners) re: prep for meeting with management on Wednesday.	0.5
09/21/2021	KM	Meeting with K. McCafferty and J. DelConte (both AlixPartners) re: prep for meeting with management on Wednesday.	0.5
09/21/2021	ADD	Call with S. Lemack, A. DePalma, and H. Bhattal (AlixPartners) re: Follow-up: System Data.	0.3
09/21/2021	HSB	Call with S.Lemack and A.DePalma (both AlixPartners) to discuss Purdue diligence requests	0.3
09/21/2021	SKL	Meeting with H. Bhattal and A. DePalma (both AlixPartners) to discuss latest inquiry re: systems data.	0.3
09/21/2021	JD	Begin preparation of long term incentive compensation income statement, cash flow and balance sheet forecast.	3.3
09/21/2021	JD	Call with J. Lowne (Purdue) re: diligence project.	0.3
09/21/2021	JD	Correspondence with Davis Polk and AlixPartners' teams re: diligence project.	0.3
09/21/2021	JD	Update KEIP/KERP analysis for OT and shift premium annual estimates.	0.8
09/21/2021	LTN	Review confirmation delay provisions in the plan and update sensitivity analysis	0.8
09/21/2021	LTN	Revise incremental professional fees section in the confirmation delay analysis based on H. Bhattal (AlixPartners) feedback	2.1
09/21/2021	LTN	Update sensitivity analysis for different delay scenarios for confirmation declaration	1.3
09/21/2021	LTN	Update TopCo/ MDT expenses under different scenarios to in the confirmation delay analysis	2.4
09/22/2021	JD	Call with Purdue management, J. DelConte, S. Lemack (both AlixPartners) re: emergence payroll payments.	0.6
09/22/2021	SKL	Call with Purdue management, J. DelConte, S. Lemack (both AlixPartners) re: emergence payroll payments.	0.6
09/22/2021	ADD	Calls with A. DePalma and S. Lemack (AlixPartners) re: outstanding diligence requests.	0.3
09/22/2021	HSB	Telephone calls with A.DePalma (AlixPartners) to discuss Purdue diligence related requests	0.9
09/22/2021	HSB	Review Purdue financial forecasts	0.8
09/22/2021	HSB	Review Purdue presentation prepared draft prepared by PJT Partners	0.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/22/2021	JD	Correspondence with Purdue management and Davis Polk re: advance creditor trust funding mechanics.	0.6
09/22/2021	JD	Prepare dynamic analysis of LTRP and AIP amounts from 2022-2025 for revised long term business plan.	2.2
09/22/2021	JD	Prepare incentive compensation expense projections for 2022-2025 long term plan.	2.0
09/22/2021	JD	Prepare updated forecast of professional fees through emergence per request from management.	0.9
09/23/2021	HSB	Telephone call with H. Bhattal, L. Nguyen (AlixPartners) to re: cash forecast at emergence	0.2
09/23/2021	LTN	Telephone call with H. Bhattal, L. Nguyen (AlixPartners) to re: cash forecast at emergence	0.2
09/23/2021	ADD	Call with A. DePalma and J. Muskovich (AlixPartners) re: Purdue HR request touchbase and draft responses for diligence request from counsel.	0.5
09/23/2021	JM	Call with A. DePalma and J. Muskovich (AlixPartners) re: Purdue HR request touchbase and draft responses for diligence request from counsel.	0.5
09/23/2021	ADD	Compile and analyze data in response to a diligence request from counsel.	2.9
09/23/2021	JD	Call with R. Aleali (Purdue) re: diligence project and outstanding AHC diligence questions.	0.5
09/23/2021	JD	Prepare initial draft incentive compensation balance sheet forecast.	2.4
09/23/2021	LTN	Format data provided by Davis Polk and upload to dataroom	1.1
09/24/2021	HSB	Review Purdue and Rhodes sales reports prepared by L.Nguyen (AlixPartners)	0.2
09/24/2021	HSB	Review Purdue board deck	1.3
09/24/2021	JD	Correspondence with Purdue management and Davis Polk re: creditor trust payment mechanics.	0.4
09/24/2021	JD	Review latest weekly sales by product analysis prior to sharing with creditors.	0.3
09/24/2021	JD	Correspondence with Purdue management and Alix team re: request for historical org charts.	0.5
09/27/2021	ADD	Call with H. Bhattal (AlixPartners) re: diligence request.	0.4
09/27/2021	HSB	Call with A.DePalma (both AlixPartners) to discuss Purdue diligence requests	0.3
09/27/2021	ADD	Finalize diligence request analysis requested by counsel.	2.8
09/27/2021	JM	Research re: diligence request from counsel.	0.8
09/27/2021	JD	Correspondence with Davis Polk and Purdue management re: creditor trust vendor profiles.	0.4
09/27/2021	JD	Correspondence with Purdue management re: trust advance funding.	0.3
09/27/2021	JD	Update long-term incentive comp forecast for Purdue management.	1.6
09/27/2021	LTN	Format files provided by Davis Polk and upload to Intralink	1.1
09/28/2021	JM	Call with J. Muskovich, J. DelConte (AlixPartners) re: diligence.	0.2
09/28/2021	JD	Call with J. Muskovich, J. DelConte (AlixPartners) re: diligence.	0.2
09/28/2021	HSB	Review Purdue financial forecasts	1.4
09/28/2021	JM	Analyze current employee roster and historical titles/cost center reconstruction	1.4
09/28/2021	JM	Supplemental review of current roster and cross-check of additional employees.	1.2
09/28/2021	JD	Call with J. Lowne (Purdue) re: 2022 retention program.	0.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/28/2021	JD	Correspondence with Purdue management and Davis Polk re: creditor trust payments.	0.4
09/28/2021	JD	Finalize long-term incentive comp forecast prior to meeting with J. Lowne (Purdue).	2.9
09/28/2021	JD	Make various updates to the long term incentive compensation file following discussions with J. Lowne (Purdue).	0.7
09/28/2021	JD	Meeting with J. Lowne (Purdue) re: long-term incentive comp forecast.	0.8
09/28/2021	JD	Review latest draft diligence project slides sent to management for review.	1.0
09/28/2021	JD	Review status of materials re: counsel diligence.	0.5
09/29/2021	JD	Call with J. DelConte and K. McCafferty (both AlixPartners) re: updated diligence project slides.	0.6
09/29/2021	KM	Call with J. DelConte and K. McCafferty (both AlixPartners) re: updated diligence project slides.	0.6
09/29/2021	JD	Call with J. Lowne (Purdue) re: latest long term plan.	0.2
09/29/2021	JD	Call with J. Lowne, R. Aleali and others from Purdue, A. Kramer (Reed Smith) re: D&O insurance.	0.8
09/29/2021	JD	Call with R. Aleali (Purdue) re: latest long term plan.	0.3
09/29/2021	JD	Call with T. Melvin (PJT) re: ongoing workstream updates.	0.4
09/29/2021	JD	Review and provide comments on diligence project slides prior to sending them to management.	0.8
09/29/2021	JD	Review and provide comments on latest D&O presentation.	0.4
09/29/2021	JD	Review August monthly flash report shared with the Board.	0.8
09/29/2021	JD	Review materials provided by management in response to follow-up questions from Davis Polk.	0.4
09/29/2021	LTN	Review confirmation delay provisions in the plan and update sensitivity analysis	0.5
09/30/2021	ADD	Call with S. Lemack (AlixPartners) to discuss open AP invoice reporting.	0.3
09/30/2021	SKL	Call with A. DePalma (AlixPartners) to discuss open AP invoice reporting.	0.3
09/30/2021	HSB	Telephone call with H. Bhattal, L. Nguyen (AlixPartners) to discuss professional fee forecast, cash at emergence	0.5
09/30/2021	LTN	Telephone call with H. Bhattal, L. Nguyen (AlixPartners) to discuss professional fee forecast, cash at emergence	0.5
09/30/2021	JM	Supplemental analysis and review of current roster and cross-check of additional employees.	0.8
09/30/2021	JD	Begin to build out stand-alone tracking and forecast incentive compensation file to leave behind with management.	2.3
09/30/2021	JD	Call with J. Turner (PJT) re: go-forward professional fee forecasting.	0.2
09/30/2021	JD	Correspondence with Davis Polk and H. Bhattal (AlixPartners) re: HSR filings.	0.3
09/30/2021	JD	Correspondence with Purdue management and Davis Polk re: creditor trust funding.	0.5
09/30/2021	JD	Review documentation around go-forward document repository funding and correspondence with management re: same.	0.4
09/30/2021	LTN	Finalize professional fee forecast	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

<u>DATE</u>	<u>CONSULTANT</u>	<u>DESCRIPTION OF SERVICES</u>	<u>HOURS</u>
09/30/2021	LTN	Review conformation delay sensitivity analysis prepared by H. Bhattal (AlixPartners) and provide comments	1.4
<b>Total Professional Hours</b>			<b><u>1,082.4</u></b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431  
0

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Business Analysis & Operations  
Code: 1.6 / 106

<b>PROFESSIONAL</b>	<b>TITLE</b>	<b>RATE</b>	<b>HOURS</b>	<b>FEES</b>
Lisa Donahue	Managing Director	\$1,295	21.0	\$ 27,195.00
Richard Collura	Managing Director	\$1,125	0.5	562.50
Jesse DelConte	Managing Director	\$1,055	248.6	262,273.00
Kevin M McCafferty	Director	\$980	12.4	12,152.00
Jason Muskovich	Director	\$980	27.5	26,950.00
Gabe J Koch	Director	\$865	238.4	206,216.00
HS Bhattal	Director	\$865	58.2	50,343.00
Jamey Hamilton	Director	\$865	0.8	692.00
Sam K Lemack	Senior Vice President	\$665	78.4	52,136.00
Andrew D DePalma	Vice President	\$625	226.4	141,500.00
Lan T Nguyen	Vice President	\$530	170.2	90,206.00
<b>Total Professional Hours and Fees</b>			<b>1,082.4</b>	<b>\$ 870,225.50</b>





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/01/2021	HSB	Review Disclosure Statement exhibit updated by L. Nguyen (AlixPartners) based on latest document drafts obtained from Davis Polk	0.3
06/01/2021	HSB	Call with L. Nguyen (AlixPartners) re: PI trust on plan projection	0.1
06/01/2021	LTN	Update plan projection exhibit based on feedback from C. Robertson (DVP)	0.7
06/01/2021	LTN	Call with H. Bhatta (AlixPartners) re: PI trust on plan projection	0.1
06/01/2021	LTN	Review DWP's language on Obligor Coverage / Collateral and provided feedback	1.6
06/01/2021	SKL	Begin updating notes and feedback re: liquidation analysis and prepare updated breakdown for the declaration.	2.0
06/01/2021	JD	Review latest draft plan and disclosure statement.	1.7
06/01/2021	JD	Review and provide comments to latest updates to the draft projections exhibit.	0.5
06/01/2021	JD	Review and provide comments on certain disclosure statement language.	0.3
06/01/2021	JD	Review revised language for disclosure statement edits.	0.2
06/02/2021	HSB	Review Disclosure Statement exhibit updated by L. Nguyen (AlixPartners)	0.4
06/02/2021	HSB	Made revisions to plan forecasts analysis based on recently negotiated updates	1.2
06/02/2021	HSB	Review updated draft of Purdue disclosure statement	1.4
06/02/2021	HSB	Call with L. Nguyen (AlixPartners) re: updates to plan projection	0.1
06/02/2021	HSB	Review due diligence request related documents	0.7
06/02/2021	LTN	Continue to review language on the disclosure statement re: trusts/obligors	0.9
06/02/2021	LTN	Update plan projection exhibit based on feedback from Houlihan Lokey	0.5
06/02/2021	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) re: updates to plan projection	0.1
06/02/2021	JD	Call with R. Aleali (Purdue) re: post-hearing update.	0.5
06/02/2021	JD	Call with C. Robertson (Purdue) re: Disclosure Statement hearing.	0.2
06/02/2021	JD	Correspondence with Davis Polk and L. Donahue (AlixPartners) re: expert reports.	0.4
06/03/2021	RC	Prepare communications to internal team re: upcoming expert disclosure designations and related information.	0.5
06/03/2021	RC	Call with M. Rule (AlixPartners) re: Plan Confirmation and expert disclosure designations.	1.0
06/03/2021	RC	Call with J. DelConte (AlixPartners) re: Plan Confirmation and expert disclosure designations.	0.2
06/03/2021	RC	Call with M. Clarens, M. Tobac and A. Whisenant (all Davis Polk) re: expert disclosure designations.	0.5
06/03/2021	RC	Review Amended Disclosure Statements and other case related updates.	0.7
06/03/2021	RC	Review materials from cash transfers of value and intercompany/non-cash transfers of value reports in advance of call with Davis Polk.	0.4
06/03/2021	LJD	Call with J. Lowne (Purdue), C. Robertson, M. Tobak, K. Benedict, D. Consla, A. Romero-Wagner, S. Ford, B. Kaminetzky (all Davis Polk), J. O'Connell, J. Turner, R. Schnitzler, T. Melvin (all PJT), H. Bhattal, L. Donahue, J. DelConte and S. Lemack (all AlixPartners) re: FA expert reports and related planning	0.5
06/03/2021	HSB	Call with J. Lowne (Purdue), C. Robertson, M. Tobak, K. Benedict, D. Consla, A. Romero-Wagner, S. Ford, B. Kaminetzky (all Davis Polk), J. O'Connell, J. Turner, R. Schnitzler, T. Melvin (all PJT), H. Bhattal, L. Donahue, J. DelConte and S. Lemack (all AlixPartners) re: FA expert reports and related planning	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/03/2021	HSB	Work on creating word document related to Purdue expert testimony (declaration of AlixPartners)	3.4
06/03/2021	HSB	Review relevant sections of the Plan and Disclosure Statement	1.6
06/03/2021	HSB	Call with S.Lemack (AlixPartners) re: Purdue bankruptcy related matters	0.3
06/03/2021	HSB	Call with L. Nguyen (AlixPartners) re: Purdue bankruptcy related matters	0.1
06/03/2021	HSB	Review documents and write-up prepared by A. DePalma (AlixPartners) in response to due diligence request	0.3
06/03/2021	HSB	Review Purdue prepared financial projections and reconciled recent updates	1.6
06/03/2021	HSB	Review documents obtained from Davis Polk in preparation for call re: ongoing plan related work	0.2
06/03/2021	LTN	Review the plan projection / shareholder contribution sections in the filed disclosure statement	1.0
06/03/2021	LTN	Call with H. Bhatta (AlixPartners) re: updates to plan projection	0.1
06/03/2021	SKL	Call with J. Lowne (Purdue), C. Robertson, M. Tobak, K. Benedict, D. Consla, A. Romero-Wagner, S. Ford, B. Kaminetzky (all Davis Polk), J. O'Connell, J. Turner, R. Schnitzler, T. Melvin (all PJT), H. Bhattal, L. Donahue, J. DelConte and S. Lemack (all AlixPartners) re: FA expert reports and related planning	0.5
06/03/2021	SKL	Call with H. Bhattal (AlixPartners) re: various case related matters.	0.3
06/03/2021	SKL	Continue to consolidate liquidation analysis source files and update formatting accordingly re: disclosure statement preparations.	2.5
06/03/2021	JD	Call with J. Lowne (Purdue), C. Robertson, M. Tobak, K. Benedict, D. Consla, A. Romero-Wagner, S. Ford, B. Kaminetzky (all Davis Polk), J. O'Connell, J. Turner, R. Schnitzler, T. Melvin (all PJT), H. Bhattal, L. Donahue, J. DelConte and S. Lemack (all AlixPartners) re: FA expert reports and related planning	0.5
06/03/2021	JD	Call with J. Turner (PJT) re: expert reports.	0.3
06/03/2021	JD	Call with R. Collura (AlixPartners) re: Plan Confirmation and expert disclosure designations.	0.2
06/03/2021	JD	Correspondence with L. Donahue and R. Collura (both AlixPartners) re: expert reports.	0.4
06/03/2021	JD	Review net shareholder proceeds presentation from Davis Polk tax.	0.3
06/03/2021	JD	Review latest detailed confirmation timeline from Davis Polk.	0.4
06/03/2021	MFR	Call with R. Collura (AlixPartners) re: Plan Confirmation and expert disclosure.	1.0
06/04/2021	RC	Review information related to the Amended Disclosure Statement and Plan Confirmation.	1.6
06/04/2021	RC	Review documentation related to special Committee's reports 1a and 1b.	1.1
06/04/2021	HSB	Continued drafting word document related to Purdue expert testimony (declaration of AlixPartners)	2.7
06/04/2021	HSB	Review precedent declarations for purposes of drafting Purdue document	0.9
06/04/2021	HSB	Review relevant sections of the Plan and Disclosure Statement	1.4
06/04/2021	HSB	Review relevant sections of liquidation analysis in connection with declaration draft preparation	0.4
06/04/2021	HSB	Review and emailed updated financial analysis to Davis Polk	0.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/04/2021	HSB	Multiple calls with S.Lemack (AlixPartners) re: various plan and declaration related matters and open items.	0.8
06/04/2021	SKL	Multiple calls with H. Bhattal (AlixPartners) re: various plan and declaration related matters and open items.	0.8
06/04/2021	SKL	Continue to consolidate liquidation analysis source files and finalize aspects of the draft declaration.	2.3
06/04/2021	JD	Call with C. Robertson (Davis Polk) re: expert reports.	0.3
06/04/2021	JD	Call with J. McClammy (Davis Polk) re: expert reports.	0.3
06/04/2021	JD	Call with M. Kesselman (Purdue) re: assistance with the monitor.	0.2
06/04/2021	JD	Draft intro section of expert report.	0.5
06/04/2021	JD	Review draft expert liquidation reports from previous cases.	0.6
06/04/2021	MFR	Review draft expert report.	0.2
06/05/2021	HSB	Review PJT prepared financial analysis and responded to email request	0.2
06/06/2021	RC	Review and provide comments to counsel re: expert witness designations.	0.4
06/07/2021	RC	Draft declaration for expert report.	2.0
06/07/2021	RC	Review materials related to report 1a and update information in draft declaration.	1.5
06/07/2021	JD	Call with J. Lowne (Purdue) re: open plan items.	0.3
06/07/2021	JD	Call with J. Lowne (Purdue) and J. Turner (PJT) re: open disclosure statement items.	0.5
06/07/2021	SKL	Call with H. Bhattal (AlixPartners) re: latest open items re: draft declaration preparation.	0.2
06/07/2021	HSB	Calls with S.Lemack (AlixPartners) re: latest open items re: draft declaration preparation.	0.2
06/07/2021	HSB	Review liquidation analysis and related documents with regards to preparation of declaration draft	2.2
06/07/2021	HSB	Review Purdue prepared Plan forecasts and related financial analysis	1.6
06/07/2021	HSB	Review Purdue transfer work plan related materials and progress	1.1
06/08/2021	RC	Review documents and information related to Plan Confirmation.	1.1
06/08/2021	RC	Continue drafting declaration for expert report.	1.7
06/08/2021	RC	Review information included in the disclosure statement re: AlixPartners reports.	0.3
06/08/2021	RC	Review expert designation disclosures.	0.1
06/08/2021	JD	Review initial draft expert report to be shared with Davis Polk.	0.7
06/08/2021	GJK	Review IAC payer party open items.	0.9
06/08/2021	SKL	Continue to review latest draft of the AlixPartners Expert Report and prepare updated notes and feedback accordingly.	1.9
06/08/2021	HSB	Review liquidation analysis	0.9
06/08/2021	HSB	Prepare list of materials for the liquidation analysis reviewed	0.6
06/08/2021	HSB	Review relevant sections of the Purdue Plan and Disclosure Statement documents	1.8
06/08/2021	HSB	Review Purdue financial projections	0.8
06/08/2021	HSB	Email AlixPartners team re: status of Purdue transfer work plan	0.1
06/09/2021	RC	Review documentation related to Plan Confirmation.	1.1



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/09/2021	JD	Call with H. Bhattal, DelConte and S. Lemack (all AlixPartners), M.Tobak, C.Robertson, A. Romero-Wagner, D.Consla, K.Benedict, S.Ford, J.Shinbrot, A.Robero-Wagner (all Davis Polk) re: expert report	0.5
06/09/2021	JD	Call with J. DelConte, H. Bhattal, S. Lemack (all AlixPartners) re: expert report draft.	0.3
06/09/2021	JD	Review previous expert report examples and draft liquidation analysis expert report.	1.2
06/09/2021	JD	Review and research initial expert designations.	0.5
06/09/2021	GJK	Call with S Lemack (AlixPartners) re: AHC diligence and the upcoming expert report.	0.4
06/09/2021	SKL	Call with H. Bhattal, DelConte and S. Lemack (all AlixPartners), M.Tobak, C.Robertson, A. Romero-Wagner, D.Consla, K.Benedict, S.Ford, J.Shinbrot, A.Robero-Wagner (all Davis Polk) re: expert report	0.5
06/09/2021	SKL	Call with G. Koch (AlixPartners) re: AHC diligence and the upcoming expert report.	0.4
06/09/2021	SKL	Prepare and circulate updated NPV calculation per Davis Polk request.	0.5
06/09/2021	HSB	Call with H. Bhattal, DelConte and S. Lemack (all AlixPartners), M.Tobak, C.Robertson, A. Romero-Wagner, D.Consla, K.Benedict, S.Ford, J.Shinbrot, A.Robero-Wagner (all Davis Polk) re: expert report	0.5
06/09/2021	HSB	Call with J. DelConte and S. Lemack (both AlixPartners) re: expert report	0.3
06/09/2021	HSB	Update word document related to Purdue expert testimony (declaration of AlixPartners) and reviewed liquidation analysis for related details	3.5
06/09/2021	HSB	Review document prepared by Davis Polk with regards to plan related analysis	1.4
06/09/2021	HSB	Review financial analysis prepared by S.Lemack in connection with Purdue Plan negotiations	0.1
06/09/2021	HSB	Review transfer work plan related presentation draft prepared by S.Lemack (AlixPartners)	0.2
06/09/2021	HSB	Review Purdue materials in response to diligence request from DOJ	0.2
06/09/2021	HSB	Call with A. DePalma (AlixPartners) re: Purdue bankruptcy related matters	0.1
06/09/2021	HSB	Review Purdue analysis prepared by J.Lowne (Purdue) in response to due diligence request	0.2
06/09/2021	HSB	Review shareholder settlement related materials	0.6
06/09/2021	ADD	Call with H. Bhattal (AlixPartners) re: Purdue bankruptcy related matters	0.1
06/09/2021	SKL	Call with J. DelConte, H. Bhattal, S. Lemack (all AlixPartners) re: expert report draft.	0.3
06/10/2021	RC	Prepare information for declaration in support of plan of reorganization.	0.6
06/10/2021	RC	Review documentation related to the cash transfers of value analysis.	1.6
06/10/2021	GJK	Read through of updated Settlement Agreement Article 2 language.	1.9
06/10/2021	SKL	Meeting with M. Tobak, D. Consla, D. Mazer, K. Benedict (all Davis Polk), and H. Bhattal (AlixPartners) re: the AlixPartners expert report.	0.5
06/10/2021	SKL	Multiple calls with H. Bhattal (AlixPartners) re: the upcoming AlixPartners Expert Report and various bankruptcy related matters	0.8
06/10/2021	SKL	Continue to review latest comments and revisions re: draft AlixPartners Expert Report.	1.8



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/10/2021	SKL	Continue to review and reconcile the liquidation analysis exhibits references in the draft AlixPartners Expert report and update open items accordingly.	1.7
06/10/2021	HSB	Call with S. Lemack (AlixPartners) and M.Tobak, C.Robertson, D.Consla, K.Benedict, S.Ford, J.Shinbrot, A.Robero-Wagner (all Davis Polk) re: expert report	0.5
06/10/2021	HSB	Update word document related to Purdue expert testimony (declaration of AlixPartners) and reviewed liquidation analysis for related details	3.7
06/10/2021	HSB	Made further revisions to word document related to Purdue expert testimony (declaration of AlixPartners) based on discussions with Davis Polk colleagues.	2.1
06/10/2021	HSB	Review liquidation analysis and prepared list of materials reviewed	1.4
06/10/2021	HSB	Multiple calls with S.Lemack (AlixPartners) re: the upcoming AlixPartners Expert Report and various bankruptcy related matters	0.8
06/10/2021	JD	Correspondence with Davis Polk re: open discovery requests.	0.4
06/10/2021	JD	Review and provide updated comments on the latest version of the expert report.	2.0
06/11/2021	RC	Work on drafting declaration for expert report.	2.6
06/11/2021	RC	Review documents and update draft declaration for expert report.	1.7
06/11/2021	GJK	Review Settlement Agreement model from Brian Olson to incorporate prepayments.	1.3
06/11/2021	GJK	Review prepayment language in latest revision of Article 2 of Settlement Agreement draft.	1.2
06/11/2021	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners), L. Scheinbach (Purdue) re: NewCo CF analysis	0.3
06/11/2021	LTN	Update plan projection models through 2027 and circulated to H. Bhattal (AlixPartners) for review	1.3
06/11/2021	LTN	Call with H.S Bhattal, L. Nguyen (AlixPartners) re: updates to NewCo cashflow 2026 - 2027	0.7
06/11/2021	LTN	Review and update NewCo cashflow models through 2027 and circulated to H. Bhattal (AlixPartners) for review	1.7
06/11/2021	HSB	Update excel files with analysis of plan projections forecasts requested by Davis Polk, in connection with plan negotiations	4.3
06/11/2021	HSB	Review excel analysis prepared by L. Nguyen (AlixPartners) in connection with analysis requested by Davis Polk for plan negotiations	1.5
06/11/2021	HSB	Review excel files prepared by Purdue management and incorporated inputs into analysis for Davis Polk	1.7
06/11/2021	HSB	Review analysis prepared by PJT and incorporated inputs into analysis for Davis Polk	1.1
06/11/2021	HSB	Review draft of AlixPartners' expert report in connection with Purdue's liquidation analysis	0.7
06/11/2021	HSB	Multiple calls with L. Nguyen (AlixPartners) re: Plan related financial analysis	0.7
06/11/2021	HSB	Call with L.Scheinbach (Purdue) and L. Nguyen (AlixPartners) re: Plan related financial analysis	0.3
06/11/2021	JD	Call with J. Lowne (Purdue) re: expert reports.	0.2
06/11/2021	JD	Call with M. Huebner (Davis Polk) re: mediation analysis.	0.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/11/2021	JD	Call with H. Bhattal (AlixPartners) re: mediation analysis.	0.2
06/11/2021	JD	Call with T. Melvin (PJT) re: mediation analysis.	0.4
06/11/2021	JD	Call with T. Melvin (PJT) re: follow up mediation analysis call.	0.3
06/11/2021	JD	Review and markup the latest version of my expert report.	0.7
06/11/2021	JD	Prepare summary of mediation analysis and share with Davis Polk and PJT.	0.5
06/11/2021	ADD	Review liquidation analysis write up in preparation for filing.	1.0
06/11/2021	HSB	Call with J. DelConte (AlixPartners) re: mediation analysis.	0.2
06/12/2021	RC	Update expert report for plan confirmation.	2.3
06/12/2021	RC	Review and update expert report for plan confirmation.	2.0
06/12/2021	GJK	Review and respond to J Finelli (Davis Polk) email re: Asset Holdco definition.	0.2
06/12/2021	HSB	Made revisions to excel files with analysis of Purdue plan projections forecasts requested by Davis Polk	2.4
06/12/2021	HSB	Review PJT prepared analysis in connection with review of Plan projections	0.4
06/12/2021	HSB	Review draft of plan related analysis and made updates	0.8
06/12/2021	JD	Review latest draft expert report edits from Davis Polk.	0.5
06/12/2021	JD	Review final mediation analysis and send along to Davis Polk and PJT for review.	0.5
06/12/2021	JD	Correspondence with Davis Polk re: mediation analysis.	0.3
06/13/2021	RC	Review and update draft expert report for plan confirmation.	1.6
06/13/2021	RC	Review documents related to the cash transfer of value analysis.	1.8
06/13/2021	LTN	Call with H. Bhattal (AlixPartners) re: plan projection through 2027 update	0.2
06/13/2021	JD	Correspondence with Davis Polk and AlixPartners team re: discovery requests.	0.4
06/13/2021	HSB	Made revisions to excel files with analysis of Purdue plan projections forecasts requested by Davis Polk	2.3
06/13/2021	HSB	Update draft of expert report based on comments from Davis Polk	0.8
06/13/2021	HSB	Telephone call with L. Nguyen (AlixPartners) re: Plan related financial analysis	0.2
06/14/2021	SJC	Call with R. Collura (AlixPartners) re: support documentation for the cash transfers expert report.	0.4
06/14/2021	RC	Call with S. Canniff (AlixPartners) re: support documentation for the cash transfers expert report.	0.4
06/14/2021	RC	Call with M. Rule (AlixPartners) to the expert declarations for the cash and non-cash transfer of value reports.	0.3
06/14/2021	RC	Prepare source relied upon appendix to expert report.	1.5
06/14/2021	RC	Review support documentation referenced in the cash transfers of value report.	1.4
06/14/2021	RC	Review and update expert report declaration.	1.2
06/14/2021	RC	Review documentation related to the cash transfers of value report.	1.6
06/14/2021	GJK	Call with J. Lowne, S. Daniel, L. Scheinbach (all Purdue), J. DelConte, G. Koch, S. Lemack (all AlixPartners) re: contract assumption and rejection schedules.	0.4
06/14/2021	GJK	Respond to D Consola (Davis Polk) inquiry re: surety providers.	0.2
06/14/2021	GJK	Respond to J Weiner (Davis Polk) questions re: Settlement Agreement mechanics including pre-payments.	1.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/14/2021	LTN	Review Core/Non Core business section in the NewCo CF projections model	1.7
06/14/2021	LTN	Review FA expert report and provided feedback to H. Bhattal (AlixPartners)	1.2
06/14/2021	LTN	Call with H. Bhattal (AlixPartners) re: expert opinion	0.4
06/14/2021	LTN	Finalize updates in the NewCo CF through FY 2027 model	0.5
06/14/2021	HSB	Review excel files with analysis of Purdue plan projections prior to call with J.Lowne (Purdue)	1.7
06/14/2021	HSB	Review updated draft of expert report prepared by Davis Polk and provided additional inputs	0.4
06/14/2021	HSB	Continue making revisions to plan related analysis	2.4
06/14/2021	HSB	Review Purdue financial model and reconciled cash flow forecasts	0.8
06/14/2021	HSB	Review list of supporting materials in connection with liquidation analysis	0.4
06/14/2021	HSB	Review Purdue financial forecasts in connection with financial analysis	0.8
06/14/2021	HSB	Review select sections of Purdue disclosure statement in connection with review of expert report draft	0.7
06/14/2021	HSB	Call with J. Lowne (Purdue), S. Lemack, J. DelConte and H. Bhattal (both AlixPartners) re: DelConte Declaration	0.4
06/14/2021	HSB	Review comments from Purdue on draft of expert report	0.3
06/14/2021	HSB	Review list of supporting materials in connection with liquidation analysis	0.4
06/14/2021	HSB	Two calls with S.Lemack (AlixPartners) re: expert report draft	0.8
06/14/2021	HSB	Call with L. Nguyen (AlixPartners) re: Purdue forecasts and related matters	0.4
06/14/2021	HSB	Call with A. DePalma (AlixPartners) re: updates to draft of AlixPartners' expert report	0.6
06/14/2021	ADD	Review liquidation analysis declaration and tie numbers to the liquidation analysis model.	2.8
06/14/2021	ADD	Call with S. Lemack (AlixPartners) re: liquidation analysis declaration filing review.	1.1
06/14/2021	ADD	Telephone call with H. Bhattal (AlixPartners); re: updates to the AlixPartners' expert report draft.	0.6
06/14/2021	SKL	Call with J.Lowne and L.Scheinbach (both Purdue), T.Melvin (PJT), H. Bhattal, S. Lemack and L. Nguyen (AlixPartners) re: Purdue financial forecasts and related matters	0.3
06/14/2021	SKL	Call with J. Lowne (Purdue), S. Lemack, J. DelConte and H. Bhattal (both AlixPartners) re: DelConte Declaration	0.4
06/14/2021	SKL	Call with J. Lowne, S. Daniel, L. Scheinbach (all Purdue), J. DelConte, G. Koch, S. Lemack (all AlixPartners) re: contract assumption and rejection schedules.	0.4
06/14/2021	SKL	Call with A. DePalma (AlixPartners) re: liquidation analysis declaration filing review.	1.1
06/14/2021	SKL	Continue to review the draft FA report and prepare updated notes accordingly.	1.7
06/14/2021	SKL	Continue to finalize updates to exhibit A of the draft FA report and consolidate files accordingly.	1.6
06/14/2021	SKL	Two calls with HS Bhattal (AlixPartners) re: expert report draft	0.8
06/14/2021	JD	Review report 1A and 1B RE: expert reports.	0.5
06/14/2021	JD	Call with J. Lowne (Purdue) re: expert report review.	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/14/2021	JD	Call with J. Lowne, S. Daniel, L. Scheinbach (all Purdue), J. DelConte, G. Koch, S. Lemack (all AlixPartners) re: contract assumption and rejection schedules.	0.4
06/14/2021	JD	Review and comment on the latest edits to the expert report prior to it being shared with Purdue management.	0.7
06/14/2021	JD	Call with J. Lowne (Purdue), S. Lemack, J. DelConte and H. Bhattal (both AlixPartners) re: DelConte Declaration	0.4
06/14/2021	JD	Provide comments on latest list of expert report reliance documents.	0.6
06/14/2021	MFR	Call with R. Collura (AlixPartners) to the expert declarations for the cash and non-cash transfer of value reports.	0.3
06/15/2021	RC	Update expert report for plan confirmation.	2.1
06/15/2021	RC	Prepare updates to expert report appendices.	1.7
06/15/2021	RC	Review information related to the cash transfers of value report.	1.8
06/15/2021	RC	Review and update expert report appendices.	1.2
06/15/2021	RC	Review and update expert report.	1.3
06/15/2021	LJD	Call with L. Donahue, J. DelConte, H. Bhattal (all AlixPartners) re: expert report review.	0.4
06/15/2021	GJK	Call with E Hwang and J Weiner (Davis Polk) and L Nguyen (AlixPartners) re: IAC proceeds debrief	0.2
06/15/2021	LTN	Call with E Hwang and J Weiner (Davis Polk) and G. Koch (AlixPartners) re: IAC proceeds debrief	0.2
06/15/2021	HSB	Review Purdue liquidation analysis excel file	0.6
06/15/2021	HSB	Call with C. Robertson (Davis Polk), J. DelConte (AlixPartners) re: expert report draft	0.4
06/15/2021	HSB	Call with L. Donahue, J. DelConte, H. Bhattal (all AlixPartners) re: expert report review.	0.4
06/15/2021	HSB	Call with J. DelConte (AlixPartners) re: expert report draft	0.2
06/15/2021	HSB	Call with J. DelConte, S. Lemack (all AlixPartners) re: expert report	1.2
06/15/2021	HSB	Call with M. Tobak, D. Mazer, Z. Khan, C. Robertson (all Davis Polk), J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) re: expert report draft.	0.6
06/15/2021	HSB	Call with A. DePalma, J. DelConte, S. Lemack, and H. Bhattal (AlixPartners); re: liquidation analysis declaration statement discussion	1.0
06/15/2021	HSB	Review multiple drafts of AlixPartners' declaration draft after multiple updates	2.4
06/15/2021	HSB	Update exhibit to the AlixPartners' declaration	1.8
06/15/2021	HSB	Review select sections of Purdue disclosure statement in connection with review of AlixPartners' expert report	1.4
06/15/2021	HSB	Multiple calls with S. Lemack (AlixPartners) re: AlixPartners expert report updates	2.1
06/15/2021	ADD	Call with M. Tobak, D. Mazer, Z. Khan, C. Robertson (all Davis Polk), J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) re: expert report draft.	0.6
06/15/2021	ADD	Call with A. DePalma, J. DelConte, S. Lemack, and H. Bhattal (AlixPartners); re: liquidation analysis declaration statement discussion (joined part of call).	0.6





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/15/2021	ADD	Review liquidation analysis declaration and tie numbers to the liquidation analysis model.	1.8
06/15/2021	ADD	Review new updated declaration versions to check that updated were incorporated.	1.8
06/15/2021	SKL	Call with J. DelConte and H. Bhattal (all AlixPartners) re: expert report.	1.2
06/15/2021	SKL	Call with A. DePalma, J. DelConte, S. Lemack, and H. Bhattal (AlixPartners); re: liquidation analysis declaration statement discussion	1.0
06/15/2021	SKL	Multiple calls and working sessions with H. Bhattal (AlixPartners) re: the expert report.	2.1
06/15/2021	SKL	Call with M. Tobak, D. Mazer, Z. Khan, C. Robertson (all Davis Polk), J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) re: expert report draft.	0.6
06/15/2021	SKL	Prepare updated severance calculation support file and circulate internally for additional sign-off.	1.4
06/15/2021	SKL	Prepare updated retention analysis calculation support file and circulate internally for additional sign-off.	1.6
06/15/2021	SKL	Finalize updates to the expert report write-up and source file listing and circulate for final sign-off.	2.3
06/15/2021	JD	Call with C. Robertson (Davis Polk) re: expert report edits.	0.2
06/15/2021	JD	Call with H. Bhattal (AlixPartners) re: expert report draft.	0.2
06/15/2021	JD	Call with J. DelConte (partial participation), H. Bhattal and S. Lemack (all AlixPartners) re: expert report comments and edits	1.0
06/15/2021	JD	Call with L. Donahue, J. DelConte, H. Bhattal (all AlixPartners) re: expert report review.	0.4
06/15/2021	JD	Call with C. Robertson (Davis Polk), H. Bhattal, J. DelConte (both AlixPartners) re: expert report comments.	0.4
06/15/2021	JD	Call with M. Tobak, D. Mazer, Z. Khan, C. Robertson (all Davis Polk), J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) re: expert report draft.	0.6
06/15/2021	JD	Review certain reliance documents to be included in the final expert report.	1.1
06/15/2021	JD	Review comments from management on the expert report and potential corresponding edits.	0.6
06/15/2021	JD	Review comments from management on other expert reports.	0.5
06/15/2021	JD	Prepare CV to be shared with the expert report.	2.8
06/15/2021	JD	Correspondence with S. Lemack and H. Bhattal (both AlixPartners) re: reliance materials.	0.6
06/15/2021	JD	Review final version of the expert report.	0.4
06/15/2021	JD	Call with A. DePalma, J. DelConte, S. Lemack, and H. Bhattal (AlixPartners); re: liquidation analysis declaration statement discussion	1.0
06/16/2021	RC	Review documents related to Plan Confirmation.	1.4
06/16/2021	RC	Review documents related to request for an examiner.	0.6
06/16/2021	HSB	Review relevant sections of the Purdue disclosure statement and related Purdue financial forecasts	1.8
06/16/2021	HSB	Review supporting excel files for Purdue financial analysis	0.8



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/16/2021	HSB	Call with S.Lemack (AlixPartners) re: expert report related matters	0.6
06/16/2021	ADD	Compile information necessary to prepare state license applications for Purdue Pharmaceuticals and update applications	3.2
06/16/2021	SKL	Call with H. Bhattal (AlixPartners) re: next steps re: expert report.	0.6
06/16/2021	SKL	Continue to gather and finalize files to be included with the expert report filing.	2.1
06/16/2021	JD	Review summary of other filed expert reports.	0.3
06/17/2021	RC	Review information included in expert reports.	1.5
06/17/2021	HSB	Review Purdue financial forecasts and underlying supporting files	1.2
06/17/2021	HSB	Review Purdue plan related analysis and supporting excel files prepared by S.Lemack (AlixPartners)	0.8
06/17/2021	SKL	Update approved vendor list based on the latest feedback from C. MacDonald (Purdue) and confirm updates to the AP database accordingly.	1.0
06/17/2021	SKL	Continue to gather and consolidate source files for the expert report filing.	1.2
06/18/2021	RC	Review documents related to Plan Confirmation.	1.2
06/18/2021	RC	Review information included in expert reports.	1.4
06/18/2021	HSB	Review Purdue forecasts and responded to email request for information from creditors	0.5
06/18/2021	HSB	Review Purdue forecasts and emailed related forecasts to Davis Polk	0.3
06/18/2021	HSB	Prepare excel analysis in connection with Purdue forecasts and reviewed results	1.3
06/18/2021	HSB	Review Purdue financial forecasts model in connection with cash forecasts prepared by L. Nguyen (AlixPartners)	0.7
06/18/2021	HSB	Review Purdue transfer work plan related materials	1.1
06/18/2021	SKL	Continue to gather and finalize files to be included with the expert report filing.	2.4
06/18/2021	SKL	Continue to gather and consolidate source files to be included with the expert report filing.	2.0
06/18/2021	JD	Correspondence with H. Bhattal (AlixPartners), Houlihan and PJT re: disclosure statement recovery numbers.	0.3
06/21/2021	RC	Review information referenced in the expert reports.	1.6
06/21/2021	SKL	Call with H. Bhattal (AlixPartners) re: consolidation of expert report source files.	0.4
06/21/2021	SKL	Finalize updates to the accrued expense forecast file to be included in the expert report.	1.3
06/21/2021	SKL	Finalize updates to the G&A expense detail to be included in the expert report.	0.9
06/21/2021	SKL	Finalize updates to the A/R intercompany matrix file to be included in the expert report.	1.1
06/21/2021	SKL	Finalize updates to the finished goods breakdown provided by the company for inclusion in the expert report.	1.2
06/21/2021	SKL	Finalize updates to the liquidation analysis model to be included in the expert report.	2.3
06/21/2021	HSB	Review Purdue plan related analysis and prepared list of open issues	1.1
06/21/2021	HSB	Call with S.Lemack (AlixPartners) re: consolidation of expert report source files.	0.4
06/21/2021	HSB	Review Purdue shareholder settlement materials	0.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/22/2021	RC	Review documentation related to the Sacklers expert reports.	1.2
06/22/2021	JD	Review and provide comments on latest expert report reliance documents.	1.5
06/22/2021	SKL	Weekly change of control/transfer work plan update meeting with R. Aleali (Purdue), K. McCarthy (Purdue), Z. Haseeb (Purdue), C. Robertson (Davis Polk), E. Turay (Davis Polk), A. Lele (Davis Polk) and G. Koch, H. Bhattal (AlixPartners).	0.7
06/22/2021	HSB	Review supporting excel files in connection with Purdue analysis prepared by S.Lemack (AlixPartners)	1.1
06/22/2021	HSB	Review KEIP/KERP related info in connection with preparation of the underlying motion	1.4
06/22/2021	HSB	Call with R.Aleali (Purdue), E.Vonnegut, D.O'Sullivan, M.Linder (all Davis Polk), J. DelConte (AlixPartners), D.Sims, J.Gartrell, C.Rogers, S.Hinden (all Willis Towers) re: KEIP/KERP	0.5
06/22/2021	HSB	Review Purdue shareholder settlement related materials prepared by Davis Polk	1.2
06/22/2021	HSB	Weekly change of control/transfer work plan update meeting with R. Aleali (Purdue), K. McCarthy (Purdue), Z. Haseeb (Purdue), C. Robertson (Davis Polk), E. Turay (Davis Polk), A. Lele (Davis Polk) and G. Koch, S. Lemack (AlixPartners).	0.7
06/22/2021	HSB	Review Purdue plan related analysis and underlying supporting files	1.4
06/23/2021	SKL	Call with H. Bhattal (AlixPartners) re: expert report related matters.	1.2
06/23/2021	SKL	Review latest inquiry re: surety bonds and provide updated feedback accordingly.	0.7
06/23/2021	SKL	Continue to prepare updates to the expert reports and circulate internally for additional review.	2.4
06/23/2021	SKL	Prepare updated notes and feedback re: expert reports, and circulate updated summary of reports internally for review.	1.6
06/23/2021	HSB	Review plan related analysis and related supporting files	1.8
06/23/2021	HSB	Conduct research and reviewed plan related materials for debtors	1.9
06/23/2021	HSB	Call with S.Lemack (AlixPartners) re: Purdue plan related matters	1.2
06/24/2021	SKL	Review latest surety bond and indemnification inquiry provided by the Davis Polk team.	1.0
06/24/2021	SKL	Call with H. Bhattal (AlixPartners) re: expert report related matters.	0.4
06/24/2021	SKL	Continue to prepare updates to the expert reports and circulate to the Davis Polk team for additional review.	2.4
06/24/2021	SKL	Prepare updated summary of expert reports and location for the Davis Polk team to review and provide notes/feedback.	2.2
06/24/2021	HSB	Review excel files with analysis of Purdue plan projections updated by L. Nguyen (AlixPartners)	1.8
06/24/2021	HSB	Update excel files with analysis of Purdue plan projections	1.1
06/24/2021	HSB	Review plan related analysis and related supporting files	1.7
06/24/2021	HSB	Update due diligence request related response prepared by Adipoma (AlixPartners)	0.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/24/2021	HSB	Review Purdue shareholder settlement related materials prepared by Davis Polk	0.9
06/24/2021	HSB	Call with S.Lemack (AlixPartners) re: Purdue plan related matters	0.4
06/24/2021	LTN	Update plan projection through 2029 and circulated to H. Bhattal (AlixPartners) for review	1.6
06/25/2021	RC	Review documentation related to information reported in the expert reports.	1.2
06/25/2021	SKL	Calls with H. Bhattal (AlixPartners) to continue to prepare expert report related items and discuss KEIP/KERP.	1.7
06/25/2021	SKL	Continue to prepare updates to various expert report related items and circulate update to Davis Polk team accordingly.	2.7
06/25/2021	HSB	Call with Z. Haseeb (Skadden), S.Hoffman and E. Casinelli (both Purdue) re: Purdue state license application process	0.4
06/25/2021	HSB	Review Purdue transfer work plan related documents	0.3
06/25/2021	HSB	Calls with S.Lemack (AlixPartners) to continue to prepare expert report related items and discuss KEIP/KERP.	1.7
06/28/2021	JD	Correspondence with Davis Polk re: Bates White reliance materials.	0.2
06/28/2021	JD	Review Bates White reliance materials for company sensitive information before production.	1.0
06/28/2021	HSB	Review Purdue materials re: post emergence NewCo work transfer	1.0
06/28/2021	HSB	Review Purdue financial projections in response to due diligence questions from other parties	1.2
06/28/2021	HSB	Review Purdue shareholder settlement agreement related materials provided by Debevoise	0.4
06/28/2021	HSB	Review Purdue plan related analysis prepared by S.Lemack (AlixPartners)	0.4
06/28/2021	HSB	Review email correspondence from Purdue and supporting files in connection with Purdue transfer work	0.3
06/28/2021	HSB	Review Purdue plan related analysis and underlying documents	1.2
06/28/2021	HSB	Call with A. DePalma (AlixPartners) re: Purdue plan related matters	0.5
06/28/2021	HSB	Review Purdue plan related analysis prepared by S.Lemack (AlixPartners)	1.3
06/28/2021	HSB	Review Purdue schedule of contracts prepared by S.Lemack (AlixPartners)	0.2
06/28/2021	HSB	Update supporting excel file in connection with Purdue plan related analysis	0.5
06/29/2021	RC	Review materials in connection with Plan Confirmation.	1.5
06/29/2021	RC	Continue to review additional materials related to expert report for Plan Confirmation.	1.6
06/29/2021	HSB	Call with L.Schwartzman (PJT) re: Purdue financial forecasts	0.1
06/29/2021	HSB	Review draft of agreement in connection with shareholder settlement	0.4
06/29/2021	HSB	Review Purdue financial projections and supporting documents	0.6
06/29/2021	HSB	Review select sections of Purdue's Plan document in connection with plan supplement related agreement	1.2
06/29/2021	HSB	Call with A. DePalma (AlixPartners) to discuss application license project status.	0.2
06/29/2021	HSB	Review PJT prepared analysis in connection with plan supplement related agreement	0.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/29/2021	HSB	Review Purdue financial model in connection with review of plan related analysis	0.4
06/29/2021	HSB	Review email correspondence from Purdue re: Purdue plan related analysis	0.1
06/30/2021	SKL	Continue to finalize reliance documents for the expert report and circulate updated notes/feedback.	1.6
06/30/2021	JD	Review of Bates White reliance documents.	0.6
06/30/2021	JD	Finalize review of Bates White reliance documents and correspondence with R. Aleali (Purdue) and Davis Polk re: same.	0.8
06/30/2021	HSB	Prepare excel analysis with reconciliation of Purdue forecasts prior to call with J.Lowne (Purdue)	1.9
06/30/2021	HSB	Review excel model prepared by Purdue team with Purdue forecasts	1.1
06/30/2021	HSB	Review PJT prepared Purdue financial analysis related to the Plan	0.8
06/30/2021	HSB	Review Plan related analysis prepared by S.Lemack (AlixPartners)	0.4
06/30/2021	HSB	Review draft of agreement in connection with plan supplement filing and reviewed underlying info	1.8
06/30/2021	LTN	Call with J. DelConte, H. Bhattal, L. Nguyen (AlixPartners), J. Lowne (Purdue), T. Melvin (PJT) re: cash flow model through 2029	0.3
06/30/2021	GJK	Email exchange with PJT, Davis Polk and J DelConte and L Nguyen (AlixPartners) re: research on local regulatory solvency requirements on potential leak of cash from net proceeds	0.4
07/01/2021	HSB	Call with W. Taylor, E. Vonnegut, C. Robertson, Z. Levine, S. Massman (all Davis Polk), R. Aleali, J. Lowne (both Purdue), J. DelConte, H. Bhattal (both AlixPartners) re: governance term sheets.	0.7
07/01/2021	HSB	Call with E.Ruiz, L.Scheinbach (both Purdue), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT),L.Nguyen (AlixPartners) re: Purdue projections	0.2
07/01/2021	HSB	Call with J. Lowne, C. Russo, S. Daniel, R. Aleali (all Purdue), J. DelConte, S. Lemack (all AlixPartners) re: contract assumption and rejection lists.	0.5
07/01/2021	HSB	Review Purdue contract-related updates prepared by S.Lemack (AlixPartners)	0.4
07/01/2021	RC	Review documents in connection with preparation for Plan Confirmation.	1.2
07/01/2021	RC	Continue review of expert reports submitted in connection with Plan Confirmation issues.	1.6
07/01/2021	HSB	Review Purdue plan related analysis and projections in connection with plan related discussions	1.7
07/01/2021	HSB	Review draft of NewCo document in connection with Purdue work transfer plan and provided comments	1.3
07/01/2021	HSB	Review Purdue emergence date cash flow forecast and related details	0.8
07/01/2021	HSB	Multiple calls with L.Nguyen (AlixPartners) to discuss Purdue plan-related matters	0.8
07/01/2021	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue plan-related matters	0.4
07/01/2021	HSB	Review Purdue shareholder settlement agreement related materials provided by Debevoise	0.6
07/01/2021	HSB	Review Purdue plan-related analysis and correspondence from S.Lemack (AlixPartners)	0.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/01/2021	JD	Call with W. Taylor, E. Vonnegut, C. Robertson, Z. Levine, S. Massman (all Davis Polk), R. Aleali, J. Lowne (both Purdue), J. DelConte, H. Bhattal (both AlixPartners) re: governance term sheets.	0.7
07/01/2021	JD	Correspondence with Davis Polk and PJT re: initial NOAT distribution in the governance agreements.	0.4
07/01/2021	JD	Review latest draft NewCo operating agreement versus the side-by-side agreement with the AHC in advance of call with Purdue management and other advisors.	1.8
07/01/2021	JD	Correspondence with Davis Polk, PJT and Purdue management re: comments on the latest NewCo operating agreement.	0.3
07/01/2021	SKL	Call with H. Bhattal (AlixPartners) to discuss various plan-related matters.	0.4
07/01/2021	GJK	Prepare for call to discuss open economic items with Purdue Legal and Finance, Davis Polk and J.DelConte (AlixPartners).	0.4
07/01/2021	LTN	Multiple calls with H. Bhattal, L. Nguyen (AlixPartners) to discuss plan related matters	0.8
07/01/2021	LTN	Call with E.Ruiz, L.Scheinbach (both Purdue), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), H. Bhattal (AlixPartners) re: Purdue projections	0.2
07/02/2021	RC	Review documentation related to cash distributions.	1.5
07/02/2021	RC	Review documentation related to cash transfer of value categories.	1.7
07/02/2021	HSB	Review Purdue plan-related analysis and correspondence from Davis Polk.	0.4
07/02/2021	HSB	Review Purdue shareholder settlement-related materials obtained from Davis Polk.	0.3
07/02/2021	HSB	Review Purdue work transfer-related correspondence and comments from J.Lowne and R.Aleali (both Purdue).	0.8
07/02/2021	HSB	Continue reviewing Purdue plan-related analysis and underlying financial projections.	1.3
07/02/2021	HSB	Review Purdue plan related analysis prepared by PJT in connection with plan-related communications with Davis Polk and Purdue management.	0.6
07/02/2021	JD	Call with J. Lowne (Purdue) re: governance agreement comments.	0.3
07/02/2021	JD	Review lower priority additional Bates White reliance materials and suggestions for redactions and production.	0.6
07/02/2021	JD	Correspondence with Purdue management, Davis Polk and PJT re: comments to the latest NewCo operating agreement draft.	0.7
07/03/2021	HSB	Review Purdue plan-related analysis and projections in connection with question from J.Lowne (Purdue).	0.2
07/03/2021	HSB	Review Purdue plan-related excel analysis in connection with question from E.Voggegut (Davis Polk).	0.2
07/04/2021	GJK	Review of recent model draft for potential illustrative scenarios.	1.7
07/05/2021	GJK	Review updated definitions of Settlement Agreement draft from Davis Polk (ongoing).	2.3
07/05/2021	GJK	Review of Settlement Agreement draft (ongoing), including Articles 3 to 8.	2.3
07/05/2021	HSB	Review draft of Purdue work transfer related agreement updated by Davis Polk	0.8
07/05/2021	HSB	Review Purdue Plan Projections and PJT prepared analysis in connection with plan related email correspondence with J.Lowne (Purdue), Davis Polk and PJT	0.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/06/2021	RC	Review support documentation related to quantification of cash transfer of value analysis.	1.3
07/06/2021	RC	Additional review of support documentation in connection with Plan Confirmation.	0.7
07/06/2021	SKL	Multiple calls with H. Bhattal (AlixPartners) to discuss various plan-related matters	0.2
07/06/2021	SKL	Finalize latest updates to the liquidation analysis reliance documents and finalize approval process to provide documents accordingly.	2.6
07/06/2021	SKL	Finalize updates to the liquidation analysis reliance document listing and circulate updated feedback to D. Mazer (Davis Polk)	2.1
07/06/2021	HSB	Attended part of the call among G. Koch, L. Nguyen (both AlixPartners), A. Libby (Davis Polk), J. Ball (Debevoise), G. Coutts, H. Schenk, A. Benjamin (all Houlihan), M. Atkinson (Province), R. Ringer (Kramer Levin), S. Gilbert (Gilbert), M. Diaz (FTI) re: shareholder settlement agreement	0.9
07/06/2021	HSB	Review Purdue Plan related analysis in connection with Purdue plan supplement to be filed by Davis Polk	2.3
07/06/2021	HSB	Review draft versions of Purdue Plan related analysis and forecasts prepared by PJT	0.8
07/06/2021	HSB	Multiple calls with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.2
07/06/2021	HSB	Review Purdue prepared financial forecasts	0.9
07/06/2021	JD	Call with J. Lowne (Purdue) re: supplemental plan agreements.	0.2
07/06/2021	JD	Call with T. Melvin (PJT) re: open plan documents.	0.2
07/06/2021	JD	Call with R. Aleali, J. Lowne (Purdue), E. Vonnegut, C. Robertson, S. Massman, Z. Levine, W. Taylor (all Davis Polk), J. DelConte, H. Bhattal (both AlixPartners), J. Turner, T. Melvin, J. Arsic (all PJT) re: supplemental plan documents.	0.8
07/06/2021	JD	Call with J. DelConte and G. Koch (both AlixPartners) re: shareholder agreement.	0.2
07/06/2021	JD	Call with J. Turner (PJT) re: governance term sheet.	0.2
07/06/2021	JD	Call with J. Lowne (Purdue), J. Turner (PJT), W. Taylor (Davis Polk) re: governance term sheet.	0.7
07/06/2021	JD	Follow-up call with J. Turner (PJT) re: open governance document issues.	0.5
07/06/2021	JD	Correspondence with Davis Polk and PJT re: changes to the governance term sheet and plan documents.	0.8
07/06/2021	JD	Review the latest NewCo and TopCo governance term sheet and issues list..	1.3
07/06/2021	JD	Correspondence with Davis Polk, Purdue management and PJT re: discussions with the AHC on changes to the plan documents.	0.5
07/06/2021	GJK	Call with J. DelConte and G. Koch (both AlixPartners) re: shareholder agreement.	0.2
07/07/2021	RC	Review materials related to Plan confirmation	1.1
07/07/2021	SKL	Prepare updated outline of liquidation analysis recovery rates and underlying assumptions.	2.4
07/07/2021	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/07/2021	HSB	Review Purdue Plan related analysis and underlying financial amounts	1.3
07/07/2021	HSB	Review drafts of NewCo related agreement and related comments	1.5
07/07/2021	HSB	Review multiple emails received in connection with discussion of plan related analysis	0.4
07/07/2021	HSB	Review shareholder settlement related documents received from Davis Polk	0.6
07/07/2021	HSB	Review select sections of Purdue Plan and DS in connection with discussion of plan related issues	0.8
07/07/2021	JD	Call with R. Aleali (Purdue) re: latest plan term sheet discussions.	0.3
07/07/2021	JD	Call with J. Turner (PJT) re: distribution amounts in the governance term sheet.	0.3
07/07/2021	JD	Call with J. Lowne (Purdue) re: latest plan document discussion updates.	0.2
07/07/2021	JD	Call with E. Vonnegut and S. Massman (both Davis Polk) re: plan document negotiations.	0.2
07/07/2021	JD	Correspondence with Davis Polk and PJT re: potential changes to plan document language.	0.3
07/07/2021	JD	Review and provide comments on updated plan documents.	1.1
07/07/2021	JD	Correspondence with Davis Polk and PJT re: proposed revisions to the plan language from the AHC.	0.7
07/07/2021	SKL	Call with H. Bhattal (AlixPartners) to discuss Purdue plan related matters	0.3
07/08/2021	RC	Review information contained in expert reports re: distributions.	1.1
07/08/2021	SKL	Call with H. Bhattal (AlixPartners) to discuss contract analysis process and other case related matters.	0.6
07/08/2021	SKL	Finalize updates to the liquidation analysis reliance materials based on the latest feedback provided by D. Mazer (Davis Polk).	1.2
07/08/2021	SKL	Continue to update the high-level outline of the liquidation analysis.	0.9
07/08/2021	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.6
07/08/2021	HSB	Review Purdue Plan related analysis and underlying financial amounts	1.5
07/08/2021	HSB	Review Purdue Mediator's report	0.3
07/08/2021	HSB	Review draft versions of Purdue work transfer related documents	2.3
07/08/2021	HSB	Review Purdue financial analysis and related underlying amount in connection with Plan related analysis	0.4
07/09/2021	RC	Review documents related to Plan Confirmation.	1.3
07/09/2021	RC	Review press coverage re: updated settlement and support from additional states.	0.3
07/09/2021	RC	Review information included in the Sackler Family's submitted expert reports.	1.4
07/09/2021	SKL	Continue to update the high-level outline of the liquidation analysis.	0.8
07/09/2021	HSB	Review shareholder settlement related documents received from Davis Polk	0.2
07/09/2021	HSB	Review draft versions of Purdue work transfer related documents	1.4
07/09/2021	HSB	Review Purdue plan related documents in connection with ongoing discussions	1.6
07/09/2021	HSB	Review Purdue financial projections in connection with plan related discussions	0.7
07/09/2021	JD	Review mediators report filed with the court.	0.3
07/12/2021	RC	Review documentation in connection preparation for plan confirmation.	1.2





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/12/2021	GJK	Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors / creditors to discuss open items on the settlement agreement	1.0
07/12/2021	SKL	Multiple calls with H. Bhattal (AlixPartners) to discuss plan related matters	0.5
07/12/2021	HSB	Call with M.Kesselman, J.Lowne, R.Aleali (all Purdue), C. Robertson, E.Vonnegut, A.Lele, W.Taylor, S.Massman (all Davis Polk), J.Turner, T. Melvin (PJT), J.DelConte (AlixPartners) re: Purdue plan related discussion	0.8
07/12/2021	HSB	Review Purdue forecasts and related analysis in connection with due diligence request	1.4
07/12/2021	HSB	Prepare draft responses in connection with due diligence request	0.6
07/12/2021	HSB	Review PJT prepared analysis in connection with ongoing Purdue plan related discussions	0.8
07/12/2021	HSB	Review excel files prepared by Purdue team with due diligence info	0.7
07/12/2021	HSB	Review shareholder settlement related materials obtained from Debevoise	1.2
07/12/2021	HSB	Review draft of Plan related materials in connection with ongoing negotiations	0.9
07/12/2021	HSB	Multiple calls with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.5
07/12/2021	HSB	Call with L.Nguyen (AlixPartners) to discuss Purdue plan related matters	0.3
07/12/2021	LTN	Call with H. Bhattal, L. Nguyen (both AlixPartners) to discuss queries about plan projection	0.3
07/12/2021	LTN	Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors / creditors to discuss open items on the settlement agreement	1.0
07/12/2021	JD	Call with M.Kesselman, J.Lowne, R.Aleali (all Purdue), C. Robertson, E.Vonnegut, A.Lele, W.Taylor, S.Massman (all Davis Polk), J.Turner, T. Melvin (PJT), H. Bhattal (AlixPartners) re: Purdue plan related discussion	0.8
07/13/2021	RC	Call with M. Rule (AlixPartners) and Davis Polk (D. Mazer, K. Benedict and J. Shinbrot) to discuss the supporting documentation for the cash and non-cash transfer of value reports.	0.3
07/13/2021	RC	Review documents related to the cash transfers of value report in response to requests from Davis Polk.	1.6
07/13/2021	RC	Continue to review support documents in preparation for Plan Confirmation.	1.4
07/13/2021	JD	Correspondence with Davis Polk and M. Rule, A. DePalma (both AlixPartners) re: M. Rule expert report reliance material review.	0.5
07/13/2021	JD	Review latest NewCo operating agreement draft.	0.4
07/13/2021	JD	Provide comments on draft summary presentation from PJT on the AHC operating agreements.	0.8
07/13/2021	JD	Correspondence with Davis Polk and S. Lemack (AlixPartners) re: expert report reliance documents.	0.3
07/13/2021	SKL	Finalize updates related to the reliance materials for the liquidation analysis and circulate update accordingly.	0.5
07/13/2021	HSB	Review Purdue plan related documents in connection with ongoing negotiations	1.8
07/13/2021	HSB	Review expert report reliance materials list	0.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/13/2021	HSB	Review select sections of Purdue plan and DS in connection with ongoing plan discussions	1.1
07/13/2021	HSB	Multiple calls with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.4
07/13/2021	ADD	Review and compile 1a/1b report reliance documents.	2.3
07/13/2021	MFR	Call with R. Collura (AlixPartners) and Davis Polk (D. Mazer, K. Benedict and J. Shinbrot) to discuss the supporting documentation for the cash and non-cash transfer of value reports	0.3
07/14/2021	RC	Review documents related to cash transfers of value report.	1.1
07/14/2021	RC	Review documents related to expert discovery.	1.3
07/14/2021	JD	Correspondence with Davis Polk re: initial NOAT distribution discussions with the AHC.	0.2
07/14/2021	HSB	Review Purdue supporting documents in connection with request from Davis Polk and provided comments to AlixPartners team.	2.9
07/14/2021	HSB	Review Purdue financial analysis in connection with due diligence request	1.3
07/14/2021	HSB	Review Purdue plan related analysis in connection with ongoing plan negotiations	1.7
07/14/2021	ADD	Review and compile 1a/1b report reliance documents.	3.1
07/15/2021	RC	Review supporting documents related to expert reports.	1.4
07/15/2021	RC	Additional review of supporting documentation related to the expert report.	1.0
07/15/2021	RC	Review documents re: Plan Confirmation and related preparation.	0.8
07/15/2021	JD	Call with J. DelConte and R. Collura (both AlixPartners) re: confirmation timeline.	0.2
07/15/2021	JD	Review and provide comments to N. Simon and L. Nguyen (both AlixPartners) on analysis of S. Miller (Purdue board member) historical compensation for the examiner.	0.4
07/15/2021	HSB	Review Purdue financial projections and updated related excel files	1.3
07/15/2021	HSB	Review Purdue prepared analysis in connection with due diligence request	0.2
07/15/2021	HSB	Review Purdue contract related files in connection with plan filings	0.8
07/15/2021	HSB	Review Plan related analysis in connection with ongoing Purdue plan negotiations	1.4
07/15/2021	HSB	Review Purdue prepared analysis in connection with due diligence request related to sales	1.5
07/15/2021	RC	Call with J. DelConte and R. Collura (both AlixPartners) re: confirmation timeline.	0.2
07/16/2021	RC	Review materials related to expert report and prepare for Plan Confirmation.	1.2
07/16/2021	RC	Review expert report support documentation produced by in connection with Plan Confirmation.	0.8
07/16/2021	GJK	Review draft edits to Scenario 1 from B Kennedy (Milbank).	0.3
07/16/2021	JD	Review confirmation prep update from Davis Polk litigation team.	0.2
07/16/2021	HSB	Review Purdue financial projections in connection with Plan related due diligence request	1.2
07/16/2021	HSB	Review Purdue contract related files in connection with plan filings	1.6



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/19/2021	RC	Review expert report materials in preparation for meeting with Davis Polk re: Plan Confirmation.	1.3
07/19/2021	RC	Review document related to information included in the cash transfers of value report.	1.4
07/19/2021	HSB	Review multiple versions of contract assumption related files prepared by S.Lemack (AlixPartners)	1.2
07/19/2021	HSB	Review plan related analysis obtained from Purdue in response to due diligence request	0.6
07/19/2021	HSB	Review Purdue sales related analysis in connection with due diligence request	0.5
07/19/2021	HSB	Review Purdue cash forecasts related input obtained from E.Ruiz (Purdue)	0.2
07/19/2021	HSB	Review relevant sections of Purdue plan and disclosure statement in connection with ongoing plan discussions	1.4
07/19/2021	HSB	Review relevant sections of shareholder settlement agreement in connection	0.4
07/19/2021	HSB	Call with H. Bhattal, L. Nguyen (AlixPartners) to discuss Newco cash flows	0.4
07/19/2021	HSB	Continued reviewing Purdue monthly board deck with financial results	1.3
07/19/2021	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.1
07/19/2021	LTN	Call among H. Bhattal, L. Nguyen (AlixPartners), J. Lowne, E. Ruiz (Purdue), T. Melvin (PJT) to discuss Newco Cashflow breakdown	0.2
07/19/2021	LTN	Call with J. DelConte, L. Nguyen (both AlixPartners) re: MOR	0.2
07/19/2021	SKL	Call with H. Bhattal (AlixPartners) to discuss Purdue plan related matters	0.1
07/19/2021	JD	Call with J. DelConte, L. Nguyen (both AlixPartners) re: MOR	0.2
07/20/2021	RC	Review Examiner's report.	0.5
07/20/2021	RC	Review documentation in preparation for meeting with Davis Polk re: Plan Confirmation.	1.2
07/20/2021	RC	Call with M. Rule (AlixPartners) and Davis Polk (M. Clarens, E. Kim and A. Whisenant) to discuss upcoming Plan Confirmation trial hearing and related follow-up.	0.8
07/20/2021	RC	Review expert report materials issues in connection with Plan Confirmation.	1.4
07/20/2021	HSB	Call among H. Bhattal, L. Nguyen (AlixPartners), L. Scheinbach (Purdue) to discuss Newco Cashflow breakdown	0.4
07/20/2021	HSB	Call with J.DelConte (AlixPartners), J.O'Connell, J.Turner, T.Melvin (both PJT), K.Benedict, M.Tobak, E.Townes, G.Cardillo (all Davis Polk) re: plan related discussions	0.8
07/20/2021	HSB	Review PJT prepared plan analysis to prepare for meeting with Davis Polk team to discuss plan related issues	0.5
07/20/2021	HSB	Review Purdue forecasts in connection with plan related analysis	1.2
07/20/2021	HSB	Review relevant sections of Purdue mediator's report	0.3
07/20/2021	HSB	Review updated Purdue plan materials prepared by Davis Polk in connection with review of financial information to be updated	1.8
07/20/2021	HSB	Review Davis Polk's comments in connection with plan related analysis prepared by PJT and related email correspondence	0.6
07/20/2021	HSB	Review multiple versions of Purdue business plan related materials in connection with request from Davis Polk	0.7
07/20/2021	HSB	Call with L.Nguyen (AlixPartners) to discuss Purdue plan related matters	0.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/20/2021	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.1
07/20/2021	JD	Call with M. Toback, K. Benedict, E. Townes (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, H. Bhattal (both AlixPartners) re: confirmation process.	0.8
07/20/2021	JD	Correspondence with Purdue management re: governance term sheet and L/C and surety bond needs.	0.4
07/20/2021	JD	Review latest updated draft NewCo operating and governance agreements and DOJ edits.	0.7
07/20/2021	JD	Correspondence with Davis Polk and Purdue management re: NewCo operating agreement and governance docs negotiations.	0.5
07/20/2021	LTN	Revise the NewCo cash flow breakdown by product level based on the internal feedback	1.5
07/20/2021	LTN	Call among H. Bhattal, L. Nguyen (AlixPartners), L. Scheinbach (Purdue) to discuss Newco Cashflow breakdown	0.4
07/20/2021	LTN	Prepare the NewCo cash flow breakdown by product level requested by UCC	1.7
07/20/2021	LTN	Call with H. Bhattal (AlixPartners) to discuss Purdue plan related matters	0.2
07/20/2021	MFR	Call with R. Collura (AlixPartners) and Davis Polk (M. Clarens, E. Kim and A. Whisenant) to discuss upcoming Plan Confirmation trial hearing and related follow-up	0.8
07/21/2021	RC	Review materials related to Plan Confirmation.	1.3
07/21/2021	RC	Review support documentation related to expert reports.	1.5
07/21/2021	HSB	Review analysis prepared by L.Nguyen (AlixPartners) and supporting excel files in connection with due diligence request	1.4
07/21/2021	HSB	Review Purdue financial forecasts in connection with analysis prepared by L.Nguyen (AlixPartners)	0.8
07/21/2021	HSB	Continue reviewing Purdue plan materials prepared by Davis Polk	2.2
07/21/2021	HSB	Made revisions to plan related analysis prepared by L.Nguyen (AlixPartners)	1.2
07/21/2021	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.4
07/21/2021	LTN	Finalize Newco cash flow breakdown by product level and circulate to CFO review	0.4
07/22/2021	RC	Review documents related to information included in the cash transfers of value report.	1.6
07/22/2021	SKL	Call with H. Bhattal (AlixPartners) to discuss latest diligence requests.	0.2
07/22/2021	HSB	Review relevant sections of latest drafts of plan documents obtained from Davis Polk	1.3
07/22/2021	HSB	Review Purdue revenues related analysis prepared by S.Lemack (AlixPartners) in connection with due diligence request	0.2
07/22/2021	HSB	Review Purdue long term financial projections model in connection with due diligence request	1.1
07/22/2021	HSB	Call with L.Nguyen (AlixPartners) to discuss Purdue plan related matters	0.3
07/22/2021	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.2
07/22/2021	HSB	Review Purdue business plan materials in connection with plan related analysis	1.1
07/22/2021	JD	Review latest draft NewCo and TopCo operating agreements.	0.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/22/2021	LTN	Meeting with S. Lemack (AlixPartners) to discuss MOR format and preparation.	0.5
07/22/2021	LTN	Call with H. Bhattal (AlixPartners) to discuss Purdue plan related matters	0.3
07/23/2021	RC	Review documentation in connection with Plan Confirmation.	1.6
07/23/2021	RC	Additional review of documents related to cash transfers of value report.	1.3
07/23/2021	SKL	Call with H. Bhattal (AlixPartners) to discuss plan related matters.	0.3
07/23/2021	HSB	Review Purdue financial analysis prepared by L.Nguyen (AlixPartners) in connection with Plan related due diligence request	1.4
07/23/2021	HSB	Updated Purdue financial analysis prepared by L.Nguyen (AlixPartners) in connection with Plan related due diligence request	2.5
07/23/2021	HSB	Review Purdue financial projections in connection with financial analysis prepared by L.Nguyen (AlixPartners)	0.7
07/23/2021	HSB	Review select sections of Purdue plan objections filed by various parties	0.8
07/23/2021	HSB	Call with L.Nguyen (AlixPartners) to discuss Purdue plan related matters	0.5
07/23/2021	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.3
07/23/2021	JD	Create summary prescription trend chart for Davis Polk discovery data room.	0.3
07/23/2021	LTN	Reconcile Rhodes profit margin vs the long term consolidated plan and update product margin	1.2
07/23/2021	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) to discuss cash schedule for POR	0.5
07/23/2021	LTN	Finalize the NewCo cashflow by product level based internal feedback and circulate to Purdue/ PJT for review	1.3
07/23/2021	LTN	Revise the NewCo cashflow by product level based on CFO feedback and circulate for internal review	2.2
07/26/2021	RC	Research request from UCC's advisors and coordinate with team re: follow-up steps.	1.0
07/26/2021	RC	Review documents related to information request by the UCC's advisors and provide follow-up responses to such requests.	1.1
07/26/2021	RC	Review materials in connection with preparing for Plan Confirmation.	1.8
07/26/2021	RC	Research information related to requests from Davis Polk and prepare communications with counsel.	1.6
07/26/2021	JD	Review potential discovery documents per Davis Polk request for business plan materials.	0.5
07/26/2021	JD	Review latest NewCo and TopCo operating agreement drafts from Kramer.	0.5
07/26/2021	JD	Review latest draft Company operations agreement.	0.3
07/26/2021	JD	Review final business plan files to be shared via the confirmation discovery process.	0.4
07/26/2021	HSB	Call among H. Bhattal, L. Nguyen (all AlixPartners), T. Melvin (PJT) to discuss long-term plan versions.	0.3
07/26/2021	HSB	Call with S.Lemack (AlixPartners) re: Purdue due diligence requests	0.4
07/26/2021	HSB	Updated excel file prepared by L.Nguyen (AlixPartners) in connection with request for Plan related exhibits	0.8
07/26/2021	HSB	Review multiple versions of excel files and compared versions in connection with request for Plan related exhibits	1.6



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/26/2021	HSB	Review Purdue board materials in connection with due diligence request for info.	1.1
07/26/2021	HSB	Prepared draft excel summary with due diligence info in connection with Purdue due diligence request	0.4
07/26/2021	HSB	Review Purdue prepared documents with financial forecasts and financial results in connection with due diligence requests	1.3
07/26/2021	HSB	Review Purdue contracts and related info in connection with due diligence request	1.5
07/26/2021	HSB	Call with A.DePalma (AlixPartners) to discuss Purdue due diligence	0.2
07/26/2021	HSB	Multiple calls with H. Bhattal, L. Nguyen (AlixPartners) re: plan projection matters	0.3
07/26/2021	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.2
07/26/2021	SKL	Call with H. Bhattal (AlixPartners) to discuss plan related matters	0.2
07/26/2021	SKL	Meeting with H. Bhattal (AlixPartners) to discuss Purdue operations info request.	0.4
07/26/2021	LTN	Review the changes on NewCo cash flow made by H. Bhattal (AlixPartners)	0.4
07/26/2021	LTN	Call among H. Bhattal, L. Nguyen (all AlixPartners), T. Melvin (PJT) to discuss long-term plan versions.	0.3
07/26/2021	LTN	Multiple calls with H. Bhattal, L. Nguyen (AlixPartners) re: plan projection matters	0.3
07/26/2021	ADD	Call with H. Bhattal (AlixPartners) to discuss Purdue due diligence	0.2
07/27/2021	RC	Review materials provided by Davis Polk in connection with Plan Confirmation.	1.4
07/27/2021	RC	Additional review of Plan Confirmation related materials.	1.3
07/27/2021	RC	Review documentation re: the cash transfers of value report.	1.5
07/27/2021	JD	Call with C. Robertson (Davis Polk) re: confirmation process timeline.	0.2
07/27/2021	HSB	Review draft of Purdue plan related materials prepared by Davis Polk	1.8
07/27/2021	HSB	Review selection sections of Purdue plan & DS in connection with ongoing analysis	0.6
07/27/2021	HSB	Review PJT prepared analysis in connection with analysis supporting ongoing Plan negotiations	1.3
07/27/2021	HSB	Review open items on various Purdue plan related issues and prepared list	0.4
07/28/2021	RC	Review information related to Plan Confirmation.	1.5
07/28/2021	HSB	Review multiple files prepared by S.Lemack (AlixPartners) in response to due diligence requests	1.5
07/28/2021	HSB	Review Purdue Plan related materials in connection with ongoing Plan negotiations	1.2
07/28/2021	HSB	Review draft declarations prepared by Davis Polk in connection with Purdue confirmation hearing	0.5
07/28/2021	HSB	Multiple calls with S.Lemack (AlixPartners) to discuss Purdue due diligence related analysis	2.0
07/28/2021	HSB	Call with A.DePalma (AlixPartners) to discuss Purdue due diligence	0.1
07/28/2021	ADD	Call with H. Bhattal (AlixPartners) to discuss Purdue due diligence	0.1



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/29/2021	HSB	Review updated draft of declaration prepared by Davis Polk in connection with Purdue confirmation hearing and provided comments	2.3
07/29/2021	HSB	Review relevant sections of Plan documents in connection with review of updated draft of declaration prepared by Davis Polk	1.7
07/29/2021	JD	Correspondence with Davis Polk re: diligence project and NewCo operating agreements.	0.5
07/29/2021	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) re: new MOR format update	0.2
07/29/2021	LTN	Call with D. Consola (DavisPolk) re: new MOR format update	0.4
07/30/2021	GJK	Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors to discuss Settlement agreement	2.7
07/30/2021	HSB	Review draft of declaration prepared by Davis Polk and related comments from multiple individuals and sent list of comments to Davis Polk for review and update	1.3
07/30/2021	HSB	Review relevant sections of Plan documents in connection with review of updated draft of declaration prepared by Davis Polk	1.7
07/30/2021	HSB	Review diligence requests list and reviewed files prepared by S.Lemack (AlixPartners)	2.3
07/30/2021	SKL	Review latest draft declaration document and provide updates to the Alix team accordingly.	1.6
07/30/2021	JD	Review and provide comments on latest draft declaration.	1.1
07/30/2021	LTN	Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors to discuss Settlement agreement	2.7
07/31/2021	HSB	Review two updated drafts of declarations prepared by Davis Polk and documented comments and edits	1.8
07/31/2021	HSB	Review Purdue Plan documents in connection with review of ongoing plan related document drafts	0.7
08/01/2021	JD	Review latest NewCo operating agreement draft to respond to questions from Davis Polk.	0.4
08/01/2021	HSB	Review updated draft of declaration prepared by Davis Polk and documented comments and edits	1.3
08/02/2021	JD	Call with J. Lowne (Purdue) re: confirmation declarations.	0.2
08/02/2021	JD	Call with J. Lowne, R. Aleali (Purdue), M. Tobak, K. Benedict, E. Kim, J. Knudson (all Davis Polk) re: Lowne declaration.	0.7
08/02/2021	JD	Call with R. Aleali (Purdue) re: confirmation process.	0.3
08/02/2021	JD	Correspondence with H. Bhattal and S. Lemack (both AlixPartners) re: open AHC diligence question draft responses.	0.4
08/02/2021	JD	Review request for diligence information potentially posted to the dataroom from Purdue management for purposes of the confirmation discovery information re: customer contract information.	0.5
08/02/2021	JD	Review and provide comments on draft Lowne declaration to be filed on Thursday.	1.3
08/02/2021	JD	Review and provide comments on on latest draft of DelConte declaration.	1.0
08/02/2021	JD	Correspondence with Davis Polk and H. Bhattal, S. Lemack (both AlixPartners) re: revision to liquidation analysis report for typo.	0.8



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/02/2021	HSB	Review draft of declaration prepared by Davis Polk and documented comments and edits	1.7
08/02/2021	HSB	Review Purdue Plan related documents in connection with ongoing analyses	1.9
08/02/2021	HSB	Review Purdue due diligence materials prepared by S.Lemack (AlixPartners)	0.8
08/02/2021	HSB	Review Purdue work transfer related document	1.8
08/02/2021	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.1
08/02/2021	HSB	Review Purdue plan projections in connection with review of declaration draft prepared by Davis Polk	1.2
08/02/2021	HSB	Review Purdue historical financial data in connection with ongoing Plan related analyses	0.4
08/02/2021	SKL	Prepare update to the latest declaration and circulate to Davis Polk team accordingly.	0.5
08/02/2021	SKL	Meeting with H. Bhattal (AlixPartners) to discuss various case related matters.	0.1
08/03/2021	HSB	Meeting with S. Lemack (AlixPartners) to discuss latest updates to the declaration document and other open items.	0.5
08/03/2021	HSB	Call with J.O'Connell, J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), J.DelConte (AlixPartners) re: update on confirmation process and planning (left meeting early)	0.4
08/03/2021	HSB	Review multiple drafts of declaration prepared by Davis Polk and documented comments and edits	2.5
08/03/2021	HSB	Review Purdue plan related materials in response to request from PJT	0.4
08/03/2021	HSB	Review Purdue due diligence materials prepared by S.Lemack (AlixPartners) in response to due diligence request	1.4
08/03/2021	HSB	Review updated draft of expert report revised by Davis Polk	1.2
08/03/2021	HSB	Review Purdue Plan related materials in connection with ongoing discussions and related analysis	1.4
08/03/2021	HSB	Call with A.DePalma (AlixPartners) to discuss Purdue due diligence	0.3
08/03/2021	HSB	Updated Purdue cash forecast analysis in response to Purdue Plan related due diligence request	1.7
08/03/2021	JD	Call with J. Lowne (Purdue) re: confirmation declarations.	0.2
08/03/2021	JD	Call with J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, H. Bhattal (both AlixPartners), C. Robertson (Davis Polk) re: update on confirmation process and planning.	0.8
08/03/2021	JD	Review and sign-off on final declaration revision.	0.3
08/03/2021	SKL	Follow-up discussion with H. Bhattal (AlixPartners) re: the latest AHC inquiry.	0.7
08/03/2021	SKL	Finalize review of expert declaration report and circulate updates/comments to the AlixPartners team for final sign-off.	1.5
08/03/2021	SKL	Meeting with H. Bhattal (AlixPartners) to discuss latest updates to the declaration document and other open items.	0.5
08/03/2021	HSB	Follow-up discussion with S. Lemack (AlixPartners) re: the latest AHC inquiry.	0.7
08/04/2021	RC	Review documents related to plan confirmation.	2.1
08/04/2021	RC	Review expert reports filed in connection with plan confirmation.	1.5





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/04/2021	RC	Review information gathered in response to requests from the UCC re: property taxes and withholding taxes.	0.5
08/04/2021	RC	Review information requests from the UCC's advisors and prepare responses.	0.4
08/04/2021	HSB	Review draft of Declaration prepared with Davis Polk in connection with Plan related testimony	0.2
08/04/2021	HSB	Review Purdue plan projections detail updated by S.Lemack (AlixPartners)	0.3
08/04/2021	HSB	Call with S.Lemack (AlixPartners) re: Purdue plan related issues	0.6
08/04/2021	SKL	Call with H. Bhattal (AlixPartners) to continue discussions re: the latest ACH inquiry.	0.6
08/04/2021	JD	Review and comment on declaration to submit my expert report for confirmation.	0.5
08/04/2021	JD	Review revised draft Lowne declaration and comments from Davis Polk to open questions.	0.5
08/04/2021	JD	Review disclosure statement in advance of confirmation hearing and testimony.	1.7
08/05/2021	RC	Revise declaration for plan confirmation.	0.5
08/05/2021	RC	Review materials related to plan confirmation.	2.2
08/05/2021	RC	Meet with M. Clarens, E. Kim and A. Whisenant (Davis Polk) to prepare for plan confirmation trial.	2.0
08/05/2021	RC	Review information and respond to diligence requests from the UCC.	0.3
08/05/2021	HSB	Review updates to Purdue forecasts prepared by S.Lemack (AlixPartners)	0.8
08/05/2021	HSB	Review Purdue plan related declaration draft prepared by Davis Polk	1.2
08/05/2021	HSB	Review Purdue MOR in connection with ongoing Purdue Plan related analysis	0.3
08/05/2021	HSB	Call with S.Lemack (AlixPartners) re: Purdue plan related issues	0.3
08/05/2021	HSB	Review Purdue due diligence related documents	1.3
08/05/2021	HSB	Review select sections of Debtors' response to Plan Objections prepared by Davis Polk	1.5
08/05/2021	HSB	Review Purdue Plan objections received from Davis Polk	0.4
08/05/2021	SKL	Call with H. Bhattal (AlixPartners) to discuss various plan related matters.	0.3
08/05/2021	JD	Correspondence with Purdue HR and Davis Polk re: Shareholder HR questions.	0.5
08/05/2021	JD	Continue to review the disclosure statement and various declarations filed in advance of confirmation to prepare for potential testimony.	2.4
08/05/2021	JD	Correspondence with Davis Polk and PJT re: DOJ claim calculations.	0.3
08/06/2021	RC	Review supporting materials related to plan confirmation.	1.6
08/06/2021	RC	Review information related to plan confirmation.	1.5
08/06/2021	HSB	Review liquidation analysis Plan exhibit and underlying calculations ahead of confirmation hearing and related planning meetings	1.8
08/06/2021	HSB	Review Purdue due diligence related materials prepared by S.Lemack (AlixPartners)	0.7
08/06/2021	HSB	Review post emergence tax estimate prepared by J.Lowne (Purdue)	0.2
08/06/2021	HSB	Review Purdue financial projections and related analysis in connection with upcoming Plan hearing	2.2
08/06/2021	HSB	Multiple calls with S.Lemack (AlixPartners) re: Purdue plan related issues	0.4
08/06/2021	SKL	Multiple calls with H. Bhattal (AlixPartners) re: Purdue plan related issues	0.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/07/2021	HSB	Review Purdue plan documents and related analysis in connection with Plan related planning and preparation	2.0
08/07/2021	HSB	Review Purdue plan related declaration provided by PJT	0.6
08/07/2021	HSB	Review sections of Purdue disclosure statement in connection with Plan Hearing related planning	1.5
08/07/2021	JD	Review declarations in advance of witness prep sessions with Davis Polk tomorrow.	1.3
08/08/2021	SKL	Meeting with M.Tobak, C.Robertson, K.Benedict (all Davis Polk), J.DelConte, S.Lemack, H. Bhattal (AlixPartners) re: witness preparation and expert report	2.3
08/08/2021	JD	Meeting with M.Tobak, C.Robertson, K.Benedict (all Davis Polk), J.DelConte, S.Lemack, H. Bhattal (AlixPartners) re: witness preparation and expert report	2.3
08/08/2021	HSB	Meeting with M.Tobak, C.Robertson, K.Benedict (all Davis Polk), J.DelConte, S.Lemack, H. Bhattal (AlixPartners) re: witness preparation and expert report	2.3
08/08/2021	HSB	Review Purdue plan documents and related analysis in connection with Plan related planning and preparation	1.2
08/09/2021	RC	Review materials related to plan confirmation.	1.1
08/09/2021	RC	Review information compiled in response to the UCC's requests for tax related information.	0.5
08/09/2021	RC	Dial into pre-trial conference for upcoming Confirmation Hearings.	2.2
08/09/2021	HSB	Review Purdue liquidation analysis and underlying assumptions	1.3
08/09/2021	HSB	Review Purdue financial projections and related analysis in connection with ongoing Plan related discussions	1.5
08/09/2021	HSB	Review Purdue diligence related files prepared by S.Lemack (AlixPartners)	0.6
08/09/2021	HSB	Review select sections of Purdue Plan Supplement and underlying documents in connection with ongoing Plan discussions	1.7
08/09/2021	HSB	Review Purdue Plan related declarations in connection with Debtors' confirmation plan hearing and related discussions	1.4
08/09/2021	HSB	Multiple calls with S.Lemack (AlixPartners) re: the liquidation analysis and plan related issues.	1.1
08/09/2021	SKL	Multiple calls with H. Bhattal (AlixPartners) re: the liquidation analysis and plan related issues.	1.1
08/09/2021	SKL	Finalize liquidation analysis summary sheet showing individual calculations and recoverables and circulate internally.	1.8
08/09/2021	SKL	Finalize and PDF liquidation analysis calculation/recoverable summary sheet.	1.4
08/09/2021	JD	Call with R. Collura (AlixPartners) re: confirmation hearing.	0.2
08/09/2021	JD	Review Debtors reply brief in preparation for confirmation testimony.	2.5
08/09/2021	JD	Finish reading through the reply brief.	2.2
08/09/2021	RC	Call with J. DelConte (AlixPartners) re: confirmation hearing.	0.2
08/10/2021	RC	Call with M. Rule (AlixPartners) to discuss plan confirmation.	0.6
08/10/2021	RC	Review materials re: plan confirmation.	2.1
08/10/2021	RC	Review non-cash and intercompany report in preparation for plan confirmation.	1.7
08/10/2021	RC	Review sources relied upon materials in preparation for plan confirmation.	2.3
08/10/2021	RC	Review additional materials filed in connection with plan confirmation.	1.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/10/2021	HSB	Participate in witness prep at Davis Polk with J. DelConte, H. Bhattal, S. Lemack (all AlixPartners), M. Tobak, K. Benedict (both Davis Polk), A. Kramer, A. Muha (both Reed Smith).	2.2
08/10/2021	HSB	Review Purdue plan related filed declarations	1.2
08/10/2021	HSB	Review liquidation analysis file prepared by S.Lemack (AlixPartners)	1.4
08/10/2021	HSB	Review relevant sections of Purdue Plan and Disclosure Statement in connection with ongoing confirmation hearing related analysis and discussions	1.6
08/10/2021	HSB	Review Purdue confirmation hearing related memo prepared by Davis Polk	0.7
08/10/2021	HSB	Multiple calls with S.Lemack (AlixPartners) to discuss various Purdue plan related issues	1.6
08/10/2021	SKL	Participate in witness prep at Davis Polk with J. DelConte, H. Bhattal, S. Lemack (all AlixPartners), M. Tobak, K. Benedict (both Davis Polk), A. Kramer, A. Muha (both Reed Smith).	2.2
08/10/2021	SKL	Multiple calls with H. Bhattal (AlixPartners) to discuss the liquidation analysis.	1.6
08/10/2021	SKL	Finalize liquidation analysis sensitivity table and circulate to Davis Polk team for additional notes/feedback.	2.5
08/10/2021	JD	Call with J. Lowne (Purdue) re: confirmation hearing.	0.1
08/10/2021	JD	Participate in witness prep at Davis Polk with J. DelConte, H. Bhattal, S. Lemack (all AlixPartners), M. Tobak, K. Benedict (both Davis Polk), A. Kramer, A. Muha (both Reed Smith).	2.2
08/10/2021	JD	Prepare for witness prep at Davis Polk.	0.6
08/10/2021	JD	Review plan of reorganization and disclosure statement in advance of hearing starting.	2.8
08/10/2021	MFR	Call with C. Duggan, M. Clarens, A. Whisenhant and E. Young (all Davis Polk) re: confirmation hearing testimony/preparation.	2.0
08/10/2021	MFR	Preparation for call with C. Duggan, M. Clarens, A. Whisenhant and E. Young (all Davis Polk) re: confirmation hearing testimony.	2.6
08/10/2021	MFR	Call with R. Collura (AlixPartners) to discuss plan confirmation.	0.6
08/11/2021	RC	Call with Davis Polk (E. Kim) to discuss logistics for testifying virtually at plan confirmation trial.	0.2
08/11/2021	RC	Call with J. DelConte (AlixPartners) re: plan confirmation.	0.5
08/11/2021	RC	Review expert report in preparation for plan confirmation testimony.	2.3
08/11/2021	RC	Review supporting documents related to expert report.	2.2
08/11/2021	RC	Review declaration and expert report supporting materials.	1.5
08/11/2021	HSB	Meeting with M.Tobak, K.Houston, K.Benedict (all Davis Polk), J.DelConte, H. Bhattal, S.Lemack (AlixPartners) re: Plan related planning, liquidation analysis and witness preparation	2.1
08/11/2021	HSB	Review Purdue plan related documents in connection with ongoing discussions	1.4
08/11/2021	HSB	Review relevant sections of Purdue Plan and Disclosure Statement in connection with ongoing confirmation hearing related analysis and discussions	1.4
08/11/2021	HSB	Review Purdue diligence related files prepared by S.Lemack (AlixPartners)	0.8
08/11/2021	HSB	Multiple calls with S.Lemack (AlixPartners) to discuss various Purdue plan related issues	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/11/2021	SKL	Meeting with M.Tobak, K.Houston, K.Benedict (all Davis Polk), J.DelConte, H. Bhattal, S.Lemack (AlixPartners) re: Plan related planning, liquidation analysis and witness preparation	2.1
08/11/2021	SKL	Multiple calls with H. Bhattal (AlixPartners) to discuss the liquidation analysis.	0.5
08/11/2021	SKL	Prepare additional updates to the liquidation analysis sensitivity table and scenarios PDF and circulate.	2.4
08/11/2021	SKL	Prepare additional scenarios for the liquidation analysis and prepare updated summary table for the Davis Polk team to review.	2.3
08/11/2021	JD	Call with R. Collura (AlixPartners) re: confirmation hearing.	0.5
08/11/2021	JD	Call with R. Aleali (Purdue) re: confirmation hearing.	0.4
08/11/2021	JD	Call with J. Lowne (Purdue) re: confirmation hearing.	0.2
08/11/2021	JD	Meeting with M.Tobak, K.Houston, K.Benedict (all Davis Polk), J.DelConte, H. Bhattal, S.Lemack (AlixPartners) re: Plan related planning, liquidation analysis and witness preparation	2.1
08/11/2021	JD	Review the plan and disclosure statement in conjunction with DelConte declarations in advance of the confirmation hearing.	3.2
08/12/2021	RC	Prepare for expert testimony at plan confirmation.	3.0
08/12/2021	RC	Review documents and provide expert testimony at plan confirmation.	0.3
08/12/2021	RC	Dial into expert witness testimony at plan confirmation.	0.5
08/12/2021	RC	Dial into additional expert witness testimony at plan confirmation.	2.5
08/12/2021	HSB	Meeting with M.Tobak, K.Benedict, K.Houston (all Davis Polk), J.DelConte, S.Lemack (AlixPartners), M.Kesselman (Purdue) re: Plan related planning and preparation	2.5
08/12/2021	HSB	Review updated Plan related analysis prepared by S.Lemack (AlixPartners)	0.6
08/12/2021	HSB	Calls with S.Lemack (AlixPartners) to discuss latest updates to the liquidation analysis scenarios deck.	0.3
08/12/2021	SKL	Prepare additional updates to the liquidation scenarios deck and circulate to Davis Polk team for further comments.	1.9
08/12/2021	SKL	Calls with H. Bhattal (AlixPartners) to discuss latest updates to the liquidation analysis scenarios deck.	0.3
08/12/2021	SKL	Prepare updated liquidation scenarios deck and circulate internally for sign-off.	0.7
08/12/2021	SKL	Prepare updated liquidation scenarios deck based on latest feedback provided and circulate update accordingly.	1.5
08/12/2021	SKL	Update liquidation scenarios deck to include asset level detail and re-circulate accordingly.	1.4
08/12/2021	SKL	Meeting with M. Tobak, K. Benedict, B. Kaminetzky (all Davis Polk), J. DelConte, H. Bhattal, S. Lemack (all AlixPartners), M. Kesselman (Purdue) re: witness prep.	2.5
08/12/2021	JD	Meeting with M. Tobak, K. Benedict, B. Kaminetzky (all Davis Polk), J. DelConte, H. Bhattal, S. Lemack (all AlixPartners), M. Kesselman (Purdue) re: witness prep.	2.5
08/12/2021	JD	Review materials in advance of testimony tomorrow.	3.2
08/12/2021	JD	Finish reviewing materials and declarations in advance of the hearing tomorrow.	1.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/13/2021	RC	Dial into plan confirmation hearings.	1.5
08/13/2021	HSB	Call with S.Lemack (AlixPartners) to discuss various Purdue plan related issues	0.6
08/13/2021	SKL	Call with H. Bhattach (AlixPartners) to discuss the liquidation analysis.	0.6
08/13/2021	JD	Review materials in preparation for testimony.	2.6
08/16/2021	RC	Review plan confirmation related materials and listen into expert witness testimony.	1.9
08/16/2021	RC	Continue to listen into plan confirmation expert witness testimony and review declarations.	1.3
08/16/2021	SKL	Call with H. Bhattach (AlixPartners) to discuss Purdue Plan related diligence requests.	0.3
08/16/2021	HSB	Call with S.Lemack (AlixPartners) to discuss various Purdue plan related diligence requests	0.3
08/16/2021	HSB	Review select sections of the updated Purdue Plan amendment	0.7
08/16/2021	MFR	Discussion with R. Collura (AlixPartners) the status of the Confirmation Hearing.	0.8
08/17/2021	RC	Review materials filed in connection with plan confirmation.	1.0
08/17/2021	RC	Dial into witness testimony re: plan confirmation.	2.4
08/17/2021	RC	Dial into afternoon session of plan confirmation hearings.	1.3
08/17/2021	SKL	Call with H. Bhattach (AlixPartners) re: case update	0.2
08/17/2021	HSB	Calls with S.Lemack (AlixPartners) re: case update	0.2
08/17/2021	JD	Correspondence with Davis Polk re: ongoing court hearing.	0.3
08/18/2021	RC	Dial into witness testimony during plan confirmation hearings.	1.5
08/18/2021	SKL	Call with H. Bhattach (AlixPartners) to discuss Purdue Plan related diligence requests.	0.3
08/18/2021	SKL	Call with J. Gleit, R.Rosenblatt, Z.Zuccarello (all S&C Law), J.DelConte, H. Bhattach (both AlixPartners) re: witness prep meeting	0.7
08/18/2021	HSB	Call with J. Gleit, R.Rosenblatt, Z.Zuccarello (all S&C Law), J.DelConte, S.Lemack (both AlixPartners) re: witness prep meeting	0.7
08/18/2021	HSB	Review plan declarations in connection with witness prep	0.5
08/18/2021	HSB	Call with S.Lemack (AlixPartners) to discuss various Purdue plan related diligence requests	0.3
08/18/2021	HSB	Call with A.DePalma (AlixPartners) to discuss Purdue diligence request	0.4
08/18/2021	JD	Call with J. Gleit, A. Zuccarello, R. Rosenblatt (all S&C), J. DelConte, H. Bhattach, S. Lemack (all AlixPartners) re: witness prep.	0.7
08/18/2021	JD	Call with C. Robertson (Davis Polk) re: status of DMP negotiations.	0.3
08/18/2021	JD	Call with R. Aleali (Purdue) re: status of DMP and insurer negotiations.	0.3
08/18/2021	JD	Call with E. Vonnegut (Davis Polk) re: negotiation update.	0.1
08/18/2021	ADD	Call with A. DePalma and H. Bhattach (AlixPartners) to discuss plan related matters.	0.4
08/19/2021	RC	Dial into witness testimony during plan confirmation.	2.5
08/19/2021	RC	Dial into afternoon session of witness testimony at plan confirmation hearing.	1.3
08/19/2021	SKL	Call with H. Bhattach (AlixPartners) to discuss Purdue Plan related diligence requests.	0.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/19/2021	HSB	Review Purdue plan related documents in connection with witness testimony	0.8
08/19/2021	HSB	Call with S.Lemack (AlixPartners) to discuss various Purdue plan related diligence requests	0.3
08/19/2021	JD	Call with J. Gleit (S&C) re: witness prep.	0.1
08/19/2021	JD	Call with J. Gleit (S&C) re: witness prep questions.	0.1
08/19/2021	JD	Call with J. Gleit (S&C) re: witness testimony.	0.1
08/19/2021	JD	Call with C. Robertson (Davis Polk) re: confirmation hearing status.	0.3
08/19/2021	JD	Call with R. Aleali, J. Doyle, D. Fogel, V. Mancinelli (all Purdue), D. Klein, C. Robertson (Davis Polk) re: DMP agreement.	0.3
08/19/2021	JD	Review materials in advance of potential testimony today or tomorrow.	2.5
08/19/2021	JD	Walk through set up for potential testimony at Alix offices.	0.4
08/19/2021	JD	Continue reviewing materials in advance of potential testimony.	1.3
08/20/2021	HSB	Review Purdue documents in connection with request from Davis Polk	1.4
08/20/2021	HSB	Correspondence with PJT and AlixPartners colleagues in connection with request from Davis Polk	0.2
08/20/2021	HSB	Review select sections of Purdue's Sixth Monitor Report	0.2
08/20/2021	HSB	Review email correspondence relating to Purdue diligence requests	0.2
08/20/2021	HSB	Call with A.DePalma (AlixPartners) to discuss Purdue diligence request	0.1
08/20/2021	ADD	Call with A. DePalma and H. Bhattal (AlixPartners) to discuss plan related matters.	0.1
08/23/2021	JD	Call with M. Huebner (Davis Polk) re: confirmation hearing prep.	0.1
08/23/2021	JD	Call with J. Turner and J. O'Connell (both PJT) re: confirmation prep.	0.2
08/23/2021	JD	Review distribution build up and analysis and correspondence with Davis Polk and PJT re: same.	0.5
08/23/2021	HSB	Review select sections of the updated Purdue Plan (eighth amendment)	0.6
08/23/2021	HSB	Multiple calls with S.Lemack (AlixPartners) to discuss various Purdue plan related diligence requests	0.7
08/23/2021	SKL	Multiple calls with H. Bhattal (AlixPartners) to discuss Purdue Plan related diligence requests.	0.7
08/25/2021	RC	Dial into Plan Confirmation closing arguments.	2.2
08/25/2021	JD	Call with M. Huebner (Davis Polk) re: confirmation hearing.	0.2
08/26/2021	HSB	Review select sections of latest Purdue Plan amendment	1.7
08/27/2021	HSB	Call with H. Bhattal, L. Nguyen (AlixPartners) re: various Purdue plan related matters matters	0.2
08/27/2021	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) re: various Purdue plan related matters matters	0.2
08/31/2021	JD	Call with M. Huebner (Davis Polk) re: settlement discussions.	0.2
09/01/2021	JD	Meeting with J. DelConte, L. Nguyen (both AlixPartners), R. Schnitzler, J. Turner, J. Arsic (all PJT) re: IAC value.	0.3
09/01/2021	LTN	Meeting with J. DelConte, L. Nguyen (both AlixPartners), R. Schnitzler, J. Turner, J. Arsic (all PJT) re: IAC value.	0.3
09/02/2021	JD	Call with M. Huebner (Davis Polk) re: settlement negotiations.	0.4
09/02/2021	JD	Correspondence with Davis Polk re: settlement analysis questions.	0.4
09/02/2021	JD	Prepare summary schedule for draft settlement analysis.	1.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/02/2021	JD	Review and provide comments on the preliminary settlement analysis.	1.0
09/03/2021	HSB	Call with H. Bhattal, L. Nguyen, S. Lemack (AlixPartners) to discuss the latest FTI contracts request from AHC	0.4
09/03/2021	LTN	Call with H. Bhattal, L. Nguyen, S. Lemack (AlixPartners) to discuss the latest FTI contracts request from AHC	0.4
09/03/2021	SKL	Call with H. Bhattal, L. Nguyen, S. Lemack (AlixPartners) to discuss the latest FTI contracts request from AHC	0.4
09/14/2021	JD	Review equitable mootness and third party release cases.	0.8
09/15/2021	JD	Conversation with G. McCarthy, M. Tobak, G. Cardillo, S. Stefanik (all Davis Polk) re: discussion on stay of confirmation.	0.4
09/16/2021	HSB	Call with J. DelConte and L. Nguyen (AlixPartners) to discuss Purdue analysis in connection with confirmation declaration	0.3
09/16/2021	JD	Call with J. DelConte, H. Bhattal and L. Nguyen (all AlixPartners) re: analysis for declaration in support of opposition to confirmation stay motion.	0.3
09/16/2021	LTN	Call with J. DelConte, H. Bhattal, L. Nguyen (AlixPartners) to discuss about analysis of settlement payment delay	0.3
09/16/2021	HSB	Call with H. Bhattal, L. Nguyen (AlixPartners) to discuss fee forecast	0.2
09/16/2021	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) to discuss fee forecast	0.2
09/16/2021	HSB	Prepare summary of Purdue financial projections in connection with confirmation declaration	1.3
09/16/2021	HSB	Review Purdue financial analysis in connection with filing	0.8
09/16/2021	HSB	Review Purdue financial projections in connection with confirmation declaration	1.3
09/16/2021	JD	Review and provide comments on draft declaration outline for opposition to the confirmation stay motion.	0.5
09/17/2021	HSB	Two calls with L. Nguyen (AlixPartners) to discuss Purdue Plan related analysis	1.6
09/17/2021	LTN	Two calls with H. Bhattal (AlixPartners) to work on payment delay for declaration and Purdue Plan related analysis	1.6
09/17/2021	HSB	Review excel analysis prepared by L. Nguyen (AlixPartners) in connection with Plan filings	1.5
09/17/2021	HSB	Review Purdue financial projections in connection with plan related analysis	0.7
09/17/2021	HSB	Review Purdue plan related agreements in connection with plan related analysis	1.2
09/20/2021	HSB	Review Purdue plan related agreements in connection with plan related analysis	0.8
09/20/2021	HSB	Update excel analysis prepared by L. Nguyen (AlixPartners) in connection with Plan filings	2.4
09/21/2021	HSB	Multiple calls with L. Nguyen (AlixPartners) to discuss Purdue Plan related analysis and payment delay for declaration	2.2
09/21/2021	LTN	Multiple calls with H. Bhattal (AlixPartners) to discuss Purdue Plan related analysis and payment delay for declaration	2.2
09/21/2021	HSB	Multiple calls with L. Nguyen (AlixPartners) to discuss Purdue Plan related analysis	2.2
09/21/2021	HSB	Review Purdue Plan related analysis prepared by L. Nguyen (AlixPartners)	0.8



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/21/2021	HSB	Update excel analysis prepared by L.Nguyen (AlixPartners) in connection with Plan filings	3.4
09/22/2021	HSB	Continue updating excel analysis prepared by L.Nguyen (AlixPartners) in connection with Plan filings	1.6
09/23/2021	HSB	Review Purdue plan and related documents in connection with analysis prepared by L.Nguyen	0.8
09/24/2021	HSB	Review Purdue plan related analysis prepared by L.Nguyen (AlixPartners)	1.2
09/24/2021	HSB	Review Purdue related email correspondence in connection with Plan related work	0.2
09/28/2021	ADD	Review updated model for declaration exhibits to identify inconsistencies and incorrect formulas.	1.2
09/28/2021	HSB	Review Purdue plan related analysis prepared by L.Nguyen (AlixPartners) and made revisions	2.2
09/29/2021	HSB	Call with H. Bhattal, L. Nguyen (AlixPartners) re: plan delay analysis	0.2
09/29/2021	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) re: plan delay analysis	0.2
09/29/2021	HSB	Call with J. DelConte, H. Bhattal, L. Nguyen (AlixPartners) to discuss analysis for confirmation declaration	1.1
09/29/2021	JD	Call with J. DelConte, H. Bhattal, L. Nguyen (AlixPartners) to discuss analysis for confirmation declaration	1.1
09/29/2021	LTN	Call with J. DelConte, H. Bhattal, L. Nguyen (AlixPartners) to discuss analysis for confirmation declaration	1.1
09/29/2021	ADD	Review updated model for declaration exhibits to identify inconsistencies and incorrect formulas.	2.6
09/29/2021	HSB	Review Purdue declaration prepared by Davis Polk	1.2
09/29/2021	HSB	Review Purdue plan related analysis prepared by L.Nguyen (AlixPartners)	2.7
09/29/2021	HSB	Update Purdue plan related analysis prepared by L.Nguyen (AlixPartners)	3.5
09/29/2021	JD	Review and develop comments on draft declaration analysis prior to meeting with Alix team.	1.2
09/29/2021	JD	Review initial draft stay declaration from Davis Polk.	0.7
09/30/2021	ADD	Two calls with H. Bhattal (AlixPartners) to discuss Purdue diligence related requests and related matters and declaration model update	0.7
09/30/2021	HSB	Two calls with A.DePalma (AlixPartners) to discuss Purdue diligence related requests and related matters and declaration model update	0.7
09/30/2021	HSB	Call with J. DelConte, H. Bhattal, L. Nguyen (all AlixPartners), C. Robertson (Davis Polk) re: draft declaration analysis.	0.5
09/30/2021	JD	Call with J. DelConte, H. Bhattal, L. Nguyen (all AlixPartners), C. Robertson (Davis Polk) re: draft declaration analysis.	0.5
09/30/2021	LTN	Call with J. DelConte, H. Bhattal, L. Nguyen (AlixPartners), C. Robertson (Davis Polk) to discuss professional fee forecast	0.5
09/30/2021	HSB	Call with G.Cardillo, G.McCarthy, S.Stefanik (all Davis Polk), J. DelConte (AlixPartners) re: Purdue plan related declaration	0.8
09/30/2021	JD	Call with G. McCarthy, G. Cardillo, S. Stefanik (all Davis Polk), J. DelConte, H. Bhattal (both AlixPartners) re: draft stay motion declaration.	0.8





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

<b>DATE</b>	<b>CONSULTANT</b>	<b>DESCRIPTION OF SERVICES</b>	<b>HOURS</b>
09/30/2021	ADD	Review updated model for declaration exhibits to identify inconsistencies and incorrect formulas.	2.7
09/30/2021	HSB	Continue making revisions to Purdue plan related analysis prepared by L.Nguyen (AlixPartners)	2.8
09/30/2021	HSB	Review Purdue declaration draft prepared by Davis Polk	1.2
09/30/2021	HSB	Review Purdue forecasts in connection with plan related analysis and reviewed underlying details	2.4
09/30/2021	JM	Review and comment on court filings draft	0.4
<b>Total Professional Hours</b>			<b>864.6</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: POR Development  
Code: 1.7 / 107

<b>PROFESSIONAL</b>	<b>TITLE</b>	<b>RATE</b>	<b>HOURS</b>	<b>FEES</b>
Lisa Donahue	Managing Director	\$1,295	0.9	\$ 1,165.50
Richard Collura	Managing Director	\$1,125	161.2	181,350.00
Jesse DelConte	Managing Director	\$1,055	121.5	128,182.50
Mark F Rule	Director	\$980	8.6	8,428.00
Jason Muskovich	Director	\$980	0.4	392.00
Gabe J Koch	Director	\$865	19.2	16,608.00
HS Bhattal	Director	\$865	365.6	316,244.00
Sam K Lemack	Senior Vice President	\$665	120.5	80,132.50
Sam J Canniff	Senior Vice President	\$665	0.4	266.00
Andrew D DePalma	Vice President	\$625	27.0	16,875.00
Lan T Nguyen	Vice President	\$530	39.3	20,829.00
<b>Total Professional Hours and Fees</b>			<b>864.6</b>	<b>\$ 770,472.50</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Executory Contracts  
Code: 1.8 / 108

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/01/2021	SKL	Finalize updates to the latest contract analysis and circulate update accordingly.	0.6
06/01/2021	JD	Review and provide comments on the latest summary contract and cure contract schedule to share with the AHC.	0.4
06/10/2021	SKL	Update contract cure analysis based on the latest feedback provided from the contract rejection call.	1.3
06/11/2021	SKL	Finalize updates to the contract cure cost analysis and contract listing to circulate to R. Aleali (Purdue) accordingly.	1.5
06/12/2021	GJK	Review contract breakdown from S Lemack (AlixPartners) including cure costs and email exchanges between R AleAli (Purdue) and L Diggs (Davis Polk).	0.6
06/14/2021	GJK	Review AHC contract email to J Lowne (Purdue) from S Lemack (AlixPartners).	0.3
06/14/2021	GJK	Walk through Pre-Petition Contract Analysis from S Lemack (AlixPartners).	1.7
06/14/2021	SKL	Finalize updates to the contract analysis schedule following call with J. Lowne (Purdue) and circulate for additional review and feedback.	1.8
06/16/2021	SKL	Finalize updates to the contract analysis file and circulate for final sign-off.	0.8
06/17/2021	SKL	Follow-up call with S. Daniel (Purdue) re: contract analysis.	0.4
06/17/2021	SKL	Meeting with S. Daniel (Purdue) re: contract analysis file.	0.5
06/17/2021	SKL	Update the contract analysis file based on the latest notes and feedback provided and circulate for final sign-off.	0.8
06/17/2021	SKL	Pull latest IT contract listing from the Intralinks site and prepare updated breakdown of contracts for the IT team to review.	2.3
06/17/2021	SKL	Finalize updates to the IT contract prioritization list and circulate to the IT team for additional feedback.	0.6
06/18/2021	SKL	Multiple calls with S. Daniel (Purdue) re: contract analysis.	0.5
06/18/2021	SKL	Prepare updates to the prepetition contract breakdown based on latest discussion with S. Daniel (Purdue) and circulate for additional updates.	1.2
06/21/2021	GJK	Call with Purdue Legal, Davis Polk and S Lemack (AlixPartners) re: IP Contract review	0.8
06/21/2021	SKL	Meeting with K. McCarthy, S. Hoffman (both Purdue), L. Digg, E. Turray, and A. Lele (both Davis Polk), G. Koch (AlixPartners) to discuss the latest IP contract reconciliation.	0.8
06/21/2021	SKL	Prepare for and participate in meeting with S. Daniel (Purdue) re: contract analysis.	0.5
06/21/2021	SKL	Finalize remaining updates to the contract listing for FTI and circulate for production.	0.3
06/25/2021	SKL	Review latest feedback re: contract rejection analysis and circulate update internally.	1.1
06/28/2021	SKL	Call with S. Daniel and C. Russo (Purdue) re: contract rejection analysis.	0.5
06/28/2021	SKL	Call with H. Ghnaimeh (Purdue) re: IT contract review.	0.2
06/28/2021	SKL	Review latest feedback provided by the IT team re: high-priority contracts and circulate update to the Davis Polk team accordingly.	1.3
06/28/2021	SKL	Review latest contract analysis provided by the Clinical Ops group and update the consolidated contract analysis file accordingly.	1.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Executory Contracts  
Code: 1.8 / 108

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/28/2021	SKL	Review latest contract analysis provided by the Avrio group and update the consolidated contract analysis file accordingly.	1.1
06/28/2021	SKL	Review latest contract analysis provided by the IP group and update the consolidated contract analysis file accordingly.	1.3
06/29/2021	SKL	Continue to finalize updates to the contract rejection analysis tracker and circulate internally.	2.3
06/30/2021	SKL	Meeting with S. Daniel and C. Russo (both Purdue) re: contract rejection process and continue to finalize exhibit.	0.5
06/30/2021	SKL	Continue to review latest feedback provided re: contract rejection analysis and update consolidated file accordingly.	2.2
06/30/2021	SKL	Update the consolidated contract rejection analysis file and circulate for additional review.	2.1
07/01/2021	JD	Call with J. Lowne, C. Russo, S. Daniel, R. Aleali (all Purdue), J. DelConte, S. Lemack, H. Bhattal (all AlixPartners) re: contract assumption and rejection lists.	0.5
07/01/2021	JD	Provide comments on a list of potential contracts to reject and assume in advance of call with management.	0.5
07/01/2021	JD	Review list of potential surety bonds to assume in comparison with prepetition list.	0.1
07/01/2021	SKL	Meeting with S. Daniel and C. Russo (both Purdue) re: contract rejection analysis.	0.7
07/01/2021	SKL	Meeting with S. Daniel and C. Russo (both Purdue) to provide additional update re: contract rejection analysis.	0.4
07/01/2021	SKL	Meeting with J. Lowne, S. Daniel, C. Russo (all Purdue), J. DelConte and H. Bhattal (both AlixPartners) to discuss contract rejection exhibit.	0.5
07/01/2021	SKL	Continue to finalize review of latest contract rejection feedback and circulate updated analysis prior to afternoon meeting.	2.4
07/01/2021	ADD	Analyze invoice level A/P data to identify vendor spend trends.	2.8
07/01/2021	JD	Correspondence with Davis Polk and Purdue management re: list of potential surety bonds to assume in comparison with prepetition list.	0.2
07/02/2021	JD	Correspondence with S. Lemack (AlixPartners) and Purdue management re: potential contract rejections.	0.3
07/02/2021	SKL	Finalize review of contract rejection analysis and circulate update to Davis Polk team accordingly.	1.1
07/03/2021	GJK	Review IP contract review documents from H Smith (Davis Polk).	0.3
07/06/2021	SKL	Review latest notes and feedback provided on the contract assumption/rejection analysis and prepare updates to the consolidated contracts tracker accordingly.	1.0
07/07/2021	SKL	Call with S. Daniel (Purdue) to discuss contract assumption process.	0.3
07/07/2021	SKL	Multiple calls with C. Robertson (Davis Polk) to discuss contract rejection/assumption analysis.	0.3
07/07/2021	SKL	Multiple calls with S. Daniel (Purdue) to discuss contract rejection/assumption analysis.	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Executory Contracts  
Code: 1.8 / 108

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/07/2021	HSB	Call with C. Robertson (Davis Polk), J. DelConte, S. Lemack, H. Bhattal (all AlixPartners), J. Lowne, S. Daniel, J. Lauriat, C. Russo (all Purdue) re: contract rejection and assumption.	0.8
07/07/2021	JD	Call with C. Robertson (Davis Polk), J. DelConte, S. Lemack, H. Bhattal (all AlixPartners), J. Lowne, S. Daniel, J. Lauriat, C. Russo (all Purdue) re: contract rejection and assumption.	0.8
07/08/2021	GJK	Call with K. McCarthy, S. Hoffman, Z. Haseeb, B. Koch, R. Kreppel, J. Doyle, R. Inz (all Purdue) and S. Lemack (AlixPartners) to discuss IP contract review process.	1.0
07/08/2021	SKL	Meeting with S. Daniel (Purdue), C. Russo (Purdue), J. Doyle (Purdue), C. Robertson (Davis Polk) and H. Bhattal (AlixPartners) to discuss open questions re: contract assumption/rejection process.	0.3
07/08/2021	SKL	Calls with C. Robertson (Davis Polk) to discuss contract rejection/assumption analysis.	0.2
07/08/2021	SKL	Meeting with R. Aleali (Purdue), S. Hoffman (Purdue), S. Brecher (Davis Polk) and C. Chandler (Wiggins Dana) to discuss employee agreements.	0.3
07/08/2021	SKL	Call with K. McCarthy, S. Hoffman, Z. Haseeb, B. Koch, R. Kreppel, J. Doyle, R. Inz (all Purdue) and G. Koch (AlixPartners) to discuss IP contract review process.	1.0
07/08/2021	SKL	Review latest notes and feedback provided by R. Inz (Purdue) and the IP team and updated the consolidated contract tracker accordingly.	2.2
07/08/2021	SKL	Finalize review of latest contracts provided by IP and prepare for discussion with C. Robertson (Davis Polk) re: contract assumptions.	0.9
07/08/2021	HSB	Meeting with S. Daniel (Purdue), C. Russo (Purdue), J. Doyle (Purdue), C. Robertson (Davis Polk) and S. Lemack (AlixPartners) to discuss open questions re: contract assumption/rejection process.	0.3
07/09/2021	SKL	Call with S. Daniel (Purdue) to discuss contract assumption process.	0.2
07/09/2021	SKL	Finalize review of latest notes and feedback provided in IP contracts from R. Kreppel and R. Inz (both Purdue) and circulate updated analysis to C. Robertson (Davis Polk) accordingly.	1.7
07/09/2021	SKL	Continue to review latest notes and feedback provided by S. Daniel (Purdue) and the procurement team re: contract analysis and prepare updates to the latest contracts tracker accordingly.	2.0
07/12/2021	SKL	Call with S. Daniel (Purdue) to discuss contract assumption process.	0.3
07/12/2021	SKL	Continue to review latest notes and feedback provided by the various subgroup teams and prepare updates to the contract analysis tracker accordingly.	2.4
07/12/2021	SKL	Continue to finalize updates to the latest contract assumption schedule.	1.4
07/13/2021	SKL	Call with S. Daniel (Purdue) to discuss contract assumption process.	0.2
07/13/2021	SKL	Call with C. Robertson (Davis Polk) to discuss contract cure analysis.	0.1
07/13/2021	SKL	Continue to review latest feedback received re: contract assumption analysis, and updated the master contract tracker accordingly.	2.4
07/14/2021	SKL	Prepare for and participate in contract cure meeting with J. Doyle, K. McCarthy, E. Ruta (all Purdue), and C. Robertson (Davis Polk)	0.4
07/14/2021	SKL	Call with J. DelConte (AlixPartners) to discuss contract cure process.	0.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Executory Contracts  
Code: 1.8 / 108

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/14/2021	SKL	Call with H. Bhattal (AlixPartners) to discuss latest feedback provided re: contract assumptions.	0.2
07/14/2021	SKL	Finalize review of Rhodes and IP feedback re: contract assumption analysis and prepare updates to the latest contract tracker accordingly.	2.7
07/14/2021	SKL	Continue review of assumed contracts with cures and begin preparing updated contract assumption schedule accordingly.	2.5
07/14/2021	SKL	Finalize review and reconciliation of newly identified contracts for the contract assumption schedule and updated and circulate and master contract tracker accordingly for additional review.	2.5
07/14/2021	HSB	Call with S. Lemack (AlixPartners) to discuss latest feedback provided re: contract assumptions.	0.2
07/14/2021	JD	Call with S. Lemack (AlixPartners) to discuss contract cure process.	0.2
07/15/2021	SKL	Review latest contract assumption feedback provided by J. Lauriat (Purdue) prior to morning meeting with Procurement.	1.3
07/15/2021	SKL	Meeting with S. Daniel, N. McQuilkin, and J. Lauriat (all Purdue) to discuss latest subgroup feedback re: contract assumption process.	1.7
07/15/2021	SKL	Meeting with R. Aleali (Purdue), C. Robertson (Davis Polk), and D. Consla (Davis Polk) to discuss contract assumption process and other change of control matters.	0.4
07/15/2021	SKL	Multiple calls with C. Robertson (Davis Polk) to discuss the contract assumption process and open items.	0.4
07/15/2021	SKL	Multiple calls with S. Daniel (Purdue) to discuss the contract assumption process and open items.	0.7
07/15/2021	SKL	Meeting with J. Lowne, S. Daniel and J. Lauriat (all Purdue) to discuss contract cure costs.	0.4
07/15/2021	SKL	Call with A. DePalma (AlixPartners) to discuss contract cure analysis and OCP reconciliation.	0.1
07/15/2021	SKL	Finalize reconciliation of contract cure exhibit against OCPs, Critical Vendors and law firms and circulate updated feedback accordingly.	2.2
07/15/2021	SKL	Finalize review of contract analysis feedback from E. Ruta (Rhodes) and S. Daniel (Purdue) and updated contract analysis accordingly for additional review and sign-off.	2.3
07/15/2021	ADD	Review contract list and identify OCP vendors and retained professionals.	1.1
07/15/2021	ADD	Call with S. Lemeck (AlixPartners) to discuss contract cure analysis and OCP reconciliation.	0.1
07/16/2021	GJK	Review update contract information and comment and questions from S Daniel and J Lowne (Purdue).	0.3
07/16/2021	SKL	Call with K. McCarthy (Purdue) to discuss contract assumption/rejection process.	0.2
07/16/2021	SKL	Review latest notes and feedback provided by IP re: contract assumptions, and update the contract exhibit accordingly.	0.8
07/16/2021	SKL	Call with J. Lowne and S. Daniel (both Purdue) to discuss latest contract assumption feedback.	0.8
07/16/2021	SKL	Prepare for upcoming cash flow projection meeting.	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Executory Contracts  
Code: 1.8 / 108

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/16/2021	SKL	Multiple calls with S. Daniel (Purdue) to discuss latest feedback provided re: contract assumptions.	0.4
07/16/2021	SKL	Multiple calls with C. MacDonald (Purdue) to discuss latest contract analysis and legal vendors.	0.6
07/16/2021	JD	Review latest contract assumption and cure amount list prior to filing on Monday.	0.5
07/16/2021	SKL	Finalize updated contract analysis tracker for S. Daniel and J. Lowne (both Purdue) review and sign-off.	1.3
07/16/2021	SKL	Reconcile contract master to IP high-priority contracts and prepare follow-up on various contracts.	0.6
07/16/2021	SKL	Finalize updates to the contract assumption exhibit and contract notice file following update meeting with J. Lowne (Purdue) and S. Daniel (Purdue).	2.1
07/17/2021	GJK	Review contract assumption and cure information for Purdue.	0.5
07/17/2021	SKL	Call with C. Robertson (Davis Polk) to discuss latest contract cure inquiry.	0.1
07/17/2021	SKL	Review latest contract assumption feedback provided and circulated updated analysis to FTI and Province accordingly.	1.6
07/17/2021	JD	Review contract list updates from S. Lemack (AlixPartners) for the filing on Monday.	0.3
07/17/2021	SKL	Finalize review of latest contracts provided by S. Daniel (Purdue) and prepare updates to the contract master accordingly.	1.3
07/18/2021	GJK	Follow-up on communication between S Lemack (AlixPartners) and D Consla (Davis Polk) re: Prime Clerk and filings on contract assumption notification.	0.1
07/19/2021	SKL	Multiple calls with D. Consla (Davis Polk) to discuss contract assumption schedules.	0.4
07/19/2021	SKL	Call with J. Lowne and E. Nowakowski (both Purdue) to discuss counterparty cure inquiry.	0.3
07/19/2021	SKL	Multiple calls with S. Daniel (Purdue) to discuss contract assumption schedule.	0.5
07/19/2021	SKL	Continue to review latest company feedback and notes re: contract assumptions, and update the contract exhibits accordingly.	2.6
07/19/2021	SKL	Finalize review of latest newly identified prepetition contracts and prepare updates to the contract exhibits accordingly.	2.2
07/19/2021	SKL	Review latest contract assumption exhibits and reconcile against the counterparty notice file to provide update to the Prime Clerk team accordingly.	2.5
07/19/2021	JD	Review vendor cure cost build up from S. Lemack (AlixPartners).	0.2
07/19/2021	JD	Review final list of contract assumptions and associated cure amounts.	0.7
07/19/2021	JD	Correspondence with Purdue management re: contract assumption list follow up questions.	0.2
07/20/2021	SKL	Call with D. Consla (Davis Polk) to discuss co-defendant contract inquiry.	0.2
07/20/2021	SKL	Finalize review of contract cure exhibit and ensure all updates are captured accordingly.	1.8
07/21/2021	SKL	Review latest Prime Clerk file re: assumption/rejection notices and prepare and provide update accordingly.	2.1
07/21/2021	SKL	Call with S. Daniel (Purdue) to discuss latest contract cure inquiry.	0.1



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Executory Contracts  
Code: 1.8 / 108

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/21/2021	SKL	Review latest co-defendant contract indemnity chart provided by Davis Polk and prepare updates accordingly.	1.7
07/21/2021	SKL	Finalize contract schedule provided by Davis Polk team and provide updated reconciliation accordingly.	0.8
07/21/2021	JD	Review SAP contract assumption and cure amount correspondence from SAP.	0.4
07/22/2021	SKL	Finalize latest counterparty contract/invoice inquiry and provide update accordingly.	1.0
07/22/2021	JD	Review contract noticing list and process for finding missing addresses from Prime Clerk.	0.2
07/23/2021	SKL	Review latest counterparty feedback provided by H. Benson (Purdue) and finalize counterparty inquiry accordingly.	0.8
07/26/2021	JD	Review questions from a specific vendor on the assumption and cure list filed with the court and correspond with Davis Polk and S. Lemack re: same.	0.4
07/26/2021	SKL	Call with E. Nowakowski (Purdue) to discuss contract cure inquiries.	0.1
07/26/2021	SKL	Finalize review of latest contract cure cost inquiry and circulate feedback accordingly.	0.6
07/27/2021	SKL	Call with E. Turay (Davis Polk) to discuss latest contract reconciliation matter.	0.2
07/27/2021	SKL	Review latest Davis Polk contract inquiry and provided updated reconciliation and documents accordingly.	2.1
07/28/2021	SKL	Call with S. Daniel (Purdue) to discuss contract cure inquiries.	0.2
07/28/2021	SKL	Multiple calls with E. Nowakowski (Purdue) to discuss contract cure inquiries.	0.3
07/28/2021	SKL	Multiple calls with C. Robertson (Davis Polk) to discuss contract cure inquiries.	0.3
07/28/2021	SKL	Finalize latest vendor cure cost reconciliation and circulate to Davis Polk team.	0.7
07/29/2021	SKL	Review latest contract cure inquiry and prepare updates to the tracker and follow-up with the company accordingly.	1.0
07/30/2021	SKL	Call with C. Robertson (Davis Polk) to discuss contract cure inquiries.	0.1
08/02/2021	SKL	Review latest counterparty cure inquiry and prepare updated notes and feedback accordingly.	1.2
08/02/2021	SKL	Review latest counterparty payment inquiry and prepare updated releases lists accordingly.	1.0
08/03/2021	JD	Review assignment / assumption rejections from various vendors and correspondence with Davis Polk re: same.	0.4
08/03/2021	SKL	Call with E. Nowakowski (Purdue) to discuss latest counterparty cure cost inquiry and discuss next steps.	0.2
08/04/2021	SKL	Finalize updated breakdown of contract detail re: the latest contract cure inquiry and prepare for discussion with S. Daniel (Purdue) accordingly.	1.8
08/05/2021	SKL	Call with R. Kreppel (Purdue) to discuss the latest contract assumption inquiry.	0.4
08/05/2021	SKL	Call with C. Robertson (Davis Polk) to discuss the latest counterparty cure inquiry.	0.2
08/05/2021	SKL	Call with S. Daniel (Purdue) to discuss latest contract cure inquiry.	0.2
08/05/2021	SKL	Prepare reconciliation of contract and amendment detail provided by R. Kreppel (Purdue) and latest counterparty contract inquiry.	1.6





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Executory Contracts  
Code: 1.8 / 108

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/05/2021	SKL	Continue to reconcile latest counterparty contract cure inquiry and discuss open items with E. Nowakowski (Purdue).	1.3
08/06/2021	SKL	Prepare for and participate in multiple calls with J. Doyle (Purdue) to discuss latest Rhodes contract inquiry.	0.3
08/06/2021	SKL	Continue to review latest counterparty contract inquiry and prepare updated reconciliation of contracts and amendments accordingly.	2.1
08/09/2021	JD	Correspondence with Davis Polk re: executory contract cure payments.	0.2
08/10/2021	SKL	Follow-up email to S. Daniel (Purdue) to discuss the latest counterparty cure inquiry.	0.3
08/11/2021	SKL	Review latest counterparty cure inquiry and prepare updated reconciliation of contracts for additional review from R. Kreppel (Purdue).	1.1
08/12/2021	SKL	Meeting with R. Kreppel (Purdue) to review latest contract cure inquiry.	0.5
08/12/2021	SKL	Prepare updated contract breakdown following call with R. Kreppel (Purdue) to help reconcile latest contract cure inquiry.	0.5
08/12/2021	SKL	Finalize reconciliation of latest contract cure inquiry and prepare updates prior to call with R. Kreppel (Purdue).	1.2
08/12/2021	SKL	Finalize updates to the prepetition contract breakdown and circulate internally for sign-off.	0.5
08/13/2021	SKL	Finalize counterparty cure inquiry and provided updated feedback for C. Robertson (Davis Polk and the IP team accordingly).	2.1
08/16/2021	RC	Discussion with M. Rule (AlixPartners) the status of the Confirmation Hearing.	0.8
08/18/2021	SKL	Finalize remaining updates to the counterparty cure descriptions and circulate for sign-off and distribute to the AHC.	1.6
08/18/2021	SKL	Reconcile latest information provided and prepare updated counterparty cure breakdown based on the latest counterparty inquiry and follow-up with the IP team accordingly.	1.5
08/24/2021	SKL	Review latest counterparty contract inquiry and circulate list of contracts to the Procurement team to pull.	0.7
08/30/2021	SKL	Prepare updated contract breakdown for the latest contract cure inquiry and prepare for tomorrow's meeting with IP to review list of contracts.	1.2
08/31/2021	SKL	Prepare updates to the latest contract cure inquiry and circulate updated breakdown and feedback to the Davis Polk team.	1.7
09/01/2021	SKL	Continue to work through the latest feedback provided re: cure cost inquiries and prepare updates accordingly.	1.4
09/01/2021	SKL	Review latest feedback from the company related to the recent contract cure inquiry and provided updated notes for the Davis Polk team.	0.8
09/03/2021	SKL	Call with D. Consla (Davis Polk) to discuss latest contract cure inquiry.	0.3
09/08/2021	SKL	Continue to prepare and finalize updates to the latest contract cure inquiry and provide updated breakdown to the Purdue IP team for review and sign-off.	2.4
09/08/2021	SKL	Finalize updates to the latest contract cure tracker and circulate the latest contract requested for counterparty review.	1.0
09/08/2021	SKL	Multiple calls with D. Consla (Davis Polk) related to the latest contract cure inquiry and next steps.	0.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Executory Contracts  
Code: 1.8 / 108

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/09/2021	SKL	Call with D. Consola (Davis Polk) to discuss the latest feedback provided re: contract cure disputes.	0.2
09/09/2021	SKL	Continue to work through remaining open contract requests and provided updated contract breakdown to the Davis Polk team for review.	2.1
09/09/2021	SKL	Review latest contract assumption inquiry provided by D. Consola (Davis Polk) and circulate updates to the team accordingly.	0.6
09/12/2021	SKL	Review latest contract inquiry provided by D. Consola (Davis Polk) and provide update accordingly.	0.4
09/13/2021	SKL	Review latest notes and feedback provided on the latest contract cure inquiry and prepare follow-ups accordingly.	0.8
09/14/2021	SKL	Continue to review the latest contract cure inquiries and follow-up with Purdue IP with additional questions accordingly.	1.4
09/16/2021	SKL	Review latest feedback provided on the recent contract cure inquiry and provide follow-up accordingly.	1.3
09/22/2021	SKL	Meeting with Purdue management, C. Robertson and D. Consola (both Davis Polk) to discuss the latest contract cure inquiry.	0.2
09/22/2021	SKL	Review latest contract cure tracker and circulate updated analysis and open items to the Purdue IP team to provide additional feedback accordingly.	1.1
09/22/2021	SKL	Review latest counterparty contract inquiry and provide follow-up request to J. Lowne (Purdue) accordingly.	0.6
09/23/2021	SKL	Continue to finalize review of latest contract cure inquiry and prepare additional feedback for the Purdue IP team to review and provide additional feedback on.	0.9
09/27/2021	SKL	Begin preparing updated contract assumption breakdown for the Davis Polk team based on the latest feedback provided re: counterparty contract/cure inquiries.	2.2
09/27/2021	SKL	Finalize updates to the latest contract exhibits and circulate latest open contract inquiries for final follow-up to the Purdue IP team.	1.4
09/27/2021	SKL	Review latest counterparty contract inquiry and follow-up with the Purdue IP team based on the latest feedback provided.	1.2
09/28/2021	SKL	Review latest feedback provided on the counterparty cure inquiry and provide update to the Davis Polk team accordingly.	0.7
09/29/2021	SKL	Finalize updates to the latest contract analysis breakdown and circulate to the Davis Polk team accordingly.	1.2
<b>Total Professional Hours</b>			<b>165.7</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Executory Contracts  
Code: 1.8 / 108

<b>PROFESSIONAL</b>	<b>TITLE</b>	<b>RATE</b>	<b>HOURS</b>	<b>FEES</b>
Richard Collura	Managing Director	\$1,125	0.8	900.00
Jesse DelConte	Managing Director	\$1,055	6.5	6,857.50
Gabe J Koch	Director	\$865	5.6	4,844.00
HS Bhattal	Director	\$865	1.3	1,124.50
Sam K Lemack	Senior Vice President	\$665	147.5	98,087.50
Andrew D DePalma	Vice President	\$625	4.0	2,500.00
<b>Total Professional Hours and Fees</b>			<b>165.7</b>	<b>\$ 114,313.50</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Claims Process  
Code: 1.9 / 109

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/13/2021	SKL	Review latest POC breakdown provided by the Davis Polk team and prepare updates accordingly.	0.4
07/14/2021	JD	Correspondence with Davis Polk re: convenience class claims analysis.	0.3
07/30/2021	SKL	Prepare updates to the trade claims in the Alix claims database	1.6
07/30/2021	SKL	Continue to finalize updates to the prepetition contracts database and prepare updated contracts breakdown per AHC request.	1.4
08/12/2021	JM	Review background materials and key filings in connection with post-confirmation claims process kick-off	1.5
08/16/2021	SKL	Review latest Prime Clerk claims register and prepare updates to the AlixPartners claims database accordingly.	2.4
08/18/2021	JM	Review background documents to plan for claims review/distribution activities.	0.4
08/20/2021	JM	Review background documents and work planning for claims review/distribution activities.	0.4
08/24/2021	SKL	Meeting with J. Muskovich (AlixPartners) to discuss claim analysis and next steps.	0.7
09/09/2021	JM	Review plan documents and claims register status for claims recon planning.	0.8
09/16/2021	JM	Meeting with S. Lemack, J. Musckovich, J. DelConte (all AlixPartners) re: go-forward claims process and diligence update	0.5
09/16/2021	JD	Meeting with S. Lemack, J. Musckovich, J. DelConte (all AlixPartners) re: go-forward claims process and diligence update	0.5
09/16/2021	SKL	Meeting with S. Lemack, J. Musckovich, J. DelConte (all AlixPartners) re: go-forward claims process and diligence update	0.5
09/28/2021	JM	Meeting with S. Lemack (AlixPartners) to discuss updates to the claims management process.	0.2
09/28/2021	SKL	Meeting with J. Muskovich (AlixPartners) to discuss updates to the claims management process.	0.2
09/30/2021	JM	Telephone call with E. Marsh and J. Muskovich (both AlixPartners) re: project overview and claims reconciliation	0.9
<b>Total Professional Hours</b>			<b>12.7</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Claims Process  
Code: 1.9 / 109

<b>PROFESSIONAL</b>	<b>TITLE</b>	<b>RATE</b>	<b>HOURS</b>	<b>FEES</b>
Jesse DelConte	Managing Director	\$1,055	0.8	844.00
Jason Muskovich	Director	\$980	4.7	4,606.00
Sam K Lemack	Senior Vice President	\$665	7.2	4,788.00
<b>Total Professional Hours and Fees</b>			<b>12.7</b>	<b>\$ 10,238.00</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/01/2021	JH	Correspondence with M. Grier (Milbank) re: Sackler data staging.	0.7
06/01/2021	JH	Correspondence with C. Oluwole (Davis Polk) re: reserve data report.	0.3
06/01/2021	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.1
06/01/2021	JH	Correspondence with K. Chau (Davis Polk) re: updates to reserve.	0.1
06/02/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	1.5
06/02/2021	JCH	Continue to update reserve data sets at request of C. Oluwole (Davis Polk).	2.5
06/02/2021	JH	Correspondence with M. Grier (Milbank) re: Sackler data staging.	0.3
06/02/2021	JH	Correspondence with A. Guo (Davis Polk) re: new user credentials.	0.4
06/02/2021	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.7
06/03/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	1.8
06/03/2021	JH	Correspondence with A. Alfano (Pillsbury Winthrop) re: user access.	0.2
06/03/2021	JH	Correspondence with M. Grier (Milbank) re: Sackler data staging.	0.1
06/03/2021	JH	Correspondence with A. Guo (Davis Polk) re: new user credentials.	0.3
06/04/2021	JCH	Correspondence with A. Skorostensky (Goodwin) re: reserve access.	0.2
06/04/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.5
06/04/2021	JH	Correspondence with C. Stanley (JHANY) re: user access.	0.2
06/04/2021	JH	Correspondence with C. Oluwole (Davis Polk) re: new user credentials.	0.4
06/04/2021	JH	Correspondence with C. Oluwole (Davis Polk) re: user access.	0.3
06/04/2021	JH	Correspondence with M. Grier (Milbank) re: Sackler data staging.	0.3
06/04/2021	JH	Correspondence with A. Guo (Davis Polk) re: user access.	0.3
06/04/2021	JH	Update data sets in reserve at request of M. Grier (Milbank).	0.9
06/05/2021	JH	Correspondence with A. Guo (Davis Polk) re: user access.	0.1
06/07/2021	JCH	Correspondence with J. Ryan (Potter) re: reserve access.	0.2
06/07/2021	JH	Correspondence with A. Guo (Davis Polk) re: user access.	0.4
06/07/2021	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	1.3
06/08/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.4
06/08/2021	JH	Correspondence with A. Guo (Davis Polk) re: user access.	0.2
06/09/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.7
06/09/2021	JG	Update reserve data sets in preparation of launch at request of C. Oluwole (Davis Polk).	1.1
06/09/2021	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.4
06/10/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.8
06/10/2021	JG	Update reserve data sets in preparation of launch at request of C. Oluwole (Davis Polk).	2.4
06/10/2021	JH	Correspondence with A. Skorostensky (Goodwin) re: downloading data.	0.3
06/10/2021	JH	Correspondence with C. Oluwole (Davis Polk) re: reporting request from Plaintiff.	0.3
06/11/2021	JH	Correspondence with A. Skorostensky (Goodwin) re: volume downloading.	0.2
06/11/2021	JH	Correspondence with A. Guo (Davis Polk) re: user access.	0.2
06/14/2021	JH	Correspondence with M. Grier (Milbank) re: new data for reserve.	0.2
06/14/2021	JH	Correspondence with C. Oluwole (Davis Polk) re: reporting request from Plaintiff.	0.7
06/14/2021	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.9



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/14/2021	JG	Update reserve data sets in preparation of launch at request of C. Oluwole (Davis Polk).	1.1
06/14/2021	JH	Correspondence with C. Oluwole (Davis Polk) re: new data for reserve.	0.3
06/15/2021	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.1
06/15/2021	JH	Review files in report noted by A. Guo (Davis Polk) to identify if they are hosted on the reserve.	0.8
06/15/2021	JH	Correspondence with M. Grier (Milbank) re: Sackler data staging.	0.2
06/15/2021	JG	Update reserve data sets in preparation of launch at request of C. Oluwole (Davis Polk).	1.7
06/16/2021	JH	Correspondence with M. Grier (Milbank) re: new data for reserve.	0.2
06/16/2021	JG	Update reserve data sets in preparation of launch at request of C. Oluwole (Davis Polk).	1.7
06/17/2021	JH	Correspondence with P. Thurmond (City of Philadelphia) re: user access.	0.2
06/18/2021	JH	Correspondence with M. Grier (Milbank) re: new data for reserve.	0.9
06/21/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	1.4
06/21/2021	JH	Correspondence with all reserve users re: notification of new data.	0.3
06/21/2021	JH	Correspondence with S. Maliarov (WLRK) re: user access.	0.1
06/21/2021	JH	Correspondence with S. Dasaro (Goodwin) re: user access.	0.1
06/21/2021	JH	Correspondence with K. Giampaolo (Milbank) re: new data for reserve.	0.4
06/21/2021	JG	Update reserve data sets in preparation of launch at request of C. Oluwole (Davis Polk).	0.9
06/22/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.8
06/22/2021	JH	Correspondence with M. Grier (Milbank) re: new data for reserve.	0.5
06/22/2021	JH	Correspondence with S. Maliarov (WLRK) re: reserve reporting.	0.2
06/22/2021	JH	Correspondence with D. Levine (DOJ) re: user access.	0.1
06/22/2021	JH	Correspondence with A. Guo (Davis Polk) re: content of reserve..	0.4
06/22/2021	JH	Correspondence with A. Guo (Davis Polk) re: user access.	0.3
06/22/2021	JH	Review reporting on content of reserve for communication with A. Guo (Davis Polk).	0.8
06/23/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.1
06/23/2021	JH	Correspondence with E. Vieyra (Reed Smith) re: reserve foldering.	0.6
06/23/2021	JH	Correspondence with A. DePalma (AlixPartners) and C. Oluwole (Davis Polk) re: materials for Examiner.	1.0
06/23/2021	JH	Correspondence with C. Oluwole and A. Guo (both Davis Polk) re: new user request.	0.1
06/23/2021	JH	Correspondence with S. Stefanik (Davis Polk) re: potential data for the reserve.	0.1
06/23/2021	JH	Follow-up correspondence with A. DePalma (AlixPartners) and C. Oluwole (Davis Polk) re: materials for Examiner.	0.6
06/23/2021	JG	Update reserve data sets in preparation of launch at request of C. Oluwole (Davis Polk).	1.9
06/23/2021	JH	Review reporting on diligence productions for communication with C. Oluwole (Davis Polk).	1.6
06/24/2021	JH	Correspondence with K. Johnson (Gilbert Legal) re: reserve access.	0.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/24/2021	JH	Correspondence with A. DePalma (AlixPartners), G. Cardillo and C. Oluwole (both Davis Polk) re: materials for Examiner.	0.5
06/24/2021	JH	Correspondence with A. Guo (Davis Polk) re: access for reserve.	0.3
06/24/2021	JH	Correspondence with J. Gutierrez (AlixPartners) and D. Riley (KLD) re: new data for reserve.	0.2
06/24/2021	JH	Correspondence with S. Stefanik (Davis Polk) re: potential data for the reserve.	0.3
06/24/2021	JH	Correspondence with C. Stezar (KLD) re: new data for reserve.	0.4
06/24/2021	JH	Correspondence with M. Grier (Milbank) re: new data for reserve.	0.3
06/24/2021	ADD	Review and classify spend for cost review analysis	2.6
06/24/2021	JG	Update reserve data sets in preparation of launch at request of C. Oluwole (Davis Polk).	3.2
06/25/2021	JH	Correspondence with J. Richards (Akin Gump) re: notifications.	0.1
06/25/2021	JH	Correspondence with C. Oluwole (Davis Polk) re: new diligence productions for reserve.	0.6
06/25/2021	JH	Correspondence with C. Oluwole (Davis Polk) re: new data for reserve.	0.6
06/25/2021	JH	Correspondence with D. Riley (KLD) re: new data for reserve.	0.2
06/25/2021	JH	Correspondence with B. Bias, and S. Stefanik (both Davis Polk) re: new data for reserve.	0.4
06/25/2021	JH	Correspondence with G. Cabrera (Milbank) re: new data for reserve.	0.7
06/25/2021	JH	Correspondence with C. Stezar (KLD) re: new data for reserve.	0.1
06/25/2021	JH	Correspondence with A. Guo (Davis Polk) re: access for reserve.	0.9
06/25/2021	JH	Correspondence with M. Grier (Milbank) re: new data for reserve.	0.7
06/25/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	2.5
06/25/2021	ADD	Compile financial and accounting data in preparation for cost assessment project.	2.9
06/26/2021	JH	Correspondence with K. Porter (Akin) re: reserve passwords.	0.2
06/28/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	1.6
06/28/2021	ADD	Review and classify vendor spend categories for cost assessment analysis.	2.9
06/28/2021	ADD	Download and clean invoice level A/P data for vendor spend analysis.	2.5
06/28/2021	KM	Call with J. Hyun and C. Nweke (AlixPartners) re: morning meeting.	0.5
06/28/2021	JHH	Call with K. McCafferty and C. Nweke (both AlixPartners) re: morning meeting.	0.5
06/28/2021	JHH	Overall project objective and scope review.	1.8
06/28/2021	JHH	Call with A. DePalma (AlixPartners) re: vendor review status.	0.3
06/28/2021	JHH	Data requirements re: manufacturing assessment.	1.2
06/28/2021	JHH	Data requirements re: third party spend.	1.3
06/28/2021	JHH	Data requirements re: other workstreams including CPP, R&D and IT.	0.7
06/28/2021	JHH	Review existing files re: Rhodes Pharma, Avrio and Adhensia businesses.	1.9
06/28/2021	JHH	Headcount and span of control preliminary assessment review.	1.4
06/28/2021	JH	Correspondence with J. Wagner (Kramer) re: user access.	0.2
06/28/2021	JH	Correspondence with S. Schinfeld (Kramer) re: reserve access.	0.3
06/28/2021	JH	Correspondence with H. Blain (Kramer) re: user access.	0.2
06/28/2021	JH	Correspondence with R. Goot (Kramer) re: reserve access.	0.1
06/28/2021	JH	Correspondence with K. Fell (Milbank) re: user access.	0.4





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/28/2021	JH	Correspondence with G. Cabrera (Milbank) re: new data for reserve.	0.1
06/28/2021	CCN	Call with K. McCafferty, and J. Hyun (AlixPartners) re: morning meeting.	0.5
06/28/2021	CCN	Project scope review re: CPP, IT, R&D workstreams	1.2
06/28/2021	CCN	Data requirements and review re: CPP.	1.8
06/28/2021	CCN	Data requirements and review re: IT.	1.1
06/28/2021	CCN	Data requirements and review re: IT.	1.3
06/28/2021	CCN	Review of existing files re: Avrio.	1.9
06/28/2021	CCN	Review existing files re: Adhansia.	1.3
06/28/2021	ADD	Call with J. Hyun (AlixPartners) to discuss vendor review status.	0.3
06/29/2021	ADD	Identify previously produced document and consolidate previously produced for examiner review.	2.5
06/29/2021	ADD	Download and clean invoice level A/P data for vendor spend analysis.	2.3
06/29/2021	KM	Call with J. Hyun and C. Nweke (AlixPartners) re: cost assessment planning meeting.	1.9
06/29/2021	KM	Data collection and analysis re: organization structure.	1.8
06/29/2021	KM	Analyze organization compensation.	1.4
06/29/2021	KM	Visualization analysis re: organization structure	1.9
06/29/2021	KM	Analyze third party spend.	1.4
06/29/2021	KM	Project planning and management re: cost assessment.	0.8
06/29/2021	JHH	Call with K. McCafferty, and C. Nweke (AlixPartners) re: cost assessment planning meeting.	1.9
06/29/2021	JHH	Employee Roster file review.	1.7
06/29/2021	JHH	Gross to net sales walk including cash discounts and rebates.	1.8
06/29/2021	JHH	Spend cube structure design and identification of elements required.	1.9
06/29/2021	JHH	Review Betadine Consumer Business Update from J. Lowne (Purdue).	1.7
06/29/2021	JH	Correspondence with J. Wagner (Kramer) re: user access.	0.4
06/29/2021	JH	Correspondence with G. Cabrera (Milbank) re: new data for reserve.	0.2
06/29/2021	JH	Correspondence with K. Chau (Davis Polk) re: diligence productions.	0.2
06/29/2021	JH	Correspondence with A. Guo (Davis Polk) re: new users.	0.1
06/29/2021	JH	Correspondence with A. Guo (Davis Polk) re: content of reserve.	0.2
06/29/2021	JH	Correspondence with C. Oluwole (Davis Polk) and C. Stezar (KLD) re: new data for reserve.	0.1
06/29/2021	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.2
06/29/2021	CCN	Call with K. McCafferty and J. Hyun (AlixPartners) re: cost assessment planning meeting.	1.9
06/29/2021	CCN	Data review re: Employee Roster, roles, and compensation.	1.9
06/29/2021	CCN	Analyze Employee Roster, roles, and compensation.	1.4
06/29/2021	CCN	Data review re: Employee Roster, roles, and compensation.	1.9
06/29/2021	CCN	Analysis and graph creation re: Avrio CPP.	1.7
06/30/2021	JG	Update reserve data sets in preparation of launch at request of C. Oluwole (Davis Polk).	1.7
06/30/2021	ADD	Download and clean invoice level A/P data for vendor spend analysis.	2.1
06/30/2021	ADD	Update outstanding state license applications and incorporate comments from Purdue legal team.	2.8



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/30/2021	KM	Call with J. Lowne, M. Kesselman, C. Landau, B. Weingarten (all Purdue), J. DelConte, K. McCafferty (both AlixPartners) re: cost assessment.	0.6
06/30/2021	KM	Prepare meeting materials re: cost study kickoff.	1.1
06/30/2021	KM	Call with J. Hyun and C. Nweke (AlixPartners) re: cost assessment planning meeting.	1.4
06/30/2021	KM	Analyze organization structure.	1.6
06/30/2021	KM	Analyze spans and layers.	1.7
06/30/2021	KM	Analysis and reporting re: CPP for Avrio.	1.9
06/30/2021	KM	Analyze manufacturing labor.	1.5
06/30/2021	JHH	Call with K. McCafferty and C. Nweke (AlixPartners) re: cost assessment planning meeting.	1.4
06/30/2021	JHH	Call with A. DePalma and J. Hyun (AlixPartners) re: vendor review status.	0.6
06/30/2021	JHH	Preliminary Avrio CPP analysis review.	1.2
06/30/2021	JHH	Wilson plant headcount department categorization.	1.6
06/30/2021	JHH	Wilson plant headcount assessment between direct and indirect.	1.8
06/30/2021	JHH	Wilson plant headcount assessment by function.	1.7
06/30/2021	JHH	Preliminary hypotheses development re: Wilson plant organization.	0.8
06/30/2021	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.4
06/30/2021	JH	Correspondence with all reserve users re: new data notification.	0.2
06/30/2021	JH	Correspondence with C. Oluwole (Davis Polk) re: questions from K. Benedict (Davis Polk).	0.5
06/30/2021	JH	Correspondence with K. Chau (Davis Polk) re: diligence productions.	0.2
06/30/2021	JH	Correspondence with C. Oluwole (Davis Polk) re: weekly diligence supplemental productions.	0.7
06/30/2021	CCN	Call with K. McCafferty and J. Hyun (AlixPartners) re: cost assessment planning meeting.	1.4
06/30/2021	CCN	Analyze data re: Customer/Brand profitability.	1.2
06/30/2021	CCN	Data review and data cleaning re: Avrio P&L.	1.9
06/30/2021	CCN	Data review and analysis re: Avrio, Ahansia.	1.8
06/30/2021	CCN	Preliminary hypotheses development re: IT, R&D, CPP workstreams.	1.8
06/30/2021	ADD	Call with A. DePalma and J. Hyun (AlixPartners) to discuss vendor review status.	0.6
06/30/2021	ADD	Call with J. Hoon, K. McCafferty and C. Nweke (AlixPartners) re: morning meeting.	1.4
06/30/2021	JH	Create supplemental diligence productions for reserve at request of C. Oluwole (Davis Polk).	2.3
07/01/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.4
07/01/2021	JHH	Call with K. McCafferty, A. DePalma, J. Hyun and C. Nweke (all AlixPartners) re: morning meeting to review project deliverables and activities.	1.1
07/01/2021	JHH	Review company diligence materials	2.1
07/01/2021	JHH	Wilson manufacturing operations overview.	1.7
07/01/2021	JHH	Review of existing diligence files re: diligence project.	1.3
07/01/2021	JHH	Review Purdue diligence materials.	0.6
07/01/2021	JHH	Weekly flash report update re: manufacturing and third-party spend.	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/01/2021	JHH	Preparation for first weekly stand-up meeting with J. Lowne (Purdue).	1.9
07/01/2021	JG	Update reserve data sets in preparation of launch at request of C. Oluwole (Davis Polk).	2.7
07/01/2021	CCN	Call with K. McCafferty, A. DePalma, J. Hyun and C. Nweke (all AlixPartners) re: morning meeting to review project deliverables and activities.	1.1
07/01/2021	CCN	Call with K. McCafferty (AlixPartners) re: CPP data and analysis.	0.8
07/01/2021	CCN	Call with K. McCafferty (AlixPartners) re: CPP data review.	0.2
07/01/2021	CCN	Call with A. DePalma (AlixPartners) re: profitability data requests.	0.2
07/01/2021	CCN	Review company detail files and prepare summary analysis.	1.9
07/01/2021	CCN	Develop customer product profitability analysis hypothesis.	1.8
07/01/2021	CCN	Review cost and revenue details on Avrio.	1.7
07/01/2021	CCN	Review cost and revenue details on Adhansia.	1.4
07/01/2021	JH	Correspondence with J. Hamilton, J. Hardy (both AlixPartners) and J. Wagner (Kramer) re: downloading issues.	0.2
07/01/2021	JH	Correspondence with J. Hamilton (AlixPartners) and C. Oluwole (Davis Polk) re reserve reporting.	0.2
07/01/2021	KM	Call with K. McCafferty, A. DePalma, J. Hyun and C. Nweke (all AlixPartners) re: morning meeting to review project deliverables and activities.	1.1
07/01/2021	KM	Analyze company overview for report.	1.0
07/01/2021	KM	Analyze comparable companies for diligence project.	2.0
07/01/2021	KM	Analyze Rhodes product profitability for diligence project.	0.9
07/01/2021	KM	Analyze development pipeline for diligence project.	0.8
07/01/2021	ADD	Call with K. McCafferty, A. DePalma, J. Hyun and C. Nweke (all AlixPartners) re: morning meeting to review project deliverables and activities.	1.1
07/01/2021	ADD	Compile and clean vendor spend data.	2.7
07/01/2021	ADD	Call with C. Nweke (AlixPartners) re: profitability data requests.	0.2
07/01/2021	KM	Call with C. Nweke (AlixPartners) re: CPP data and analysis.	0.8
07/01/2021	KM	Call with C. Nweke (AlixPartners) re: CPP data review.	0.2
07/02/2021	JHH	Meeting with J. Lowne (Purdue), J. Hyun, C. Nweke, A. DePalma, J. DelConte, K. McCafferty (AlixPartners) re: weekly stand-up meeting.	0.5
07/02/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.2
07/02/2021	CCN	Meeting with J. Lowne (Purdue), C. Nweke, A. DePalma, J. DelConte, K. McCafferty (AlixPartners) re: weekly stand-up meeting.	0.5
07/02/2021	CCN	Call with K. McCafferty (AlixPartners) re: Avrio margin analysis.	0.2
07/02/2021	CCN	Being preparing the initial Tableau CPP Analysis.	1.7
07/02/2021	CCN	Review and analyze various cost files uploaded into the dataroom.	1.8
07/02/2021	CCN	Begin preparation of R&D and IT Data overview.	0.3
07/02/2021	JH	Correspondence with J. Hamilton (AlixPartners) and A. Guo (Davis Polk) re: user access.	0.8
07/02/2021	JH	Correspondence with J. Hamilton (AlixPartners), P. Astras (KLD), and C. Oluwole (Davis Polk) re: new data for reserve.	0.2
07/02/2021	JH	Correspondence with J. Hamilton (AlixPartners) and R. Atkinson (Cobra) re: reserve access.	0.1



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/02/2021	JH	Correspondence with J. Hamilton and D. Reynolds (both AlixPartners) re new media shipment from TCDI.	0.1
07/02/2021	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.5
07/02/2021	JH	Correspondence with J. Hamilton (AlixPartners), K. Chau and C. Oluwole (both Davis Polk) re: new diligence productions.	0.2
07/02/2021	KM	Call with C. Nweke (AlixPartners) re: Avrio margin analysis.	0.2
07/02/2021	KM	Meeting with J. Lowne (Purdue), C. Nweke, A. DePalma, J. DelConte, K. McCafferty (AlixPartners) re: weekly stand-up meeting.	0.5
07/02/2021	KM	Analysis and reporting re: company overview.	2.1
07/02/2021	ADD	Meeting with J. Lowne (Purdue), C. Nweke, A. DePalma, J. DelConte, K. McCafferty (AlixPartners) re: weekly stand-up meeting.	0.5
07/02/2021	ADD	Compile and clean vendor spend data.	2.7
07/02/2021	ADD	Review materials for diligence project.	1.7
07/06/2021	JH	Correspondence with J. Hamilton (AlixPartners), and M. Puiggari (Law Offices of Paul Rothstein) re reserve access.	0.5
07/06/2021	JH	Correspondence with J. Hamilton (AlixPartners), and J. Kleinman (FGLLP) re password reset.	0.2
07/06/2021	JH	Correspondence with J. Hamilton (AlixPartners) and A. Guo (Davis Polk) re new user access.	0.3
07/06/2021	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.0
07/06/2021	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: preliminary review of IT and CPP analysis.	0.8
07/06/2021	KM	Analyze company details for diligence project.	2.2
07/06/2021	KM	Analyze company comparables for diligence project.	1.5
07/06/2021	KM	Analyze customer profitability for diligence project.	1.4
07/06/2021	KM	Analyze third party spend for diligence project.	1.9
07/06/2021	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.0
07/06/2021	JHH	Spend file review (based on Accounts Payables data from Jan. 2019 to June 2021).	1.7
07/06/2021	JHH	Data cleansing of Accounts Payables file, including simplification and standardization of key fields.	1.7
07/06/2021	JHH	Existing inventory file review, snapshot in December 2020.	1.6
07/06/2021	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.0
07/06/2021	ADD	Review and categorize vendors for spend analysis.	2.4
07/06/2021	ADD	Analyze invoice level A/P data to identify vendor spend trends.	2.8
07/06/2021	ADD	Compile and clean vendor spend data.	2.1
07/06/2021	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.0
07/06/2021	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: preliminary review of IT and CPP analysis.	0.8
07/06/2021	CCN	Analyze Avrio profitability by customer	1.9



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/06/2021	CCN	Analyze research and development project spending.	1.8
07/06/2021	CCN	Analyze research and development project net present values.	1.9
07/06/2021	CCN	Review detailed Avrio spend and revenue files.	1.7
07/07/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.4
07/07/2021	KM	Analyze expenses breakdown for diligence project.	1.9
07/07/2021	KM	Analyze company details for summary diligence.	2.1
07/07/2021	KM	Call with Neal Davis (Purdue), K. McCafferty and C. Nweke (both AlixPartners) re: Rhodes product pipeline tracking.	0.8
07/07/2021	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.7
07/07/2021	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: R&D analysis for diligence project.	0.8
07/07/2021	KM	Analyze product profitability for diligence project.	1.9
07/07/2021	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.7
07/07/2021	JHH	Call with J. Hyun, A. DePalma (both AlixPartners) re: Purdue spend analysis.	0.7
07/07/2021	JHH	Data cleansing of Accounts Payables file, including simplification and standardization of key fields.	1.9
07/07/2021	JHH	Preliminary analysis of vendor spend, summary by company code and spend type.	1.8
07/07/2021	JHH	Prepare diligence questions re: vendor spend data.	0.7
07/07/2021	JHH	Cross-referencing of third party spend with company departments.	1.7
07/07/2021	ADD	Call with J. Hyun, A. DePalma (both AlixPartners) re: Purdue spend analysis.	0.7
07/07/2021	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.7
07/07/2021	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.7
07/07/2021	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: R&D analysis for diligence project.	0.8
07/07/2021	CCN	Call with Neal Davis (Purdue), K. McCafferty and C. Nweke (both AlixPartners) re: Rhodes product pipeline tracking.	0.8
07/07/2021	CCN	Develop consolidated research and development analysis.	1.9
07/07/2021	CCN	Work on brand allocations for the customer product profitability analysis for Avrio.	1.8
07/07/2021	CCN	Analysis of Rhodes research and development projects and underlying timelines.	1.7
07/07/2021	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.4
07/07/2021	JH	Correspondence with J. Hamilton (AlixPartners) and J. Chen (Davis Polk) re content of reserve.	0.4
07/08/2021	KM	Call with Ron Haberlin (Purdue), and K. McCafferty and C. Nweke (AlixPartners) re: Rhodes financial diligence data request.	0.5
07/08/2021	KM	Meeting with H. Ghnaimeh and E. Liesmann (Purdue), and K. McCafferty, C. Nweke and A. DePalma (all AlixPartners) re: re: IT diligence interview and data request.	1.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/08/2021	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.9
07/08/2021	KM	Document creation re: weekly diligence project stand-up meeting with J. Lowne.	0.8
07/08/2021	KM	Meeting with C. Nweke (AlixPartners) re: Avrio CPP preliminary findings.	1.0
07/08/2021	KM	Presentation and reporting re: company overview for diligence project.	2.3
07/08/2021	KM	Presentation and reporting re: product profitability for diligence project.	1.1
07/08/2021	KM	Analyze manufacturing operations for diligence project.	1.8
07/08/2021	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.9
07/08/2021	JHH	Call with Jon Carlisle (Purdue) re: Wilson inventory data request.	0.6
07/08/2021	JHH	Meeting with S. Daniel (Purdue), A. DePalma and J. Hyun (AlixPartners) re: Purdue vendor review and categorization.	1.2
07/08/2021	JHH	Review of new third party spend data.	1.9
07/08/2021	JHH	Mapping of key fields: cost centers, company codes.	1.8
07/08/2021	JHH	Consolidation and simplification of key fields for the diligence report.	1.2
07/08/2021	ADD	Meeting with S. Daniel (Purdue), A. DePalma and J. Hyun (AlixPartners) re: Purdue vendor review and categorization.	1.2
07/08/2021	ADD	Meeting with H. Ghnaimh and E. Liesmann (Purdue), and K. McCafferty, C. Nweke and A. DePalma (AlixPartners) re: re: IT diligence interview and data request.	1.7
07/08/2021	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.9
07/08/2021	ADD	Download G&A account data including vendor mapping.	1.8
07/08/2021	ADD	Compile and analyze updated G&A data.	2.3
07/08/2021	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.9
07/08/2021	CCN	Call with Ron Haberlin (Purdue), and K. McCafferty and C. Nweke (AlixPartners) re: Rhodes financial diligence data request.	0.5
07/08/2021	CCN	Meeting with H. Ghnaimh and E. Liesmann (Purdue), and K. McCafferty, C. Nweke and A. DePalma (AlixPartners) re: re: IT diligence interview and data request.	1.7
07/08/2021	CCN	Meeting with K. McCafferty (AlixPartners) re: Avrio CPP preliminary findings.	1.0
07/08/2021	CCN	Analyze customer profitability by form of product for diligence project.	1.9
07/08/2021	CCN	Analyze product profitability by customer for diligence report.	1.8
07/08/2021	JH	Correspondence with J. Hamilton (AlixPartners) and A. Guo (Davis Polk) re new user access.	0.2
07/09/2021	KM	Slide preparation re: diligence project stand-up meeting with J. Lowne.	0.7
07/09/2021	KM	Meeting with J. Lowne (Purdue); J. DelConte, K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	0.8
07/09/2021	KM	Meeting with T. Au (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: R&D expenses analysis for diligence project.	0.4



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/09/2021	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.1
07/09/2021	KM	Meeting with J. Tran (Purdue); K. McCafferty, A. DePalma and C. Nweke (AlixPartners) re: Avrio customer and product profitability data request.	0.5
07/09/2021	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: customer and product profitability analysis.	0.8
07/09/2021	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: Avrio CPP data review for diligence project.	0.2
07/09/2021	KM	Presentation and reporting re: product profitability for diligence project.	1.2
07/09/2021	KM	Analyze third party spend categorization for diligence project.	1.9
07/09/2021	JHH	Meeting with J. Lowne (Purdue); J.DelConte, K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	0.8
07/09/2021	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.1
07/09/2021	JHH	Call with J. Hyun, A. DePalma (both AlixPartners) re: Purdue analysis status.	0.1
07/09/2021	JHH	Review of new vendor activity data.	1.5
07/09/2021	JHH	Standardization of company codes in vendor activity data.	1.4
07/09/2021	JHH	Preliminary summary of vendor activity by businesses: Purdue, Rhodes, Avrio, etc.	1.5
07/09/2021	JHH	Standardization of elements by cross reference original Accounts Payable file.	1.9
07/09/2021	ADD	Meeting with J. Lowne (Purdue); J.DelConte, K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	0.8
07/09/2021	ADD	Call with J. Hyun, A. DePalma (both AlixPartners) re: Purdue analysis status.	0.1
07/09/2021	ADD	Meeting with J. Tran (Purdue); K. McCafferty, A. DePalma and C. Nweke (AlixPartners) re: Avrio customer and product profitability data request.	0.5
07/09/2021	ADD	Reconcile data from SAP accounting system and files provided by the client.	2.0
07/09/2021	ADD	Review and categorize vendors for analysis.	1.6
07/09/2021	ADD	Analyze invoice level A/P data to identify vendor trends.	1.3
07/09/2021	CCN	Meeting with J. Lowne (Purdue); J.DelConte, K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	0.8
07/09/2021	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.1
07/09/2021	CCN	Meeting with T. Au (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: R&D analysiss for diligence project.	0.4
07/09/2021	CCN	Meeting with J. Tran (Purdue); K. McCafferty, A. DePalma and C. Nweke (AlixPartners) re: Avrio customer and product profitability data request.	0.5
07/09/2021	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: customer and product profitability analysis.	0.8
07/09/2021	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: Avrio CPP data review for diligence project.	0.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/09/2021	CCN	Call with C. Nweke and A. DePalma (AlixPartners) re: profitability data requests.	0.2
07/09/2021	CCN	Analyze Avrio CPP.	1.9
07/09/2021	CCN	Analysis and hypothesis generation re: CPP for Avrio.	1.8
07/09/2021	CCN	Review diligence data re: Avrio customers, sales and margins data.	1.7
07/09/2021	CCN	Diligence data review re: Adhansia revenue and spend files.	1.4
07/09/2021	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities	1.1
07/09/2021	ADD	Call with C. Nweke and A. DePalma (both AlixPartners) re: profitability data requests.	0.2
07/10/2021	JH	Correspondence with A. Guo (Davis Polk) re new user access.	0.3
07/11/2021	JH	Correspondence with A. Guo (Davis Polk) re content of reserve.	0.2
07/12/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	2.8
07/12/2021	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.3
07/12/2021	JHH	Vendor file: identification of bankruptcy related vendors.	1.6
07/12/2021	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to review and analyze vendor data.	0.8
07/12/2021	JHH	Review historical Wilson operational performance, e.g. OEE, production volume and financial absorption.	1.7
07/12/2021	JHH	Mapping cost centers to department roll-up hierarchy for spend summaries.	1.2
07/12/2021	JHH	Sales file consolidation of 2020 and 2021 monthly data for analysis preparation.	1.9
07/12/2021	JHH	Preparation of multiple client meetings on July 13, list of questions and final data requests.	0.6
07/12/2021	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.3
07/12/2021	KM	Analyze company information for diligence project.	2.3
07/12/2021	KM	Continue to review company diligence details.	1.4
07/12/2021	KM	Review comparable company details for diligence projection.	1.9
07/12/2021	KM	Analyze Avrio customer profitability and coop spend analysis.	1.8
07/12/2021	KM	Analyze R&D vendor spend for diligence project.	0.8
07/12/2021	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.3
07/12/2021	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: to review and analyze vendor data.	0.8
07/12/2021	ADD	Review and analyze vendor data.	2.4
07/12/2021	ADD	Compile cost center mapping file using data from client's SAP centers.	2.7
07/12/2021	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.3
07/12/2021	CCN	Analyze Avrio profitability by customer, brand - allocation.	1.9
07/12/2021	CCN	Analyze profitability analysis and graphs.	1.9
07/12/2021	CCN	Analyze Avrio brand analysis and comparison.	1.8





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/12/2021	CCN	Prepare analysis of the net present value of various research and development projects	1.7
07/12/2021	CCN	Analyze Rhodes R&D pipeline	1.6
07/12/2021	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.5
07/13/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.5
07/13/2021	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.0
07/13/2021	JHH	Meeting with W. Sielert (Purdue); J. Hyun and A. DePalma (AlixPartners) re: SAP A/P data.	0.6
07/13/2021	JHH	Meeting with R. Haberlin, D. Fogel, J. Carlisle, N. Davis, E. Flath (Purdue); K. McCafferty, C. Nweke, A. DePalma and J. Hyun (AlixPartners) re: due diligence game plan.	0.5
07/13/2021	JHH	Meeting with E. Liesman (Purdue); K. McCafferty, C. Nweke, A. DePalma and J. Hyun (AlixPartners) re: cost center mapping.	0.3
07/13/2021	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to provide status update on vendor analysis.	0.1
07/13/2021	JHH	2020FY and 2021 June YTD historical sales analysis by SKU and product grouping.	1.9
07/13/2021	JHH	Vendor analysis without bankruptcy / non-recurring costs: summary charts and key insights.	1.6
07/13/2021	JHH	Preliminary Purdue inventory analysis by units and dollars.	1.8
07/13/2021	JHH	Preparation of multiple client meetings on July 14, list of questions/clarifications and final data requests.	0.6
07/13/2021	KM	Meeting with R. Haberlin, D. Fogel, J. Carlisle, N. Davis, E. Flath (Purdue); K. McCafferty, C. Nweke, A. DePalma and J. Hyun (AlixPartners) re: due diligence game plan.	0.5
07/13/2021	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.0
07/13/2021	KM	Meeting with J. Lowne (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: diligence project.	1.2
07/13/2021	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: Avrio pricing by customer and SKU analysis.	1.0
07/13/2021	KM	Company analysis re: margin analysis for diligence project.	2.3
07/13/2021	KM	Reporting re: sales analysis for diligence project.	0.8
07/13/2021	KM	Analyze Medical Affairs vendors for diligence project.	0.7
07/13/2021	KM	Review manufacturing operations overview.	1.8
07/13/2021	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.0
07/13/2021	ADD	Meeting with W. Sielert (Purdue); J. Hyun and A. DePalma (AlixPartners) re: SAP A/P data.	0.6
07/13/2021	ADD	Meeting with R. Haberlin, D. Fogel, J. Carlisle, N. Davis, E. Flath (Purdue); K. McCafferty, C. Nweke, A. DePalma and J. Hyun (AlixPartners) re: due diligence game plan.	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/13/2021	ADD	Meeting with E. Liesman (Purdue); K. McCafferty, C. Nweke, A. DePalma and J. Hyun (AlixPartners) re: cost center mapping.	0.3
07/13/2021	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: status update on vendor analysis.	0.1
07/13/2021	ADD	Review and analyze vendor data.	2.8
07/13/2021	ADD	Compile cost center mapping file using data from client's SAP centers.	1.6
07/13/2021	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.0
07/13/2021	CCN	Meeting with R. Haberman, D. Fogel, J. Carlisle, N. Davis, E. Flath (Purdue); K. McCafferty, C. Nweke, A. DePalma and J. Hyun (AlixPartners) re: due diligence game plan.	0.5
07/13/2021	CCN	Meeting with E. Liesman (Purdue); K. McCafferty, C. Nweke, A. DePalma and J. Hyun (AlixPartners) re: cost center mapping.	0.3
07/13/2021	CCN	Meeting with J. Lowne (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: diligence project.	1.2
07/13/2021	CCN	Analyze overview of IT & R&D.	1.4
07/13/2021	CCN	Continue the review of customer profitability by form in the CPP analysis.	1.3
07/13/2021	CCN	Continued analysis of Rhodes research and development projects.	1.5
07/13/2021	CCN	Analyze medical expenses in various research and development projects.	1.6
07/13/2021	JH	Correspondence with B. Bias (Davis Polk) re potential new data for reserve.	0.2
07/13/2021	JH	Correspondence with A. Tsier (White & Case) re password link.	0.2
07/13/2021	JH	Correspondence with A. Guo (Davis Polk) re new user access.	0.2
07/13/2021	JH	Correspondence with S. Tonnesen (OAG) re new user link.	0.5
07/13/2021	JH	Correspondence with K. Arendsen (SPB) re searching reserve.	0.2
07/13/2021	JH	Correspondence with A. Guo, and C. Oluwole (both Davis Polk) re re: reserve structure and notification.	0.3
07/13/2021	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: Avrio pricing by customer and SKU analysis.	1.0
07/13/2021	KM	Meeting with E. Liesman (Purdue); K. McCafferty, C. Nweke, A. DePalma and J. Hyun (AlixPartners) re: cost center mapping.	0.3
07/14/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	1.8
07/14/2021	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.9
07/14/2021	JHH	Meeting with J. Carlisle (Purdue); K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: Wilson production plan and COGS vendors.	1.3
07/14/2021	JHH	Meeting with R. Brown (Purdue); A. DePalma and J. Hyun (AlixPartners) re: bankruptcy costs (non-recurring).	0.3
07/14/2021	JHH	Meeting with D. McGuire, J. Carlisle (Purdue); K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: Wilson operations.	0.9
07/14/2021	JHH	Meeting with D. McGuire (Purdue); K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: manufacturing overview.	1.0
07/14/2021	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to provide status update on vendor analysis.	0.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/14/2021	JHH	Vendor summaries by all major categories without bankruptcy/non-recurring costs.	1.8
07/14/2021	JHH	Mapping of company codes, cost centers and cost elements.	1.1
07/14/2021	JHH	Manufacturing review: conversion cost reductions driven by plant consolidation.	1.7
07/14/2021	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.9
07/14/2021	KM	Meeting with J. Carlisle (Purdue); K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: Wilson production plan and COGS vendors.	1.3
07/14/2021	KM	Meeting with J. Lowne (Purdue); J. DelConte, K. McCafferty and C. Nweke (AlixPartners) re: diligence project.	1.0
07/14/2021	KM	Meeting with D. McGuire, J. Carlisle (Purdue); K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: Wilson operations.	0.9
07/14/2021	KM	Meeting with D. McGuire (Purdue); K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: manufacturing overview.	1.0
07/14/2021	KM	Analyze Wilson OEE and asset productivity.	1.9
07/14/2021	KM	Analyze Inventory levels and gap analysis.	2.0
07/14/2021	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.9
07/14/2021	ADD	Meeting with J. Carlisle (Purdue); K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: Wilson production plan and COGS vendors.	1.3
07/14/2021	ADD	Meeting with R. Brown (Purdue); A. DePalma and J. Hyun (AlixPartners) re: bankruptcy costs (non-recurring).	0.3
07/14/2021	ADD	Meeting with D. McGuire, J. Carlisle (Purdue); K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: Wilson operations.	0.9
07/14/2021	ADD	Meeting with D. McGuire (Purdue); K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: manufacturing overview.	1.0
07/14/2021	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: status update on vendor analysis.	0.2
07/14/2021	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.9
07/14/2021	CCN	Meeting with J. Lowne (Purdue); J. DelConte, K. McCafferty and C. Nweke (AlixPartners) re: diligence project.	1.0
07/14/2021	CCN	Review and analyze Rhodes pipeline timelines and spend.	1.9
07/14/2021	CCN	Continue analysis of product profitability by customer for Rhodes.	1.5
07/14/2021	CCN	Analyze product profitability by customer for Rhodes.	1.8
07/14/2021	CCN	Analyze Rhodes research and development net present value analyses by project.	1.7
07/14/2021	JH	Correspondence with L. Kelleher (OAD MD) re access.	0.3
07/14/2021	JH	Correspondence with A. DePalma (AlixPartners) re new productions for reserve.	0.2
07/14/2021	JH	Correspondence with P. Astras (KLD) re new data for reserve.	0.2
07/14/2021	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.7
07/15/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/15/2021	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.4
07/15/2021	JHH	Meeting with T. Au (Purdue); A. DePalma, C. Nweke and J. Hyun (AlixPartners) re: Opioid claims processing vendors.	0.4
07/15/2021	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to review inventory analysis.	0.4
07/15/2021	JHH	Monthly sales analysis by SKU and by sales units.	1.3
07/15/2021	JHH	Monthly sales analysis by SKU and by sales dollars, gross and net.	1.6
07/15/2021	JHH	Month to month sales trends and fluctuations for proper inventory considerations.	1.3
07/15/2021	JHH	Purdue inventory analysis: obsolescence risk and potential shortages by SKU.	1.9
07/15/2021	JHH	Preparation for weekly update discussion with client on July 16.	0.7
07/15/2021	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.4
07/15/2021	KM	Meeting with N. Davis (Purdue); K. McCafferty, and C. Nweke (both AlixPartners) re: Rhodes product pipeline valuation.	1.0
07/15/2021	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: Rhodes pipeline analysis and slides for weekly update.	1.9
07/15/2021	KM	Presentation and reporting re: manufacturing overview for diligence project.	2.3
07/15/2021	KM	Presentation and reporting re: product profitability for diligence project.	1.1
07/15/2021	KM	Analyze performance data for diligence project.	1.8
07/15/2021	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.4
07/15/2021	ADD	Meeting with T. Au (Purdue); A. DePalma, C. Nweke and J. Hyun (AlixPartners) re: Opioid claims processing vendors.	0.4
07/15/2021	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: to review inventory analysis.	0.4
07/15/2021	ADD	Compile and analyze company performance.	2.7
07/15/2021	JG	Update reserve data sets in preparation of launch at request of C. Oluwole (Davis Polk).	1.6
07/15/2021	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.4
07/15/2021	CCN	Meeting with T. Au (Purdue); A. DePalma, C. Nweke and J. Hyun (AlixPartners) re: Opioid claims processing vendors.	0.4
07/15/2021	CCN	Meeting with N. Davis (Purdue); K. McCafferty, and C. Nweke (both AlixPartners) re: Rhodes product pipeline valuation.	1.0
07/15/2021	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: Rhodes pipeline analysis and slides for weekly update.	1.9
07/15/2021	CCN	Avrio customer and product profitability data review for diligence project.	1.6
07/15/2021	CCN	Conduct IT diligence interviews and update analysis.	1.7
07/15/2021	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.2
07/15/2021	JH	Correspondence with L. Readinger (Potter Anderson) re updated reporting.	0.8
07/15/2021	JH	Correspondence with P. Astras (KLD) re new data for reserve.	0.1
07/15/2021	JH	Correspondence with M. O'Neil (Taft) re access.	0.2



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/16/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.5
07/16/2021	NPJ	Call with S. Vangavolu, N. Janysek, K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: third party spend opportunity.	1.0
07/16/2021	NPJ	Researching 3rd party spend suppliers.	0.5
07/16/2021	JHH	Meeting with J. Lowne (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	0.9
07/16/2021	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.5
07/16/2021	JHH	Call with S. Vangavolu, N. Janysek, K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: vendor review.	1.0
07/16/2021	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to review updated inventory analysis.	0.3
07/16/2021	JHH	Manufacturing overview summary.	1.8
07/16/2021	JHH	Process bottleneck (packaging line) overview with current shift patterns.	1.2
07/16/2021	JHH	Accounts payable data review by vendors and spend categories.	1.1
07/16/2021	JHH	Preliminary inventory savings potentials for Purdue managed finished goods.	1.9
07/16/2021	KM	Slide preparation re: diligence project stand-up meeting with J. Lowne.	0.8
07/16/2021	KM	Meeting with J. Lowne (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	0.9
07/16/2021	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.5
07/16/2021	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: Rhodes pipeline NPV analysis and slippage.	0.8
07/16/2021	KM	Call with S. Vangavolu, N. Janysek, K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: vendor analysis.	1.0
07/16/2021	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: pipeline NPV breakdown.	0.5
07/16/2021	KM	Report creation re: company overview.	1.7
07/16/2021	KM	Analyze Rhodes pipeline value and performance.	1.5
07/16/2021	ADD	Meeting with J. Lowne (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	0.9
07/16/2021	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.5
07/16/2021	ADD	Call with S. Vangavolu, N. Janysek, K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: vendor analysis.	1.0
07/16/2021	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: to review updated inventory analysis.	0.3
07/16/2021	JG	Update reserve data sets in preparation of launch at request of C. Oluwole (Davis Polk).	1.7
07/16/2021	CCN	Meeting with J. Lowne (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	0.9
07/16/2021	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/16/2021	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: Rhodes pipeline NPV analysis and slippage.	0.8
07/16/2021	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: pipeline NPV breakdown.	0.5
07/16/2021	CCN	Continue to work on customer and product profitability analysis by customer.	1.9
07/16/2021	CCN	Review change in NPVs due to slippage in research and development projects.	1.7
07/16/2021	CCN	Analyze Rhodes profitability by customer and product.	1.8
07/16/2021	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.4
07/19/2021	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.7
07/19/2021	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to review and analyze vendor data.	0.4
07/19/2021	JHH	Categories for vendor data analyses.	1.6
07/19/2021	JHH	Vendor data analyses and summary for client review and feedback.	1.9
07/19/2021	JHH	Comparison of Accounts Payable data to SAP download for 2020.	1.3
07/19/2021	JHH	Incorporation of departments derived from cost centers into spend cube and summaries.	0.9
07/19/2021	JHH	Update of vendor summaries to reflect latest spend cube.	1.8
07/19/2021	NPJ	Review suppliers for Purdue and estimated type of work performed for categorization and savings benchmarking.	3.2
07/19/2021	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.7
07/19/2021	KM	Meeting with J. Ducharme (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: R&D diligence discussion and opportunity review.	1.0
07/19/2021	KM	Analyze company overview for diligence project.	2.2
07/19/2021	KM	Analyze R&D and Medical Affairs vendors.	2.4
07/19/2021	KM	Analyze Rhodes Pharma product pipeline for diligence project.	1.8
07/19/2021	KM	Analyze vendor details for diligence project.	1.7
07/19/2021	KM	Prepare slides and visualization re: R&D and Medical overviews.	2.0
07/19/2021	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.7
07/19/2021	CCN	Meeting with J. Ducharme (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: R&D diligence discussion.	1.0
07/19/2021	CCN	Diligence data re: Avrio customers and brand, sales and margins data.	1.9
07/19/2021	CCN	Analyze Avrio profitability by customer /brand	1.8
07/19/2021	CCN	Avrio customer and product profitability analysis and slide creation.	1.8
07/19/2021	CCN	Analyze Avrio vendor data.	1.7
07/19/2021	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.7
07/19/2021	ADD	Review diligence project action items and compile necessary data.	0.8
07/19/2021	ADD	Review and analyze new vendor data and incorporate it into the model.	2.2
07/19/2021	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.4
07/20/2021	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/20/2021	JHH	Call with N. Janysek, J. Hyun and A. DePalma (AlixPartners) re: vendor overview by category.	0.7
07/20/2021	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to review and analyze vendor data.	0.5
07/20/2021	JHH	Summary of vendor data based on discussion with internal pharma procurement expert.	1.4
07/20/2021	JHH	Preparation for client reviews: key points, questions and clarifications.	0.6
07/20/2021	JHH	Review of operations data and monthly reports to provide comprehensive manufacturing overview.	1.9
07/20/2021	JHH	Review of Purdue Pharma inventory information by material type and SKU.	1.8
07/20/2021	JHH	Review of Rhodes Pharma inventory information by material type - SKU detail not yet provided.	1.6
07/20/2021	NPJ	Call with N. Janysek, J. Hyun and A. DePalma (AlixPartners) re: Purdue Third Party Spend potential savings estimates by category.	0.7
07/20/2021	NPJ	Review suppliers for Purdue and estimated type of work performed for categorization and savings benchmarking.	3.8
07/20/2021	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.3
07/20/2021	KM	Meeting with H. Ghnaimeh (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: IT overview and reporting responsibilities.	0.7
07/20/2021	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: Avrio CPP analysis for diligence.	0.8
07/20/2021	KM	Meeting with V. Mancinelli, D. Fogel (both Purdue); K. McCafferty and C. Nweke (both AlixPartners) re: Rhodes Pharma P&L and pipeline interview and discussion.	1.3
07/20/2021	KM	Review IT vendor details.	2.2
07/20/2021	KM	Analyze Avrio profitability by brand and customer.	1.5
07/20/2021	KM	Prepare slides and visualities re: IT overview.	0.8
07/20/2021	KM	Prepare slides and visualition re: Rhodes Pharma pipeline.	0.6
07/20/2021	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.3
07/20/2021	CCN	Meeting with H. Ghnaimeh (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: IT overview.	0.7
07/20/2021	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: Avrio CPP analysis for diligence.	0.8
07/20/2021	CCN	Meeting with V. Mancinelli, D. Fogel (both Purdue); K. McCafferty and C. Nweke (both AlixPartners) re: Rhodes Pharma P&L and pipeline interview and discussion.	1.3
07/20/2021	CCN	CPP analysis re: Avrio product profitability by customer.	1.9
07/20/2021	CCN	CPP analysis re: Rhodes product profitability by customer.	1.9
07/20/2021	CCN	CPP analysis re: Avrio customer profitability by form.	1.8
07/20/2021	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/20/2021	ADD	Call with N. Janysek, J. Hyun and A. DePalma (AlixPartners) re: vendor overview by category.	0.7
07/20/2021	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: to review and analyze vendor data.	0.5
07/20/2021	ADD	Review manufacturing operation overview.	2.7
07/20/2021	ADD	Review and update vendor analysis to reflect updated data.	2.4
07/21/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.9
07/21/2021	JCH	Correspondence with J. Hardy (AlixPartners) and T. O'Neill (WA Attorney General) re reserve access.	0.1
07/21/2021	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.9
07/21/2021	JHH	Meeting with J. Carlisle (Purdue); J. Hyun and A. DePalma (AlixPartners) re: vendor analysis to gather client feedback.	1.0
07/21/2021	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to review and analyze vendor data.	0.2
07/21/2021	JHH	Review manufacturing operations.	1.7
07/21/2021	JHH	Modifications to vendor analysis based on client feedback.	0.3
07/21/2021	JHH	Monthly sales / demand evaluation by SKU and product groups.	1.8
07/21/2021	JHH	Month on hand assessment of finished goods inventory at Purdue, including purchased items.	1.3
07/21/2021	JHH	Month on hand assessment and graphical summary of finished goods inventory at Rhodes, including purchased items.	1.2
07/21/2021	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.9
07/21/2021	KM	Meeting with J. Lowne (Purdue); J. DelConte and K. McCafferty (AlixPartners) re: 2022 planning.	0.5
07/21/2021	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: Rhodes Pharma CPP analysis for diligence.	0.8
07/21/2021	KM	Review 2022 budgeting assumptions.	2.4
07/21/2021	KM	Prepare slides re: 2022 budgeting assumptions and planning.	1.1
07/21/2021	KM	Prepare overview deck re: diligence project.	1.2
07/21/2021	KM	Analyze Rhodes Pharma pipeline NPV and discount rates for diligence project.	2.3
07/21/2021	KM	Continue analysis of manufacturing operational structure.	1.0
07/21/2021	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.9
07/21/2021	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: Rhodes Pharma CPP analysis for diligence.	0.8
07/21/2021	CCN	Update analysis of Rhodes pipeline asset NPVs.	1.9
07/21/2021	CCN	R&D analysis re: Rhodes current and plan of emergence analysis.	1.8
07/21/2021	CCN	Continue building analysis of Rhodes research and development pipeline.	1.8
07/21/2021	CCN	CPP analysis re: Rhodes customer profitability by form.	1.8
07/21/2021	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.9





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/21/2021	ADD	Meeting with J. Carlisle (Purdue): J. Hyun and A. DePalma (AlixPartners) re: vendor analysis to gather client feedback.	1.0
07/21/2021	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: review and analyze vendor data.	0.2
07/21/2021	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: to review and analyze manufacturing data.	0.6
07/21/2021	ADD	Review and analyze new vendor data and incorporate it into the model.	2.7
07/21/2021	ADD	Reconcile data provided by the client to the general ledger.	2.4
07/21/2021	JH	Correspondence with J. Chen (Davis Polk) re updated report.	0.2
07/21/2021	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to review and analyze manufacturing data.	0.6
07/22/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.4
07/22/2021	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.3
07/22/2021	JHH	Meeting with S. Daniel (Purdue): J. Hyun and A. DePalma (AlixPartners) re: vendor analysis to gather client feedback.	0.6
07/22/2021	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: diligence project.	0.5
07/22/2021	JHH	Modifications to vendor analysis based on client feedback.	0.2
07/22/2021	JHH	Overall inventory analysis by material type and SKU where available.	1.8
07/22/2021	JHH	Sales data clean-up for roll-up and SKU level deviations from month to month.	1.7
07/22/2021	JHH	SKU sales velocity vs. month-to-month sales deviation chart.	1.9
07/22/2021	JHH	Month on Hand chart by Purdue SKUs by product groups.	1.8
07/22/2021	JHH	Weekly client update meeting preparation.	0.4
07/22/2021	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.3
07/22/2021	KM	Call with S. Daniel, S. Daniel (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: Purdue discussion around CRO cost and what is base business (e.g. in DSP) vs non-recurrent cost.	0.5
07/22/2021	KM	Call with V. Mancinelli, D. Fogel (Purdue); K. McCafferty and C. Nweke (both AlixPartners) re: Rhodes pharma CPP and revenue analysis review and update.	1.0
07/22/2021	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: Avrio CPP analysis and improvement opportunities.	1.6
07/22/2021	KM	Analyze Rhodes Pharma pipeline projects and costs.	2.6
07/22/2021	KM	Prepare slides re: Rhodes Pharma pipeline projects and costs.	1.2
07/22/2021	KM	Analysis review re: Rhodes customer and product profitability.	1.9
07/22/2021	KM	Analyze Avrio profitability overview.	1.9
07/22/2021	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.3
07/22/2021	CCN	Call with V. Mancinelli, D. Fogel (Purdue); K. McCafferty and C. Nweke (both AlixPartners) re: Rhodes pharma CPP and revenue analysis review and update.	1.0
07/22/2021	CCN	Call with S. Daniel, and S. Daniel (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: Purdue discussion around CRO cost and what is base business (e.g. in DSP) vs non-recurrent cost.	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/22/2021	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: Avrio CPP analysis and improvement opportunities.	1.6
07/22/2021	CCN	Analyze Rhodes R&D pipeline	1.9
07/22/2021	CCN	Analyze Rhodes R&D NPV	1.8
07/22/2021	CCN	Rhodes CPP analysis re: product profitability by customer.	1.7
07/22/2021	ADD	Update diligence project presentation slides to reflect updated analysis.	1.8
07/22/2021	ADD	Analyze manufacturing processes.	1.8
07/22/2021	ADD	Review and analyze new vendor data and incorporate it into the model.	1.7
07/22/2021	ADD	Reconcile data provided by the client to the general ledger.	1.9
07/22/2021	JH	Correspondence with A. DePalma (AlixPartners) re search functionality.	0.1
07/22/2021	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.3
07/22/2021	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: review company details.	0.5
07/22/2021	ADD	Meeting with S. Daniel (Purdue); J. Hyun and A. DePalma (AlixPartners) re: vendor analysis to gather client feedback.	0.6
07/23/2021	JHH	Meeting with J. Lowne (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	1.1
07/23/2021	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.5
07/23/2021	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to align on remaining tasks for project closure.	0.5
07/23/2021	JHH	Modifications to vendor analysis based on client feedback.	0.4
07/23/2021	JHH	Operational overview re: SIOP (Sales, Inventory and Operations Planning).	1.9
07/23/2021	JHH	Manufacturing section executive summary - draft version.	1.2
07/23/2021	JHH	Review Betadine rationalization plan.	0.7
07/23/2021	JHH	Revision of potential inventory reduction assessment.	1.9
07/23/2021	KM	Meeting with J. Lowne (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	1.1
07/23/2021	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.5
07/23/2021	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: Rhodes R&D pipeline NPV analysis.	1.0
07/23/2021	KM	Presentation and reporting re: diligence project flash report.	1.2
07/23/2021	KM	Analyze Rhodes pipeline valuation.	2.4
07/23/2021	KM	Prepare company overview for diligence project.	2.1
07/23/2021	KM	Continue preparing company overview for diligence project.	0.9
07/23/2021	CCN	Meeting with J. Lowne (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	1.1
07/23/2021	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.5
07/23/2021	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: Rhodes R&D pipeline NPV analysis.	1.0
07/23/2021	CCN	Update Avrio customer and product profitability analysis focused on various customers.	1.9



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/23/2021	CCN	Update Rhodes customer and product profitability analysis focused on various customers.	1.1
07/23/2021	CCN	Update Avrio customer and product profitability analysis based on product form.	1.8
07/23/2021	CCN	Update Rhodes customer and product profitability analysis based on product form.	1.7
07/23/2021	ADD	Meeting with J. Lowne (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	1.1
07/23/2021	ADD	Review draft slides to include in the final presentation.	0.3
07/23/2021	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: to align on remaining tasks for project closure.	0.5
07/23/2021	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.5
07/23/2021	ADD	Prepare overview of manufacturing operations.	2.2
07/23/2021	ADD	Update diligence project presentation slides to reflect updated overview.	1.7
07/23/2021	ADD	Review and update vendor analysis to reflect updated data.	2.5
07/23/2021	JH	Correspondence with A. Guo (Davis Polk) re new user access.	0.1
07/23/2021	JH	Correspondence with R. Tuchman (KKWC) re volume encryption.	0.4
07/26/2021	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.5
07/26/2021	JHH	Monthly sales trend assessment completion.	1.8
07/26/2021	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.2
07/26/2021	JHH	Meeting with J. Carlisle, D. Fogel (Purdue); J. Hyun and A. DePalma (AlixPartners) re: inventory opportunities at Purdue and Rhodes pharma.	1.2
07/26/2021	JHH	Incorporation of feedback re: month on hand inventory for Rhodes pharma product groups and SKUs.	1.7
07/26/2021	JHH	Incorporation of feedback re: month on hand inventory for Purdue product groups and SKUs.	1.4
07/26/2021	JHH	Finalization of vendor data section with updated figures.	1.6
07/26/2021	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.2
07/26/2021	KM	Call with D. Fogel, J. Carlisle (Purdue) re: Rhodes overview for diligence project.	1.2
07/26/2021	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: CPP analysis for Rhodes Pharma and Avrio for diligence project.	2.9
07/26/2021	KM	Summarize company details for diligence project.	2.4
07/26/2021	KM	Prepare slides re: Avrio CPP review and assessment.	1.8
07/26/2021	ADD	Meeting with J. Carlisle, D. Fogel (Purdue); J. Hyun and A. DePalma (AlixPartners) re: inventory opportunities at Purdue and Rhodes pharma.	1.2
07/26/2021	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.2
07/26/2021	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.2
07/26/2021	CCN	Review diligence data re: Avrio customers, sales and margins data.	1.9



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/26/2021	CCN	Revise Avrio analysis of customer profitability.	1.8
07/26/2021	CCN	Continue working on Rhodes product profitability breakdowns.	1.9
07/26/2021	CCN	Revise slides for Rhodes research and development analysis.	1.7
07/26/2021	CCN	Update Avrio customer and product profitability analysis based on brand allocations.	1.5
07/26/2021	JH	Correspondence with L. Readinger (Potter) re user access.	0.2
07/26/2021	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: CPP analysis for Rhodes Pharma and Avrio for diligence project.	2.9
07/27/2021	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.6
07/27/2021	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: vendor data discussion.	0.3
07/27/2021	JHH	Meeting #1 with P. Shafer, S. Bingham, G. Baron, A. Johnson (FTI); K. McCafferty, J. Hyun and A. DePalma (AlixPartners) re: vendor data and spend cube.	1.2
07/27/2021	JHH	Meeting with T. Garvey, J. Tran (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: Avrio CPP analysis.	1.1
07/27/2021	JHH	Separation of Avrio products from various charts: MOH and sales velocity vs variation.	0.6
07/27/2021	JHH	Review of company diligence materials.	1.7
07/27/2021	JHH	Review of company diligence materials (continued).	1.8
07/27/2021	JHH	Create write-up and presentation slides for the diligence project.	1.9
07/27/2021	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.6
07/27/2021	KM	Meeting with P. Shafer, S. Bingham, G. Baron, A. Johnson (FTI); K. McCafferty, J. Hyun and A. DePalma (AlixPartners) re: vendor data and spend cube.	1.2
07/27/2021	KM	Meeting with T. Garvey, J. Tran (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: Avrio CPP analysis.	1.1
07/27/2021	KM	Analyze Rhodes product pipeline for diligence project.	1.5
07/27/2021	KM	Slide and analysis prep re: diligence project discussion with FTI.	2.2
07/27/2021	KM	Analyze company overview diligence materials.	0.7
07/27/2021	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.6
07/27/2021	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: vendor data status discussion.	0.3
07/27/2021	ADD	Meeting with P. Shafer, S. Bingham, G. Baron, A. Johnson (FTI); K. McCafferty, J. Hyun and A. DePalma (AlixPartners) re: vendor analysis and spend cube.	1.2
07/27/2021	ADD	Meeting with T. Garvey, J. Tran (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: Avrio CPP analysis.	1.1
07/27/2021	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.6
07/27/2021	CCN	Meeting with T. Garvey, J. Tran (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: Avrio CPP analysis.	1.1



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/27/2021	CCN	Update analysis for Rhodes customer profitability.	1.9
07/27/2021	CCN	Continue work on Avrio customer profitability analysis.	1.9
07/27/2021	CCN	Analyze Rhodes R&D pipeline	1.8
07/27/2021	CCN	Update slides for Rhodes customer profitability.	1.9
07/27/2021	JH	Correspondence with L. Readinger (Potter) re reporting.	0.2
07/27/2021	JH	Correspondence with A. Guo (Davis Polk) re user access.	0.3
07/27/2021	JH	Correspondence with K. Giampaolo (Milbank) re new data for reserve.	0.2
07/27/2021	JH	Correspondence with C. Oluwole and D. Consola (both Davis Polk) re reserve reporting.	0.9
07/28/2021	JHH	Call with K. McCafferty, J. Hyun and C. Nweke (AlixPartners) re: morning meeting to review project deliverables and activities.	1.0
07/28/2021	JHH	Revision of average monthly sales vs variation analysis and charts.	1.8
07/28/2021	JHH	Compare MOH vs margin and gross sales for Avrio product groups.	1.7
07/28/2021	JHH	Revision of company overview presentation slides.	1.4
07/28/2021	JHH	Finalize manufacturing operational overview.	1.5
07/28/2021	JHH	Manufacturing, packaging and distribution/supply chain analyses.	1.4
07/28/2021	KM	Call with K. McCafferty, J. Hyun and C. Nweke (AlixPartners) re: morning meeting to review project deliverables and activities.	1.0
07/28/2021	KM	Analysis and slide preparation re: Avrio CPP for diligence project.	1.9
07/28/2021	KM	Analysis and slide preparation re: Rhodes CPP for diligence project.	2.1
07/28/2021	KM	Analyze G&A details.	1.9
07/28/2021	KM	Research and analysis re: pharma benchmarking.	2.3
07/28/2021	CCN	Call with K. McCafferty, J. Hyun and C. Nweke (AlixPartners) re: morning meeting to review project deliverables and activities.	1.0
07/28/2021	JH	Update data sets in reserve at request of K. Giampaolo (Milbank).	0.4
07/28/2021	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.6
07/29/2021	JHH	Call with K. McCafferty, J. Hyun and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.6
07/29/2021	JHH	Review of Wilson plant operations data and performance.	1.7
07/29/2021	JHH	2020 actuals and 2021 budget volumes and expenses for Wilson plant.	0.9
07/29/2021	JHH	Labor and overhead cost trend and resulting conversion cost per tablet.	1.3
07/29/2021	JHH	Wilson plant summary and overview.	1.8
07/29/2021	JHH	Distribution and supply chain related overviews.	1.5
07/29/2021	KM	Call with K. McCafferty, J. Hyun and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.6
07/29/2021	KM	Presentation and reporting re: company overview for diligence project.	2.3
07/29/2021	KM	Analyze company comparables for diligence project.	1.9
07/29/2021	KM	Presentation and reporting re: product profitability for Rhodes Pharma.	1.3
07/29/2021	KM	Presentation and reporting re: company overview for CEO/CFO meeting.	2.1
07/29/2021	ADD	Call with K. McCafferty, J. Hyun and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.6
07/30/2021	JHH	Meeting with J. Lowne (Purdue); J. DelConte, K. McCafferty and J. Hyun (AlixPartners) re: diligence project weekly stand-up meeting.	0.8



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/30/2021	JHH	Call with K. McCafferty and J. Hyun (both AlixPartners) re: morning meeting to review project deliverables and activities.	0.7
07/30/2021	JHH	Meeting with C. Landau, J. Lowne and M. Kesselman (Purdue); J. DelConte, K. McCafferty and J. Hyun (AlixPartners) re: review of draft diligence project.	0.9
07/30/2021	JHH	Meeting with P. Shafer, G. Baron, A. Johnson (FTI); K. McCafferty and J. Hyun (AlixPartners) re: Avrio CPP.	1.1
07/30/2021	JHH	Distribution and supply chain overview analyses.	1.7
07/30/2021	JHH	Draft of manufacturing section executive summary.	1.9
07/30/2021	JHH	Continue working on the manufacturing section overview.	1.8
07/30/2021	KM	Meeting with J. Lowne (Purdue); J. DelConte, K. McCafferty and J. Hyun (AlixPartners) re: diligence project weekly stand-up meeting.	0.8
07/30/2021	KM	Call with K. McCafferty and J. Hyun (both AlixPartners) re: morning meeting to review project deliverables and activities.	0.7
07/30/2021	KM	Meeting with C. Landau, J. Lowne and M. Kesselman (Purdue); J. DelConte, K. McCafferty and J. Hyun (AlixPartners) re: diligence project.	0.9
07/30/2021	KM	Meeting with P. Shafer, G. Baron, A. Johnson (FTI); K. McCafferty and J. Hyun (AlixPartners) re: Avrio CPP.	1.1
07/30/2021	KM	Create company overview slides for diligence project.	2.7
07/30/2021	KM	Slide and analysis prep re: diligence review with FTI.	1.7
07/30/2021	JH	Correspondence with C. Oluwole (Davis Polk) and L. Readinger (Potter) re new user access.	0.2
08/02/2021	KM	Analysis and summary slides re: diligence project.	1.8
08/02/2021	KM	Analyze various revenue and expense details RE: diligence project.	2.7
08/02/2021	JH	Correspondence with A. Guo (Davis Polk) re: user access.	0.2
08/03/2021	KM	Analyze income statement breakdown for diligence project.	1.9
08/03/2021	KM	Analyze additional operational outlines for diligence project.	0.9
08/03/2021	KM	Slide and analysis prep re: diligence project update with FTI.	2.4
08/03/2021	JH	Correspondence with J. Chen (Davis Polk) re: exhibit productions.	0.2
08/03/2021	JH	Correspondence with J. Chen and C. Oluwole (both Davis Polk) re: response to J. Remi at KKWC.	0.7
08/03/2021	JH	Correspondence with A. Guo and G. Cardillo (both Davis Polk) re: user access.	0.5
08/03/2021	JH	Call with A. Guo (Davis Polk) re: updated reporting.	0.1
08/03/2021	JH	Correspondence with J. Chen (Davis Polk) re: new exhibit site.	0.3
08/04/2021	JHH	Review operational processes and update summary analysis for diligence project.	1.7
08/04/2021	JHH	Meeting with P. Shafer, S. Bingham, G. Baron, A. Johnson (FTI); K. McCafferty (AlixPartners) re: diligence project.	1.0
08/04/2021	JHH	Call with A. DePalma (AlixPartners) re: closure items (reconciliation of two diligence files).	0.6
08/04/2021	JHH	Prepare materials on detailed income statement for meeting with FTI.	1.5
08/04/2021	JHH	Prepare materials on Wilson overview for FTI diligence project meeting.	1.4
08/04/2021	JHH	Continue preparing materials on Wilson overview in advance of meeting with FTI.	1.7



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/04/2021	JHH	Prepare materials on operational processes for FTI diligence meeting.	1.1
08/04/2021	KG	Download and log data for Exhibits site at request of J. Chen (Davis Polk).	0.9
08/04/2021	KM	Meeting with P. Shafer, S. Bingham, G. Baron, A. Johnson (FTI) and J. Hyun (AlixPartners) re: diligence project.	1.0
08/04/2021	KM	Meeting with V. Mancinelli, D. Fogel (Purdue); and K. McCafferty (AlixPartners) re: current and pipeline Rhodes product overviews.	1.5
08/04/2021	KM	Slide and analysis prep re: diligence project discussion with FTI.	2.1
08/04/2021	KM	Review Rhodes pipeline projects.	2.4
08/04/2021	KM	Slide preparation re: Rhodes pipeline overview.	1.2
08/04/2021	JH	Correspondence with A. Quach (Davis Polk) re: exhibits for FTP upload.	0.4
08/04/2021	JH	Correspondence with J. Remi (KKWC) re: file download.	0.2
08/04/2021	JH	Correspondence with J. Chen (Davis Polk) re: testing FTP site.	0.4
08/04/2021	JH	Correspondence with G. Asbill (TCDI) re: new data for reserve.	0.2
08/04/2021	JH	Correspondence with E. Townes (Davis Polk) re: user access.	0.5
08/04/2021	JH	Update data sets on second exhibits FTP for J. Chen and A. Quach (both Davis Polk).	0.6
08/04/2021	ADD	Call with J. Hyun (AlixPartners) re: closure items (reconciliation of two diligence files).	0.6
08/05/2021	JHH	Prepare various files and analysis for upload to the FTI dataroom.	1.9
08/05/2021	KM	Meeting with P. Shafer, G. Baron, A. Johnson (FTI) and A. DePalma (AlixPartners) re: file sharing.	0.5
08/05/2021	KD	Download and log data for Exhibits site at request of J. Chen (Davis Polk).	0.3
08/05/2021	JH	Update data sets on second exhibits FTP for J. Chen and A. Quach (both Davis Polk).	1.1
08/05/2021	JH	Correspondence with E. Townes (Davis Polk) re: user access.	0.4
08/05/2021	JH	Correspondence with A. Quach (Davis Polk) re: updates to Exhibit content.	0.2
08/05/2021	JH	Correspondence with L. Murray (SHB) re: user access.	0.2
08/05/2021	JH	Correspondence with P. Roberts (Cozen) re: site access.	0.3
08/05/2021	JH	Correspondence with A. Guo (Davis Polk) re: new user access to reserve.	0.3
08/05/2021	JH	Correspondence with J. Remi (KKWC) re: extraction of files from reserve.	0.2
08/05/2021	JH	Correspondence with J. Richards (Akin Gump) re: additional user access.	0.2
08/05/2021	JH	Correspondence with M. Plevin (Davis Polk) re: access.	0.2
08/06/2021	JHH	Call with K. McCafferty (AlixPartners) re: Purdue diligence project.	1.1
08/06/2021	JHH	Update last section of the diligence project slides.	1.9
08/06/2021	JHH	Continue to make revisions to the diligence project slides.	1.7
08/06/2021	JHH	Update and finalize diligence project analyses.	0.9
08/06/2021	JHH	Make revisions to various diligence project slides.	1.1
08/06/2021	JHH	Review and prepare various files to be shared with FTI.	1.8
08/06/2021	KM	Call with K. McCafferty and J. Hyun (AlixPartners) re: Purdue diligence project.	1.1
08/06/2021	KM	Meeting with J. Lowne, B. Weingarten (Purdue) re: diligence project.	1.3
08/06/2021	KM	Review and create slides on operational processes.	2.5
08/06/2021	KM	Presentation and reporting re: diligence project.	1.4
08/06/2021	KM	Review expense details for diligence project.	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/06/2021	KD	Download and log data for Exhibits site at request of J. Chen (Davis Polk).	0.6
08/06/2021	JH	Correspondence with E. Townes (Davis Polk) re: questions from B. Masumoto.	0.2
08/06/2021	JH	Correspondence with E. Townes (Davis Polk) re: new user access.	0.7
08/06/2021	JH	Correspondence with B. Masumoto (DOJ) re: additional files.	0.1
08/06/2021	JH	Correspondence with S. Tonnesen (OAG MD) re: passwords.	0.2
08/06/2021	JH	Correspondence with E. Townes (Davis Polk) re: password notifications.	0.2
08/06/2021	JH	Correspondence with P. Astras (KLD) re: new data for reserve.	0.2
08/06/2021	JH	Correspondence with A. Guo (Davis Polk) re: content of reserve.	0.2
08/06/2021	JH	Correspondence with J. Chen and E. Townes (both Davis Polk) re: updates to exhibit sets.	0.6
08/08/2021	JH	Correspondence with K. Houston (Davis Polk) re: new user access.	0.3
08/08/2021	JH	Correspondence with A. Guo (Davis Polk) re: new user requests.	0.2
08/08/2021	JH	Correspondence with E. Townes (Davis Polk) and J. Giglio (Capdale) re: user credentials.	0.4
08/09/2021	JH	Correspondence with C. Oluwole (Davis Polk) re: new user access.	0.3
08/09/2021	JH	Correspondence with J. Chen (Davis Polk) re: updates to exhibits site.	0.2
08/09/2021	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.8
08/09/2021	JH	Correspondence with J. Richards (Akin Gump) re: access to exhibits.	0.1
08/09/2021	JH	Correspondence with A. Guo (Davis Polk) re: Gasdia deposition transcripts.	0.5
08/09/2021	JH	Correspondence with K. Houston (Davis Polk) re: user access.	0.2
08/09/2021	JH	Correspondence with K. Giampaolo (Milbank) re: new documents for the reserve.	0.1
08/09/2021	KM	Review comparable company details for diligence project.	2.5
08/09/2021	ADD	Draft correspondence requesting approval to upload diligence materials.	0.4
08/09/2021	KD	Download and log data for Exhibits site at request of J. Chen (Davis Polk).	0.3
08/09/2021	KM	Meeting with S. Lemack (AlixPartners) to discuss Rhodes lease inquiry from the AHC.	0.2
08/10/2021	JH	Correspondence with L. Fogelman (USANYs) re: database access.	0.2
08/10/2021	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	1.3
08/10/2021	JH	Correspondence with E. Townes and K. Houston (both Davis Polk) re: new exhibit site access.	0.3
08/10/2021	JH	Correspondence with J. Remi (KKWC) re: reserve content.	0.1
08/10/2021	KM	Call with J. Lowne, B. Weingarten (both Purdue), J. DelConte (AlixPartners) re: diligence project.	1.5
08/10/2021	KM	Call with J. DelConte, K. McCafferty (both AlixPartners), J. Lowne, M. Kesselman, B. Weingarten (all Purdue) re: diligence project.	0.5
08/10/2021	KM	Analyze revenue forecasts for diligence project.	2.6
08/10/2021	KM	Slides and report re: revenue details follow up for diligence project.	1.8
08/10/2021	KM	Slide deck prep re: meeting with Lowne/Weingarten for diligence project.	0.7
08/10/2021	ADD	Manage Project Omega data room and give access to appropriate files.	1.9
08/10/2021	KD	Download and log data for Exhibits site at request of J. Chen (Davis Polk).	0.3
08/11/2021	KG	Download and log data for Exhibits site at request of J. Chen (Davis Polk).	0.7
08/11/2021	JH	Correspondence with R. McCoy (PullCom) re: user access.	0.2
08/11/2021	JH	Correspondence with K. Giampaolo (Milbank) re: new data for reserve.	0.1





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/11/2021	JH	Correspondence with M. D'Angelo (D'Angelo Law) re: exhibits accesss.	0.4
08/11/2021	JH	Correspondence with J. Chen (Davis Polk) re: updates to exhibits site.	0.5
08/11/2021	ADD	Manage Project Omega data room and give access to appropriate files.	2.0
08/12/2021	KG	Download and log data for Exhibits site at request of J. Chen (Davis Polk).	0.3
08/12/2021	JH	Correspondence with R. McCoy (PullCom) re: user access.	0.1
08/12/2021	JH	Correspondence with E. Townes (Davis Polk) re: exhibit site credentials.	0.4
08/12/2021	JH	Correspondence with D. Lennard (Kramer Levin) re: user access.	0.3
08/12/2021	JH	Update data sets in reserve at request of K. Giampaolo (Milbank).	0.3
08/12/2021	KM	Update diligence project analysis following discussion with management.	1.6
08/13/2021	JH	Correspondence with J. Chen (Davis Polk) re: new exhibit data.	0.4
08/13/2021	JH	Correspondence with G. Medina (Dentons) re: encryption.	0.1
08/13/2021	JH	Correspondence with K. Blake (NYAG) re: exhibit site.	0.1
08/13/2021	KM	Presentation and reporting re: different sections of diligence project.	1.2
08/13/2021	KM	Analyze largest vendor spending categories for diligence project.	1.9
08/13/2021	ADD	Review diligence project supporting files in preparation for meeting with creditors.	2.1
08/13/2021	ADD	Compile and format data and other materials submitted in response to diligence requests by the client in preparation for processing and upload to Project Omega data room.	2.5
08/13/2021	KD	Download and log data for Exhibits site at request of J. Chen (Davis Polk).	0.3
08/16/2021	JH	Correspondence with R. Atkinson (Cobra) re: user access.	0.1
08/16/2021	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.2
08/16/2021	JH	Correspondence with M. Farrell (Guardian Law) re: user access.	0.2
08/16/2021	JH	Correspondence with J. Chen (Davis Polk) re: exhibit updates.	0.2
08/16/2021	ADD	Compile and upload material responsive to AHC diligence requests.	2.8
08/16/2021	ADD	Prepare and upload documents provided by Davis Polk's eDiscovery team for upload to the data room.	2.4
08/16/2021	ADD	Review data sources and numbers from diligence project and compare to other materials provided.	1.4
08/16/2021	ADD	Review outstanding diligence requests and follow up with remaining items.	1.5
08/16/2021	KD	Download and log data for Exhibits site at request of J. Chen (Davis Polk).	0.3
08/17/2021	ADD	Format data and other materials submitted in response to diligence requests by the client in preparation for processing and upload to Project Omega data room.	2.5
08/17/2021	ADD	Compile and prepare material responsive to FTI diligence requests.	1.8
08/17/2021	ADD	Call with K. McCafferty (AlixPartners) to discuss FTI diligence.	0.3
08/17/2021	JH	Correspondence with J. Chen (Davis Polk) re: updates to exhibit sets.	0.3
08/17/2021	KM	Call with A. DePalma (AlixPartners) to discuss FTI diligence.	0.3
08/17/2021	KM	Analyze various expense forecasts for diligence project.	2.6
08/17/2021	KM	Prepare summary of Purdue retirement programs for diligence project.	1.1
08/17/2021	KM	Analyze post-emergence long term business plan.	2.7
08/17/2021	KM	Analyze post-emergenceorg operational overview.	2.2
08/17/2021	KG	Download and log data for Exhibits site at request of J. Chen (Davis Polk).	0.3
08/18/2021	ADD	Format data and other materials submitted in response to diligence requests by the client in preparation for processing and upload to Project Omega data room.	2.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/18/2021	JH	Correspondence with A. Rykov (Milbank) re: exhibit site access.	0.2
08/18/2021	JH	Correspondence with J. Chen (Davis Polk) re: new data for exhibit site.	0.3
08/18/2021	KM	Analyze post-emergence long-term business plan forecast.	1.7
08/18/2021	KM	Create organigrams outlining the post-emergence business structure.	0.9
08/18/2021	KM	Create updated slides for final diligence project presentation.	1.1
08/18/2021	KM	Prepare summary slides in response to open FTI diligence requests.	0.9
08/19/2021	JH	Correspondence with C. Oluwole (Davis Polk) re: coverage.	0.1
08/19/2021	JH	Correspondence with K. Houston (Davis Polk) re: exhibits access.	0.2
08/19/2021	KD	Download and log data for Exhibits site at request of J. Chen (Davis Polk).	0.2
08/20/2021	JH	Correspondence with K. Houston (Davis Polk) re: user access.	0.3
08/20/2021	KM	Revise operational overview for diligence project.	1.0
08/20/2021	KM	Update summary of Wilson processes for diligence project.	0.4
08/20/2021	KM	Analyze updated post-emergence processes for the company.	0.6
08/20/2021	KM	Create new detailed slides for the diligence project.	1.5
08/23/2021	KM	Summarize additional expense details for the diligence project.	0.9
08/23/2021	TG	Review ongoing eDiscovery work and prepare workplans for go-forward activities.	0.4
08/24/2021	KM	Prepare management requested analysis for final diligence project slides.	2.0
08/24/2021	KM	Review and summarize post-emergence operational requirements.	2.1
08/24/2021	KM	Update slide for latest diligence project analyses.	1.7
08/24/2021	JH	Correspondence with K. Chau (Davis Polk) re: updates to exhibits.	0.1
08/24/2021	TG	Continue review eDiscovery workstream status and go-forward planning.	0.6
08/25/2021	KG	Download and log data for Exhibits site at request of J. Chen (Davis Polk).	0.3
08/25/2021	KM	Continue preparing final summary slides for the ongoing diligence project.	2.6
08/25/2021	KM	Update analysis for latest information received from Purdue management.	1.5
08/25/2021	JH	Correspondence with J. Chen (Davis Polk) re: updates to exhibits site.	0.6
08/25/2021	JH	Correspondence with K. Blake (NY AG) re: password reset.	0.1
08/26/2021	KG	Download and log data for Exhibits site at request of J. Chen (Davis Polk).	0.4
08/26/2021	JG	Update reserve data sets in preparation of launch at request of C. Oluwole (Davis Polk).	0.6
08/26/2021	JH	Correspondence with A. DePalma (Davis Polk) re: new productions of reserve.	0.3
08/26/2021	JH	Update data sets in reserve at request of A. Guo (Davis Polk).	0.5
08/26/2021	TG	Review documentation and reconciliation of open eDiscovery items.	0.4
08/27/2021	JG	Update reserve data sets in preparation of launch at request of C. Oluwole (Davis Polk).	1.4
08/27/2021	JH	Update data sets in reserve at request of A. Guo (Davis Polk).	1.1
08/30/2021	ADD	Compile contracts from Purdue's client management system in response to diligence request.	1.8
08/30/2021	ADD	Review outstanding diligence requests and compile responsive materials.	1.9
08/30/2021	JH	Update data sets in reserve at request of A. Guo (Davis Polk).	0.5
08/31/2021	ADD	Call with K. McCafferty and A. DePalma (AlixPartners) re: diligence project.	0.4
08/31/2021	ADD	Compile contracts from Purdue's client management system in response to diligence request.	2.4
08/31/2021	ADD	Review outstanding diligence requests and compile responsive materials.	1.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/31/2021	KM	Update slides for latest information provided by management.	2.2
08/31/2021	KM	Report analysis and edits re: Rhodes Pharma inventory summary.	1.8
08/31/2021	KM	Analyze Rhodes Pharma long term business plan for diligence project.	1.4
08/31/2021	KM	Analyze Avrio long term business plan for diligence project.	1.3
08/31/2021	KM	Report edits re: summary diligence project slides.	1.3
08/31/2021	KM	Call with K. McCafferty and A. DePalma (AlixPartners) re: diligence project.	0.4
09/01/2021	KM	Analyze recommendations for diligence project.	1.6
09/01/2021	KM	Analyze various diligence project scenarios.	1.1
09/01/2021	KM	Revise diligence project slides using feedback from J. Lowne and B. Weingarten.	2.5
09/01/2021	KM	Continue revising diligence project slides per feedback from J. Lowne and B. Weingarten.	2.9
09/02/2021	KM	Analyze Rhodes analysis for project Omega.	1.6
09/02/2021	KM	Implementation analysis re: diligence project.	2.3
09/02/2021	KM	Update analysis and slides for diligence project.	1.9
09/02/2021	KM	Presentation and reporting re: project Omega.	2.1
09/03/2021	KM	Edit and circulate report re: project Omega diligence section 1.	0.4
09/03/2021	KM	Edit and circulate report re: project Omega diligence section 2.	1.3
09/03/2021	KM	Edit and circulate report re: project Omega diligence section 3.	2.2
09/03/2021	KM	Edit and circulate report re: project Omega diligence: section 4.	0.6
09/07/2021	KM	Analyze company details for diligence project.	2.2
09/07/2021	KM	Analyze benchmarking data for diligence project.	1.5
09/07/2021	KM	Edit report re: diligence project section 1.	1.1
09/07/2021	KM	Edit report re: diligence project section 2.	0.7
09/08/2021	KM	Analyze planning steps for project Omega.	2.1
09/08/2021	KM	Analyze latest information for due diligence project.	2.1
09/08/2021	KM	Create report pages re: implementation planning.	1.5
09/08/2021	KM	Create report pages re: section 3 of diligence project.	1.2
09/08/2021	KM	Develop slides re: company overview for project Omega.	2.8
09/09/2021	KM	Revise latest analysis for project Omega.	2.3
09/09/2021	KM	Update analysis for latest Omega diligence materials.	0.9
09/09/2021	KM	Meeting with J. Lowne, B. Weingarten (Purdue) re: project Omega Executive presentation deck review.	1.0
09/09/2021	KM	Revise project Omega executive presentation deck.	1.3
09/10/2021	KM	Analyze benchmarking data for diligence project.	0.8
09/10/2021	KM	Edit executive presentation re: project Omega.	1.5
09/13/2021	KM	Rework diligence project analysis per updated information.	2.2
09/13/2021	KM	Analyze additional benchmarking data for diligence project.	1.6
09/13/2021	KM	Meeting with Purdue management re: Avrio overview.	1.2
09/13/2021	KM	Review and edit summary overview of Avio.	1.4
09/13/2021	KM	Review and edit re: analysis for Project Omega.	1.3
09/14/2021	ADD	Meeting with J. Lowne (Purdue); K. McCafferty and A. DePalma (AlixPartners) re: diligence project.	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/14/2021	KM	Meeting with J. Lowne (Purdue); K. McCafferty and A. DePalma (AlixPartners) re: diligence project.	0.5
09/14/2021	KM	Analyze business development project details.	1.6
09/14/2021	KM	Analyze company details for project Omega.	1.5
09/14/2021	KM	Analyze Rhodes R&D projects.	1.9
09/14/2021	KM	Review and edit re: project Omega presentation.	2.2
09/16/2021	KM	Overview and analysis re: Colace.	1.3
09/16/2021	KM	Overview and analysis re: Senokot.	1.1
09/16/2021	KM	Overview and analysis re: Slow Mag.	0.9
09/16/2021	KM	Analyze expense details by account.	2.6
09/16/2021	KM	Presentation and reporting re: Avrio for diligence project.	2.3
09/17/2021	JH	Communication with C. Scherer (TCDI) re: new data for reserve.	0.2
09/17/2021	KM	Analyze expense overview for diligence project.	0.9
09/17/2021	KM	Meeting with Purdue management re: inventory observations.	1.0
09/17/2021	KM	Meeting with Purdue management re: section 3 presentation.	1.0
09/17/2021	KM	Presentation and reporting re: section 4 slides for diligence project.	1.6
09/20/2021	JH	Update tracking details for new data for reserve.	0.4
09/20/2021	KM	Analyze company long-term plan details.	2.2
09/20/2021	KM	Analyze pre- and post-emergence structure.	1.3
09/20/2021	KM	Revise and edit latest diligence project slides.	1.2
09/20/2021	KM	Revise project Omega report out.	2.8
09/21/2021	ADD	Call with K. McCafferty and A. DePalma (AlixPartners) re: diligence touchbase.	0.6
09/21/2021	KM	Call with K. McCafferty and A. DePalma (AlixPartners) re: diligence touchbase.	0.6
09/21/2021	KM	Review and edit existing presentation slides.	1.4
09/21/2021	KM	Analyze comparable company structures.	2.2
09/21/2021	KM	Update analysis and revise slides for Section 1.	2.6
09/21/2021	KM	Presentation and report creation re: organization report-out for executive review for diligence project.	2.5
09/22/2021	JD	Meeting with J. Lowne, M. Kesselman, C. Landau, B. Weingarten (all Purdue), J. DelConte, K. McCafferty (both AlixPartners) re: diligence project.	1.2
09/22/2021	KM	Meeting with J. Lowne, M. Kesselman, C. Landau, B. Weingarten (all Purdue), J. DelConte, K. McCafferty (both AlixPartners) re: diligence project.	1.2
09/22/2021	JD	Meeting with J. DelConte and K. McCafferty (both AlixPartners) re: prep for meeting with management.	0.3
09/22/2021	KM	Meeting with J. DelConte and K. McCafferty (both AlixPartners) re: prep for meeting with management.	0.3
09/22/2021	JH	Communication with J. Gutierrez (AlixPartners) re staging new data for reserve.	0.9
09/22/2021	KM	Analyze sales breakdown for diligence project.	2.3
09/22/2021	KM	Analyze project Omega summary analysis.	2.1
09/22/2021	KM	Presentation edits and changes re: report-out for executive review.	2.9
09/23/2021	KM	Analyze latest information provided for diligence project.	1.8



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/23/2021	KM	Presentation and reporting re: diligence project.	1.2
09/23/2021	KM	Report edits and analysis re: post-emergence business plan.	2.7
09/23/2021	KM	Report edits and analysis re: diligence project.	2.6
09/27/2021	JH	Update document reserve at request of A. Guo (Davis Polk).	0.3
09/27/2021	KM	Analyze pipeline opportunities for diligence project.	2.4
09/27/2021	KM	Meeting with D. Lundie (Purdue) re: Rhodes 2022 planning.	1.0
09/27/2021	KM	Report edits re: pipeline opportunities for diligence project.	1.6
09/28/2021	JH	Communication with L. Readinger (Potter Anderson) re: text of volume on reserve.	0.2
09/28/2021	JH	Update document reserve at request of A. Guo (Davis Polk).	0.4
09/28/2021	KM	Analyze latest expenses for diligence project.	1.5
09/28/2021	KM	Analyze company long term plan for diligence project.	2.2
09/28/2021	KM	Analyze benchmarking for diligence project.	1.9
09/28/2021	KM	Report edits re: Section 2 for diligence project.	1.4
09/28/2021	KM	Report edits re: Section 3 for diligence project.	1.9
09/29/2021	ADD	Call with A. DePalma and K. McCafferty (AlixPartners); G. Baron, A. Johnson, M. Knaak, and P. Shafer (FTI) re: diligence and project Omega analysis and reports	1.0
09/29/2021	KM	Call with A. DePalma and K. McCafferty (AlixPartners); G. Baron, A. Johnson, M. Knaak, and P. Shafer (FTI) re: diligence and project Omega analysis and reports	1.0
09/29/2021	ADD	Review diligence project presentation and provide comments.	1.4
09/29/2021	JH	Update document reserve at request of A. Guo (Davis Polk).	0.8
09/29/2021	KM	Analyze long term plan details for diligence project.	2.8
09/29/2021	KM	Analyze benchmarking for diligence project.	1.9
09/29/2021	KM	Analyze updated long term plan information for diligence project.	1.5
09/29/2021	KM	Presentation edits and changes re: report-out for executive review.	2.7
<b>Total Professional Hours</b>			<b>1,123.3</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Special Projects  
Code: 1.10 / 110

<b>PROFESSIONAL</b>	<b>TITLE</b>	<b>RATE</b>	<b>HOURS</b>	<b>FEES</b>
Jesse DelConte	Managing Director	\$1,055	1.5	1,582.50
Tarek Ghalayini	Managing Director	\$1,055	1.4	1,477.00
Kevin M McCafferty	Director	\$980	409.8	401,604.00
Joon H Hyun	Director	\$980	220.5	216,090.00
Jamey Hamilton	Director	\$865	74.8	64,702.00
Nate P Janysek	Director	\$865	9.2	7,958.00
Kasia Duda	Senior Vice President	\$710	2.3	1,633.00
Kristina Galbraith	Senior Vice President	\$665	2.9	1,928.50
Charles C Nweke	Vice President	\$650	189.5	123,175.00
Andrew D DePalma	Vice President	\$625	164.0	102,500.00
Julia Gutierrez	Vice President	\$625	23.7	14,812.50
Julia Caitlin Hardy	Vice President	\$530	23.7	12,561.00
<b>Total Professional Hours and Fees</b>			<b>1,123.3</b>	<b>\$ 950,023.50</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Retention and Engagement Administration  
Code: 112

<b>DATE</b>	<b>CONSULTANT</b>	<b>DESCRIPTION OF SERVICES</b>	<b>HOURS</b>
08/13/2021	AG	Prepare relationship disclosures for Purdue Pharma supplemental report (A-F)	2.7
08/13/2021	AG	Prepare relationshipd disclosures for Purdue Pharma Supplemental report (F-K)	2.8
08/16/2021	AG	Prepare relationship disclosures for Purdue Pharma 2nd Supplemental report (K-R)	2.9
08/16/2021	AG	Prepare relationship disclosures for Purdue Pharma 2nd Supplemental report (R-Z)	2.7
08/17/2021	AG	Analyze relationship disclosures for Purdue Pharma 2nd supplemental report (A-M)	2.8
08/17/2021	AG	Analyze relationship disclosures for Purdue Pharma 2nd supplemental report (K-Z)	2.9
08/17/2021	AG	Finalize relationship disclosures for Purdue Pharma 2nd supplemental report (A-B)	0.3
08/18/2021	AG	Finalize relationship disclosures for Purdue Pharma 2nd supplemental report (B-Z)	2.9
08/26/2021	HS	Review draft disclosures for supplemental declaration	0.2
08/30/2021	JD	Review and comment on latest conflict disclosures.	0.2
<b>Total Professional Hours</b>			<b>20.4</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Retention and Engagement Administration  
Code: 112

<b>PROFESSIONAL</b>	<b>TITLE</b>	<b>RATE</b>	<b>HOURS</b>	<b>FEES</b>
Jesse DelConte	Managing Director	\$1,055	0.2	211.00
Heather Saydah	Senior Vice President	\$480	0.2	96.00
Andrew Gettler	Associate	\$375	20.0	7,500.00
<b>Total Professional Hours and Fees</b>			<b>20.4</b>	<b>\$ 7,807.00</b>





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Fee Statements and Fee Applications  
Code: 1.13 / 113

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/01/2021	MSM	Prepare professional fees for May 2021 fee statement	3.7
06/01/2021	JD	Begin to review April monthly fee statement.	1.5
06/01/2021	JD	Finish review of April monthly fee statement	2.4
06/04/2021	MSM	Prepare professional fees for May 2021 fee statement	2.1
06/04/2021	JD	Review and comment on latest April fee statement.	0.3
06/05/2021	MSM	Prepare professional fees for May 2021 fee statement	4.0
06/07/2021	MSM	Prepare professional fees for May 2021 fee statement	2.5
06/08/2021	MSM	Prepare professional fees for May 2021 fee statement	3.0
06/08/2021	MSM	Continue to prepare professional fees for May 2021 fee statement	2.0
06/08/2021	TB	Prepare 20th monthly fee application and exhibits for April 2021.	2.6
06/08/2021	TB	Prepare fees and expenses status chart for Purdue.	0.6
06/09/2021	MSM	Prepare professional fees for May 2021 fee statement	3.0
06/09/2021	JD	Review updated and final fee statement draft.	0.2
06/10/2021	TB	Email to M. Pera, D. Consla, C. Robertson (all Davis Polk) attaching the 20th monthly fee statement for April 2021 for filing on the court docket.	0.2
06/14/2021	MSM	Prepare professional fees for May 2021 fee statement	3.5
06/14/2021	MSM	Continue to prepare professional fees for May 2021 fee statement	3.7
06/21/2021	TB	Update 20th monthly fee statement for April per the request of counsel.	0.5
06/24/2021	JD	Begin review of May fee application to file with the Court.	1.3
06/29/2021	JD	Finish initial review of draft May fee statement	2.2
06/30/2021	TB	Prepare monthly fee statement and exhibits for May 2021.	1.5
07/01/2021	JD	Review final draft May fee application to be filed with the court.	0.3
07/01/2021	TB	Update monthly fee statement and exhibits for May 2021 per J. DelConte (AlixPartners).	0.3
07/02/2021	TB	Update twenty-first monthly fee statement and exhibits per the request of J. Hamilton (AlixPartners)	0.6
07/06/2021	LMB	Update fee application summary status chart	0.5
07/06/2021	TB	Update May monthly fee statement.	0.2
07/06/2021	JD	Review updated May fee statement	0.2
07/08/2021	LMB	Prepare Fifth Interim Fee Application	3.8
07/08/2021	LMB	Prepare schedules to Fifth Interim Fee Application	1.2
07/09/2021	LMB	Prepare fifth interim fee application, supporting exhibits and schedules	2.2
07/09/2021	LMB	Prepare professional fees for June 2021 monthly fee statement	1.0
07/09/2021	JD	Begin review of 5th interim fee application to be filed with the court.	0.5
07/12/2021	LMB	Prepare professional fees for June 2021 monthly fee statement	3.0
07/12/2021	LMB	Continue to prepare professional fees for June 2021 monthly fee statement	2.8
07/13/2021	LMB	Prepare professional fees for June 2021 monthly fee statement	2.5
07/13/2021	LMB	Emails to/from C. Nweke (AlixPartners) re: June 2021 professional fees	0.2
07/14/2021	LMB	Revise fifth interim fee application and compile exhibits	1.2
07/14/2021	JD	Finalize review and edit of 5th interim fee application to be filed with the court.	2.2
07/15/2021	LMB	Prepare professional fees for June 2021 monthly fee statement	3.1
07/15/2021	JD	Call with E. Kardos, H. Saydah, L. Bonito, J. DelConte (all AlixPartners) re: 5th interim fee application.	0.3



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Fee Statements and Fee Applications  
Code: 1.13 / 113

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
07/15/2021	LMB	Call with E. Kardos, L. Bonito, J. DelConte (all AlixPartners) re: 5th interim fee application.	0.3
07/16/2021	LMB	Finalize fifth interim fee application	0.8
07/16/2021	LMB	Email to M. Pera (Davis Polk) attaching the fifth interim fee application for filing on the Court docket	0.2
07/21/2021	LMB	Prepare professional fees for June 2021 monthly fee statement	1.8
07/22/2021	LMB	Prepare professional fees for June 2021 monthly fee statement	3.2
07/23/2021	LMB	Prepare professional fees for June 2021 monthly fee statement	1.3
07/27/2021	JD	Begin review of draft June fee application.	2.5
07/27/2021	JD	Continue review of draft June fee application to be filed with the court.	2.0
07/28/2021	JD	Finalize review of draft June fee application.	1.7
07/28/2021	LMB	Prepare professional fees for June 2021 monthly fee statement	1.7
07/29/2021	LMB	Prepare professional fees for June 2021 monthly fee statement	1.5
07/30/2021	JD	Review latest draft version of the June fee application to be filed with the court.	0.4
08/02/2021	LMB	Prepare 22nd monthly fee statement (July 2021), supporting schedules and exhibits	1.8
08/02/2021	JD	Provide comments on the latest draft fee application to be filed with the Court.	0.3
08/02/2021	JD	Review initial draft 5th interim fee application Fee Examiner report from D. Klauder.	0.4
08/03/2021	HS	Review fee examiner's report re: Fifth Interim Fee Application	0.2
08/03/2021	HS	Revise draft response to fee examiner re: Fifth Interim Fee Application	0.6
08/03/2021	BFF	Draft response to Fee Examiner's report re: AlixPartners' Fifth Interim Fee Application	1.9
08/04/2021	LMB	Revise 22nd monthly fee statement (June 2021)	0.4
08/05/2021	LMB	Telephone call with H. Saydah (AlixPartners) re: July monthly fee statement	0.5
08/05/2021	LMB	Prepare professional fees for July 2021 monthly fee statement	1.2
08/05/2021	LMB	Finalize 22nd monthly fee statement for June 2021	0.4
08/05/2021	LMB	Email to M. Pera (Davis Polk) attaching the June monthly fee statement for filing on the Court docket	0.2
08/05/2021	HS	Telephone call with L. Bonito (AlixPartners) re: July monthly fee statement	0.5
08/05/2021	JD	Finalize initial draft response to the fee examiner's report to the fifth interim fee application.	1.2
08/06/2021	HS	Review J. DelConte revisions to response to fee examiner's report	0.3
08/06/2021	HS	Prepare July professional fees	3.0
08/06/2021	HS	Review professional fees for July 2021 monthly fee statement	1.8
08/06/2021	BFF	Revise response to Fee Examiner	0.4
08/09/2021	HS	Prepare professional fees for July 2021 monthly fee statement	3.0
08/09/2021	HS	Review professional fees for July 2021 monthly fee statement	1.0
08/09/2021	JD	Correspondence with fee examiner and L. Donahue, E. Kardos (both AlixPartners) re: response to the fifth interim fee application.	0.3
08/10/2021	HS	Continue to prepare professional fees for July 2021 fee application	2.4
08/10/2021	HS	Prepare professional fees for July 2021	3.0
08/11/2021	HS	Prepare professional fees for July fee application	3.0
08/11/2021	HS	Continue to prepare professional fees for July fee application	2.1



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Fee Statements and Fee Applications  
Code: 1.13 / 113

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/11/2021	JD	Correspondence with L. Donahue and E. Kardos (AlixPartners) and the fee examiner re: settlement.	0.2
08/12/2021	LMB	Prepare professional fees for July 2021 monthly fee statement	3.2
08/13/2021	JD	Begin review of draft July fee application	2.0
08/13/2021	JD	Continue review of draft July professional fees for monthly fee statement	1.3
08/14/2021	JD	Continue review of draft July professional fees for monthly fee statement	1.5
08/15/2021	JD	Finish review of July fee applications to be filed with the court.	0.7
08/16/2021	LMB	Prepare professional fees for July 2021 monthly fee statement	3.2
08/17/2021	LMB	Update July fee application	0.4
08/17/2021	LMB	Continued preparation of professional fees for July 2021 monthly fee statement	1.3
08/17/2021	LMB	Prepare 23rd monthly fee statement for July 2021	1.2
08/17/2021	JD	Review updated draft July fee statement to be filed with the court.	0.4
08/18/2021	LMB	Prepare professional fees for August 2021	1.8
08/18/2021	LMB	Revise July 2021 monthly fee statement, supporting schedules and exhibits	0.4
08/24/2021	LMB	Update fee application status chart	0.2
08/24/2021	LMB	Preparation of professional fees for August 2021 monthly fee statement	1.2
08/25/2021	LMB	Revise July 2021 monthly fee statement, supporting schedules and exhibits	0.8
08/25/2021	JD	Review and edit July fee application per client request.	1.6
08/26/2021	JD	Review and provide comments on the latest turn of the fee application revision.	0.6
08/26/2021	LMB	Revise and finalize July 2021 monthly fee statement, supporting schedules and exhibits	1.2
08/30/2021	JD	Finalize revised July fee application to be filed with the court.	0.4
08/30/2021	LMB	Update July monthly fee statement, supporting schedules and exhibits	1.2
08/31/2021	JD	Finalize revised July fee application to be filed with the court.	0.3
09/08/2021	LMB	Prepare professional fees for August 2021 monthly fee statement	3.6
09/15/2021	JD	Review professional fees for privilege and other disclosures for August 2021 monthly fee statement	1.8
09/15/2021	JD	Continue review of draft August fee application.	3.0
09/15/2021	JD	Finish review of August fee application.	1.1
09/16/2021	LMB	Review professional fees for privilege disclosures for August 2021 monthly fee statement	2.4
09/17/2021	LMB	Email to T. Nobis attaching excels for June/July 2021	0.2
09/17/2021	LMB	Prepare excel workbooks for professional fees for June and July monthly fee statements	0.4
09/20/2021	JD	Review and sign-off on final draft fee application before sending to client for review.	0.7
09/20/2021	LMB	Prepare monthly fee statement, supporting schedules and exhibits for August 2021	1.8
09/20/2021	LMB	Review professional fees for August 2021 monthly fee statement for privilege disclosures	1.0
<b>Total Professional Hours</b>			<b>155.3</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Fee Statements and Fee Applications  
Code: 1.13 / 113

<b>PROFESSIONAL</b>	<b>TITLE</b>	<b>RATE</b>	<b>HOURS</b>	<b>FEES</b>
Jesse DelConte	Managing Director	\$1,055	35.8	37,769.00
Heather Saydah	Senior Vice President	\$480	20.9	10,032.00
Tammy Brewer	Vice President	\$465	6.5	3,022.50
Brooke F Filler	Vice President	\$460	2.3	1,058.00
Melanie McCabe	Vice President	\$430	27.5	11,825.00
Lisa Marie Bonito	Associate	\$465	62.3	28,969.50
<b>Total Professional Hours and Fees</b>			<b>155.3</b>	<b>\$ 92,676.00</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Court Hearings  
Code: 1.14 / 114

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/01/2021	JD	Listen to Disclosure Statement Status hearing telephonically	0.8
06/02/2021	HSB	Listen to Disclosure Statement hearing telephonically.	1.7
06/02/2021	JD	Participate in Disclosure Statement hearing telephonically.	1.6
06/16/2021	HSB	Listen to hearing telephonically re: extension of preliminary injunction and appointment of examiner	4.0
06/16/2021	JD	Listen to hearing telephonically re: extension of preliminary injunction and appointment of examiner	5.0
06/21/2021	JD	Listen to Insurance Adversary Proceeding hearing telephonically	1.5
06/21/2021	JD	Dial back into Insurance Adversary Proceeding hearing telephonically	2.1
07/29/2021	HSB	Attended Purdue Ch11 b/k court hearing re: Kerp	2.0
07/29/2021	JD	Participate in court hearing re: KEIP/KERP.	2.0
08/09/2021	JD	Participate in Purdue pretrial conference court hearing.	2.8
08/12/2021	HSB	Attend bankruptcy court Purdue plan confirmation Hearing	6.5
08/12/2021	ADD	Listen to hearing and provide updates on hearing progress to 1a report declarant.	3.0
08/12/2021	MFR	Provide confirmation hearing testimony.	2.3
08/13/2021	HSB	Attend bankruptcy court Purdue plan confirmation Hearing	6.0
08/13/2021	JD	Attend bankruptcy court Purdue plan confirmation Hearing	0.6
08/16/2021	HS	Attend hearing on Fifth Interim Fee Application	0.3
08/16/2021	HSB	Attend bankruptcy court Purdue plan confirmation Hearing	5.0
08/17/2021	HSB	Attend Purdue Plan Confirmation Hearing	5.0
08/18/2021	HSB	Attend Purdue Plan Confirmation Hearing	3.0
08/19/2021	HSB	Attend Purdue Plan Confirmation Hearing	4.0
08/23/2021	RC	Participate telephonically in the Purdue plan confirmation hearing.	2.4
08/23/2021	RC	Continue listening to the Purdue plan confirmation hearing.	2.2
08/23/2021	RC	Dial back into the Purdue plan confirmation hearing.	1.0
08/23/2021	HSB	Attend Purdue Plan Confirmation Hearing	3.5
08/25/2021	JD	Participate telephonically in Purdue confirmation hearing oral arguments.	5.9
08/25/2021	HSB	Attend Purdue Plan Confirmation Hearing	4.5
08/27/2021	HSB	Attend Purdue Plan Confirmation Hearing	1.4
08/27/2021	JD	Attend Purdue Plan Confirmation Hearing	1.8
09/01/2021	HSB	Partial telephonic attendance at Judge Drain's ruling on Plan Confirmation.	3.5
09/01/2021	JD	Listen to Judge Drain's ruling on Plan Confirmation.	6.8
09/01/2021	RC	Partial telephonic attendance at Judge Drain's ruling on Plan Confirmation.	3.0
09/13/2021	HSB	Attend Hearing on the KEIP/KERP.	3.0
09/13/2021	JD	Participate in Hearing on the KEIP/KERP.	4.7
09/30/2021	JD	Partial participation in the Purdue status conference on the stay motion.	0.8
<b>Total Professional Hours</b>			<b>103.7</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Court Hearings  
Code: 1.14 / 114

<b>PROFESSIONAL</b>	<b>TITLE</b>	<b>RATE</b>	<b>HOURS</b>	<b>FEES</b>
Richard Collura	Managing Director	\$1,125	8.6	9,675.00
Jesse DelConte	Managing Director	\$1,055	36.4	38,402.00
Mark F Rule	Director	\$980	2.3	2,254.00
HS Bhattal	Director	\$865	53.1	45,931.50
Heather Saydah	Senior Vice President	\$480	0.3	144.00
Andrew D DePalma	Vice President	\$625	3.0	1,875.00
<b>Total Professional Hours and Fees</b>			<b>103.7</b>	<b>\$ 98,281.50</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Forensic Analysis  
Code: 115

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/03/2021	MFR	Review Report 1B related to the Plan Confirmation and expert disclosure.	2.3
06/04/2021	FOS	Call with M. Rule (AlixPartners) re: expert designation for Report 1B.	0.3
06/04/2021	MFR	Call with F. Silva (AlixPartners) re: Plan Confirmation and expert disclosure.	0.3
06/07/2021	MFR	Review Report 1B and supporting documentation. Preparation of the Rule Expert Report.	2.2
06/08/2021	MFR	Review Report 1B and supporting documentation. Preparation of the Rule Expert Report.	2.4
06/09/2021	MFR	Review Report 1B and supporting documentation. Preparation of the Rule Expert Report.	2.1
06/10/2021	MFR	Review Report 1B and supporting documentation. Preparation of the Rule Expert Report.	2.6
06/11/2021	MFR	Review Report 1B and supporting documentation for preparing the Rule Expert Report.	2.1
06/14/2021	SJC	Review support for expert report.	1.1
06/14/2021	RC	Call with A. DePalma (AlixPartners) re: the cash and non-cash transfers of value expert report declarations.	0.5
06/14/2021	RC	Call with A. DePalma (AlixPartners) re: discovery and productions in the Chapter 11 case.	0.4
06/14/2021	RC	Call with M. Rule, F. Silva, A. DePalma and R. Collura (AlixPartners); D. Mazer and M. Clarens (Davis Polk) re: Purdue - 1A and 1B reports - materials discussion and Rule and Collura expert reports	0.7
06/14/2021	FOS	Call with M. Rule, F. Silva, A. DePalma and R. Collura (AlixPartners); D. Mazer and M. Clarens (Davis Polk) re: Purdue - 1A and 1B reports - materials discussion and Rule and Collura expert reports	0.7
06/14/2021	FOS	Draft list of documents re: support relied upon for Expert Reports on Report 1B.	1.8
06/14/2021	ADD	Call with M. Rule, F. Silva, A. DePalma and R. Collura (AlixPartners); D. Mazer and M. Clarens (Davis Polk) re: Purdue - 1A and 1B reports - materials discussion and Rule and Collura expert reports	0.7
06/14/2021	ADD	Call with R. Collura (AlixPartners) to discuss the cash and non-cash transfers of value expert report declarations.	0.5
06/14/2021	ADD	Call with R. Collura (AlixPartners) re: 1A reports declaration appendix.	0.4
06/14/2021	ADD	Compile Report 1A source information data and draft Report 1A declaration appendix.	2.3
06/14/2021	MFR	Preparation of Rule Expert Report.	5.7
06/14/2021	MFR	Preparation for call with Davis Polk re: Rule and Collura Expert Reports	1.0
06/14/2021	MFR	Call with M. Rule, F. Silva, A. DePalma and R. Collura (AlixPartners); D. Mazer and M. Clarens (Davis Polk) re: Purdue - 1A and 1B reports - materials discussion and Rule and Collura expert reports	0.7
06/15/2021	SJC	Review expert report.	1.3
06/15/2021	RC	Call with A. DePalma (AlixPartners) re: documents related to the cash transfers of value report.	0.4
06/15/2021	FOS	Compile and review draft and list of sources re: M. Rule Expert Reports on Report 1B.	1.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Forensic Analysis  
Code: 115

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
06/15/2021	ADD	Review report 1a declaration and check information against the 1a report.	3.1
06/15/2021	ADD	Call with R. Collura (AlixPartners) re: documents related to the cash transfers of value report.	0.4
06/15/2021	MFR	Preparation of Rule Expert Report.	6.0
06/17/2021	ADD	Call with S. Lemack (AlixPartners) re: AHC diligence requests.	0.5
06/17/2021	SKL	Call with A. DePalma (AlixPartners) re: AHC diligence requests.	0.5
06/22/2021	MFR	Review Sackler expert reports.	2.6
06/23/2021	MFR	Review Sackler expert reports.	2.2
06/23/2021	MFR	Review Rule Expert Report and supporting documentation in preparation for deposition and confirmation hearing.	3.3
06/24/2021	MFR	Review Sackler expert reports.	2.7
06/24/2021	MFR	Review Rule Expert Report and supporting documentation in preparation for deposition and confirmation hearing.	2.8
06/28/2021	MFR	Review Rule Expert Report and supporting documentation in preparation for deposition and confirmation hearing.	2.6
06/29/2021	MFR	Review Rule Expert Report and supporting documentation in preparation for deposition and confirmation hearing.	3.3
06/30/2021	MFR	Review Rule Expert Report and supporting documentation in preparation for deposition and confirmation hearing.	3.1
07/02/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents in preparation for deposition and/or confirmation hearing testimony.	2.9
07/06/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for deposition and/or confirmation hearing testimony.	3.2
07/07/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for deposition and/or confirmation hearing testimony.	2.9
07/08/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for deposition and/or confirmation hearing testimony.	3.1
07/09/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for deposition and/or confirmation hearing testimony.	3.3
07/12/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for deposition and/or confirmation hearing testimony.	3.0
07/13/2021	MFR	Preparation for call with Davis Polk on the Rule Report and Collura Report and pending confirmation hearing testimony.	2.4
07/13/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for deposition and/or confirmation hearing testimony.	2.8
07/14/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for deposition and/or confirmation hearing testimony.	3.3





Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Forensic Analysis  
Code: 115

<b>DATE</b>	<b>CONSULTANT</b>	<b>DESCRIPTION OF SERVICES</b>	<b>HOURS</b>
07/15/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for deposition and/or confirmation hearing testimony.	3.1
07/16/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	3.4
07/19/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	2.8
07/20/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	2.4
07/21/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	2.9
07/22/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	3.0
07/23/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	2.6
07/26/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	2.8
07/27/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	3.1
07/28/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	2.7
07/29/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	2.8
07/30/2021	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	3.1
08/02/2021	FOS	Email to A. DePalma, M. Rule, R. Collura (all AlixPartners) re: Rent payments for One Stamford Realty.	0.1
08/02/2021	MFR	Review of Rule Report Exhibits 4H - 4J in preparation for confirmation hearing.	3.3
08/02/2021	MFR	Review of Rule Report Exhibits 4C - 4D in preparation for confirmation hearing.	2.8
08/02/2021	MFR	Review of Rule Report Exhibits 4E - 4G in preparation for confirmation hearing.	2.9



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Forensic Analysis  
Code: 115

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
08/03/2021	AH	Prepare trial binders for the Testimony of Mark Rule for Court hearing	3.5
08/03/2021	MFR	Review of Rule Report Exhibits 1D - 1F in preparation for confirmation hearing.	2.7
08/03/2021	MFR	Review of Rule Report Exhibits 1A - 1C in preparation for confirmation hearing.	2.3
08/04/2021	MFR	Call with K. Benedict (Davis Polk) re: Rule Declaration.	0.3
08/04/2021	MFR	Review of Rule Report Exhibits 1G - 1I in preparation for confirmation hearing.	3.1
08/04/2021	MFR	Review of Rule Report Exhibits 1J - 1K in preparation for confirmation hearing.	2.9
08/04/2021	MFR	Review of Rule Report Exhibits 1L - 1M in preparation for confirmation hearing.	2.5
08/05/2021	MFR	Review of Rule Report Exhibits 3A - 3B in preparation for confirmation hearing.	2.1
08/05/2021	MFR	Review of Rule Report Exhibits 1N - 1P in preparation for confirmation hearing.	2.8
08/05/2021	MFR	Review of Rule Report Exhibits 1Q - 1R in preparation for confirmation hearing.	2.7
08/05/2021	MFR	Review of Rule Report Exhibits 2A - 2C in preparation for confirmation hearing.	2.9
08/06/2021	FOS	Retrieve documentation of follow-up items re: Report 1B, Appendix 3.	1.0
08/06/2021	MFR	Confirmation hearing preparation session with E. Kim, K. Benedict and M. Clarens (all Davis Polk).	3.0
08/06/2021	MFR	Review of Rule Report Exhibits 4A - 4B in preparation for confirmation hearing.	3.0
08/06/2021	MFR	Review of Rule Report Exhibits 3C - 3D in preparation for confirmation hearing.	3.2
08/06/2021	MFR	Review of Rule Report Exhibits 3E - 3F in preparation for confirmation hearing.	3.3
08/08/2021	MFR	Preparation for confirmation hearing testimony and review of Rule Report Exhibits 1A-1E and supporting documents.	2.7
08/08/2021	MFR	Preparation for confirmation hearing testimony and review of Rule Report Exhibits 1C-1E and supporting documents.	2.9
08/09/2021	MFR	Review of Rule Report Exhibits 1J-1M and supporting documents to prepare for confirmation hearing testimony.	2.8
08/09/2021	MFR	Review of Rule Report Exhibits 1N-1P and supporting documents to prepare for confirmation hearing testimony.	2.6
08/09/2021	MFR	Review of Rule Report Exhibits 1Q-1R and supporting documents to prepare for confirmation hearing testimony.	2.3
08/09/2021	MFR	Review of Rule Report Exhibits 2A-2B and supporting documents to prepare for confirmation hearing testimony.	2.6
08/10/2021	FOS	Telephone call with M. Rule (AlixPartners) re: Report 1B Appendix 3.	0.5
08/10/2021	MFR	Preparation for confirmation hearing testimony.	4.3
08/10/2021	MFR	Telephone call with F. Silva (AlixPartners) re: Report 1B Appendix 3.	0.5



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Forensic Analysis  
Code: 115

<b>DATE</b>	<b>CONSULTANT</b>	<b>DESCRIPTION OF SERVICES</b>	<b>HOURS</b>
08/11/2021	MFR	Preparation for confirmation hearing testimony. Review of Rule Report Exhibits 4A-AC and supporting documents.	3.2
08/11/2021	MFR	Review of Rule Report Exhibits 4H-4J and supporting documents to prepare for confirmation hearing testimony	3.2
08/11/2021	MFR	Review of Rule Report Exhibits 4E-4G and supporting documents to prepare for confirmation hearing.	3.3
08/12/2021	MFR	Review of Rule Report Appendix 1 and Appendix 2 and supporting documents to prepare for confirmation hearing testimony	2.7
08/12/2021	MFR	Review of Rule Report Appendix 3 and supporting documents to prepare for confirmation hearing testimony	1.8
<b>Total Professional Hours</b>			<b>214.5</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Forensic Analysis  
Code: 115

<b>PROFESSIONAL</b>	<b>TITLE</b>	<b>RATE</b>	<b>HOURS</b>	<b>FEES</b>
Richard Collura	Managing Director	\$1,125	2.0	2,250.00
Mark F Rule	Director	\$980	192.3	188,454.00
Sam K Lemack	Senior Vice President	\$665	0.5	332.50
Fernando O Silva	Senior Vice President	\$665	5.9	3,923.50
Sam J Canniff	Senior Vice President	\$665	2.4	1,596.00
Andrew D DePalma	Vice President	\$625	7.9	4,937.50
Adrianne Hazelwood	Vice President	\$460	3.5	1,610.00
<b>Total Professional Hours and Fees</b>			<b>214.5</b>	<b>\$ 203,103.50</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Travel  
Code: 1.17

DATE	CONSULTANT	DESCRIPTION OF SERVICES	HOURS
09/09/2021	KM	Travel from Toronto to Stamford.	4.5
09/10/2021	JD	Travel home from Purdue Stamford office.	1.0
09/10/2021	JD	Travel to Purdue Stamford office.	1.0
09/10/2021	KM	Travel from Stamford to Toronto.	4.5
Total Professional Hours			11.0



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Travel  
Code: 1.17

<b>PROFESSIONAL</b>	<b>TITLE</b>	<b>RATE</b>	<b>HOURS</b>	<b>FEES</b>
Jesse DelConte	Managing Director	\$1,055	2.0	2,110.00
Kevin M McCafferty	Director	\$980	9.0	8,820.00
<b>Subtotal Professional Hours and Fees</b>			<b>11.0</b>	<b>\$ 10,930.00</b>
Less 50% Travel Time				(5,465.00)
<b>Total Professional Fees</b>				<b>\$ 5,465.00</b>



Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
1 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Re: Expenses  
Code: 1.18 / 150

DATE	DESCRIPTION OF SERVICES	AMOUNT
6/8/2021	Postage/Messenger/Courier FedEx / FedEx shipment sent to Tom Fitzsimmons	22.86
6/10/2021	Cab Fare/Ground Transportation Mark Rule Office to Home	43.16
6/23/2021	Postage/Messenger/Courier FedEx / FedEx shipment sent to Thomas Fitzsimmons	15.34
6/30/2021	Hosting Fees (GB)	63,897.60
7/31/2021	Hosting Fees (GB)	64,512.00
8/31/2021	Hosting Fees (GB)	65,006.40
8/12/2021	Lodging Mark Rule Water Color Inn - Santa Rosa Beach 08/12/2021 - 8/13/2021	225.00
8/12/2021	Individual Meal - Mark Rule - Breakfast	25.00
8/12/2021	Taxi/Car Service Jesse Delconte Davis Polk to Home	60.19
8/12/2021	Taxi/Car Service Jesse Delconte Home to Davis Polk	48.06
8/13/2021	Taxi/Car Service Jesse Delconte Home to Davis Polk	36.36
8/13/2021	Taxi/Car Service Jesse Delconte Davis Polk to Home	35.91
8/13/2021	Taxi/Car Service Jesse Delconte Davis Polk to Home	8.64
8/14/2021	Taxi/Car Service Jesse Delconte Home to Davis Polk	7.27
8/19/2021	Taxi/Car Service Jesse Delconte AlixPartners to Home	43.70
8/19/2021	Taxi/Car Service Jesse Delconte Home to AlixPartners	41.48